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“…What the eyes perceive in herbs or stones or trees is not yet a remedy;  
the eyes see only the dross.  But inside, under the dross,  
there the remedy lies hidden.  
First it must be cleaned from the dross, then it is there. 
This is alchemy, and this is the office of Vulcan;  
he is the apothecary and chemist of the medicine…” 
Paracelsus (1493 – 1541) 
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SUMMARY 
Tropical parasitic diseases such as malaria, human African trypanosomiasis, chagas disease, and 
leishmaniasis affect hundreds of millions of people worldwide and have devastating consequences. 
Current drugs available to treat these diseases have serious drawbacks. New drugs are urgently needed.  
Natural products (NPs) play a dominant role in drug discovery for the treatment of human diseases. 
Particularly, quinine and artemisinin have their origin in nature and have inspired successful drugs for 
malaria treatment. 
In a medium throughput screening, a total of 507 extracts from South African plants were assayed for 
their antiprotozoal activity against Plasmodium falciparum, Trypanosoma brucei rhodesiense, 
Trypanosoma cruzi and Leishmania donovani. Extracts from Abrus precatorius L. ssp. africanus Verdc. 
(Fabaceae) and Drypetes gerrardii Hutch. var. gerrardii (Putranjivaceae) inhibited at least one of the 
parasites at a test concentration considered relevant. With the aim of identifying the compounds 
responsible for these activities, a HPLC-based activity profiling approach followed by dereplication was 
applied. Targeted isolation of promising compounds was achieved by a combination of chromatography 
techniques. Structure elucidation was achieved by HR-ESI-MS and NMR (1H, 13C, COSY, HMBC, 
HSQC, and NOESY spectroscopy). Absolute configuration was determined by comparison of electronic 
circular dichroism (ECD) spectra with calculated ECD data. 
HPLC-based activity profiling of A. precatorius allowed the identification of abruquinones, a series of 
isoflavan quinones, as responsible for the trypanocidal activity of the crude extract. A total of ten 
abruquinones were isolated. Among these were five new compounds, and one compound was reported for 
the first time as natural product. Abruquinone B, I, A, D, K, and L showed remarkable inhibition (0.16 ± 
0.060, 0.28 ± 0.051, 0.02 ± 0.003, 0.01 ± 0.001, 0.11 ± 0.053, and 0.02 ± 0.053, respectively) and notable 
selectivity, expressed as selectivity indices (SIs) which were calculated from cytotoxicity data in L-6 cells 
(51, 74, 1379, 668, 508, and 374, respectively). These results warrant in vivo assessment of abruquinones. 
Abruquinones are promising hits due to their strong and selective in vitro inhibition of T. b. rhodesiense, 
their good compliance with Lipinski’s “rule-of-5” and other molecular properties, as well as their 
predicted low/moderate toxic potential. Therefore, further studies are necessary to guarantee a botanical 
or chemical source, and to assess in vivo efficacy. 
Two different extracts of D. gerrardii showed antiprotozoal activity, and the active constituents were 
tracked and isolated by HPLC-based activity profiling. The CH2Cl2/MeOH (1:1) stems extract inhibited L. 
donovani and P. falciparum. The major compound, a new phenanthrenone, showed good in vitro activity 
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(IC50 of 0.9 ± 0.3 µM) and selectivity (SI of 68) against P. falciparum. Based on these promising results, 
in-vivo studies were conducted. However, the compound was not able to reduce parasitemia in the P. 
berghei mouse model. A phenanthrenone heterodimer was also isolated and showed in vitro 
antiplasmodial activity (IC50 of 2.04 ± 0.15 µM and SI of 31). Furthermore, the CH2Cl2/MeOH (1:1) 
leaves extract displayed trypanocidal properties, and the known saponin putranoside A was isolated and 
tested against T. b. rhodesiense, (IC50 of 18.0 ± 3.8 µM and a SI of 4). 
The phenanthrenone was the most active and selective in vitro inhibitor of P. falciparum, but showed no 
inhibition in vivo against P. berghei. However, the compound fulfilled Lipinski’s “rule-of-5” and other 
molecular properties, which indicates a potential to meet requirements of an ideal antimalarial drug such 
as, oral bioavailability and blood-brain barrier permeability. According to Medicines for Malaria Venture 
compound progressing criteria, the phenanthrenone complies with some of the features of a validated hit 
such as sufficient activity against P. falciparum in vitro (˂ 1 µM). The assessment of in vivo activity in 
additional animal models, e.g. Pf-huMouse model could be considered for compound progression in the 
drug discovery pipeline.  
Additionally, as part of a project aimed at investigating antiprotozoal European plants Chrysanthemum 
cynerariifolium (Trevir.) Vis. (Asteraceae), Laurus nobilis L. (Lauraceae), and Eupatorium cannabinum 
L. (Asteraceae) were studied. A hexane extract of C. cynerariifolium showed promising activity against P. 
falciparum. Pyrethrins (irregular monoterpenes) were the metabolites responsible for the antiplasmodial 
activities. Particularly, pyrethrin II and jasmolin II inhibited P. falciparum (IC50 4.0 ± 1.1 µM and 5.0 ± 
0.4 µM, respectively and SI of 24 and 6, respectively) in vitro. Synthetic pyrethroids were also tested, but 
they did not show activity. However, none of the two compounds fulfilled activity and selectivity 
requirements for in vivo evaluation. 
Finally, as a contribution to the structure activity relationship study of sesquiterpene lactones showing 
activity against T. b. rhodesiense, costunolide and zaluzanin D were isolated from Laurus nobilis L. 
(Lauraceae) and eupatoriopicrin from Eupatorium cannabinum L. (Asteraceae). Germacrolides, i.e. 
costunolide and eupatoriopicrin, showed a higher inhibition (IC50 of 1.3 ± 0.4 µM and 1.2 ± 0.2 µM, 
respectively) on the protozoon, than the guaianolide zaluzanin D (IC50 of 10.8 µM). However, none of the 
sesquiterpene lactones showed sufficient activity and selectivity to warrant in vivo testing. 
In brief, a total of 22 secondary metabolites were isolated from five species. Among them, seven new 
compounds were discovered. These compounds belong to the structural classes of isoflavonoids, 
phenanthrenones, and terpenes such as, sesquiterpene lactones, irregular monoterpenes and triterpenoid 
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saponins. Most of them (15 compounds) exhibited in vitro antiprotozoal activity, albeit at differing extent. 
The most promising compounds were the abruquinones and the phenanthrenone, which strongly and 
selectively inhibited T. b. rhodesiense and P. falciparum, respectively. Abruquinones and the 
phenanthrenone are drug-like compounds with a calculated toxic potential ranging from low to moderate.  
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ZUSAMMENFASSUNG 
Tropische parasitäre Krankheiten wie Malaria, afrikanische Trypanosomiasis (Schlafkrankheit), Chagas-
Krankheit und Leishmaniose betreffen Hunderte von Millionen Menschen weltweit und haben 
verheerenden Folgen. Aktuelle Medikamente, die zur Behandlung dieser Krankheiten zur Verfügung 
stehen, haben gravierende Nachteile. Neue Medikamente werden dringend benötigt. 
Naturstoffe (NP) spielen eine dominierende Rolle in der Wirkstoffforschung für die Behandlung von 
menschlichen Erkrankungen. So haben Chinin und Artemisin ihren Ursprung in der Natur und führten zu 
erfolgreichen Medikamenten zur Malariabehandlung. 
In einem mittleren Durchsatz-Screening wurden insgesamt 507 Extrakte von südafrikanischen Pflanzen 
auf ihre Aktivität gegen Protozoen - Plasmodium falciparum, Trypanosoma brucei rhodesiense, 
Trypanosoma cruzi und Leishmania donovani - getestet. Extrakte von Abrus precatorius L. ssp. africanus 
Verdc. (Fabaceae) und Drypetes gerrardii Hutch. var. gerrardii (Putranjivaceae) haben mindestens einen 
der Parasiten in einer als relevant bezeichneten Testkonzentration gehemmt. 
Mit dem Ziel die für diese Aktivitäten verantwortlichen Verbindungen zu identifizieren wurde ein Ansatz 
bestehend aus HPLC-basiertes Aktivitäts-Profiling gefolgt von Dereplikation verwendet. Gezielte 
Isolierung der vielversprechenden Verbindungen erfolgte durch eine Kombination von Chromatographie-
Techniken. Die Strukturaufklärung wurde durch HR-ESI-MS und NMR (1H, 13C, COSY, HMBC, HSQC, 
und NOESY Spektroskopie) durchgeführt. Die absolute Konfiguration wurde durch den Vergleich der 
elektronischen Zirkulardichroismus-(ECD)-Spektren mit berechneten ECD-Daten bestimmt. 
HPLC-basiertes Aktivitäts-Profiling von A. precatorius ermöglichte die Identifizierung von 
Abruquinonen, einer Reihe von Isoflavan-Chinonen, als verantwortliche Substanzen für die trypanozide 
Aktivität des Rohextrakts. Es wurden insgesamt 10 Abruquinone isoliert, darunter fünf neue 
Verbindungen. Eine Verbindung wurde zum ersten Mal als Naturstoff beschrieben. Abruquinone B, I, A, 
D, K und L zeigten bemerkenswerte Hemmung (0.16 ± 0.060, 0.28 ± 0.051, 0.02 ± 0.003, 0.01 ± 0.001, 
0.11 ± 0.053, und 0.02 ± 0.053) und beachtenswerte Selektivität, wiedergegeben als Selektivitätsindizes 
(SIs) die aus der Zytotoxizität in L-6 Zellen (51, 74, 1379, 668, 508, und 374) ermittelt wurden. Diese 
Ergebnisse rechtfertigen eine Prüfung der in vivo-Aktivität von Abruquinonen. 
Wegen ihrer starken und selektiven in vitro Hemmung von T. b. rhodesiense, ihrer guten 
Übereinstimmung mit Lipinski’s „5er Regel“ und anderen molekularen Eigenschaften, sowie ihrem 
niederen/mässigen toxischen Potenzial sind Abruquinone vielversprechende Hits. Deshalb sind weitere 
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Studien notwendig um botanische oder chemische Quellen sicherzustellen und die in-vivo Wirksamkeit 
dieser Verbindungen zu bestimmen. 
Zwei verschiedene Extrakte von D. gerrardii zeigten Aktivität gegen Protozoen. Die aktiven Bestandteile 
wurden mit Hilfe vom HPLC-basiertem Aktivitäts-Profiling identifiziert und isoliert. Der CH2Cl2/MeOH 
(1:1) Extrakt aus den Stängeln hemmte L. donovani und P. falciparum. Die Hauptverbindung, ein neues 
Phenanthrenon, zeigte gute in vitro Aktivität (IC50 von 0.9 ± 0.3 µM) und Selektivität (SI von 68) gegen 
P. falciparum. Basierend auf diesen vielversprechenden Resultaten wurden in vivo Studien durchgeführt. 
Allerdings war diese Verbindung nicht in der Lage die Parasitenbelastung im P. berghei Mausmodell zu 
reduzieren. Es wurde ebenfalls ein Phenanthrenon-Heterodimer isoliert, der in vitro Aktivität gegen 
Plasmodien (IC50 von 2.04 ± 0.15 µM und SI von 31) aufwies. Ausserdem zeigte der CH2Cl2/MeOH (1:1) 
Blattextrakt ausgewiesene trypanozidale Eigenschaften. Aus diesem Extrakt wurde das bekannte Saponin 
Putranoside A isoliert und gegen T. b. rhodesiense, (IC50 von 18.0 ± 3.8 µM und SI von 4) getestet. 
Das Phenanthrenon war der aktivste und selektivste in vitro Inhibitor von P. falciparum, zeigte jedoch 
keine Hemmung in vivo gegen P. berghei. Die Verbindung erfüllte jedoch Lipinski’s „5er Regel“ und 
andere molekulare Eigenschaften, wie orale Bioverfügbarkeit und Durchlässigkeit der Blut-Hirn-
Schranke, was ein mögliches Potenzial aufzeigt den Anforderungen eines idealen Antimalariawirkstoffs 
gerecht zu werden. Nach „Medicines for Malaria Venture“-Kriterien für die weitere Entwicklung eines 
Wirkstoffs erfüllt das Phenanthrenon einige der Merkmale eines validierten Hits wie ausreichende in vitro 
Aktivität gegen P. falciparum (˂ 1 µM). Die Bewertung der in vivo Aktivität in weiteren Tiermodellen, 
z.B. Pf-huMaus-Modell könnte für den weiteren Wirkstoffentwicklungsprozess in Betracht gezogen 
werden. 
Als weiterer Teil des Projekts wurde die Wirkung von europäischen Heilpflanzen Chrysanthemum 
cynerariifolium (Trevir.) Vis. (Asteraceae), Laurus nobilis L. (Lauraceae), und Eupatorium cannabinum 
L. (Asteraceae) gegen Protozoen studiert. Ein Hexan-Extrakt von C. cynerariifolium zeigte 
vielversprechende Aktivität gegen P. falciparum. Phyrethrine (unregelmässige Monoterpene) waren die 
Inhaltsstoffe verantwortlich für die antiplasmodiale Aktivität. Besonders Pyrethrin II und Jasmolin II 
hemmten P. falciparum (IC50 4.0 ± 1.1 µM und 5.0 ± 0.4 µM, und SI von 24 und 6) in vitro. Es wurden 
auch synthetische Pyrethroide getestet, sie zeigten aber keine Aktivität. Keiner der beiden Wirkstoffe 
erfüllte die Anforderungen an Aktivität und Selektivität für in vivo Evaluierung. 
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Schliesslich, als Beitrag zu den Struktur-Aktivitätsuntersuchungen von Sesquiterpenlactonen mit 
Aktivität gegen T. b. rhodesiense, wurden Costunolid und Zaluzanin D aus Laurus nobilis L. (Lauraceae) 
und Eupatoriopicrin aus Eupatorium cannabinum L. (Asteraceae) isoliert. Germacrolides, d.h. Costunolid 
und Eupatoriopicrin, zeigten eine höhere Hemmung (IC50 von 1.3 ± 0.4 µM und 1.2 ± 0.2 µM) auf 
Protozoen als das Guaianolid Zaluzanin D (IC50 von 10.8 µM). Keines der Sesquiterepenelactone zeigte 
ausreichende Aktivität und Selektivität für in vivo Tests. 
Es wurden insgesamt 22 Sekundärmetaboliten aus fünf Arten isoliert, darunter sieben neue Verbindungen. 
Diese Substanzen gehören zu den Strukturklassen der Isoflavonoide, Phenanthrenone und Terpene 
einschliesslich Sesquiterpenelactone, unregelmässige Monoterpene und Triterpenoidsaponine. Die 
meisten von ihnen (15 Verbindungen) zeigten in vitro Aktivität gegen Protozoen wenn auch in 
unterschiedlichem Ausmass. Die vielversprechendsten Verbindungen waren die Abruquinone und das 
Phenanthrenon, die starke und selektive Hemmung gegen T. b. rhodesiense und P. falciparum zeigten. 
Abruquinone und das Phenanthrenon sind drug-like Verbindungen mit einem rechnerischen toxischen 
Potential von gering bis mässig.  
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Tropical parasitic diseases blight the lives of hundreds of millions of people worldwide and result in 
significant mortality. The social and economic consequences are devastating [1, 2]. Malaria, human 
African trypanosomiasis (HAT), Chagas disease, and leishmaniasis accounted in 2011 for estimated 
669.274 deaths and 61.012.393 disability-adjusted life years (DALYs) [3, 4]. Most of the drugs available 
to treat these diseases have serious drawbacks in efficacy, show severe side effects, poor patient 
compliance, and resistance [2, 5]. Hence, new drugs are urgently needed [6-8]. 
Natural products (NPs) play a dominant role in drug discovery for the treatment of human diseases [9, 
10]. Particularly, several well-established antiprotozoal drugs such as quinine and artemisinin have their 
origins in nature [11]. In fact, the history of antimalarial drug discovery contributed fundamentally to the 
modern concept of chemotherapy [12]. 
The aim of this work was to find hit compounds from medicinal plants and to determine their potential for 
future optimization as a part of a drug discovery program attempting to develop drugs intended for the 
treatment of parasitic tropical diseases. 
As a first step, 118 South African plant species, belonging to 69 botanical families were selected mainly 
based on their traditional use. The plants were recollected and three extracts were obtained by successive 
extraction with solvents of increasing polarity. The resulting 507 extracts were formatted into a focused 
extract library. 
The extracts were screened in a medium throughput platform against Plasmodium falciparum, 
Trypanosoma brucei rhodesiense, Trypanosoma cruzi, and Leishmania donovani, causative agents of 
malaria, HAT, chagas disease, and leishmania, respectively. Every extract was assayed in two 
concentrations and the most active ones (>95% inhibition at 10 µg/mL) were subjected to IC50 
determination. Extracts with an IC50 values ≤ 5 µg/mL were considered to be active. To select extracts for 
further investigation, activity, potential structural novelty of substances contained in the extract, and 
taxonomic criteria of the plant were considered. 
Selected extracts had to be fractionated in microgram amounts and in parallel, on-line spectroscopic 
(PDA), spectrometric (ESI-MS), and ELSD data had to be recorded. Collected one-minute fractions had 
to be re-assayed against the corresponding parasites. Biological results, chromatograms, and analytical 
data are combined to obtain a HPLC-based activity profiling [13-15]. Dereplication is supported with 
natural product databases, SciFinder Scholar, and other bibliographic resources to prioritize the extracts 
[16]. 
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Subsequently, constituents responsible for the activity had to be isolated in small amounts (1 - 5 mg) for 
structure elucidation and in vitro antiprotozoal assessment. Compounds which comply with acceptance 
criteria for activity, selectivity, and novelty, are classified for in vivo evaluation in primary rodent models.   
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 2.1 Natural Products and Drug Discovery 
 
2.1.1 Historical Background 
Medicinal plants have been used since the dawn of mankind to alleviate and treat diseases [1-3]. Pre-
helenic civilizations documented their knowledge in different kind of documents.  
The Sumerian healers recorded the knowledge about medicinal agents, mostly plants, in more than 600 
tablets of clay, written around 1700 BC [4]. The registers contain information regarding the used 
formulations, plant decoctions and other preparations [3, 4]. 
Ancient Egyptians listed in the Ebers Papyrus more than 800 prescriptions. This document dates back to 
around 1550 BC and describes remedies for skin, ocular, and gastrointestinal complaints. Most of the 
prescriptions include culinary plants, such as grapes, figs, wheat, and spices (coriander, caraway, fennel, 
peppermint, and thyme). Furthermore, fragrant resins of Boswellia ssp. (frankincense) and Commiphora 
myrrh (myrrh) were highly valued by Egyptian embalmers. In Egypt, the physicians were priests. At that 
time, elements of religion and magic were closely intertwined with use of herbal drugs [1, 3, 4].  
In India, one of the most traditional systems of medicine is the Ayurveda. The word Ayurveda is derived 
from the Sanskrit word “Ayus” (all aspects of life from birth to death) and “Veda” (knowledge or science), 
meaning science of long life. In the Vedic time, treatment of diseases was done by specific persons called 
ascetic people. They transmitted their knowledge to the next generations in three books called “Brihat 
Trayees” (major three), written between 1000 BC to 7th AD. These books contain basic concepts of 
health, disease, herbal formulations, and the description of about 900 plant species. One of the best known 
plant in western culture is serpaghanda, Rauwolfia serpentina, which contains the antihypertensive and 
antipsychotic alkaloid reserpine [3-5].   
Chinese knowledge in medicinal plants was collected in treatises called “Bencao”. The first one appeared 
during the late Han dynasty (206 BC - 200 AD). However, the most comprehensive and best known 
treatise is the “Bencao” Gangmu or “Systematic Materia Medica”, compiled during the Ming dynasty 
(1518 - 1596 AD) [4, 6, 7]. One of the most valued Chinese medicinal plants is Ginkgo biloba, used to 
improve the memory and to sharpen mental alertness. The main constituents responsible for these effects 
are reported to be the ginkgolides and flavonoids. Panax ginseng is reported to maintain health. Its main 
constituents are saponins (ginsenosides). The number of medicinal plants currently used in China is larger 
than 5.000 [1, 3].    
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 Most of the ancient civilizations explained illness as a supernatural phenomenon, and healing as an art 
related to magic and religion. However, the Greeks changed this, and supernatural beliefs were rejected in 
favor of rational concepts. They postulated that diseases were caused by an imbalance in body humors 
(blood, phlegm, yellow bile, and black bile). Consequently, finding drugs became based on the belief that 
they had to correct this imbalance. These ideas were mentioned for the first time in the “Hippocratic 
Corpus”, a written work comprised of about 60 treatises, attributed to Hippocrates (born in Cos 460 or 
450 BC). Moreover, from the Greek time the book “Historia Plantarum”, written by Theophrastus (ca. 
370 - 287 BC), a former student of Aristotle (384 - 322 BC), classified and described more than 500 
plants [3, 4]. 
In Rome, Dioscorides (ca. 40 - 90 AD) wrote “De Materia Medica”, the major source of information 
about medicinal herbs used in the Hellenic world, in which he cited more than 600 plants. He provided a 
description of each herb and its habitat, discussed its humoral qualities and its characteristics so that 
adulteration could be recognized. Dioscorides also reported side effects. Amongst others, he described 
belladonna, cassia, cinnamon, cumin, fennel, ginger, liquorice, lavender, mint, mustard, olive oil, opium, 
rhubarb, rosemary, sage, and thyme. The “De Materia Medica” may be considered as the first 
compendium of pharmacy [3, 4].   
Galen (129 - 199 AD), the most influential Roman physician, wrote the “Opera Omnia”, a collection of 
20 volumes in which he expressed his agreement with Hippocrates and Dioscorides [4]. Galen’s approach 
to therapy involved polypharmacy. He prescribed medicines in simple or complex mixtures called 
“galenics” which were specifically devised for each therapy. He argued that for each disease, the body 
would be able to select the appropriate ingredient [3, 4].  
After the fall of the Roman Empire, Europe entered the Medieval Age (5th to 15th centuries), and the 
cultural center was transferred to the East, to the Byzantine Empire and Arab world [3]. The Greco-Latin 
texts were translated into Arabic, and three important scientific figures emerged during that era.  
Abu Bakr al-Razi, known in the West as Rhazes, was born in Iran (865 - 925). He was a physician and a 
philosopher and wrote about 200 books, including the two main works related to medicine “Kitab al-
Mansuri fi al-tibb” (“The Book of Medicine for Mansur”) and “Kitab al-Hawi fi al-tibb” (“The 
Comprehensive Book on Medicine”). Rhazes introduced sedative procedures with opium before 
performing surgery on his patients and also recommended to test the drugs in animals before 
administering them to humans. Later on, another physician from Persia surpassed his influence, Abu Ali 
al-Hussain ibn Abdallah ibn Sina (Avicenna in Latin) (980 - 1037). Avicenna merged Greek and Arab 
traditions, further developed Galen’s complex ideas, and described the use and efficacy of 760 drugs 
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 arranged alphabetically in his work “al-Qanun fi at-tibb” (“The Canon of Medicine”). In the 12th century 
this treatise was translated by Gerardo de Cremona into Latin (after the Arabs were driven out of Spain) 
and was adopted as a standard text for medical students throughout Europe until the 18th century [3, 4]. 
Abu al-Qasim Al-Zahrawi (Abulcasis in Latin) born in Cordoba, wrote the medical encyclopedia “al-
Tasrif”. Volume 28 describes the correct manner of handling plant products for medicinal application, 
with an emphasis on the importance of drying and storage techniques. He included more than 1500 herbal 
drugs, such as liquorice root, opium, aloes, sandalwood, acacia, and cardamom, described the plants and 
their natural habitats, specified the selection of the plant organs as well as the season in which they should 
be collected. There is also information about the preparation of oils, vinegars, decoctions and other 
dosage forms. The work was translated into Latin by Simon of Genoa and printed in Venice in 1471, 
becoming known as “Liber Servitoris”. Many generations of European apothecaries relied on it as a first-
hand source of information on pharmaceutical processes [3, 4].    
With the development of the printing press by Johann Gutenberg in the mid-15th century, printed herbals 
and formularies listing drugs and their use became more widely accessible. In 1530, Otto Brunfels 
(Germany, 1488 - 1534), a Lutheran preacher, published the “Herbarium Vivae Eicones”. The most 
influential herbal writer was Leonhart Fuchs (Germany, 1501 - 1566) whose “De Historia Stirpium” was 
published in 1542. He was a professor of medicine in Tübingen and described in his book more than 500 
plants. Subsequently, Hieronymus Bock (1498 - 1554) published in 1546 his “Kreuterbuch” in German, 
in which he includes own observations on plants. Subsequently, Rembert Dodoens (Belgium, 1517 - 
1585) wrote “Cruydeboeck” (1554) and “Pemptades” (1583). Later on, Valerius Cordus (Germany 1515 - 
1544) collected the herbs described by Dioscorides in “De Materia Medica” and his observations and 
work were published by the Council of the city of Nuremberg under the name “Dispensatorium” in 1546 
and 1561. It was edited and published as the herbal “Historia Plantarum” by the Swiss naturalist Conrad 
Gesner. In 1544, the Italian medical botanist Pietro Andrea Gregorio Mattioli (1501-1577) published “Di 
Pedacio Dioscoride Anazarbeo Libri Cinque”, his translation of the work of Dioscorides [4]. Renaissance 
herbals contain a large collection of plants and combine information from Greek, Roman, and Arabic 
traditions. They were the predecessors of the pharmacopoeias [8]. 
In 1498, the first official pharmacopoeia was compiled and printed in Florence by the Guild of 
Apothecaries and the Medical Society, under the name “Nuovo Receptario”. Other cities produced their 
own pharmacopoeias, including Barcelona and Zaragoza (1535), Nuremberg (1556), Basel (1561), 
Augsburg (1564), Cologne (1565), and London (1618) [9].    
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 Amid the Renaissance, Philip Theophrastus Bombastus von Hohenheim - he called himself Paracelsus 
(1493 – 1541) - was born in Einsiedeln (Switzerland). His advanced ideas changed drug therapy, but were 
regarded as strongly controversial in his time. He used metals such as antimony and mercury to treat his 
patients. He knew that such substances were toxic, but he realized that the hazardous effects depended on 
the dose (“sola dosis facit venenum”). In this way, Paracelsus became the “Father of toxicology”. He gave 
also great importance to the way the remedies were prepared. Separation was considered the fundamental 
process in his chemical philosophy: “what the eyes perceive in herbs or stones or trees is not yet a 
remedy; the eyes see only the dross. But inside, under the dross, there the remedy lies hidden” [4, 10-12].  
The discovery of America in 1492 brought with it the incorporation of new plants used for medicinal 
purposes in Europe. Ipecacuanha root (Cephaelis ipecacuanha) and cinchona bark (Cinchona ssp.) were 
some of the best known [13-16]. 
• History of Cinchona Bark 
The origin of the cinchona bark and how it first came to Europe lacks of precise information, and some 
legends and false statements have sprout around its history [17].  
Allegedly, the cinchona bark was introduced in Europe in the early 17th century by Jesuit priests. They 
were doing missionary work among the new-world indigenous communities. During 1630, the Jesuit 
apothecary Agostino Salumbrino (1561-1642) learnt that Peruvian indigenous chewed the bark while 
working in cold airflows in Spanish-owned mines to stop shivering. He reasoned that the bark also might 
stop the shivering coming from attacks of the ague (British name for malaria1). The Jesuits brought this 
information together with the bark to southern Europe, where malaria was a serious problem. The bark 
became known as the Jesuit’s powder, Peruvian bark, or quina-quina, amongst others [13-16].  
Initially, cinchona bark was met with a lot of skepticism due to religious beliefs of that time. Some 
Protestants in England called it “the powder of the devil”. Additionally, the evidence of efficacy was 
confusing. On the one hand, a number of European physicians had remarkable success in treating patients 
with cinchona bark, but there was also numerous failures. They could be attributed to a wide variety of 
cinchona species, which showed great differences in the active component (quinine) and due to lack of 
                                                            
1
 Malaria is the most important parasitic disease in human beings. It is a protozoan disease transmitted by 
Anopheles mosquitoes. Five species of the genus Plasmodium causes malarial infections in humans. The 
most characteristic symptom is fever that occurs in four-to-eight hour cycles. First, a feeling of coldness 
with shivering that lasts for up to an hour appears, then a fever that lasts for two to six hours develops, 
accompanied by severe sweating [23]. 
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 authenticity of the herbal samples. Usually, the merchants collected the bark only after the bitter taste [13, 
14].  
Later, the use of cinchona bark became firmly established throughout Europe thanks to the sustained 
therapeutic success of practitioners like Sir Robert Talbor (England, 1642 - 1681). The publication of 
books which favorably advocated cinchona for its antimalarial properties, namely “The English Remedy 
or Talbor's Wonderful Secret for Curing of Agues and Feavers” in 1686, and “Pyretologia, A Rational 
Account of the Causes and Cure of the Agues” in 1692, are both attributed to Talbor. Cinchona bark 
became one of the most valuable commodities shipped from America to Europe [13-17]. 
In 1741, Carl Linneus (Sweden, 1707-1778) established his system of botanical classification of plants 
and gave to the genus the name Cinchona, in honor of the Countess of Chinchón from Spain. Confusion 
over Spanish, Latin, and Italian orthography led to the accidental dropping of the first “h” [13, 16, 17].  
By the late 18th century, formulations were standardized and prepared in pharmacies, which during this 
time started to grow to become into pharmaceutical companies. Cinchona was more widely accepted as a 
treatment for specific intermittent fevers. However, adulteration with other herbs, quality (content of 
active principles), and availability were still an issue. Several species of cinchona trees became almost 
extinct. The desire to overcome these problems together with the curiosity regarding biological activity 
prompted the isolation of the active principles [4, 13, 14, 18, 19].   
In 1820, the French pharmacists Pierre Pelletier and Joseph Caventou isolated quinine from Cinchona 
cordifolia [2, 4] by repeating the experiments previously performed by the Portuguese surgeon 
Bernardino Gomez, who managed to isolate cinchonine in 1811 [4]. Quinine was not only more reliable, 
but also less bitter than the bark and soon became the norm in the treatment of malaria. Caventou 
established a factory for the production of quinine in the mid-1820s. This alkaloid became hence the first 
commercial pure drug substance [2, 13, 14]. The early 19th century became the first days of modern 
medicinal chemistry in which the focus was laid on the isolation of active principles from plants, mainly 
of alkaloids such as morphine, emetine, and atropine [2, 18, 19].  
There was the need to establish cinchona tree plantations to obtain plant material to isolate quinine. 
Charles Ledger, an English entrepreneur, discovered together with his servant Manuel Incra Mamani a 
variety of cinchona species with high quinine content (C. ledgeriana). The seeds were sold to the Dutch 
government in 1865. Within a short time, the Dutch plantations established in Java were producing 97% 
of the world’s supply of bark, in the 1930s about 10 million kilograms of bark per year. From the mid-19th 
century to the 1940s, quinine was the standard drug for malaria throughout the world [13, 16]. Cinchona 
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 bark is one of the historically most successful herbal remedies and illustrates the value of folk medicine 
[6].  
The total synthesis of quinine was achieved by Robert Woodward and Eggers Doering in 1944. However, 
the bark still remains the only economically practical source of quinine [13, 15].    
By the end of the 19th century, the understanding of organic synthesis and chemical structures led to the 
structure elucidation and to the synthesis of first derivatives of isolated natural products. The chemical 
structure of quinine was elucidated in 1908 (Fig. 1) [2, 4, 13]. The course of structure determination in the 
early days of the natural product chemistry was a complex, indirect process combining evidence from 
many types of experiments [1].  
 
Figure 1. Chemical Structure of Quinine 
The English chemist William Perkins failed in synthesizing quinine, but succeeded in synthesizing 
“mauveine”, the first synthetic textile dye that did not wash off in water. This sparked the development of 
a German synthetic dye industry which had a profound influence on organic chemistry and medicine [4, 
14, 20]. The German physician Paul Ehrlich (1854 - 1915) discovered the affinity of dyes for biological 
tissues. Based on these observations he postulated the existence of “chemoreceptors”. Ehrlich later argued 
that certain chemoreceptors on parasites, microorganisms, and cancer cells would be different from 
analogous structures and claimed that these differences could be exploited therapeutically. This was the 
birth of chemotherapy. During his work with dyes, Ehrlich tested the effects of methylene blue on malaria 
parasites and trypan red on trypanosomes, and he became the first scientist searching for drugs against 
parasites [16, 20, 21].  
Until the mid-20th century, most drug prototypes were derived from plants and once again, the fight 
against malaria became a good example of drug discovery during this era [4]. In World War I (1914 - 
1918), German soldiers suffered from malaria, but Germany could not access quinine sources in Java. 
Bayer, one of the leading chemistry companies, was therefore commissioned during the 1920s to find a 
synthetic alternative based on quinine as prototype. Bayer developed plasmoquine (1925), mepacrine 
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 (1932), resochin (1934), and sontochin (1936). The latter was considered as the most effective and toxic 
compound, and its production was initiated (Fig. 2) [13-15]. 
 
 
Figure 2. Some Antimalarial Derivatives Based on Quinine as a Prototype  
In World War II the Allies neither had access to sontochin, since the trade with Germany had stopped, nor 
to quinine because of the Japanese occupation of Java. Thus, the Allies had to develop new synthetic 
antimalarials. British, Australian and American scientists synthesized and screened around 16.000 
molecules. The most active and less toxic of these compounds was SN-7618. Subsequently, the 
assessment of its antimalarial properties in both animal models and humans was performed and its utility 
as a powerful antimalarial demonstrated. The compound was called chloroquine. This compound had 
previously been discovered and dropped by Germans (this became later on known as the “Resochin 
error”) [13, 14, 16, 22].  
In the 1950s and 1960s the World Health Organization (WHO) started a program for eradicating malaria. 
Chloroquine was selected as the WHO drug for a wide eradication campaign. In addition, DDT (dichloro-
diphenyltrichloroethane) was recommended by the WHO as insecticide against the mosquito Anopheles 
ssp. which transmits the parasite. This action was very successful in areas such as Sri Lanka, where the 
cases of malaria fell from 3 million in 1946 to 29 cases in 1964. Yet, the resistance of Plasmodium ssp. to 
chloroquine (and Anopheles ssp. to DDT) gradually appeared in the 1960s and spread throughout the 
endemic areas. Therefore, new antimalarial drugs were needed [13, 14, 22, 23].  
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 • History of Artemisinin 
In 1960s, the government of the People’s Republic of China embarked on a systematic examination of 
traditional remedies as sources for new drugs [7, 23]. One of the examined plants was qing hao, Artemisia 
annua L. (sweet worm-wood or annual wormwood), first mentioned in the “bencao Gangmu” nearly 
2000 years ago and many times subsequently [6, 7, 15, 23].       
In 1972, the female Chinese chemist Tu Youyou (1930-) isolated seven sesquiterpene compounds from an 
ethyl ether extract of A. annua obtained at low temperature. One of them, called qinghaosu (extract of 
qing hao), was found to bear the principal antimalarial activity. Its Western name is artemisinin [6, 7, 15].  
The structure of artemisinin was determined in 1979 (Fig. 3). In the 1970s, there were already a number 
of physicochemical, spectroscopic, and spectrometric techniques available for structure elucidation. Still 
at that time, it was a major intellectual achievement. Its structure and absolute configuration was deduced 
with the aid of tehcniques as NMR, mass spectrometry, and X-ray diffraction analysis. Artemisinin is a 
sesquiterpene lactone with an unusual feature in its chemical structure, a 1,2,4-trioxane peroxide group [6, 
7, 13].  
 
Figure 3. Chemical Structure of Artemisinin and Some Derivatives  
The antimalarial activity of artemisinin in vitro was comparable with that of chloroquine. In vivo the 
compound was assessed in rodent, avian, and monkey malarial models with positive antimalarial activity, 
and total clearance of parasitemia was achieved [13, 23].  
The toxicity of artemisinin was found to be low when tested in animal models, and no mutagenic or 
teratogenic effects were observed [7, 13].   
In 1974, large-scale clinical trials started. During the first studies in China, more than 2099 cases of 
malaria (P. vivax and P. falciparum in a ratio of about 3:1) were treated with different dosage forms of 
artemisinin, leading to the clinical cure of all patients. Additionally, 143 cases of chloroquine-resistant 
falciparum malaria and 141 cases of cerebral malaria were successfully treated [7]. In summary, 
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 artemisinin showed rapid action, low toxicity, and was effective against chloroquine-resistant P. 
falciparum [23]. 
Today, artemisinin is considered as one of the most potent and effective antimalarial drugs. Although it 
rapidly suppresses the parasitemia caused by of P. falciparum and P. vivax, the problems encountered 
with recrudescence and solubility, led to efforts to improve the natural product by modifying its chemical 
structure. The essentiality of the endoperoxide group became readily apparent when testing seven other 
sesquiterpenes isolated from A. annua which lacked this particular moiety [7, 24]. Dihydroartemisinin 
(DHA), which is obtained by reduction of artemisinin, showed better potency [7]. The two main types of 
DHA derivatives currently used in the treatment of malaria are ethers and esters (Fig. 4). The most active 
ether is artemether, and the most promising ester derivative is artesunate [7]. In general, artemisinin 
derivatives are more potent than the parent compound [23]. To avoid resistance and to overcome the 
recrudescence problem, artemisinin and its derivatives must be used in combination with other 
antimalarials [7, 13, 15, 25].   
The mechanism of action of artemisinin is not fully understood, despite advances in the biology and 
biochemistry of the Plasmodium parasite. It is known that the integrity of the endoperoxide bridge is 
necessary, but not sufficient on its own, for antimalarial activity. The most likely mode of action is the 
ion-dependent alkylation of the heme group and the malarial translationally controlled tumour protein 
(TCTP). Nevertheless, it is clear and remarkable of that artemisinin has an entirely different mode of 
action than chloroquine [13, 24, 26].  
  
R = H dehydroartemisinin (DHA)
R = CH3 artemether
R = C2H5 arteether
R = COCH2CH2CO2Na sodium artesunate
 
Figure 4. Artemisinin Derivatives  
As a result of the clinical and pharmacological research carried out during the last decades, standard 
therapy for uncomplicated falciparum malaria is an artemisinin derivative in combination with other 
antimalarial drugs (artemisinin combination therapy, ACT). In the case of severe malaria (caused by P. 
falciparum, P. knowlesi, or P. vivax), which constitutes a medical emergency, parenteral artesunate is the 
treatment of choice. ACT plays an important role in any program attempting to control malaria. The 
major problem today is to find a steady and inexpensive supply of artemisinin [13, 25, 27].       
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 From a developing world perspective, plant-derived artemisinin remains expensive. The price ranges from 
US$ 150 to 1600 per Kg of compound. If the drug was made available at an affordable cost, it could be 
used not only for the treatment of malaria, but also of other parasitic tropical diseases such as 
schistosomiasis and leishmaniasis, for which artemisinin has also shown promising activity [28]. Even 
though different synthetic routes have been reported so far, A. annua still remains the best source of 
artemisinin worldwide [6, 7, 15]. The artemisinin content varies between 0.01 and 1% (w/w) of the dry 
leaves. Consequently, the production of artemisinin is struggling to keep up with the demand. To 
overcome this shortage, several strategies for the production of the drug have been developed as follow: i) 
semi-synthesis; ii) plant cell fermentation; iii) heterologous expression of the biosynthetic pathway in 
yeast or bacteria, frequently with modification of the genes to optimize production; iv) genetically modify 
A. annua per se to increase artemisinin yield by overexpression of the farnesyl diphosphate synthase. Yet 
these efforts have not resulted in dramatic improvements [7, 15, 29].  
The discovery of artemisinin did not only contribute to a structurally novel and well-tolerated class of 
rapidly acting antimalarial agents, but also encouraged the investigation of folk medicine [7].  
The history of malaria chemotherapy is a good example of how natural product-based drug discovery has 
evolved. The process can be summarized as follows: i) identification of medicinal plants (e.g. Cinchona 
ssp. and Artemisia ssp.) used by indigenous people to treat diseases; ii) early period of random isolation 
of active principles, and subsequent determination of structure and biological activity (e.g. quinine); iii) 
further isolation and structure elucidation of compounds (facilitated by the rapid advancement in 
chromatographic and spectroscopic techniques), semisynthesis of derivatives, and elucidation of 
biosynthetic pathways in the plants (e.g. artemisinin) [1, 4, 13-15, 18, 19, 30]. 
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 2.1.2 Current Drug Discovery Process 
The process of drug discovery and development (DDD) requires between 12 – 15 years, 13.5 on average, 
and an estimated investment of US$ 1.5 billion for a single new drug [31-33]. Figure 5 provides a 
summary of the sequential steps that are necessary for a drug to progress through the DDD pipeline [34-
36].   
The initial phase of DDD is the drug discovery process, which typically involves three main stages: target 
identification and validation, hit generation, lead generation, and optimization. In the last 20 years, the 
incorporation of new technologies along these steps has evolved into a “new” concept in drug discovery. 
[35, 37]. 
 
 
Figure 5. Drug Discovery and Development Pipeline. The figure shows an overview of the DDD 
course (arrows). Drug discovery comprises the first 3 phases (peach), while the drug development phase 
consists of the 4 following steps (blue). The rectangles (upper part) describe the objectives and major 
activities performed during each one of the development phases. The registration step (green) takes place 
in the different countries or regions where the drug is to be commercialized, i.d. USA (Food and Drug 
Administration, FDA), Europe (European Medicine Agency, EMA), and Japan (Ministry of Health, 
Labor, and Welfare of Japan, MHLW). At the bottom: average time span in each phase and required 
authorizations issued by regulatory agencies along the process. IND (Investigational New Drug 
application) to conduct clinical trials in the USA, IMP (Investigational Medicinal Product dossier) in 
Europe. NDA (New Drug Application) to approve a new pharmaceutical product in the USA, MAA 
(Marketing Authorization Application) in Europe. PK (pharmacokinetics). Adapted from [34, 36, 38, 39].   
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 Identifying and validating disease-modifying targets is an essential early step in the drug discovery 
pipeline. The development of genomics, proteomics, and mouse gene knock-out models has opened the 
possibility to find a wide variety of molecular targets [33, 35, 37]. This has represented a major paradigm 
shift from older drug discovery strategies, which only utilized whole-animal physiology-based testings 
[33]. The target validation consists of confirmation of the role of the target prior to passing into the 
following drug discovery pipeline. It is accomplished by using either cellular or animal models for 
modulation of gene expression and/or protein function [40]. 
The next step is to perform a screening to find hits. A hit is an active compound which exceeds a certain 
activity threshold in a given assay [31, 41-43]. Currently there are several hit discovery techniques. Since 
approximately two decades one of the most commonly used approach is the high throughput screening 
(HTS). In the automated and miniaturized HTS formats, a large number of biochemical and cellular 
targets are exposed to a great number of small molecules [43].  
The small molecules which should be tested can be derived from many sources. Theoretically the optimal 
strategy would be to screen as many molecules as possible. However, it is the resources required that 
indicate the optimal size of the compound collection. Therefore, assessing the chemical space and 
diversity of compound collections are essential components of the solution of this problem [32, 43].  
Among this “new” drug discovery concept (HTS capability combined with a great number of molecular 
targets), it is possible to carry out a whole screening program within short time (typically around 3 
months). This new approach is potentiated with the capability to synthesize a great number of new 
molecules through combinatorial chemistry, parallel synthesis, and other techniques. Consequently, a 
considerable amount of “hits” can be identified [19, 37, 41, 44-46]. Yet, the identified hits must be 
validated by demonstrating a desirable response in different biochemical and cellular assays [32, 43].         
Once the hit has been validated, the hit-to-lead process starts. Not all biologically active compounds (hits) 
have the desired properties to become a drug. An optimized lead is a molecule with a good balance 
between potency, favorable pharmacokinetics (PK) properties, and and a good safety profile. Hence, 
during the hit-to-lead process, strategies such as bioisosteric replacement are applied to synthesize series 
of compounds with well established structure-activity relationship (SAR), wherein compounds with 
similar structures exhibit similar target binding affinities but with varying PK properties and safety 
profiles. Potency, PK, and safety of synthesized compounds are assessed in a set of in silico, in vitro, and 
in vivo tests which guide the compound selection [31, 35, 43, 47, 48].      
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 Within the drug discovery process and particularly in the PK process where ADME (absorption, 
distribution, metabolism, and excretion) properties are assessed, the concept of drug-likeness is a key tool. 
This concept is associated with properties defined by Lipinski’s “rule of five”. Nineteen percent of the 
orally available drugs have fewer than 5 hydrogen-bond donors (expressed as the sum of OHs and NHs), 
less than 10 hydrogen-bond acceptors (expressed as the sum of Ns and Os), molecular masses of less than 
500 Da, and logP values (a measurement of lipophilicity) of less than 5. Computational calculations 
predict “rule of five” properties for prospective compounds [31, 32, 41, 47, 49].  
Figure 6 illustrates the optimization process from hit-to-lead of an imidazolepiperazine intended to be 
administered orally as antimalarial. After the lead optimization, the DDD course continues to the pre-
clinical and further development phases (Fig. 5).   
 
Figure 6. Optimization of an HTS Hit to Lead for an Orally Active Antimalarial. In this example the 
Novartis natural products (NP) and natural product-like synthetic compounds library was screened. 
Compound 11, an imidazolepiperazine, was chosen as a hit due to its potency in vitro against P. 
falciparumand its favorable physicochemical and ADME properties. However, the compound showed 
some toxicity issues (hERG binding). After early optimization, a lead compound (12) was selected. Its in 
vitro potency, PK, and in vivo efficacy were improved in comparison to the hit, but the hERG binding 
was still a problem. After understanding the SAR of hERG binding and differentiation from potency, both 
safety and potency of the leadcould be improved alongside with its PK (the substitution of the benzylic 
carbon of the piperazine was a key point). As a result, an optimized lead compound was obtained (13) 
[50].   
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 So far, the above described “new” concept of drug discovery has not been as productive as expected. 
Only very few leads and developed compounds can be attributed to the new drug discovery paradigm. 
From 2003 to 2009, a total of 12 compounds originated from HTS hits were introduced into the 
pharmaceutical market [19, 32, 41, 44-46].  
• Natural Products (NPs) and Their Role in Current Drug Discovery 
There is no doubt that NPs have been historically very valuable in the drug discovery process and that 
they still constitute a successful source for new drugs [1, 30, 41, 44, 46, 48, 51].    
According to Newman and Cragg, a total of 1355 new chemical entities (NCEs) were approved between 
1981 and 2010, including vaccines, biologicals, and “small molecules” [52]. In these 30 years, NPs were 
the source of 35% of all small molecules ranging from 12% in 1997 to 50% in 2010 [52-54].  
Moreover, many semi-synthetic NPs analogs or synthetic compounds based on NPs pharmacophores have 
been obtained. Particularly, about 38 NPs-based drugs, 10 NPs, 15 semi-synthetic compounds, 12 NPs 
derivatives, and 1 synthetic congener were approved and launched in the market between 2000 and 2010. 
Fifteen were intended to treat infectious diseases, 7 to treat cancer, 7 against neurological disorders, 4 
against metabolic and cardiovascular ailments, 1 to treat diabetes, and 4 intended for other areas 
(inflammation, immunomodulation, pain, etc.) [52-55].  
Challenges   
Despite of the NPs success, many large pharmaceutical companies have reduced and cut down the use of 
natural products in the drug discovery programs. The reasons for this decreased interest range from 
commercial to scientific, but one of the main explanations is that NPs are not amenable to the aggressive 
timelines of the HTS [30, 41, 44-46, 56, 57].  
Additionally, NPs sources have some disadvantages compared to synthetic libraries concerning their 
incorporation into HTS programs: i) NPs show a higher number of false-positive results in the assays, due 
to the presence of compounds with non-specific activities, or interference with the assay read-out; ii) 
repeated isolation of the same compounds is challenging; iii) NPs may contain only very small quantities 
of a bioactive substance, often as a mixture with structurally related molecules, which requires labor-
intensive and time-consuming purification procedures; sometimes the concentration of these small 
quantities of bioactive substances may even be too low to be effectively detected; iv) NPs are often 
structurally complex (a lot of functional groups and chiral centers); these factors delay the identification 
process and contribute to problems of supply and manufacture; v) increasing complications arise in the 
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 handling of intellectual property and in the access of bio-materials as a result of the Rio Convention on 
Biological Diversity in 1992; vi) seasonal or environmental variations in the composition of living 
organisms can cause problems with initial detection of active compounds as well as subsequent repetition 
of assays or purification; the loss of source is also possible (extinction) and vii) NPs discovery has been 
perceived as old-fashioned compared to emerging technologies [30, 41, 44-46, 52, 58]. 
Opportunities  
The pharmaceutical industry is currently facing high economic pressure due to product recalls, aggressive 
generic competition, and the looming patent cliff. Due to the lack of productivity of the “new” drug 
discovery concept, there is a steady decreased number of NCEs launched into the market. For instance, 
the number of small molecules introduced per year between 1981 and 1989 was 50, in the next decade the 
number lessened to 40, and between 2001 and 2010 it was around 20 (with the exception of the years 
2002- 2005, when the figures climbed above 30). Moreover, not only less NCEs have been introduced in 
the market, but more money has been invested in discovery and development. As a result, the costs of 
bring a drug to market has increased [30, 33, 45, 52, 57, 59-61].  
Owing to these factors, the industry has refocused efforts on strategies that are most likely to yield 
sustainable products. A critical part of this refocusing includes the re-evaluation of drug discovery 
processes. This is where the NPs may play an important role again in generating novel and structurally 
unique scaffolds [30, 41, 44-46, 61].  
There is a number of characteristics that make NPs structures “privileged” to elicit a biological activity: i) 
higher chemical diversity and complexity. Even though, this is considered as an incompatibility factor 
with an HTS program, this is one of the noteworthy characteristics for both finding active compounds and 
new mechanisms of action; ii) biochemical specificity. NPs are produced by biosynthesis in living 
organisms as a result of evolutionary pressures to interact with a wide variety of proteins and other 
biological targets. This means that NPs have an imprint of biological space (protein fold topology) and 
preferentially bind to these folds. The fold space is the total repertoire of three-dimensional protein 
structures; iii) drug-like properties. NPs show compliance with Lipinski’s type descriptors in 
approximately 90% [41, 45, 46, 51, 57, 58].      
In addition to the priviledged structure of NPs, still much of the nature remains to be explored as source 
of novel active agents [52]. For instance, fewer than 1% of microbial species are culturable, and fewer 
than 12% of higher plants species have been examined for bioactivity [62]. Certain insects and other 
animals have been targeted for specific bioactivities, such as toxins, but are not generally subjected to 
28
 HTS efforts. Clearly, the biological resource is there, but access and examination is problematic, 
especially if there is pressure because of a short time frame for discovery of new compounds [57].  
However, this renewed interest on NPs can only be sustained if NPs research can be competitive with 
other drug discovery techniques. Key factors to achieve this competitiveness include uninterrupted 
technological improvements in the NPs-based lead discovery, such as speed of dereplication, isolation, 
structure elucidation, and compound supply processes. Some of these approaches will be discussed in the 
next subchapter [30, 45].    
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 2.1.3 Current State of NP Discovery 
In the classical approach for NPs isolation, the process of “bioassay-guided fractionation” starts when a 
extract, obtained from terrestrial plants, marine organisms, microorganisms, and/or animals, shows a 
positive response in a screening. Then, it is necessary to isolate the pharmacologically active pure 
constituent from the total extract. However, extracts are complex matrices that require a long process, 
substantial material amount and financial resources [1, 42].  
The original crude material (large amounts) is split into fractions which are tested in biological assays to 
track the active compounds. Typically, liquid-liquid partitioning between immiscible phases and 
consecutive chromatographic separations in open column chromatography (normal phase) are performed. 
Subsequent steps are generally of higher resolution by using RP-HPLC. The separation performance in 
these initial fractionation steps is poor and very often the activity is lost in the course of the isolation. 
Furthermore, the compounds’ structures are disclosed only at the end of the whole elaborated and 
resource-consuming process. This can turn out in disappointment if the isolated compounds are already 
known structure. Therefore, the approach described above does not match the timelines and the workflow 
of modern drug discovery [30, 42, 58].  
However, technological advances in instrumentation, robotics, and bioassay miniaturization have 
increased the speed of bioassay-guided isolation and structure elucidation of NPs considerably, and these 
improvements have allowed NPs research to be more competitive with synthetic compounds screening 
and HTS. Some of the most important advances in this field are discussed below [30, 45]. 
• Libraries  
Ideally, NPs screening libraries would consist of pure compounds in order to obviate confounding 
responses derived from mixtures, and to avoid the lag time required to deconvolute a mixture for the 
identification of the active component [61]. Libraries of pure compounds, present in known amounts, are 
screen-friendly and accommodate the desire for short timelines in examination of a large number of 
molecules. These libraries combine one of the strengths of HTS with the concept of chemical diversity 
[32, 57].  
Additionally, with a NPs compound library it is possible to create a target-oriented or focused-library 
approach which seeks to elaborate structural modifications onto an existing bioactive NP scaffold in a 
parallel, systematic fashion to improve the compound’s inherent biological activity or drug-like 
properties. This can be performed either by semi-synthetic modification of the parent molecules, or by 
fully synthetic methods [41, 45]. 
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 However, assembling a highly diverse library of NPs for screening is a major endeavor because, the 
commercial availability of pure NPs remains quite limited. An alternative can be pre-fractionated NPs 
libraries, which combine the benefits of incorporating much greater chemical diversity with reasonable 
consistent biological readouts. Simplified mixtures resulting from pre-fractionation expedite the 
downstream processes of dereplication and of compound purification and therefore reduce the lag time. 
Pre-fractionation schemes aim to include the bulk of constituents, rather than only including major 
components or “peaks” hence the opportunity to discover novel compounds is preserved [30, 42, 61]. 
Some approaches go beyond and propose to create libraries of initial optimized extracts to lead-like and 
drug-like space with a particular emphasis on logP, one of the most important physicochemical 
parameters, followed by fractionation to afford a HTS-friendly NP screening library [51].   
• High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) is one of the most powerful tools in chemistry, with 
the ability to separate, identify, and quantitate the compounds present in any sample that can be dissolved 
in a liquid. HPLC can separate water-soluble, thermally-labile, non-volatile compounds with speed, 
precision, and high resolution. HPLC is used routinely in phytochemistry both in analytical and 
preparative scale [63].  
In recent years, a wide variety of stationary and mobile phases have been developed to give a large 
potential of different kinds of separations. Most common used stationary phases are reverse phase (RP), 
based on octadecyl (RP-18) and octyl (RP-8) materials with particle diameter around 5 µm. Current 
reverse-phases are highly selective, offer high separation power, robustness, stability, and efficiency. The 
introduction of spherical particles has led to a reduction in the size of the particles and the length of the 
columns, from 25 cm (8000-10000 plates/m) to around 10 cm, with the same number of plates/m. In ultra 
high-performance liquid chromatography (UHPLC), particle sizes of around 1.7 µm are used. Other 
modified phases such as cyano, phenyl, trimethylsilane, triazole, secondary and tertiary amines are 
available. Typically, the mobile phases are combinations of water and either methanol or acetonitrile [63, 
64].  
When HPLC is applied to analytical work, the goal is to get information about the sample. The most 
important parameters are resolution, sensitivity and fast analysis time. In preparative HPLC, larger 
columns and larger quantities of packing materials are needed. The aim here is to isolate and/or purify 
compounds, and the most important parameters in this kind of chromatography are the degree of solute 
purity, the throughput, measured as the amount of compound produced per unit time, and the load 
capacity [63].   
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 The potential of HPLC has been boosted by coupling the LC part with different detectors such as 
UV/DAD (HPLC-UV), MS (HPLC-MS), MS/MS (HPLC-MS/MS), ELSD (HPLC-ELSD), NMR (HPLC-
NMR) and circular dichroism (CD) (HPLC-CD). This hyphenation of HPLC with spectroscopic methods 
has led to new strategies that permit i) to authenticate botanical samples by creating fingerprints; ii) to 
obtain complete spectroscopic characterization of present compounds to differentiate between known and 
unknown compounds; iii) to determine the structure of unknown plant metabolites directly without 
previous isolation and minimum amounts of material iv) to establish the absolute configuration of the new 
compounds by measuring their CD spectra. Most of these applications are useful in analytical work, but 
also for preparative separations, the introduction of HPLC-MS has enhanced the range of application [58, 
63-65].   
• LC-MS 
Mass spectrometry is one of the most sensitive analytical methods which provides information about the 
structure of analytes and about their molecular weight. This technique has had a dramatic and rapid 
advance in recent years. An LC-MS system includes the HPLC system, the ionization source (which 
interfaces the LC to the MS), and the mass spectrometer [1, 63, 66].  
Their most common ionization sources are electrospray ionization (ESI) and atmospheric pressure 
chemical ionization (APCI). Both ESI and APCI ionization occurs at atmospheric presure, hence these 
sources are referred to as atmospheric pressure ionization (API) sources. In ESI, the high voltage field (3-
5 kV) causes about nebulization of the column eluents resulting in charged droplets that are directed 
toward the mass analyzer. Ions are then released from the charged droplets by direct ion emission (a 
process called “ion-evaporation”), and are finally separated according to their mass/charge ratio in the 
mass spectrometer. In APCI, heat is applied to vaporize the column eluents, and then a corona discharge 
ionizes the solvent molecules, which results in the formation of analyte ions via chemical ionization [63, 
66].    
The most frequently used mass spectrometer for HPLC-MS is the single quadrupole, which provides a 
mass spectrum for each chromatographic peak that elutes from the LC column. Another type of 
spectrometer used in NPs research is the time-of-flight (TOF), which provides a high resolution spectrum 
for each analyzed component [66]. 
• Dereplication  
Dereplication is the process of identifying known compounds that are responsible for the activity of an 
extract before bioassay-guided isolation begins. This process is used to eliminate, group, and/or prioritize 
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 extracts for further studies, and it can save considerable research time. The chemical and biological 
characteristics of the unknown compounds are compared with the chemical and biological characteristics 
of known compounds from the data-bases to eliminate those that have been isolated previously [41, 45, 
46, 58, 67]. 
The procedure involves separation of an extract using RP-HPLC and splitting of the eluent post column 
into a fraction collector using microtiter plates and in a mass spectrometer for analytical purposes. The 
collected fractions in the microtiter plates are dried, redisolved in an appropriate solvent, typically 
DMSO, and assayed. The retention times, UV spectra, MS data, and activity of the fractions are analysed, 
and commercial and in-house databases are used for comparison. Databases such as the Dictionary of 
Natural Products contain chemotaxonomic, pharmacological, and molecular weight information. This 
approach constitutes an off-line HPLC-based activity profiling. Other setups are fully integrated on-line 
approaches, where HPLC fractionation is coupled directly to biochemical assays, such as on-flow post-
column bioassays and at-line settings. However, the off-line format is highly versatile because it can be 
applied to different kinds of bioassays after adaption of the fractionation protocol to the required 
sensitivity of the assay [30, 45, 58]. Some examples of the off-line approach include the HPLC-based 
activity profiling for the identification of NPs with GABAA receptor modulating activities [68] and for 
NPs with antiprotozoal activities [69]. The off-line approach has been used with numerous other targets, 
such as, for inhibitors of the DYRK1A kinase, a target implicated in neurodegenerative diseases [70], or 
for anti-HIV inhibitors [71]. 
Tracking bioactivity in extracts, which are complex matrices, remains a highly challenging task. But 
HPLC-based activity profiling allow not only to dereplicate known active compounds, but also to carry 
out a target preparative isolation of the active principles present in the active fraction [58, 67]. 
• Structure Elucidation 
With the advances in X-ray crystallographic, NMR, chiroptical, and mass spectrometric techniques, 
structure determinations for NPs has become quite routine [1, 72]. 
NMR 
Introduction of nuclear magnetic resonance (NMR) spectroscopy into organic chemistry has changed the 
way of structure determination. Fifty years ago, NPs structure elucidation was an extremely difficult and 
lengthy task which required carrying out several synthetic steps and degradation reactions. The thereby 
obtained data was combined to eventually allow the determination of the structure. However, even total 
chemical synthesis of compounds of interest was needed to corroborate the proposed structures. By the 
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 1950s, the development of commercial IR and UV/VIS spectrometers allowed NPs chemists to use these 
techniques for functional group characterization. Following the discovery of the NMR phenomenon, its 
potential was early recognized and its application for the identification of organic compounds started. In 
1950, NMR spectrometers required a skilled operator. However, with the introduction of user-friendly 
NMR spectrometers since the 1960s, the potential of this technique has become more accessible for the 
scientific community and over the time, the improvements in the commercial instrumentation have 
revolutionized NPs structure elucidation [1, 72, 73].  
The NMR sensitivity has considerably improved. In 1960, a signal to noise (S/N) ratio of 10:1 on a 1.0% 
sample was obtained. With today’s spectrometers, the S/N ratio is 10.000:1 on a 0.1% sample prepared in 
the same solvent. This improvement was achiveed by the introduction of: i) higher field spectrometers 
using superconducting solenoids; ii) progress in pulsed-field gradients (PEGs). Sensitivity itself is not the 
only determinant for spectral quality, the level of noise is another important factor. Any instability of the 
NMR system, fluctuations of the field-frequency-regulation circuit (the “lock”) and fluctuations in room 
temperature or magnetic disturbances may introduce noise. When PEGs are used in experiments, only the 
desired coherences enter into the receiver, and the effects of short-term fluctuations interfere in a lesser 
extent; iii) probeheads with superior sensitivity. Cryogenically cooled probes (so-called “cryoprobes”): 
upon cooling the radio-frequency coil to a temperature of ca. 20 K, thermal noise is dramatically lowered, 
resulting in S/N ratios generally 3 or 4 times higher than for a conventional probe heads. All these 
advances provide sufficient sensitivity to record full sets of 2D data within a few hours and with sub-
milligrams amounts of sample [72, 73].   
Other important improvements were the introduction of Fourier-transformation, allowing more rapid 
acquisition of spectra and the development of multiple pulse sequences. Two-dimensional (2D) pulse 
sequences used for structure elucidation, including COSY (1H-1H correlation), HETCOR (1-bond 1H-13C 
correlations), and NOESY (1H-1H nuclear Overhouser enhancement spectroscopy), among others. 
Another technological improvement for the application of NMR to NPs analysis is the hyphenation with 
HPLC. The objective is to create an interface able to deliver the HPLC fractions/pure compounds to the 
NMR coil. Flow NMR methods has been developed for this purpose. The HPLC fraction is transferred 
via capillaries into a flow NMR probe. A modification of this technique is the so-called “stopped –flow 
NMR”, and the “loop storage”. All these flow NMR methods have two main drawbacks. Firstly, due to 
the significantly lower sensitivity of NMR compared to MS, it is possible to obtain only a 1H NMR 
spectrum in the limited time that the sample is present in the coil region of the flow cell. Secondly, 
deuterated solvents have to be used or alternative, multiple solvent peak suppression must be carried out. 
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 The most successful approach, so far implemented, is the use of solid phase extraction (SPE) cartridges in 
combination with LC. By establishing such procedures, multiple injections can be done to build up 
amounts of isolated samples and the problem with the solvents is eliminated by evaporating the 
protonated solvents from the cartridges and eluting off the cartridges with deuterated solvents [72, 73]. 
The most widely used strategy, to determine the skeletal structures of NPs is combining 1H-1H 
correlations spectra (COSY or TOCSY) with one-bond 13C-1H correlations (HSQC and HMBC) to attach 
together the fragments. However, the actual pulse sequences used to obtain the data have been improved 
significantly, and additional methods to supplement these techniques has been developed [72, 73]. 
Previous determination of the molecular formula is very important to support the information deduced 
from the NMR analysis. Once the skeletal structure of the compound has been determined, the three-
dimensional structure must be established. Again NMR information can be useful for doing this. The 
vicinal 1H-1H and germinal and vicinal 13C-1H coupling constants can be used to determine the dihedral 
angle, alongside with the 2D NOESY and/or ROESY, which constitute powerful methods for indentifying 
pairs of protons which are spatially close, even if separated by a large number of bonds [72, 73]. 
However, to assign the absolute configuration (AC) in an unequivocal way, chiroptical, X-ray 
christallographic, enzymatic or chiral derivatization methods must be applied [74].  
Absolute Configuration 
Most NPs and biologically active compounds are chiral and their biological functions are related to their 
chirality, i.e. their AC. Therefore, the determination of the AC of chiral compounds is critical for the 
studies of NPs. One of the most sensitive and versatile methods for this purpose is electronic circular 
dichroism (ECD) spectroscopy, because two enantiomers are unambiguously characterized by their fully 
opposite CD spectra. In the case of NPs, ECD is the most common approach for AC determination and 
nowadays, it is even possible to apply hyphenation of CD measurements with HPLC techniques. From the 
CD spectra, whether taken online or offline, the AC of the respective steroisomer can easily be 
determined by i) comparison of the CD spectrum with experimental data from structurally related 
compounds of known absolute configuration; ii) if the structure fits into semiempirical CD rules, e.g., the 
octant rule; iii) for novel-type structures, the most efficient alternative for the interpretation of CD spectra 
is the quantum chemical calculation simulation of the curve for both enantiomers, and their comparison 
with the experimental ones [65, 75].  
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 2.2 Drug Discovery for Neglected Tropical Diseases (NTD) 
2.2.1 Neglected Tropical Diseases  
Today, there are 17 parasitic and bacterial infections classified by the WHO as neglected tropical diseases 
(NTD). These diseases are a substantial health and economic burden in Africa, Asia, and Latin America 
and cause about 534000 deaths every year. Among them we have Chagas disease, human African 
Trypanosomiasis (HAT), and leishmaniasis. NTD share common features such as: i) they constitute a 
proxy for poverty and disadvantage, ii) they affect populations with low visibility and little political 
voice, iii) their distribution is restricted to the tropics due to allocation of the vectors and their reservoirs, 
iv) they cause disfigurement and disability leading to social discrimination, v) they can be controlled, 
prevented, and potentially eliminated by using appropriate chemotherapy and preventive actions such as 
vector control, good hygiene practices, and personal preventive measures [1, 2].  
Malaria was once considered as a NTD, but since 2000, a lot of progress has been made in fighting the 
disease. In doing so, a reduction of about 45% in mortality rates could be achieved. However, the political 
commitment and international community awareness must be sustained to avoid losing the progress so far 
obtained. The burden of malaria is still devastating and the need for drug discovery and development of 
new antimalarial drugs is urgent [3-7]. In the context of the present work, malaria will be addressed 
among the NTD. General information about the above mentioned NTD is shown in Table 1. 
• Malaria 
Malaria has caused greater suffering and mortality over the course of human history than perhaps any 
other disease. Nowadays, malaria is still the most important parasitic disease of humankind. In 2012, 
there was an estimated of 62700 deaths, mostly of children under 5 years of age in Africa. This implies 
that 1300 young lives are lost to malaria every day [3, 8].  
The life cycle of Plasmodium parasites has two stages. The asexual stage develops in humans (or in 
tetrapod vertebrates, such as mammals, birds, reptiles), and the sexual stage evolves (or develops) in 
mosquito vectors (Anopheles spp.). The mosquito inoculates sporozoitos into the human body, while 
having a blood meal. Sporozoites are motile cells that target the human liver and invade hepatocytes, 
where they proliferate quickly [8].  
After about one week, the developed schizonts burst in the liver, and thousands of merozoites are released 
into the human blood stream. The merozoites invade red blood cells, and the asexual reproduction begins. 
The intraerythrocytic cycle has three stages, ring, trophozoite, and schizont. Some parasites develop into 
gametocytes (the sexual forms), which can be transmitted back to anopheline mosquitos, where the sexual 
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 reproduction starts. Firstly, an ookinete is formed, which develops into an oocyst and finally evolves into 
sporozoites [4, 8].   
Table 1. Neglected Tropical Diseases [1, 8-13] 
 Malaria HAT Chagas disease Leishmaniasis 
Causative agent 
Plasmodium 
falciparum, vivax, 
malarie, ovale, and 
knowlesi 
Tripanosoma 
brucei rhodesiene, 
T. b. gambiense 
Tripanosoma cruzi Leishmania spp. (~21 species) 
Vector Anopheles spp.  
Glossina spp.  
(tsetse fly) 
Triatomine spp. 
Triatoma spp.  
Panstrongylus spp  
(Kissing bug) 
Phlebotomus spp, 
Lutzomya spp. 
(sandflies) 
Geographic 
distribution World-wide 
Sub-saharan 
Africa (countries 
~21) 
South and Central 
America (18 
countries) 
South and Central 
America, Europe, 
Africa, Asia (88 
endemic countries) 
DALYs 55 413.529 1 345.594 499067 3 754.202 
Deaths in 2011 589218 19026 7356 53675 
Estimated cases 219 million cases 50000-70000 cases 7-8 million people infected 
30000 cases of 
visceral form/  
5 million cases in 
total 
DALYs: Disability-adjusted life years 
In endemic areas, malaria is often the most common cause of fever. The first symptoms of malaria are 
nonspecific, and include a vague absence of wellbeing, headache, fatigue, and abdominal discomfort, 
among others. Most patients with uncomplicated malaria have fever, mild anemia, and after several days a 
palpable spleen. Manifestations of severe falciparum malaria are anemia, hypoglycemia, acute pulmonary 
edema, acute kidney injury, coma in the case of cerebral malaria, and acidosis [8].  
Malaria was mainly treated with chloroquine until the 1960s (Fig. 2). But resistance of the parasites to 
this drug appeared and spread around the world. Currently, sodium artesunate (Fig. 4) is the treatment of 
choice for severe malaria worldwide (including falciparum, vivax, and knowlesi malaria), due to its 
effectiveness against cerebral malaria. In uncomplicated falciparum malaria cases, artemisinin 
combination treatment (ACT) (artemether-lumefantrine, artesunate-mefloquine, and dihydroartemisinin-
piperaquine) is the recommended fist-line therapy in all endemic areas. This therapy is also highly 
effective against other human malarias. In the chloroquine-sensitive strains of P. vivax, P. malariae, P. 
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 ovale, and P. knowlesi, chloroquine is still being used. But emerging resistance to ACT can make malaria 
resurge [14].  
• Human African Trypanosomiasis (HAT)/ sleeping sickness 
Human African Trypanosomiasis (HAT) is caused by the protozoa Trypanosoma spp. The life cycle of 
African trypanosomes begins in the disease vectors, which are the tsetse flies (Glossina spp.) and various 
mammals. HAT exists in two forms, depending on the subspecies of Trypanosoma involved. T. b. 
gambiense infection is characterized by a chronic progressive course of around 3 years and is endemic in 
24 countries of western and central Africa. This infection is responsible for more than 98% of reported 
cases of HAT. In contrast, T. b. rhodesiense causes an acute form of the disease, and death can occur 
within weeks or months. This type of HAT is endemic in 13 countries of eastern and southern Africa and 
represents less than 2% of the cases. HAT is characterized by two stages. In the first stage, the parasites 
are in the blood and produce symptoms such as intermitent fever, headache, and pruritus. In the second 
stage, parasites are able to cross the blood-brain barrier (BBB), which causes clinical manifestations such 
as sleep disturbances and neuro-psychiatric disorders [1, 9, 15-17].        
Currently there are five drugs used for the treatment of HAT, namely pentamidine, suramin, melarsoprol, 
nifurtimox, and eflornithine (Fig. 7). Pentamidine and suramin are used to treat first stage HAT caused by 
T. b. gambiense and T. b. rhodesiense, respectively. Eflornithine and melarsoprol are applied in the 
second stage of the disease. Regrettably, all used drugs show problems such as (i) lack of oral 
bioavailability (all compounds must be administered by parenteral route) and lack of chemical stability 
(suramin rapidly decomposes in air), (ii) complicated and long dose regimens (suramin administration can 
last up to 30 days) and short half-life (four infusions of eflornithine per day are necessary), and (iii) 
deadly adverse drug reactions (pentamidine is nephrotoxic, melarsoprol causes a fatal encephalopathy in 
10% of the treated patients) [15, 18, 19]. In 2009, a new combination therapy including nifurtimox and 
eflornithine was released into the market for second stage treatment of HAT caused by T. b. gambiense. 
This treatment shows large advantages over the eflornithine monotherapy since it is easier to administer, 
reduces the amount of drug required to reach therapeutic effects and requires a significantly shorter 
hospital stay [13, 17, 19, 20]. 
• Chagas disease (American trypanosomiasis) 
Chagas disease is a life-long infection caused by the protozoa parasite Trypanosoma cruzi. This pathogen 
was first described in 1909 by Carlos Chagas and has a life cycle with four developmental stages, two of 
them (epimastigotes and trypomastigotes) in the vector (kissing bug), and two of them in mammalian 
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 hosts (amastigotes and bloodstream trypomastigotes). The kissing bug transmits the parasites to 
mammals, where the host cells are located in the heart, gut, CNS, smooth muscle, and adipose tissue. 
Clinically the disease is characterized by three phases: acute phase (4-8 weeks), indeterminate phase (10-
20 years), and chronic phase. The severity of the disease depends on the parasite load, strain, and on 
patient immune responses. An estimated 30% of infected individuals develop the chronic form, which 
may be cardiac (arrhythmias, congestive heart failure, cardiac enlargement, thromboembolism, and 
sudden cardiac death), digestive (enlargement of esophagus and colon), or combined cardiac and 
digestive, which affects up to 10% of patients [1, 10].      
Only two drugs are available for the therapeutic use against T. cruzi in humans: nifurtimox and 
benznidazole (Fig. 7). Both compounds are nitroheterocycles and act as prodrugs. The nitro group is 
responsible for the toxicity in the parasite, most likely via DNA damage [10]. Both drugs show variable 
efficacy in different T. cruzi strains and cause various side effects which result in treatment 
discontinuation. In general, benznidazole is the first-choice treatment because it is better tolerated. 
However, treatment failures are frequently reported [1, 10, 13, 21].   
• Leishmaniasis 
There are more than 21 species of Leishmania spp. The parasites’ life cycle includes different stages and 
hosts. The promastigotes are present in sandflies (vector), the amastigotes are present in mammalian 
macrophages. There are three different types of manifestations of the disease: i) The cutaneous 
leishmaniasis (CL) is the most common form. Parasites are restricted to the skin and cause ulcers on the 
face, arms, and legs, which leads to disability and permanently disfiguring scars; ii) the mucocutaneous 
leishmaniasis (ML) is the most disfiguring form because the parasites destroy the soft tissues of nose, 
mouth, and throat; iii) the visceral leishmaniasis (VL), also called kala azar, is a systemic and the most 
severe form. If left untreated, the disease is fatal within 2 years. VL causes fever, weight loss, swelling of 
the spleen and liver, and pancytopenia. Additionally, some cases of VL may evolve to CL. 
Pentavalent antimonials, sodium stibogluconate, and meglumine antimoniate have been used to treat the 
disease. But resistance has appeared in India, the treatments are long (28 days), and parenteral 
administration is required. In India, the first line of treatment of VL is amphotericin B. A recently 
developed liposomal formulation of amphotericin B (AmBisome) is highly effective, but very expensive. 
Paromomycin (aminoglycoside) is also effective against VL and VC and shows less adverse effects than 
amphotericin B. Miltefosine, the first oral treatment of VL, has markedly improved leishmaniasis 
chemotherapy, but its use is limited due to teratogenicity and high costs (Fig. 7) [1, 9, 10, 13, 19].  
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Figure 7. Drugs Currently Used for Treatment of HAT (A), Chagas Disease (B), and Leishmaniasis 
(C)   
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 Available drugs for the treatment of NTD (Fig. 2, 4, and 7) are far from optimal, have shortcomings such 
as limited efficacy, severe side effects, poor patient compliance, and/or resistance [10, 22, 23]. 
Accordingly, new drugs are urgently needed. In general, requirements for an ideal drug intended to treat 
NTD are: sufficient effectiveness, safety, oral administration, short-course treatments, low-costs, stability 
of the drug in climatic zone IV for at least 3 years, suitability of the drug for children and for pregnant 
women. There are specific requirements depending on the disease such as activity against the different 
stages of the disease (HAT) or against a particular species (P. vivax) [4, 9, 13, 22, 24-26].       
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 2.2.2 Drug Discovery for NTD 
Drug discovery and development for parasitic diseases has little commercial incentives for the 
pharmaceutical industry. Sales are limited by the short duration of the treatment with antiparasitics 
compared to other drugs, which are consumed daily for prolonged periods (e.g. cholesterol-lowering and 
antihypertensive drugs). Nonetheless, development costs are similar for both antiparasitic and “long-
term” drugs. Additionally, NTD are prevalent in the developing world and affect low-income people. 
Thus the deficit of new drugs entering development stage for tropical diseases results mainly from the gap 
between basic scientific research (early drug discovery), which is usually publicly funded, and clinical 
development, which is funded by pharmaceutical companies [1, 24, 27].  
After this problem had been identified at the beginning of the last decade, a new collaborative mindset 
was created to produce a sustainable pipeline of new drug candidates to enter development. A new model 
for drug discovery based on networks and public-private partnerships was implemented. In this context, 
researchers, institutes, and pharmaceutical industry work in a coordinated effort using open innovation 
approach to discover and develop drugs to treat tropical neglected diseases. A number of non-profit 
organizations such as the Bill and Melinda Gates Foundation have supported this initiative. Examples of 
public-private partnerships and networks are “Medicines for Malaria Venture” (MMV) and “Drugs for 
Neglected Diseases initiative” (DNDi). Overall, the objective was to create a sustainable and scalable 
model of drug innovation for NTD with a collaborative work of industry, governments, and non-profit 
organizations. As a result of those joint efforts, it has been a renaissance of DDD in NTD during the last 
decade. Nevertheless, there are still major gaps and so far, these initiatives have brought to market only 
new formulations and combinations of already existing drugs. However, there is a series of compounds in 
the drug discovery pipeline [5, 7, 13, 23, 24, 28-30].  
• Compounds in Drug Discovery and Development Pipeline Against NTD 
Current projects of DNDi and MMV are listed in Table 2 and are shortly commented. 
BCX4945 
Plasmodium parasites are purine auxotrophs and require preformed purine bases for the synthesis of 
nucleotides, cofactors, and nucleic acids. Purine salvage in P. falciparum uses hypoxanthine, which is 
converted into inosine monophosphate, a precursor for all required purines. The purine nucleoside 
phosphorylase (PNP) is essential for the formation of hypoxanthine, making PNP a target for the purine 
salvage pathway. Blocking PNP kills parasites by purine starvation. BCX4945 (Fig. 8) causes depletion 
of hypoxanthine from Aotus blood (monkey model of falciparum malaria), demonstrating inhibition of 
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 both hPNP and PfPNP in vivo. The efficacy, oral availability, chemical stability, unique mechanism of 
action, and low toxicity of BCX4945 demonstrate a potential for the development of combination 
therapies [31]. Currently this compound is undergoing preclinical studies [29].  
Table 2. Some Projects of the Global Portafolio of DDD and MMV Pipeline [13, 32, 33] 
Disease Drug discovery 
Development 
Implementation 
Pre-clinical Phase I Phase IIa Phase IIb/III 
Malaria 
Oxaboroles 
Imidazol 
BCX4945 
SAR116242 
PA1103/SAR116242 
DHODH OZ-439 OZ-277 
Artesunate-
amodiaquine 
 
HAT 
Nitroimidazole 
Oxaborole 
 
SCYX-
7158 
(Oxaborale) 
 Fexinidazole Nifurtimox-Elfornithine 
Chagas Nitroimidazole 
Fenarimol series 
K777 
Tak-187 Azoles (E1224)  
Benznidazole 
Pediatric  
Leishmania Nitroimidazole 
VL-2098 
Fenarimol series 
 
 
Fexinidazole 
(VL) 
Anfoleish 
(CL) 
 
Sodium 
stibogluconate 
& paramomycin 
  
OZ-277 and OZ-439 
Artemisinin and its semi-synthetic derivatives are sesquiterpene lactones which bear an endoperoxide 
bridge. It is thought that the endoperoxide opens by reduction to alkylate the heme. However, artemisinin 
has a very short half-life. As a result, new fully synthetic peroxides with better pharmacokinetics have 
been synthesized. Arterolane (OZ-277) (Fig. 8) was assessed in clinical trials to treat uncomplicated 
falciparum malaria. Arterolane showed a rapid action, effectiveness, and safety in Phase II of clinical 
trials. These results prompted a phase III clinical trial to evaluate the drug in a combination therapy with 
piperaquine phosphate. As a result of these studies, arterolane was recently registered by Ranbaxy 
Laboratories Ltd. in India to treat acute uncomplicated malaria [28, 34, 35]. Another ozonide, OZ439 
(Fig. 8), showed a remarkable efficacy, cured P. berghei infected mice with a single oral dose of 20 
mg/Kg, and had a prolonged plasma exposure in animals and humans. It is currently in Phase II, showing 
good efficacy in the treatment of both P. falciparum and P. vivax patients. Due to its PK properties, this 
compound can potentially reach the goal of a single-dose oral cure [28].   
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Figure 8. Some Compounds in the DDD Pipeline against Malaria, Trypanosomiasis, Leishmania, 
and Chagas disease 
PA1103/SAR116242 
Trioxaquines are hybrid (or chimeric) molecules which target the free heme. These molecules combine 
two active pharmacophores: a trioxane motif, thought to alkylate the heme and/or the proteins of the 
Plasmodium parasite, and an aminoquinoline moiety to facilitate accumulation in the parasite and 
interaction with free heme. PA1103/SAR116242 (Fig. 8) is highly active in vitro on P. falciparum strains 
at nanomolar concentrations, is also active on multidrug-resistant strains obtained from fresh patient 
isolates, and is active in the Pf-HuMouse models. These promising results combined with a good drug 
profile (preliminary absorption, metabolism, and safety) have led to further development. Currently, 
PA1103/SAR116242 is in preclinical stage [36, 37]. 
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DSM265 
DHODH has emerged as the best validated new target for the development of novel antimalarials. 
DHODH catalyzes the fourth step in the de novo pyrimidine biosynthetic pathway. The malaria parasite is 
uniquely vulnerable to inhibition of this pathway because it lacks the salvage enzymes that serve as an 
additional source of pyrimidine nucleosides in other organisms, including the human host. DSM265 (Fig. 
8) is a potent and selective inhibitor of DHODH and is able to kill both drug-sensitive and drug-resistant 
strains of the parasite. The compound is currently in Phase I of clinical trials due to its good antimalarial 
activity, easy synthetic route, and good results in rodent PK studies [38]. 
Spiroindolones 
Spiroindolones were found to inhibit P. falciparum in vitro with IC50 values around 1 nM. The optimized 
candidate NITD609 seems to have a different mechanism of action, cured mice infected with P. berghei, 
and showed PK profiles compatible with one-daily oral dosing. The compound has reached clinical Phase 
IIa [28, 39].  
Fexinidazole 
Fexinidazole (Fig. 8) is a nitroimidazole active against drug-resistant and drug-sensitive T. brucei spp. 
The compound also cured mice infected with T. b. rhodesiense and T. b. gambiense, and is able to cross 
the blood-brain barrier (BBB). Fexinidazole already went successfully through Phase I and currently is 
under clinical evaluation in Phase IIb/III [13, 28].  
SCYX-7158 
The oxaborol SCYX-7158 is a boro-containing molecule (Fig. 8) active in vitro against both T. b. 
rhodesiense and T. b. gambiense. The compound displays an excellent physicochemical profile, showed 
good efficacy in mice against stage 1 and 2 of the disease, is characterized by in vitro metabolic stability, 
low potential for CYP450 inhibition, lack of active efflux by the P-glycoprotein transporter, and high 
permeability. SCYX-7158 is currently in Phase I of clinical trials [13, 40].  
K777 
K777 is a vinyl sulfona (Fig. 8) compound which inhibits the cystein protease inhibitor cruzain in an 
irreversible way. Cruzain is a key protease required for the viability of T. cruzi. K777 was effective in 
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 acute and chronic Chagas disease models. The compound is currently in pre-clinical phase and in vivo 
pharmacokinetic studies are in process, [13, 32, 41].  
VL-2098 
VL-2098 is a nitroimidazole with a very potent activity in vitro against a panel of L. donovani strains. In 
vivo, it is also active in rodent and hamster models with similar potency to miltefosine. Currently the 
compound is in pre-clinical stage of development [13].  
Fenarimol 
Fenarimol (Fig. 8) inhibited the proliferation of Leishmania spp promastigotes and amastigotes in vitro 
and ameliorated lesions caused by the parasites in mice. Biochemical studies demonstrated that fenarimol 
inhibited sterol biosynthesis by impairing the function of leishmania 14α-sterol demethylase, a key 
enzyme in the sterol biosynthetic pathway. Currently, this compound is in pre-clinical evaluation [13, 42].   
• Screening for Neglected Tropical Diseases (NTD) 
There are two opposing yet complementary screening strategies, namely the target-based and the 
phenotypic approach (whole organism screening). Both strategies have advantages and disadvantages. 
However, in the case of antiparasitic drugs, the whole organism screening has a successful historical base. 
The advantages of this approach are: i) initial chosen hits are cell-permeable and are devoid of efflux 
issues; ii) provide the opportunity to discover a new target and a potential new mechanism of action; iii) 
many of the antiprotozoal drugs used today exert their activity through the simultaneous inhibition of 
multiple targets within a host [4, 23, 43, 44, 45]. Furthermore, NPs are ideally suited for phenotypic 
screening because they are nature’s fully developed small molecules effectors [45]. 
The target-based approaches have been extensively used in the pharmaceutical industry. However, there 
are relatively few validated drug targets across the infectious diseases. The target is the key to success in 
target-based drug discovery. The biology of the pathogens responsible for NTD is very complex and still 
a lot of research is needed. Nevertheless, the greatest advantage of this approach in NTD is that many 
proteins and enzymes in the parasite differ from their mammalian counterparts, which enhances the 
specificity of the drugs [4, 21, 43, 46]. In Table 3, some of the targets are listed.  
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Table 3. Examples of Molecular Targets for Drug Discovery  
Disease Molecular target Examples Ref.  
Malaria 
Dihydrofolate reductase 
Dihydropteroate synthase (DPR) 
Pyrimetamine,  
DPR inhibitor 
[43] 
Mitocondrial bc1 complex 
Dihydroorotate dehydrogenase (DHODH) 
Atavaquone  [38, 43] 
Pathway from DOXP to IPP   - [4] 
Nutrient channels (parasite-encoded nutrient 
uptake channels in erythrocyte membranes) 
 [4] 
AMA1 (apical membrane antigen 1)  [4] 
HAT 
N-Myristoyltransferase   [17, 43] 
Trypanothione synthetase (TryS)  [17, 18, 43, 47] 
Ornithine decarboxylase (ODC) Eflornithine [18, 48] 
 6-phosphogluconate dehydrogenase  [18] 
Hexokinase, phosphofructokinase  [18] 
Protein farnesyl transferases (PFT)  [17, 18] 
Polyamide pathway enzymes (γ-glutamyl cysteine 
synthetase, spermidine synthetase) 
 [18] 
CRK3 (Cdc2-Related Kinase 3*)  [43] 
Leishmania 
Sterol 14-α-demethylase (CYP51) Posaconazole, 
E1224 (prodrug 
of ravuconazole) 
[43] 
Cystein proteinase (CP) - [49] 
Chagas 
TcCa (α-carbonic anhydrase)  [50] 
Cruzipain K777 [32] 
  * This is a protein kinase potential for drug targets in kinetoplastid diseases. 
• Critical Pathway for Discovering Neglected Parasitic Diseases  
Establishing a standardized pathway for drug discovery of NTD speeds-up the process and optimizes 
resources of the international research community. Since the last decade, a standardized system for 
antimalarial drug screenings emerged, together with a compound progression criteria. In 2009, similar 
standards were developed for leishmaniasis and HAT (Table 4, Figures 9 and 10) [9, 25].  
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Table 4. MMV Compound Progression Criteria for Antimalarial Compounds [33] 
Test Consensus 
Screening Hits 
Target assay  Biological activity at IC50 ˂3 µM 
Cellular assay Activity against P. falciparum 3D7, HB3, DD2 NF54 or W2 at IC50 ˂1 µM 
Validated Hits 
Re-testing  Re-synthesis if necessary to validate results on compound > 90% pure 
Activity IC50 against biological target (if known) and whole parasites (strains as above) ˂ 1 µM 
Selectivity Activity against mammalian enzyme and HepG2 cells show > 10-fold sensitivity 
Chemistry Looks drug-like and some initial SAR is established 
ADMET Good predicted computational ADMET properties 
Early Leads 
Chemistry 
Stable as solid and in test media with good solubility in PBS, initial SAR studies indicate 
opportunities for chemical targets with straightforward synthesis to yield Rule-of-5 
compliant compounds  
Biology 
IC50 against biological target (if known) and whole cells ˂ 1 µM, whole cell activity extends 
to key drug resistant strains, mode of action known or strategies to address it, depresses 
parasitemia in mouse model of malaria (oral administration) 
ADMET 
Stable in human and mouse plasma, reasonable stability with microsomes, CaCo-2 
permeability > 2 x 10-6 cm/s, no known toxicophores/reactive groups, no preliminary mouse 
toxicity  
Late Leads 
Chemistry 
 
Structural identification of the compound is confirmed by H and C NMR, LC-MS, and 
elemental analysis, suitable physicochemical properties, easy, cheap, and environmentally 
friendly synthesis. Patentable 
Biology 
IC50 against biological target (if known) and whole cells ˂ 1 µM, whole cell activity extends 
to key drug resistant strains and clinical isolates, ability to clear parasitemia in mouse model 
of malaria when administered by oral route daily for no more than 4 days with an ED50 ˂ 10 
mg/Kg and ED90 ˂30 mg/Kg, using a formulation acceptable for PK and toxicology studies 
ADMET 
Soluble in PBS at > 20 µg/mL, stability in human and murine plasma > 90% over 1h, extent 
of plasma protein binding known, fully PK in rat and dog after oral and iv dosing ok, 
including oral bioavailability > 20%, hERG and phototoxicity ok, no overt signs of toxicity 
in in vivo efficacy studies and MTD in mice at least x 10 curative dose 
In a typical discovery program for antiprotozoal compounds, the first step is the selection of compounds 
which show in vitro activity against whole-cell assays and sufficient selectivity towards the parasite. 
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 Compounds which match established cut-off values are ranked based on their in silico/in vitro ADMET 
and lead-like/drug-like properties. The best ranked compounds are tested in vivo in primary models to test 
efficacy. Further steps comprise evaluation of mechanisms of action, activity in in vivo secondary tests, 
together with medicinal chemistry and lead optimization efforts. Nowadays the drug-like properties are 
being screened in parallel with biological activity and constitute a selection criterion [6, 14 22, 23, 51].  
 
Fig 9. New Paradigm for Critical Path of Compound Progression in Antimalarial Drug Discovery 
from Jimenez-Diaz et al., 2013 [6] 
Still, there is the need of more standardization to evaluate the potential of compounds active against 
trypanosomiasis, Chagas disease, and leishmaniasis. There is i) a lack of reference strains for compound 
screening, particularly for T. b. gambiense; ii) a lack of optimal animal models for testing compounds, 
particularly for studying some in vivo stages, e.g. the “late state” of Trypanosomiasis; iii) immense 
variability in the behavior among strains which makes it difficult to compare results of laboratories [17, 
52, 53].  
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 In this work, the activity of compounds (plant extracts/fractions) was tested in in vitro whole-cell assays 
(Table 5), alongside with testing the cytotoxicity in mammalian cells. The main purpose of the 
cytotoxicity test was to calculate the selectivity index (SI), which allows the discrimination of attractive 
compounds from poorly selective molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. Algorithm for Screening of Drugs Against HAT and Leishmaniasis [9] 
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T. b. rhodesiense 
 >50% inhibition  
  at 10 µg/mL 
 
 IC50˂0.5µg/mL 
SI > 10 
 
 Cures at 4 x 50 
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  4 x 20 mg/Kg ip 
 
 Cures at 4 x 50 
mg/Kg ip 
 
 In vitro IC50 on 
T. b. rhodesiense 
 
 In vivo STIB795 
acute T. b. brucei 
 
 In vivo STIB900 acute 
T. b. rhodesiense 
 
 In vivo dose response 
STIB900 acute T. b. 
rhodesiense 
 
 In vivo GVR35 CNS 
T. b. brucei 
 
 In vivo IC50 on cell lines (L6, 
THP1, MRC5, J774, HT29 or KB)  
 
 MTS on L. donovani  
axenic amastigotes  
 
 In vitro IC50 on L. donovani  
axenic amastigotes  
 
 > 50% inhibition at 
10 µg/mL  
 
 In vitro IC50 on L. donovani  
in macrophages  
 
 In vivo IC50 LV9  
L. donovani  
 
 IC50 ˂ 0.5 µg/mL 
SI > 10  
 
 IC50 ˂ 1.0 µg/mL 
SI > 20  
MTS = medium throughput screening 
SI = selectivity index (IC50 on cell line/IC50 parsite on parasite 
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 Compounds which complied with selection criteria of the Swiss TPH (Table 5) were challenged in 
primary in vivo models. 
This approach was applied not only to malaria but also to HAT, Chagas disease, and leishmaniasis, 
resulting in an integrated screening approach for tropical diseases. This strategy is a more efficient tool 
for discovering high-quality hits with good efficiency compared to those which target pathogens 
individually [23].  
Table 5. In vitro Activity Criteria [54] 
Parasite (strain) IC50 activity criteria 
Active Mod. activity Inactive 
Plasmodium falciparum (K1/NF54) 
(intraeritrocitic forms) 
˂ 0.5 µg/mL 
SI>100 
0.5 – 5 µg/mL > 5 µg/mL 
Trypanosoma brucei rhodesiense 
(STIB900) (blood stream forms) 
˂ 0.5 µg/mL 
SI>20 
0.2 – 3 µg/mL > 3 µg/mL 
Leishmania donovani (axenic 
amastigotes) (MHOM/ET/67/L82) 
˂ 0.5 µg/mL 
SI>20 
0.5 – 3 µg/mL > 3 µg/mL 
Trypanosoma cruzi (amastigotes in L6 
cells) (Tulahuen C2C4 w/LacZ) 
˂ 2 µg/mL SI>50 2 – 30 µg/mL > 30 µg/mL 
Cytotoxicity L6 cells                            
(rat skeletal myoblast cell line) 
- - - 
SI (selectivity index): IC50 mammalian cell / IC50 parasite  
• Natural products and Drug Discovery for NTD 
The antiprotozoal activity of NPs derived from plants, bacteria, fungi, and marine organisms has been 
extensively studied. Published reviews retrieve this information and show that many secondary 
metabolites with a wide variety of scaffolds, namely diverse kind of alkaloids, terpenes, and phenolic 
compounds (e.g. lignans, tannins, coumarins, flavonoids) show potent inhibition on parasites responsible 
for NTD. Most of the compounds have been assayed in the whole-cell model and in some cases 
mechanistic studies have been conducted, mainly in the case of malaria and HAT. Despite the promising 
activity of some NPs, some of them showed limitations such as toxicity, low bioavailability, and/or poor 
solubility, which restrict their scope of use in humans. Nonetheless, these hits can be modified by 
semisynthetic approaches to overcome their drawbacks and to boost their benefits [17, 44, 49, 53, 55].   
Networking among different areas such as biology, medical chemistry, and pharmacokinetics is required 
to move forward natural hits and leads through the drug discovery pipeline. The discovery of new 
validated drug targets and the recent technical progress in the field of NPS chemistry might facilitate this 
process [17].  
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 Even tough, DDD focuses on pure chemical entities, the local and traditional knowledge remains an 
essential starting point. The observational knowledge about the effect of a plant, an animal, or a 
microorganism on other organisms offers ideal opportunities to limit the huge diversity of possible leads 
to more promising ones (knowledge-based drug discovery). Such observational knowledge is exemplified 
by the discovery of drugs used against parasitic diseases such as malaria [56].    
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 3.1 In Vitro Screening of Traditional South African Malaria Remedies Against Trypanosoma brucei 
rhodesiense, Trypanosoma cruzi, Leishmania donovani, and Plasmodium falciparum 
Tsholofelo Mokoka, Stefanie Zimmermann, Tasqiah Julianti, Yoshie Hata, Nivan Moodley, Monica Cal, 
Michael Adams, Marcel Kaiser, Reto Brun, Neil Koorbanally, Matthias Hamburger 
Planta Med., 2011, 77: 1663–1667.  DOI: 10.1055/s-0030-1270932 
 
Three hundred extracts from 107 South African plant species (42 botanical families) with antiparasitic 
traditional use were tested against a panel of 4 parasites (Plasmodium falciparum, Trypanosoma brucei 
rhodesiense, Leishmania donovani, and Trypanosoma cruzi). For the most active plants (24), an extensive 
bibliographic search was performed to select the most promising ones. Ten extracts, corresponding to 10 
species, were prioritized to perform HPLC-activity profiles. 
 
 
 
 
My contributions to this work were: (1) literature search for 24 of the active plants in the screening to 
select the most promising ones to follow up; (2) data interpretation for 34 HPLC-activity profiles 
performed for 10 selected extracts against P. falciparum, T. b. rhodesiense, and/or L. donovani.  
Tasqiah Julianti performed the HPLC-activity profiling of the extracts and Tsholofelo Mokoka wrote the 
first draft of the paper. The antiprotozoal activity of the extracts and HPLC fractions was assessed at the 
Swiss TPH. Extracts were provided by the CSIRteam. 
Yoshie Hata-Uribe 
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Abstract
!
Three hundred extracts were prepared from
plants traditionally used in South Africa to treat
malaria and screened in vitro for activity against
Trypanosoma brucei rhodesiense, Trypanosoma
cruzi, Leishmania donovani, and Plasmodium falci-
parum. For the 43 extracts which inhibited the
growth of one or more parasites to more than
95% at 9.7 µg/mL, the IC50 values against all four
protozoal parasites and cytotoxic IC50s against
rat myoblast L6 cells were determined. Amongst
the most notable results are the activities of Aga-
thosma apiculata (IC50 of 0.3 µg/mL) against Plas-
modium falciparum, as well as Salvia repens and
Maytenus undata against Leishmania donovani
with IC50s of 5.4 µg/mL and 5.6 µg/mL, respective-
ly. This screening is the starting point for a HPLC-
based activity profiling project in antiprotozoal
lead discovery.
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!
Half a billion people get infected with malaria
every year, and 1–2 million die of the disease
[1]. Up to thirty million people annually contract
one of the so called “neglected tropical diseases”,
Chagas disease, human African trypanosomiasis,
or leishmaniasis, and the three disorders lead to
120000 deaths annually [2]. All these diseases
are caused by protozoal parasites which are
transmitted by insect vectors, and affect the
poorest populations. Malaria drugs are reason-
ably affordable, available, and safe, yet few in
number and increasingly compromised by resist-
ances [3]. Only a few drugs are on the market to
treat trypanosomatid infections (Trypanosoma
and Leishmania), and their pharmacological pro-
files are insufficient by modern standards [1]. For
decades, large pharmaceutical companies have
been reluctant to invest in the development of
new drugs for economic reasons. This may be
changing though because there have been in-
creasing drug discovery and development efforts
in recent years from private initiatives and non-
profit organizations. The Medicines for Malaria
Venture (MMV), for instance, has initialized re-
search networks [4], and philanthropist organiza-
tions like the Bill and Melinda Gates foundationMokoka TA
62and others have contributed substantial assets to
such endeavors [5].
We report here on the outcome of a screen which
is the starting point in the collaboration between
the University of Basel, the Swiss Tropical and
Public Health Institute, and the South African
Council for Scientific and Industrial Research.
The goal is to evaluate the antiprotozoal potential
of plants used by traditional communities in
South Africa to treat malaria. Extracts were
screened against the most important protozoal
parasites, Plasmodium falciparum (malaria), Try-
panosoma cruzi (Chagas disease), Trypanosoma
brucei rhodesiense (sleeping sickness), and Leish-
mania donovani (leishmaniasis). This screening
study forms the base for an ongoing HPLC-based
activity profiling project in antiprotozoal lead dis-
covery. This library had been previously screened
for antiplasmodial activity against chloroquine
sensitive Plasmodium falciparum D10 strain [6].Material and Methods
!
Plant species selection
Plants were collected from the wild at various lo-
cations in South Africa by different ethnobotan-
ists based on their ethnomedicinal uses againstet al. In vitro Screening… Planta Med 2011; 77: 1663–1667
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l.parasitic diseases, mainly malaria. A list of these uses can be
found in an earlier publication [6]. Samples were identified at
the South African National Biodiversity Institute (SANBI) by dif-
ferent botanists specializing in specific plant families, and vouch-
er specimens deposited at the South African National Biodiver-
sity Institute (SANBI). The plants project numbers are given in Ta-
ble 1S as Supporting Information.
Preparation of plant extracts
The plant parts (roots, leaves, twigs, fruits, and stem bark) were
dried in an oven at 30–60°C. Dried plant material was ground to
a coarse powder using a hammer mill and stored at ambient tem-
perature prior to extraction. Of each sample, 100–500 g of pow-
dered material was sequentially extracted, typically with 1 L of
cold dichloromethane (DCM), DCM/methanol (MeOH) (1/1),
MeOH, and purified water in 2-L glass jars with screw on lids.
The extracts were filtered; the plant material was dried overnight
in a fume hood and then extracted with the next more polar sol-
vent. Organic extracts were concentrated using a rotary vacuum
evaporator at a temperature below 45°C and then further dried
in vacuo at ambient temperature for 24 h. The aqueous extracts
were concentrated by freeze-drying. The yields of the extracts,
in terms of starting plant material, were recorded. All dried ex-
tracts were stored at − 20°C. Analytical grade solvents for extrac-
tion were purchased from Romil Pure Chemistry. HPLC grade
water was obtained from a TKAUltra Purewater purification sys-
tem.
Evaluation of in vitro antiprotozoal activity
Screening of the extract library against Plasmodium falciparum
(K1 strain), Trypanosoma brucei rhodesiense (STIB 900 strain),
Trypanosoma cruzi trypomastigote forms (Tulahuen strain), and
Leishmania donovani (strain MHOM/ET/67/L82) was performed
in 96-well plates at concentrations of 9.7 and 1.8 µg/mL. Tests
were done in duplicate and repeated twice. IC50 values against
the parasites as well as cytotoxic effects against rat myoblast
(L6-cells) were determined by serial dilution and repeated twice.
Trypanosoma brucei rhodesiense (STIB 900) were grown in axenic
medium as described by Baltz et al. [7]. The samples were tested
using the Alamar Blue assay protocol [8] to determine the 50% in-
hibitory concentration (IC50). A Spectramax Gemini XS micro
plate fluorescence reader (Molecular Devices Cooperation) with
an excitation wavelength of 536 nm and an emission wavelength
of 588 nmwas used tomeasure the plates. Melarsoprol (Arsobal®,
purity > 95%, Sanofi-Aventis) was used as a reference drug
(IC50 = 0.03 ± 0.01 µM). The IC50 values were calculated by using
Softmax Pro software (Molecular Devices Cooperation).
Trypanosoma cruzi trypomastigote forms [Tulahuen strain C2C4
containing β-galactosidase (Lac Z) gene] were cultured as de-
scribed by Buckner et al. [9] in rat myoblast cells (L6-cells). Benz-
nidazole (purity > 95%, Sigma-Aldrich) was used as a standard
drug (IC50 = 0.48 µg/mL). After incubation, the substrate chloro-
phenyl red β-D-galactopyranoside agent CPRG/Nonident was
added to all wells, and a color change was developed within 2 to
6 h. The plates were read photometrically at 540 nm (Molecular
Devices). Data were evaluated and IC50 values calculated using
Softmax Pro software (Molecular Devices).
Axenically grown L. donovani amastigotes (strain MHOM/ET/67/
L82) were cultured, and tests were done as previously described
using the resazurin assay [10]. The plates were developed for 2–4
hours and read on a Spectramax Gemini XS micro plate fluo-
rometer (Molecular Devices) using an excitation wavelength ofMokoka TA et al. In vitro Screening… Planta Med 2011; 77: 1663–1667
6536 nm and emission wavelength of 588 nm. Fluorescence devel-
opment was measured and expressed as a percentage of the neg-
ative control. Miltfosine (purity > 95%, VWR) was used as a refer-
ence drug (IC50 = 0.241 µg/mL). Data were transferred to the
graphics program Softmax Pro (Molecular Devices), with which
IC50 values were calculated.
Screening of the extract library and determination of activity
against Plasmodium falciparum K1 strain was done using a modi-
fied version of the 3H-hypoxanthine incorporation assay by Trag-
er and Jensen [11]. After incubation the plates were harvested us-
ing a Betaplate cell harvester (Wallac) onto glass-fiber filters and
washed. The dried filters were inserted into plastic foils with
10ml scintillation fluid. The radioactivity was counted with a
Betaplate liquid scintillation counter (Wallac) as counts per min-
ute per well at each drug concentration and compared to the un-
treated controls. Chloroquine (purity > 95%, Sigma-Aldrich) was
used as a positive control (IC50 = 0.05 ± 0.01 µM). IC50 values were
calculated by linear interpolation. All assays were run in dupli-
cate and repeated two times.
The cytotoxicity assay was performed by a similar protocol as the
Alamar Blue assay whereby L6-cells were seeded in 100 µL RPMI
1640 supplemented in 96-well microtiter plates (4000 cells/
well). Podophyllotoxin (purity > 95%, Sigma-Aldrich) was used
as the reference drug (IC50 = 0.05 ± 0.01 µM). After 68 h of incuba-
tion under humidified 5% CO2 atmosphere, 10 µL of the Alamar
Blue marker was added to all wells. The plates were incubated
for an additional 2 h. A Spectramax Gemini XS microplate fluo-
rescence reader (Molecular Devices Cooperation) was used to
measure the plates (Molecular Devices) using an excitationwave-
length of 536 nm and an emission wavelength of 588 nm. The
IC50s were calculated by Softmax Pro software (Molecular De-
vices Cooperation).
Supporting information
A table (Table 1S) is provided containing the results of the initial
antiprotozoal screen of 300 extracts tested at two concentrations
against Trypanosoma brucei rhodesiense, Trypanosoma cruzi,
Leishmania donovani and Plasmodium falciparum.Results
!
One hundred and seven medicinal plants were selected because
they had a reported tradition of being used as antiparasitic rem-
edies. Dried plant parts were extracted using solvents of different
polarity [DCM, DCM/MeOH (1:1), MeOH, and water] to give 300
extracts [6]. In a first step, the extracts were screened for their
potential antiparasitic properties against T.b. rhodesiense, T. cru-
zi, L. donovani, and P. falciparum at the test concentrations 9.7
and 1.6 µg/mL (Supporting Information, Table 1S).
In a second stage, extracts which in the first step had shownmore
than 95% inhibition of one or more parasites at a test concentra-
tion of 9.7 µg/ml were selected as potential “hits”, and their IC50
values against all four parasites as well as their cytotoxicity
against rat myoblast cells (l" Table 1) were determined. This en-
abled the direct comparison of activities, parasite specific actions
and toxicities of each of our “hits” and served as a basis for the
selection of the most promising extracts for HPLC-based activity
profiling and identification of the active principles [10].
In general, P. falciparumwas themost sensitive protozoal parasite
towards the extract library. The most potent extract in the entire
screen was the DCM/MeOH (1:1) extract of Agathosma apiculata3
Table 1 Antiprotozoal in vitro activity (IC50s in µg/mL) of 43 plant extracts against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania donovani, and
Plasmodium falciparum. Extracts were considered “potential hits”when they inhibited one or more of the parasites at 9.7 µg/mL in a preliminary screen (Supporting
Information see Table 1S). The positive controls melarsoprol, benznidazol, miltefosine, chloroquine, and podophyllotoxin were tested likewise. Tests were done
twice in duplicate.
Plant name Plant part Bioprospect-
ing no.
Extract type T.b. rho-
desiense
T. cruzi L. dono-
vani
P. falci-
parum
Cyto-
toxicity
Agathosma apiculataG. Mey. whole plant P09995b DCM/MeOH (1 :1) 11.1 41.5 16.0 0.209 42.9
Agathosma puberula (Steud.) Forc. roots P02011a DCM 32.2 28.9 15.1 8.53 57.9
Alepidea amatymbica Eckl. & Zeyh. whole plant P02873b DCM/MeOH (1 :1) 20.3 73.1 12.1 3.7 52.7
Artabotrys monteiroaeOliv. leaves P18314b DCM/MeOH (1 :1) 10.3 41.3 16.6 8.79 40.9
Artemisia afra Jacq. exWilld. leaves P00484b DCM/MeOH (1 :1) 21.9 54.5 8.8 7.5 15.8
Artemisia afra Jacq. exWilld. leaves P00484a DCM 9.6 27.6 5.68 6.22 21.5
Artemisia afra Jacq. exWilld. leaves P00484c MeOH 15.9 41.8 15.1 13.3 47.4
Asystasia gangetica T. Anderson leaves P05623b DCM/MeOH (1 :1) 13.2 74.7 12.4 4.2 15.9
Catha edulis (Vahl) Forssk. ex Endl. roots P00469a DCM 14.2 19.1 7.65 4.91 17.8
Conyza albida Spreng. whole plant P12954b DCM/MeOH (1 :1) 18.8 38.3 16.2 5.79 40.8
Conyza podocephala DC. whole plant P03063b DCM/MeOH (1 :1) 13.9 47.2 15.8 5.45 51.6
Conyza scabridaDC. leaves P03170b DCM/MeOH (1 :1) 30.0 49.4 6.65 6.66 48.1
Crotonmenyhartii Pax leaves P12951b DCM/MeOH (1 :1) 11.7 33.3 15.8 2.63 46.4
Crotonmenyhartii Pax twigs P12952b DCM/MeOH (1 :1) 11.3 41.1 15.9 2.88 45.4
Crotonmenyhartii Pax whole plant P14867b DCM/MeOH (1 :1) 8.76 38.6 16.3 10.8 51.1
Cymbopogon validus (Stapf) Stapf ex Burtt
Davy
whole plant P12881b DCM/MeOH (1 :1) 11.9 47.1 17.9 6.67 48.7
Ekebergia capensis Sparrm. fruits P03111b DCM/MeOH (1 :1) 11.5 24.4 4.8 3.5 9.9
Ekebergia capensis Sparrm. twigs P03112b DCM/MeOH (1 :1) 15.6 46.4 15.9 13.3 55.4
Euclea natalensis A.DC. roots P08227b DCM/MeOH (1 :1) 28.1 43.7 14.8 7.59 57.9
Eucomis autumnalis (Mill.) Chitt. flowers/buds P01463a DCM 37.1 29.7 7.62 22.1 51.3
Helichrysum nudifolium (L.) Less. whole plant P02847b DCM/MeOH (1 :1) 33.1 43.9 15.3 9.36 47.7
Hypericum aethiopicum Thunb. leaves P02817b DCM/MeOH (1 :1) 4.47 18.1 4.74 2.35 15.2
Leonotis leonurus (L.) R.Br. leaves P03269b DCM/MeOH (1 :1) 14.7 50.1 4.7 2.9 14.1
Leonotis ocymifolia var. ocymifolia (Burm. f.)
Iwarsson
leaves P00480a DCM 9.1 63.5 18.5 2.7 22.1
Leonotis ocymifolia var. ocymifolia (Burm. f.)
Iwarsson
leaves P00480b DCM/MeOH (1 :1) 9.7 91.2 13.3 4.5 18.2
Maytenus undata (Thunb.) Blakelock roots P00153a DCM 35.2 28.4 5.58 8.53 52.4
Pentzia globosa Less. roots P01516a DCM 5.76 31.3 14.4 4.27 50.2
Pentzia globosa Less. stem bark P01517a DCM 6.32 46.5 22.0 6.04 63.9
Pentzia globosa Less. roots P01516b DCM/MeOH (1 :1) 6.69 40.6 17.5 6.89 54.2
Pentzia globosa Less. stem bark P01517b DCM/MeOH (1 :1) 15.2 55.6 49.5 9.14 > 100
Plumbago zeylanica L. leaves P00631b DCM/MeOH (1 :1) 13.0 54.5 17.8 12.4 14.4
Ptaeroxylon obliquum (Thunb.) Radlk leaves P01870a DCM 11.3 41.5 17.2 10.9 46.3
Rauvolfia caffra Sond. roots P00734a DCM 17.9 41.1 15.5 8.44 46.6
Salvia repens Burch. ex Benth. whole plant P08214b DCM/MeOH (1 :1) 10.8 36.2 5.36 7.65 41.5
Schefflera umbellifera (Sond.) Baill. roots P00246a DCM 20.9 57.6 5.03 2.7 13.9
Schefflera umbellifera (Sond.) Baill. roots P00246b DCM/MeOH (1 :1) 30.2 99.5 14.1 7.7 48.3
Setaria megaphylla (Steud.) T. Durand &
Schinz
whole plant P12880b DCM/MeOH (1 :1) 16.8 43.9 16.9 4.44 48.1
Tarchonanthus camphorates L. roots P01154b DCM/MeOH (1 :1) 13.4 42.9 16.3 17.7 31.9
Tarchonanthus camphorates L. whole plant P02554b DCM/MeOH (1 :1) 3.93 18.6 4.86 6.23 16.1
Vernonia hirsuta (DC.) Sch.Bip. exWalp. whole plant P02834b DCM/MeOH (1 :1) 18.1 43.0 16.2 10.2 31.6
Vernonia natalensis Sch.Bip. exWalp. whole plant P08212b DCM/MeOH (1 :1) 12.6 39.3 17.2 8.53 38.6
Vernonia oligocephala (DC.) Sch.Bip. exWalp. leaves P01015a DCM 4.67 14.3 16.1 7.69 6.54
Vernonia oligocephala (DC.) Sch.Bip. exWalp. leaves P01015b DCM/MeOH (1 :1) 10.9 44.5 19.9 9.51 22.3
Melarsoprol 0.004
Benznidazole 0.482
Miltefosine 0.241
Chloroquine 0.052
Podophyllotoxin 0.003
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l.(Rutaceae) with an IC50 of 0.21 µg/mL against Plasmodium falci-
parum. Seven more lipophilic (DCM/MeOH [1:1]) extracts
showed antiplasmodial IC50s of under 5 µg/mL: that of Hyperi-
cum aethiopicum leaves (IC50 = 2.4 µg/mL), Leonotis leonurus
leaves (2.9 µg/mL), Ekebergia capensis fruits (3.5 µg/mL), Alepidea
amatymbica whole plant (3.7 µg/mL), Asystasia gangetica leaves
(4.2 µg/mL), Setaria megaphyllawhole plant (4.4 µg/mL), and Leo-64notis ocymifolia var ocymifolia leaves (4.5 µg/mL). Also, the DCM
extract of Leonotis ocymifolia var ocymifolia leaves was very ac-
tive (2.7 µg/mL) (l" Table 1).
Against Trypanosoma brucei rhodesiense, the DCM/MeOH (1:1)
extracts of Tarchonardus camphorates whole plant (3.9 µg/mL),
Hypericum aethiopicum leaves (4.7 µg/mL), Leonotis ocymifolia
var ocymifolia leaves (9.1 µg/mL), Croton menyhartii whole plantMokoka TA et al. In vitro Screening… Planta Med 2011; 77: 1663–1667
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ria
l.(8.8 µg/mL), and the DCM extracts of Pentzia globosa roots
(5.8 µg/mL), Vernonia oligocephala leaves (4.7 µg/mL), Artemisia
afra leaves (9.6 µg/mL), and Leonotis ocymifolia var ocymifolia
leaves (9.7 µg/mL) showed IC50s lower than 10 µg/mL. Three fur-
ther DCM, eighteen DCM/MeOH extracts, and one MeOH extract
had IC50s between 10 and 20 µg/mL against Trypanosoma brucei
(l" Table 1). Despite the fact that most of the 43 “selected hits”
showed relatively good activity against T. brucei, none showed
selectivity towards this parasite, as it had been the case for the
Plasmodium falciparum screen.
Trypanosoma cruzi was the least sensitive protozoal test orga-
nism. Three extracts, the DCM/MeOH extract of Hypericum ae-
thiopicum leaves (18.1 µg/mL), the DCM extract of Catha edulis
roots (19.1 µg/mL), and the DCM/MeOH extract of Tarchonardus
camphoratus whole plant (18.6 µg/mL) inhibited T. cruzi with
IC50s under 20 µg/mL.
Seven extracts showed IC50 of less than 6 µg/mL against Leish-
mania donovani. These were the DCM/MeOH extract of Hy-
pericum aethiopicum leaves (4.7 µg/mL), Leonotis leonurus leaves
(4.7 µg/mL), Ekebergia capensis fruits (4.8 µg/mL), Schefflera um-
bellifera (5.0 µg/mL), Salvia repens (5.4 µg/mL), Tachonanthus
camphorates (4.9 µg/mL), and the DCM extract ofMaytenus unda-
ta (5.6 µg/mL).D
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We screened an extract library generated from plants selected for
their traditional antimalarial use against the most important hu-
man protozoal parasites. The goal was to identify extracts with
potent and, ideally, selective activity against any one of the para-
sites. These hits are being followed up in an ongoing HPLC-based
activity profiling project in antiprotozoal lead discovery.
The initial screening of this focused extract library delivered forty
three “potential hits”. Thesewere defined as samples with almost
complete (> 95%) inhibition at 9.7 µg/mL. Twelve of them showed
activity against Plasmodium falciparum, twenty-eight against
Trypanosoma brucei rhodesiense. Six of these extracts were active
against both parasites (Supporting Information, Table 1S).
Against Leishmania donovani eleven extracts fulfilled the criteria
for “potential hits”. Five of thesewere also active against T. brucei.
One extract, the DCM extract of Catha edulis roots, inhibited both
P. falciparum and Leishmania, and the DCM/MeOH extract of Hy-
pericum aethiopicum leaves inhibited the growth of all three par-
asites. No extract showed > 95% inhibition of Trypanosoma cruzi
at 9.7 µg/mL. This parasite is generally less sensitive than Trypa-
nosoma brucei because it is an intracellular test system.
In a second phase, the IC50s of the 43 “potential hits”were deter-
mined against all the parasites and against L6 cells (l" Table 1).
Agathosma apiculata (Rutaceae) was exceptional in the sense that
it was by far the most active extract against Plasmodium falcipa-
rum and showed at the same time good selectivity. An IC50 of
0.3 µg/mL against Plasmodium compared to 43 µg/mL in L6 cells
corresponded to a selectivity value of 143. The extract was also
140 times more active against P. falciparum than against T. cruzi,
53 times more active than against Leishmania donovani, and 37
times more active than against T. brucei.Mokoka TA et al. In vitro Screening… Planta Med 2011; 77: 1663–1667
6Nine of the 43 selected active extracts showed IC50s of < 10 µg/mL
against Trypanosoma brucei rhodesiense (l" Table 1). Yet, despite
the relatively high activity, none showed selectivity towards this
parasite.
Salvia repens and Maytenus undata were shown to be preferen-
tially active against Leishmania donovani, whilst showing only
moderate cytotoxic effects (l" Table 1).
The most active extracts against T. cruzi showed nonspecific ef-
fects. The DCM/MeOH extracts of Hypericum aethiopicum leaves
(18.1 µg/mL) and Tarchonardus camphoratus (18.6 µg/mL) and
the DCM extract of Catha edulis roots (19.1 µg/mL) at the same
time strongly inhibited L6 cells, which are T. cruziʼs host cells
(l" Table 1). The DCM/MeOH and/or DCM extracts of Hypericum
aethiopicum, Leonotis leonurus, Ekebergia capensis, Catha edulis,
Asystasia gangetica, Schefflera umbellifera, and Tarchonardus
camphoratus all showed relatively high cytotoxicity, with
IC50s < 20 µg/mL, and activities against most protozoal test or-
ganisms. Therefore, these extracts were not shortlisted for fur-
ther follow-up.
In summary, screening of our focused library led to a shortlist of
extracts with high activity against Plasmodium falciparum, Trypa-
nosoma brucei rhodesiense, and Leishmania donovani in a primary
screen. The percents of inhibition at the two initial test concen-
trations were roughly indicative of the half maximum inhibition
concentration (IC50 values) to be expected in the second stage of
the screening. Given the cellular test systems and their inherent
variability, some extracts showed IC50s slightly higher or lower
than could have been predicted from the primary screen. For di-
rect comparison of activities, it is therefore necessary to deter-
mine IC50s by serial dilution (l" Table 1). This data, together with
cytotoxicity data, helps to determine whether an activity is spe-
cific or just a generally toxic effect. Extracts with favorable activ-
ities are followed up by HPLC-based activity profiling [12]. We
have recently developed and validated a microtiter-based proto-
col for the miniaturized and efficient identification of antiproto-
zoal compounds in extracts [10] and successfully applied this ap-
proach to the discovery of new antiprotozoal natural products in
other library-based discovery projects [13–15]. Results from the
profiling and identification of the active principles from the ex-
tracts in this screen will be reported in due course.
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 Supporting information Table S1 Antiprotozoal in vitro activity (% inhibition at 9.7 and 1.8 µg/mL) of 300 plant extracts tested 
against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum. Plants were 
selected due to their reported traditional use against malaria in South Africa.  
  
68
Plant species Family Project 
number 
Plant 
part 
Solvent T. brucei rhodesiense T. cruzi  L. donovani P. falciparum 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
             
Acacia nilotica (L.) kraussianna Fabaceae P12859b Twigs  DCM/MeOH(1:1) 18 17 6 5 22 11 43 0 
Acacia nilotica (L.) kraussianna Fabaceae P12859c Twigs  Aqueous 6 9 10 1 18 2 0 0 
Acacia tortilis (Forssk) Hayne Fabaceae P12869b Whole plant DCM/MeOH(1:1) 17 4 12 3 28 7 59 4 
Achyranthes aspera L. Amaranthaceae P15190b Whole plant DCM/MeOH(1:1) 12 10 0 0 36 0 53 0 
Agathosma apiculata G.Mey. Rutaceae P09995b Whole plant DCM/MeOH(1:1) 99 0 0 0 73 14 80 21 
Agathosma puberula (Steud.) Forc. Rutaceae P02011a Roots DCM 98 7 0 0 68 8 58 1 
Agathosma puberula (Steud.) Forc. Rutaceae P02011b Roots DCM/MeOH (1:1) 0 1 0 0 29 1 34 1 
Agathosma puberula (Steud.) Forc. Rutaceae P02022a Stem bark DCM 3 8 10 2 53 5 95 9 
Agathosma puberula (Steud.) Forc. Rutaceae P02022b Stem bark DCM/MeOH (1:1) 5 0 4 0 17 4 25 14 
Ageratum conyzoides L. Asphodelaceae P12944b Whole plant DCM/MeOH (1:1) 4 1 9 3 27 17 36 0 
Ageratum conyzoides L. Asphodelaceae P12944c whole plant Aqueous 0 0 0 8 40 20 4 4 
Alepidea amatymbica Eckl. & Zeyh. Apiaceae P02873b Whole plant DCM/MeOH (1:1) 2 0 0 0 89 23 56 1 
Aloe ferox Mill. Asphodelaceae P01713a Fruits DCM 10 0 2 0 7 1 14 0 
Aloe ferox Mill. Asphodelaceae P01713b Fruits DCM/MeOH (1:1) 15 0 0 5 17 9 1 0 
Aloe ferox Mill. Asphodelaceae P01713c Fruits Aqueous 1 7 7 5 13 0 0 0 
Aloe ferox Mill. Asphodelaceae P03153b Whole plant DCM/MeOH (1:1) 9 4 0 0 42 11 59 5 
Aloe marlothii A.Berger Asphodelaceae P00054b Leaves DCM/MeOH (1:1) 13 10 0 0 5 0 0 4 
Aloe marlothii A.Berger Asphodelaceae P00054d Leaves Aqueous 15 8 0 0 21 9 3 0 
Aloe marlothii A.Berger Asphodelaceae P00770b Whole plant DCM/MeOH (1:1) 0 0 0 0 21 2 16 1 
Annona senegalensis Pers. subsp. 
senegalensis 
Annonaceae P01034b Leaves DCM/MeOH (1:1) 0 3 0 0 11 0 93 0 
Anthocleista grandiflora Gilg Gentianaceae P01455c Leaves Aqueous 0 3 0 0 17 3 2 0 
Anthocleista grandiflora Gilg Gentianaceae P01455a Leaves DCM 43 24 0 0 32 5 26 0 
Anthocleista grandiflora Gilg Gentianaceae P01455b Leaves DCM/MeOH (1:1) 18 21 0 0 20 16 2 0 
Artabotrys brachypetalus Benth. Annonaceae P02239b Twigs/Leaves DCM/MeOH (1:1) 4 6 0 0 16 12 17 3 
Artabotrys brachypetalus Benth. Annonaceae P02239c Twigs/Leaves Aqueous 2 1 0 1 16 3 0 0 
Artabotrys monteiroae Oliv. Annonaceae P18314b Leaves DCM/MeOH (1:1) 99 0 9 8 25 5 40 0 
Artabotrys monteiroae Oliv. Annonaceae P18314c Leaves Aqueous 0 0 15 5 18 10 0 0 
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Plant species Family Project 
number 
Plant 
part 
Solvent T. brucei rhodesiense T. cruzi  L. donovani P. falciparum 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
Artemisia afra Jacq. ex Willd. Asteraceae P00484a Leaves DCM 98 0 0 0 100 26 89 8 
Artemisia afra Jacq. ex Willd. Asteraceae P00484b Leaves DCM/MeOH (1:1) 97 0 0 0 100 43 77 3 
Artemisia afra Jacq. ex Willd. Asteraceae P00484c Leaves MeOH 96 5 0 0 81 0 35 0 
Asparagus virgatus Baker Asparagaceae P08216b Whole plant DCM/MeOH (1:1) 11 9 0 11 35 14 55 3 
Asystasia gangetica T.Anderson Acanthaceae P05622b Twigs  DCM/MeOH (1:1) 6 0 0 0 28 0 40 3 
Asystasia gangetica T.Anderson Acanthaceae P05623b Leaves DCM/MeOH (1:1) 0 0 2 0 18 0 100 51 
Barringtonia racemosa (L.) Roxb. Lecythidaceae P15194c Leaves Aqueous 0 6 3 0 15 9 0 1 
Barringtonia racemosa (L.) Roxb. Lecythidaceae P15194b Leaves DCM/MeOH(1:1) 3 0 5 4 25 3 33 6 
Barringtonia racemosa (L.) Roxb. Lecythidaceae P15193b Twigs  DCM/MeOH(1:1) 32 5 6 2 26 0 27 0 
Berula erecta (Huds.) Coville Apiaceae P05646b Whole plant DCM/MeOH(1:1) 17 9 0 0 36 5 44 6 
Bidens pilosa L. Asteraceae P00071b Leaves DCM/MeOH (1:1) 20 21 0 0 26 14 43 15 
Bidens pilosa L. Asteraceae P00071c Leaves MeOH 21 17 0 0 37 14 47 5 
Bidens pilosa L. Asteraceae P00071d Leaves Aqueous 19 15 0 0 23 14 13 0 
Bruguiera gymnorhiza (L.) Lam. Rhizophoraceae P18322b Twigs  DCM/MeOH(1:1) 0 0 0 1 26 9 35 0 
Capparis tomentosa Lam. Capparaceae P00665a Leaves DCM 30 24 0 0 39 7 5 0 
Capparis tomentosa Lam. Capparaceae P00667a Stem bark DCM 8 6 0 0 30 0 15 0 
Capparis tomentosa Lam. Capparaceae P00669a Roots DCM 5 6 0 0 18 9 0 4 
Capparis tomentosa Lam. Capparaceae P00665b Leaves DCM/MeOH(1:1) 6 0 0 0 19 0 21 0 
Capparis tomentosa Lam. Capparaceae P00667b Stem bark DCM/MeOH(1:1) 4 17 0 0 10 0 1 0 
Capparis tomentosa Lam. Capparaceae P00669b Roots DCM/MeOH(1:1) 22 3 0 0 32 4 0 0 
Carissa edulis Vahl Apocynaceae P00334a Stem bark DCM 0 6 0 0 36 12 28 3 
Carissa edulis Vahl Apocynaceae P00334b Stem bark DCM/MeOH (1:1) 9 7 0 0 33 7 14 0 
Carissa edulis Vahl Apocynaceae P00334c Stem bark MeOH 13 16 0 0 19 0 0 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00465a Seed DCM 0 0 0 0 33 10 37 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00465b Seed DCM/MeOH (1:1) 0 11 0 0 19 0 11 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00465c Roots MeOH 0 9 0 0 16 7 9 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00469a Roots DCM 57 10 0 0 100 23 99 9 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00469b Roots DCM/MeOH (1:1) 0 8 0 0 31 0 24 0 
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Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00469c Leaves MeOH 3 3 0 0 9 3 18 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00470a Leaves DCM 5 0 0 0 21 0 29 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00470b Leaves DCM/MeOH (1:1) 0 8 0 0 14 0 42 8 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00465d Seed Aqueous 0 7 3 2 6 4 0 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00469d Roots Aqueous 0 0 10 0 24 12 0 0 
Catha edulis (Vahl) Forssk. ex Endl. Celastraceae P00470d Leaves Aqueous 0 4 2 6 24 9 92 0 
Centella asiatica (L.) Urb. Apiaceae P05632b Leaves DCM/MeOH (1:1) 0 0 0 3 43 2 39 7 
Clausena anisata (Willd.) Hook.f. ex 
Benth var. anisata 
Rutaceae P09997b Twigs  DCM/MeOH(1:1) 5 0 0 0 21 8 18 1 
Clausena anisata (Willd.) Hook.f. e  
Benth var. anisata  
Rutaceae P09998b Leaves DCM/MeOH(1:1) 5 0 4 0 31 3 25 0 
Clutia hirsuta E.Mey. ex Sond. Euphorbiaceae P11867b Whole plant DCM/MeOH(1:1) 8 4 0 1 40 12 69 10 
Clutia hirsuta E.Mey. ex Sond. Euphorbiaceae P11867c Whole plant Aqueous 26 15 1 0 20 9 0 0 
Combretum zeyheri Sond. Combretaceae P13042b Twigs  DCM/MeOH(1:1) 10 0 47 0 26 4 33 0 
Combretum zeyheri Sond. Combretaceae P13042c Twigs  Aqueous 7 0 0 0 11 7 19 0 
Conyza albida Spreng. Asteraceae P12954b Whole plant DCM/MeOH(1:1) 100 0 0 3 63 10 97 6 
Conyza albida Spreng. Asteraceae P12954C whole plant Aqueous 0 3 0 1 21 11 1 0 
Conyza podocephala DC. Asteraceae P03063b Whole plant DCM/MeOH (1:1) 6 4 0 0 53 4 99 12 
Conyza scabrida DC. Asteraceae P03168b 
Flowers/ 
Buds 
DCM/MeOH (1:1) 2 6 0 0 93 12 60 0 
Conyza scabrida DC. Asteraceae P03169b Twigs  DCM/MeOH (1:1) 2 15 0 0 45 18 41 0 
Conyza scabrida DC. Asteraceae P03170b Leaves DCM/MeOH (1:1) 0 3 0 0 100 5 53 7 
Crinum macowanii Baker  Amaryllidaceae P05637b 
Flowers/ 
Buds 
DCM/MeOH (1:1) 52 26 1 3 36 5 47 0 
Crinum macowanii Baker  Amaryllidaceae P05637c 
Flowers/ 
Buds 
Aqueous 0 0 0 0 2 0 2 0 
Crotalaria burkeana Benth. Fabaceae P00417b Roots DCM/MeOH (1:1) 25 9 0 0 22 5 21 0 
Crotalaria burkeana Benth. Fabaceae P00418b Seed DCM/MeOH (1:1) 18 8 0 0 63 10 66 5 
Crotalaria burkeana Benth. Fabaceae P00417c Leaves MeOH 6 5 0 0 29 9 5 0 
Crotalaria burkeana Benth. Fabaceae P00417d Leaves Aqueous 11 7 0 0 23 0 0 0 
Crotalaria burkeana Benth. Fabaceae P00418d Roots Aqueous 7 3 0 0 22 7 0 0 
Croton gratissimus Burch. var. 
gratissimus 
Euphorbiaceae P00010c Leaves MeOH 14 13 0 0 31 5 24 13 
Croton gratissimus Burch. var. 
gratissimus 
Euphorbiaceae P00010d Leaves Aqueous 4 17 0 0 10 3 0 0 
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Croton menyhartii Pax Euphorbiaceae P12951b Leaves DCM/MeOH(1:1) 99 2 8 0 66 7 100 27 
Croton menyhartii Pax Euphorbiaceae P12952b Twigs  DCM/MeOH(1:1) 98 10 0 2 56 20 100 33 
Croton menyhartii Pax Euphorbiaceae P12951c Leaves Aqueous 16 7 0 12 28 17 4 0 
Croton menyhartii Pax Euphorbiaceae P12952c Twigs  Aqueous 4 5 0 3 28 26 1 0 
Cussonia spicata Thunb. Araliaceae P00042a Roots DCM 12 13 0 0 31 4 28 0 
Cussonia spicata Thunb. Araliaceae P00042c Leaves MeOH 15 7 0 0 92 16 17 2 
Cussonia spicata Thunb. Araliaceae P02612b Leaves DCM/MeOH (1:1) 2 6 11 3 68 6 71 12 
Cymbopogon validus (Stapf) Stapf ex 
Burtt Davy 
Poaceae P12881b Whole plant DCM/MeOH(1:1) 99 6 6 6 41 7 97 7 
Diosma sp
 
(exact species not 
identified) 
Rutaceae P02051a Roots DCM 17 13 1 0 69 15 93 17 
Diosma sp (exact species not identified) Rutaceae P02051b Roots DCM/MeOH (1:1) 10 3 0 0 18 0.0 13.8 0.0 
Diplorhynchus condylocarpon 
(Müll.Arg.) Pichon 
Apocynaceae P00940b Roots DCM/MeOH (1:1) 0 6 0 0 19 0 4 3 
Dodonaea viscosa Jacq. Sapindaceae P02291b Leaves DCM/MeOH (1:1) 1 1 5 5 65 14 32 0 
Ekebergia capensis Sparrm. Meliaceace P03111b Fruits DCM/MeOH (1:1) 99 12 0 0 96 20 81 17 
Ekebergia capensis Sparrm. Meliaceace P03112b Twigs  DCM/MeOH (1:1) 58 0 0 0 68 7 44 4 
Ekebergia capensis Sparrm. Meliaceace P03111c Fruits Aqueous 0 0 0 0 10 1 0 0 
Elephantorrhiza elephantina (Burch.) 
Skeels 
Fabaceae P08224b Roots DCM/MeOH(1:1) 0 3 0 0 32 3 23 0 
Elephantorrhiza elephantina (Burch.) 
Skeels 
Fabaceae P08224b Leaves DCM/MeOH(1:1) 2 0 0 3 27 6 35 0 
Elephantorrhiza elephantina (Burch.) 
Skeels 
Fabaceae P08224c roots Aqueous 41 20 18 0 29 20 6 0 
Elephantorrhiza elephantina (Burch.) 
Skeels 
Fabaceae P08225c Leaves Aqueous 7 12 0 1 22 7 4 0 
Euclea natalensis A.DC. Ebenaceae P08226b Stem bark DCM/MeOH(1:1) 4 0 0 0 53 0 40 0 
Euclea natalensis A.DC. Ebenaceae P08227b Roots DCM/MeOH(1:1) 98 0 0 0 43 0 80 17 
Euclea undulata Thunb. Ebenaceae P09984b Leaves DCM/MeOH(1:1) 0 0 0 4 58 6 39 0 
Euclea undulata Thunb. Ebenaceae P09985b Twigs  DCM/MeOH(1:1) 4 0 7 5 35 5 66 0 
Eucomis autumnalis (Mill.) Chitt. Hyacinthaceae P01463a Flowers/Buds DCM 2 0 0 0 96 33 23 2 
Eucomis autumnalis (Mill.) Chitt. Hyacinthaceae P01463b Flowers/Buds DCM/MeOH (1:1) 7 9 55 0 29 7 3 0 
Eucomis autumnalis (Mill.) Chitt. Hyacinthaceae P01463c Flowers/Buds Aqueous 18 19 0 0 16 8 0 0 
Euphorbia heterophylla L. Euphorbiaceae P12864b Whole plant DCM/MeOH(1:1) 7 7 0 1 30 6 41 7 
Euphorbia tirucalli L. Euphorbiaceae P00788a Leaves DCM 86 0 0 0 44 8 60 0 
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Euphorbia tirucalli L. Euphorbiaceae P00788b Leaves DCM/MeOH (1:1) 0 0 0 0 22 0 15 3 
Euphorbia tirucalli L. Euphorbiaceae P00788c Leaves MeOH 19 21 4 6 29 2 0 0 
Flacourtia indica (Burm.f.) Merr. Flacourtiaceae P00904a Roots DCM 0 1 0 0 11 2 9 0 
Flacourtia indica (Burm.f.) Merr. Flacourtiaceae P00904c Roots Aqueous 11 5 0 0 11 0 0 0 
Gloriosa superba L. Colchicaceae P08215b Whole plant DCM/MeOH(1:1) 7 9 27 0 25 13 44 11 
Gloriosa superba L. Colchicaceae P08215c whole plant Aqueous 0 17 23 0 12 4 0 0 
Gomphocarpus fruticosus (L.) 
Aiton.f. 
Apocynaceae P09988b Fruits DCM/MeOH(1:1) 1 0 7 0 22 14 5 0 
Gomphocarpus fruticosus (L.) 
Aiton.f. 
Apocynaceae P09989b Leaves DCM/MeOH(1:1) 9 1 3 3 21 11 23 0 
Helichrysum nudifolium (L.) Less. Asteraceae P02847b Whole plant DCM/MeOH (1:1) 0 11 0 0 100 14 63 3 
Hippobromus pauciflorus (L.f.) Radlk. Sapindaceae P12876b Leaves DCM/MeOH(1:1) 0 0 0 0 32 15 59 0 
Hippobromus pauciflorus (L.f.) Radlk. Sapindaceae P12876c Leaves Aqueous 14 1 1 0 15 4 0 0 
Hippobromus pauciflorus (L.f.) Radlk. Sapindaceae P12877b Twigs  DCM/MeOH(1:1) 4 7 2 0 73 6 91 13 
Hypericum aethiopicum Thunb. Clusiaceae P02817b Leaves DCM/MeOH (1:1) 99 75 6 3 100 55 100 33 
Hypericum aethiopicum Thunb. Clusiaceae P02817c Leaves Aqueous 0 5 0 0 15 2 0 5 
Hyptis pectinata (L.) Poit.  Lamiaceae P02459b Leaves DCM/MeOH (1:1) 0 2 27 0 37 6 34 0 
Hyptis pectinata (L.) Poit.  Lamiaceae P02459c Twigs/Leaves Aqueous 9 1 2 3 32 27 7 1 
Justicia flava (Vahl) Vahl Acanthaceae P05636b Whole plant DCM/MeOH (1:1) 0 12 0 0 12 0 21 0 
Kigelia africana (Lam.) Benth. Bignoniaceae P00692a Leaves DCM 12 12 0 0 33 3 6 0 
Kigelia africana (Lam.) Benth. Bignoniaceae P00692b Leaves DCM/MeOH (1:1) 15 4 0 0 10 9 6 0 
Kirkia wilmsii Engl. Kirkiaceae  P13041c Leaves Aqueous 0 0 0 0 18 7 61 0 
Leonotis leonurus (L.) R.Br. Lamiaceae P03268b Twigs  DCM/MeOH (1:1) 3 13 0 0 48 0 86 8 
Leonotis leonurus (L.) R.Br. Lamiaceae P03269b Leaves DCM/MeOH (1:1) 32 9 0 0 85 5 81 16 
Leonotis leonurus (L.) R.Br. Lamiaceae P02414c roots Aqueous 7 8 1 1 32 26 8 0 
Leonotis leonurus (L.) R.Br. Lamiaceae P03268c Twigs  Aqueous 5 0 0 1 12 2 0 0 
Leonotis leonurus (L.) R.Br. Lamiaceae P03269c Leaves Aqueous 17 0 0 0 13 3 0 0 
Leonotis ocymifolia (Burm.f.) 
Iwarsson var. raineriana (Vis.) 
Iwarsson 
Lamiaceae P14867b Whole plant DCM/MeOH(1:1) 98 14 0 0 36 5 39 0 
Leonotis ocymifolia (Burm.f.) 
Iwarsson   var. raineriana (Vis.) 
Iwarsson 
Lamiaceae P00480d Leaves Aqueous 7 7 4 7 16 1 0 0 
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Leonotis ocymifolia (Burm.f.) 
Iwarsson var. raineriana (Vis.) 
Iwarsson 
Lamiaceae P00481d Fruits Aqueous 0 3 0 0 26 10 0 0 
Leonotis ocymifolia (Burm.f.) 
Iwarsson var. raineriana (Vis.) 
Iwarsson 
Lamiaceae P00482c Roots MeOH 1 2 0 0 14 0 1 0 
Leonotis ocymifolia (Burm.f.) 
Iwarsson var. raineriana (Vis.) 
Iwarsson 
Lamiaceae P00482d Roots Aqueous 0 0 0 0 0 0 0 0 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00480a Leaves DCM 100 13 0 0 54 10 74 9 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00480b Leaves DCM/MeOH (1:1) 99 22 0 0 60 9 81 1 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00480c Leaves MeOH 20 27 0 0 46 11 66 4 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00481a Fruits DCM 13 13 0 0 49 8 36 3 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00481b Fruits DCM/MeOH (1:1) 0 0 0 0 36 4 7 0 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00481c Fruits MeOH 0 0 1 0 21 8 6 0 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00482a Roots DCM 20 11 0 0 37 0 22 0 
Leonotis ocymifolia var. ocymifolia 
(Burm.f.) Iwarsson 
Lamiaceae P00482b Roots DCM/MeOH (1:1) 14 5 0 0 5 0 9 0 
Leucas martinicensis (L.) R.Br. Lamiaceae P12950b Whole plant DCM/MeOH(1:1) 91 19 4 12 53 12 84 10 
Leucas martinicensis (L.) R.Br. Lamiaceae P12950c whole plant Aqueous 9 6 6 8 30 20 2 0 
Macrostylis squarrosa Bartl. & H.L. 
Wendl. 
Rutaceae P02402b Stem bark DCM/MeOH (1:1) 8 7 0 0 41 0 79 13 
Maesa lanceolata Forssk. Maesaceae P12946c Twigs  Aqueous 0 0 8 6 27 19 6 4 
Maytenus senegalensis (Lam.) Exell. Celastraceae P00690a Roots DCM 14 2 0 0 28 8 35 0 
Maytenus senegalensis (Lam.) Exell. Celastraceae P00693a Stem bark DCM 0 6 0 0 24 0 25 1 
Maytenus senegalensis (Lam.) Exell. Celastraceae P00693b Stem bark DCM/MeOH (1:1) 11 11 0 0 19 0 5 0 
Maytenus senegalensis (Lam.) Exell. Celastraceae P00693d Stem bark Aqueous 0 1 2 0 10 0 0 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00151b Leaves DCM/MeOH (1:1) 0 12 0 0 46 5 24 18 
Maytenus undata (Thunb.) Blakelock Celastraceae P00152a Stem bark DCM 18 13 3 0 83 17 26 5 
Maytenus undata (Thunb.) Blakelock Celastraceae P00152b Stem bark DCM/MeOH (1:1) 0 2 0 0 54 10 11 6 
Maytenus undata (Thunb.) Blakelock Celastraceae P00153a Roots DCM 1 6 0 0 99 30 42 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00153b Roots DCM/MeOH (1:1) 6 7 0 0 82 16 17 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00153c Roots MeOH 0 2 0 0 29 2 5 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00151c Leaves MeOH 4 7 0 0 19 4 14 9 
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Maytenus undata (Thunb.) Blakelock Celastraceae P00152c Stem bark MeOH 0 2 4 3 39 14 6 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00151a Leaves DCM 3 9 0 0 41 0 8 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00151d Leaves Aqueous 3 0 9 9 17 0 0 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00152d Stem bark Aqueous 0 0 13 3 16 11 0 0 
Maytenus undata (Thunb.) Blakelock Celastraceae P00153d Roots Aqueous 9 0 14 4 20 13 0 0 
Momordica balsamina L. Cucurbitaceae P04038b Stem bark DCM/MeOH (1:1) 2 1 0 0 34 3 83 17 
Momordica balsamina L. Cucurbitaceae P04039b Leaves DCM/MeOH (1:1) 21 23 0 0 49 8 65 5 
Ocimum americanum L. var.  
Americanum 
Lamiaceae P12866b Whole plant DCM/MeOH(1:1) 0 4 0 0 30 2 100 0 
Olea europaea L. subsp. africana    
(Mill.) P.S.Green   
Oleaceae P12848b Leaves DCM/MeOH(1:1) 55 0 15 6 52 8 46 0 
Olea europaea L. subsp. africana    
(Mill.) P.S.Green   
Oleaceae P12849b Twigs  DCM/MeOH(1:1) 46 0 10 4 44 13 50 0 
Osteospermum imbricatum L. Asteraceae P02640b Stem bark DCM/MeOH (1:1) 7 13 3 2 51 3 93 3 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00253a Leaves DCM 0 3 0 0 67 22 53 0 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00253b Leaves DCM/MeOH (1:1) 19 5 0 0 26 0 9 0 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00253c Leaves MeOH 0 1 0 0 11 0 0 0 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00253d Leaves Aqueous 0 8 0 0 17 7 3 0 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00254b Roots DCM/MeOH (1:1) 0 12 0 0 27 11 23 0 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00254c Roots MeOH 14 8 0 0 23 14 12 0 
Parinari curatellifolia Planch. ex 
Benth. 
Chrysobalanaceae P00254d Roots Aqueous 9 7 0 0 14 2 0 2 
Parkinsonia aculeata L. Fabaceae P09990b Twigs  DCM/MeOH(1:1) 6 2 0 3 26 3 32 0 
Pelargonium alchemilloides (L.) 
L'Hér.     
Gentianaceae P08205b Whole plant DCM/MeOH(1:1) 7 11 0 0 33 8 87 10 
Pentzia globosa Less. Asteraceae P01514a Leaves DCM 91 0 7 0 84 2 63 8 
Pentzia globosa Less. Asteraceae P01514b Leaves DCM/MeOH (1:1) 0 0 0 3 26 0 39 0 
Pentzia globosa Less. Asteraceae P01514c Leaves Aqueous 9 0 2 0 25 4 6 15 
Pentzia globosa Less. Asteraceae P01516a Roots DCM 99 7 10 9 63 18 96 21 
Pentzia globosa Less. Asteraceae P01516b Roots DCM/MeOH (1:1) 98 3 4 1 36 0 62 7 
Pentzia globosa Less. Asteraceae P01517a Stem bark DCM 99 0 8 0 34 12 76 5 
Pentzia globosa Less. Asteraceae P01517b Stem bark DCM/MeOH (1:1) 100 0 0 0 16 0 30 0 
Piliostigma thonningii (Schumach.) 
Milne-Redh 
Fabaceae P18548c Fruits Aqueous 17 3 1 0 20 5 0 0 
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Piliostigma thonningii (Schumach.) 
Milne-Redh 
Fabaceae P18547c Leaves Aqueous 24 27 0 0 21 8 6 0 
Piliostigma thonningii (Schumach.) 
Milne-Redh 
Fabaceae P18549c Twigs  Aqueous 19 6 4 0 22 3 0 0 
Pittosporum viridiflorum Sims Pittosporaceae P00213b Whole plant DCM/MeOH (1:1) 50 11 0 0 29 11 59 3 
Pittosporum viridiflorum Sims Pittosporaceae P00213c Whole plant MeOH 0 4 0 2 15 9 15 0 
Pittosporum viridiflorum Sims Pittosporaceae P00215a Leaves DCM 7 5 0 0 31 7 25 3 
Pittosporum viridiflorum Sims Pittosporaceae P00215b Leaves DCM/MeOH (1:1) 1 0 0 0 4 0 0 0 
Pittosporum viridiflorum Sims Pittosporaceae P00215c Leaves MeOH 0 5 0 0 23 9 0 0 
Plantago major L. Plantaginaceae P01571b Whole plant DCM/MeOH (1:1) 0 0 0 0 18 5 16 1 
Plumbago zeylanica L. Plumbaginaceae P00630a Roots DCM 20 19 0 0 20 0 16 0 
Plumbago zeylanica L. Plumbaginaceae P00630b Roots DCM/MeOH (1:1) 11 9 0 0 8 0 19 0 
Plumbago zeylanica L. Plumbaginaceae P00630c Roots MeOH 19 9 0 0 12 0 0 10 
Plumbago zeylanica L. Plumbaginaceae P00631b Leaves DCM/MeOH (1:1) 97 8 0 0 32 2 32 8 
Pollichia campestris Aiton Illecebraceae P00390b Leaves DCM/MeOH (1:1) 0 8 6 3 25 3 23 0 
Pollichia campestris Aiton Illecebraceae P00390c Leaves MeOH 18 9 0 0 18 6 0 0 
Pollichia campestris Aiton Illecebraceae P00391a Fruits DCM 4 0 0 0 42 6 58 0 
Pollichia campestris Aiton Illecebraceae P00391b Fruits DCM/MeOH (1:1) 4 8 0 0 22 6 7 0 
Pollichia campestris Aiton Illecebraceae P00391c Leaves MeOH 13 16 0 0 27 2 3 0 
Pollichia campestris Aiton Illecebraceae P03065b Whole plant DCM/MeOH (1:1) 9 10 0 0 51 0 84 8 
Pollichia campestris Aiton Illecebraceae P00390d Leaves Aqueous 0 0 0 0 16 6 0 0 
Pollichia campestris Aiton Illecebraceae P03065c whole plant Aqueous 0 0 0 0 15 0 0 0 
Pollichia campestris Aiton Illecebraceae P03318c Twigs  Aqueous 19 0 0 1 17 2 0 0 
Psiadia punctulata (DC.) Oliv. & Hiern 
ex Vatke 
Asteraceae P00819b Leaves DCM/MeOH (1:1) 19 3 0 0 48 8 35 4 
Psiadia punctulata (DC.) Oliv. & Hiern 
ex Vatke 
Asteraceae P02527b Whole plant DCM/MeOH (1:1) 24 0 10 4 48 8 49 0 
Ptaeroxylon obliquum (Thunb.) 
Radlk. 
Ptaeroxylaceae P01842a Roots DCM 10 13 9 5 35 1 44 1 
Ptaeroxylon obliquum (Thunb.) 
Radlk. 
Ptaeroxylaceae P01842b Roots DCM/MeOH (1:1) 5 12 10 0 45 12 57 4 
Ptaeroxylon obliquum (Thunb.) 
Radlk.  
Ptaeroxylaceae P01870a Leaves DCM 100 0 0 0 55 5 41 5 
Ptaeroxylon obliquum (Thunb.) 
Radlk.  
Ptaeroxylaceae P01870b Leaves DCM/MeOH (1:1) 0 0 0 0 19 2 24 0 
Ptaeroxylon obliquum (Thunb.) 
Radlk.  
Ptaeroxylaceae P01890a Stem bark DCM 10 0 0 0 53 1 80 17 
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Plant species Family Project 
number 
Plant 
part 
Solvent T. brucei rhodesiense T. cruzi  L. donovani P. falciparum 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
Ptaeroxylon obliquum (Thunb.) 
Radlk.  
Ptaeroxylaceae P01890b Stem bark DCM/MeOH (1:1) 30 5 0 0 40 4 65 13 
Pterocarpus angolensis DC. Fabaceae P00304b Stem bark DCM/MeOH (1:1) 0 7 0 0 17 9 0 0 
Pterocarpus angolensis DC. Fabaceae P00304c Stem bark MeOH 7 6 0 0 16 6 1 1 
Pterocarpus angolensis DC. Fabaceae P00305b Roots DCM/MeOH (1:1) 18 0 0 0 21 5 17 0 
Pterocarpus angolensis DC. Fabaceae P00305c Roots MeOH 16 2 0 0 12 0 0 0 
Rauvolfia caffra Sond. Apocynaceae P00734a Roots DCM 100 8 0 3 3 0 45 0 
Rauvolfia caffra Sond. Apocynaceae P00734b Fruits DCM/MeOH (1:1) 5 9 0 0 24 1 20 4 
Rauvolfia caffra Sond. Apocynaceae P00735b Roots DCM/MeOH (1:1) 6 0 0 0 15 1 10 0 
Rauvolfia caffra Sond. Apocynaceae P00735d Roots Aqueous 6 7 0 0 13 0 0 0 
Rauvolfia caffra Sond. Apocynaceae P00735a Fruits DCM 13 16 0 1 20 8 15 0 
Ricinus communis L. var. communis Euphorbiaceae P02300b Leaves DCM/MeOH (1:1) 0 4 0 0 63 1 56 10 
Ricinus communis L. var. communis Euphorbiaceae P02311b Fruits DCM/MeOH (1:1) 5 1 0 0 7 0 13 0 
Ricinus communis L. var. communis Euphorbiaceae P02355b Stem bark DCM/MeOH (1:1) 0 0 0 0 46 0 79 14 
Ricinus communis L. var. communis Euphorbiaceae P02300c Leaves Aqueous 7 2 11 1 35 22 2 7 
Ricinus communis L. var. communis Euphorbiaceae P02311c Fruits Aqueous 8 5 10 0 40 27 7 0 
Ricinus communis L. var. communis Euphorbiaceae P02355c Stem bark Aqueous 5 10 0 0 38 28 7 0 
Rumex crispus L. Polygonaceae P01689b Roots DCM/MeOH (1:1) 0 0 0 0 20 8 21 5 
Rumex crispus L. Polygonaceae P01634a Leaves DCM 2 0 0 0 12 4 10 2 
Rumex crispus L. Polygonaceae P01634b Leaves DCM/MeOH (1:1) 0 4 0 0 19 0 0 0 
Rumex crispus L. Polygonaceae P01689a Roots DCM 1 4 0 0 28 5 55 5 
Rumex sagittatus Thunb. Polygonaceae P12875b Whole plant DCM/MeOH(1:1) 7 0 4 0 19 4 38 0 
Salvia repens Burch. ex Benth. Lamiaceae P08214b Whole plant DCM/MeOH(1:1) 21 7 3 1 101 35 63 2 
Scaevola plumieri (L.) Vahl Goodeniaceae P08206b Twigs  DCM/MeOH(1:1) 7 10 0 1 27 5 22 0 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00245b Leaves DCM/MeOH (1:1) 23 8 0 0 69 16 64 16 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00245c Leaves MeOH 8 11 0 0 39 11 24 5 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00246a Roots DCM 0 11 0 0 80 16 26 9 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00246b Roots DCM/MeOH (1:1) 0 16 0 0 71 15 39 6 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00248a Stem bark DCM 5 0 9 0 57 9 46 5 
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Solvent T. brucei rhodesiense T. cruzi  L. donovani P. falciparum 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition  
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(1.8 µg/mL) 
% inhibition  
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
% inhibition 
(9.7 µg/mL) 
% inhibition  
(1.8 µg/mL) 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00248b Stem bark DCM/MeOH (1:1) 0 0 0 0 49 12 28 0 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00248c Stem bark MeOH 10 6 0 0 28 6 3 0 
Schefflera umbellifera (Sond.) Baill. Araliaceae P00248d Stem bark Aqueous 13 15 9 10 17 9 0 0 
Senecio oxyriifolius DC. Asteraceae P08209b Whole plant DCM/MeOH(1:1) 0 7 9 0 32 10 51 6 
Senna didymobotrya (Fresen.) Irwin 
& Barneby 
Fabaceae P08219b Leaves DCM/MeOH(1:1) 13 0 0 3 31 1 36 3 
Senna didymobotrya (Fresen.) Irwin 
& Barneby 
Fabaceae P08220b Twigs  DCM/MeOH(1:1) 22 17 0 0 39 5 54 10 
Senna didymobotrya (Fresen.) Irwin 
& Barneby 
Fabaceae P08221b Pods DCM/MeOH(1:1) 10 2 0 0 29 8 34 3 
Senna didymobotrya (Fresen.) Irwin 
& Barneby 
Fabaceae P08220c Twigs  Aqueous 11 8 11 2 30 15 0 0 
Senna didymobotrya (Fresen.) Irwin 
& Barneby 
Fabaceae P08219c Leaves Aqueous 3 3 0 0 13 3 0 0 
Senna petersiana (Bolle) Lock Fabaceae P18564c Leaves Aqueous 2 0 3 4 28 23 0 1 
Senna petersiana (Bolle) Lock Fabaceae P18565c Twigs  Aqueous 0 2 15 8 31 21 0 0 
Setaria megaphylla (Steud.) T.Durand 
& Schinz 
Poaceae P12880b Whole plant DCM/MeOH(1:1) 18 2 4 7 34 4 100 19 
Spilanthes mauritiana (Pers.) DC. Asteraceae P00274a Stem bark DCM 11 10 0 0 60 9 71 1 
Spilanthes mauritiana (Pers.) DC. Asteraceae P00274b Stem bark DCM/MeOH (1:1) 2 11 0 0 35 9 30 1 
Spilanthes mauritiana (Pers.) DC. Asteraceae P00274c Stem bark MeOH 4 0 0 0 17 1 0 0 
Syzigium cordatum Hochst. ex Sond.  
var. cordatum 
Myrtaceae P18315c Twigs  Aqueous 13 16 2 8 15 6 17 0 
Syzigium cordatum Hochst. ex Sond.  
var. cordatum 
Myrtaceae P18315b Twigs  DCM/MeOH(1:1) 0 1 0 0 51 16 54 11 
Syzigium cordatum Hochst. ex Sond.  
var. cordatum 
Myrtaceae P18316b Leaves DCM/MeOH(1:1) 0 5 0 0 57 12 42 0 
Syzigium cordatum Hochst. ex Sond.  
var. cordatum 
Myrtaceae P18316c Leaves Aqueous 0 0 0 0 9 0 84 0 
Tarchonanthus camphoratus L. Asteraceae P01089a Leaves DCM 86 0 7 1 75 16 76 2 
Tarchonanthus camphoratus L. Asteraceae P01089b Leaves DCM/MeOH (1:1) 14 0 0 0 62 8 42 0 
Tarchonanthus camphoratus L. Asteraceae P01154b Roots DCM/MeOH (1:1) 95 0 0 0 52 1 18 4 
Tarchonanthus camphoratus L. Asteraceae P02554b Whole plant DCM/MeOH (1:1) 99 64 6 1 100 25 49 0 
Tetradenia riparia (Hochst.) Codd Lamiaceae P00741a Leaves DCM 0 0 0 2 36 0 38 0 
Tetradenia riparia (Hochst.) Codd Lamiaceae P00741b Leaves DCM/MeOH(1:1) 6 0 2 2 16 0 7 7 
Tetradenia riparia (Hochst.) Codd Lamiaceae P00741d Leaves Aqueous 0 7 4 7 9 0 0 0 
Trichilia emetica Vahl subsp. emetica Meliaceace P02470c Twigs/Leaves Aqueous 13 6 0 0 15 7 1 0 
Turraea floribunda Hochst. Meliaceace P15192c Leaves Aqueous 24 27 0 2 21 5 1 4 
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Vangueria infausta Burch. subsp. 
infausta 
Rubiaceae P02497b Fruits DCM/MeOH (1:1) 3 4 0 0 33 0 33 0 
Vernonia colorata (Willd.) Drake 
subsp. colorata  
Asteraceae P18569c Twigs  Aqueous 0 6 6 8 29 19 1 0 
Vernonia fastigiata Oliv. & Hiern Asteraceae P00393b Leaves DCM/MeOH (1:1) 58 4 0 0 29 0 30 0 
Vernonia fastigiata Oliv. & Hiern Asteraceae P00393c Leaves MeOH 10 11 0 0 24 8 21 0 
Vernonia hirsuta (DC.) Sch.Bip. Ex 
Walp. 
Asteraceae P02834b Whole plant DCM/MeOH (1:1) 99 5 0 0 81 6 46 0 
Vernonia myriantha Hook.f. Asteraceae P00170a Roots DCM 0 0 0 0 19 0 21 0 
Vernonia myriantha Hook.f. Asteraceae P00170b Roots DCM/MeOH (1:1) 6 15 0 0 31 10 16 5 
Vernonia myriantha Hook.f. Asteraceae P00170d Roots Aqueous 7 8 0 0 17 6 16 8 
Vernonia myriantha Hook.f. Asteraceae P00171a Leaves DCM 5 10 0 0 34 10 35 1 
Vernonia myriantha Hook.f. Asteraceae P00171b Leaves DCM/MeOH (1:1) 6 10 0 0 23 9 11 0 
Vernonia myriantha Hook.f. Asteraceae P00170c Roots MeOH 10 0 0 0 22 4 0 0 
Vernonia natalensis Sch.Bip. ex 
Walp. 
Asteraceae P08212b Whole plant DCM/MeOH(1:1) 100 5 1 2 46 8 57 10 
Vernonia oligocephala (DC.) Sch.Bip.   
ex Walp. 
Asteraceae P00989b Roots DCM/MeOH (1:1) 0 0 3 0 13 1 24 0 
Vernonia oligocephala (DC.) Sch.Bip.   
ex Walp. 
Asteraceae P01015a Leaves DCM 99 78 23 0 60 4 89 11 
Vernonia oligocephala (DC.) Sch.Bip.   
ex Walp. 
Asteraceae P01015b Leaves DCM/MeOH (1:1) 99 0 0 0 21 6 29 0 
Ximenia caffra Sond. var. caffra Olacaceae P00351a Leaves DCM 0 7 0 0 31 6 12 0 
Ximenia caffra Sond. var. caffra Olacaceae P00351b Leaves DCM/MeOH (1:1) 0 7 0 0 16 10 6 0 
Ximenia caffra Sond. var. caffra Olacaceae P00351d Leaves Aqueous 8 11 5 4 17 0 0 0 
Ximenia caffra Sond. var. caffra Olacaceae P00352a Roots DCM 5 12 0 0 21 4 1 0 
Ximenia caffra Sond. var. caffra Olacaceae P00352b Roots DCM/MeOH(1:1) 1 2 0 0 16 8 0 0 
Ximenia caffra Sond. var. caffra Olacaceae P00352c Roots MeOH 1 7 0 0 19 4 0 0 
Xysmalobium undulatum (L.) Aiton.f. Apocynaceae P12869b Whole plant DCM/MeOH(1:1) 8 10 0 0 30 0 28 0 
Zehneria scabra (L.f.) Sond. subsp.  
scabra 
Cucurbitaceae P08210b Whole plant DCM/MeOH(1:1) 5 8 9 6 22 0 21 5 
Zehneria scabra (L.f.) Sond. subsp.  
scabra 
Cucurbitaceae P08210c whole plant Aqueous 28 0 0 4 17 13 0 4 
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 3.2 Antiprotozoal Screening of 60 South African Plants, and the Identification of the 
Antitrypanosomal Germacranolides Schkuhrin I and II 
Tsholofelo Mokoka, Peter K. Xolani, Stefanie Zimmermann, Yoshie Hata, Michael Adams, Marcel 
Kaiser, Nivan Moodley, Vinesh Maharaj, Neil A. Koorbanally, Matthias Hamburger, Reto Brun, Gerda 
Fouche 
Planta Med., 2013, 79: 1380–1384.  DOI: 10.1055/s-0033-1350691 
 
 
 
Two hundred and seven extracts from 59 South African plant species (27 botanical families) with 
antiparasitic traditional use were tested against a panel of 4 parasites (Plasmodium falciparum, 
Trypanosoma brucei rhodesiense, Leishmania donovani, and Trypanosoma cruzi). The 10 most active 
plants were selected, among them S. pinnata and V. mespilifolia.  The identification of the active 
compounds from these species was achieved with the aid of HPLC-based activity profiling. 
 
 
My contributions to this work were: (1) HPLC microfractionation of 10 extract from 5 species; (2) 
recording and interpretation of analytical data for the 18 HPLC-activity profiles, obtained for the 
different parasites P. falciparum, T. b. rhodesiense, and/or L. donovani; (3) dereplication of the known 
constituents of the active fractions; (4) participation in drafting the paper.  
Tsholofelo Mokoka performed the HPLC-activity profiling of additional 10 extracts, achieved the 
isolation of schkuhrin I, II, and cynaropicrin and wrote the first draft of the paper. The antiprotozoal 
activity of the extracts and HPLC fractions was assessed at the Swiss TPH. Extracts were provided by the 
CSIR team. 
Yoshie Hata-Uribe 
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Abstract
!
Two hundred and seven extracts were prepared
from sixty plants from South Africa and screened
for in vitro activity against Trypanosoma brucei
rhodesiense, Trypanosoma cruzi, Leishmania dono-
vani, and Plasmodium falciparum. For the 21 ex-
tracts which inhibited the growth of one or more
parasites with more than 95% at 10 µg/mL, the
IC50 values against all four protozoal parasites
and cytotoxic IC50 values against L6 myoblasts
were determined. Amongst the most notable re-
sults are the activities of Psoralea pinnata (IC50 of
0.15 µg/mL), Schkuhria pinnata (2.04 µg/mL), and
Vernonia mespilifolia (1.01 µg/mL) against Trypan-
soma brucei rhodesiense. HPLC-based activity
profiling was used to identify the active constitu-
ents in the extracts, and the germacranolide ses-
quiterpene lactones schkuhrin I and II from S. pin-
nata, and cynaropicrin from V. mespilifolia were
identified, with IC50 values of 0.9, 1.5, and
0.23 µM, respectively.
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http://www.thieme-connect.de/ejournals/toc/
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l.Introduction
!
Neglected tropical diseases (NTDs) caused by
Leishmania species (leishmaniasis), Trypanosoma
brucei (sleeping sickness), and Trypanosoma cruzi
(Chagas disease) are life-threatening and repre-
sent a risk to large parts of the populations in
poor tropical countries. These diseases affect
about 21 million people worldwide, mostly in
economically challenged regions [1]. It is esti-
mated that these three diseases are responsible
for over 110000 deaths every year [2]. In addition,
malaria caused by Plasmodium species was re-
sponsible for approximately 216 million infec-
tions and over 655000 deaths in 2010 [3]. The
control of these parasitic infections relies on a
few chemotherapeutic agents, most of which
were discovered many decades ago [4] and pose
many challenges due to adverse side effects, long
treatment cycles, poor efficacy, high costs, the oc-
currence of drug resistances, and limited avail-
ability [1]. Therefore, the discovery of novel, safe,
and effective antiprotozoal agents is an urgent
need.
Natural products play a significant role in the dis-
covery of new drug leads because of the un-
matched availability of chemical diversity. Wening of… Planta Med 2013; 79: 1380–1384
81previously reported a screen of 300 extracts from
plants traditionally used to treat malaria and their
antiprotozoal effects against L. donovani, T.b. rho-
desiense, P. falciparum, and T. cruzi in vitro [5].
This work is a continuation of the project, where
207 further extracts have been tested. Further-
more, we report the identification of three anti-
trypanosomal sesquiterpene lactones from the
most active extracts, which were identified by
HPLC-based activity profiling [6].Results and Discussion
!
A total of 207 plants extracts from 60 plant spe-
cies were assessed for antiprotozoal activity
against four protozoan parasites at 10 and 2 µg/
mL, respectively (Table S1 in the Supporting In-
formation). The most active extracts from the
preliminary screening were subjected to IC50 val-
ue determination. Extracts which exhibited an
IC50 value ≤ 5.0 µg/mL were considered active
and were subjected to HPLC-based activity profil-
ing to identify potential antiprotozoal com-
pounds. The lipophilic extracts of Psoralea pinna-
ta (Fabaceae) and Drypetes gerrardii (Euphorbia-
ceae) exhibited very good antiprotozoal activity
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l.against T.b. rhodesiense (IC50, 0.15 ± 0.02 and 0.31 ± 0.02 µg/mL)
and P. falciparum (IC50, 0.50 ± 0.23 µg/mL), respectively (l" Table
1). In addition, these extracts showed the best selectivity index
values ranging between 97 and 139, indicating their selectivity
towards killing the parasites with very little toxicity towards the
myoblasts L-6 cells. Vernonia mespilifolia Less. (Asteraceae), Oe-
dera genistifolia (Asteraceae), Abrus precatorius africanus (Faba-
ceae), and Ekebergia capensis (Meliaceae) also exhibited IC50 val-
ues ranging between 1.0 and 1.7 µg/mL against T.b. rhodesiense
and L. donovani, however, withmoderate selectivity indices rang-
ing from 24 to 48.
The active extracts of Psoralea pinnata, Schkuhria pinnata (Aster-
aceae), and Vernonia mespilifolia (Asteraceae) were further
studied to identify their active constituents. For the purpose of
this study, we report the identification of active compounds from
S. pinnata and V. mespilifoliawith the aid of an HPLC-based activ-
ity profiling technique. However, the identification of active con-
stituents from P. pinnata will be reported in a separate publica-
tion.
The one minute microfractions from the active DCM/MeOH ex-
tract from Schkuhria pinnatawere tested against T.b. rhodesiense,
and it was shown that the activity was concentrated in the active
time windows of minutes 14 and 16 (l" Fig. 1), which showed
100% inhibition. These fractions both contained one main sub-
stance, which was isolated by semipreparative HPLC and struc-
turally elucidated by NMR, high-resolution MS, and comparison
of spectral data to the literature [7]. The compound from fraction
14 was shown to be schkuhrin I (1) and the one from fraction 16
was schkuhrin II (2) (l" Fig. 3). The two structurally similar ger-
macranolides showed antiprotozoal activity against T.b. rhode-
siensewith IC50 values of 0.86 and 1.50 µM, respectively, and anti-
plasmodial activity with IC50 values of 2.05 and 1.67 µM, respec-
tively (l" Table 2).
The HPLC activity profile of the DCM/MeOH extract of
V. mespilifolia showed significant antiprotozoal activity in frac-
tions 12 and 13 against T.b. rhodesiense (l" Fig. 2). The compound
was isolated, and, by use of NMR, high-resolution MS, and com-
parison to literature data [8], identified as the known sesquiter-
pene lactone cynaropicrin (3) (l" Fig. 3). The IC50s of 3 were
0.23 µM against T.b. rhodesiense and 1.56 µM against P. falcipa-
rum. L. donovani exhibited an IC50 value of 1.56 µM, whereas T.
cruzi was the least susceptible parasite with an IC50 value of
5.14 µM.
This study is a continuation of our efforts of collecting and
screening South African plants against protozoan parasites [5].
The results of a large screen of 207 extracts are shown (Support-
ing Information Table S1). Furthermore, by using HPLC-based ac-
tivity profiling, the sesquiterpene lactones schkuhrin I (1) and II
(2) from Schkuhria pinnata, and cynaropicrin (3) from Vernonia
mespilifolia, were identified as potent antiprotozoal agents. The
powdered leaf of S. pinnata has been used as a remedy for ma-
laria, influenza, and colds [9]. Also, S. pinnata has been used as
an insecticide, particularly to kill fleas [11]. Extracts from S. pin-
nata were shown to inhibit Brucella abortus in vitro [10], and
have yielded several sesquiterpene lactones and the phenyl prop-
anoids [11]. Both schkuhrin I (1) and II (2) have been isolated
from the same species and other Schkuhria species, but their
antiprotozoal activities have not been reported previously.
Some of the species belonging to the genus Vernonia have been
used in folk medicine to treat malaria [12]. V. mespilifolia Less. is
used traditionally by Zulus to treat malaria-related feverish con-
ditions [13].M
82Sesquiterpenes are the largest known group of natural products
[14] and are a chemical marker for the largest plant family, the
Asteraceae [15]. Numerous sesquiterpene lactones have been
tested for antiprotozoal activity in vitro. Schmidt et al. [16]
showed in an antitrypanosomal-QSAR study of 40 STLs and, in
2012, supplied two excellent reviews of antiprotozoal in vitro ef-
fects of 883 plant-derived natural products including 83 sesqui-
terpene lactones [14,16]. This study is the first report of the anti-
protozoal effects of 1 and 2, whereas the antitrypansomal effects
of 3 have already been described by Zimmermann et al. [17]. In
fact, 3was the first and so far only plant-derived compound to in-
hibit T.b. rhodesienese in vivo. The mode of action of 3was shown
to be its ability to form stable bis-adducts with trypanothione via
a Michael addition, thus depleting the parasites of their only
means of redox control [18].
With this screening study we report recent in vitro results of a
plant extract screen. This may provide a basis for selecting plants
in the future for further phytochemical and bioactivity studies.
Furthermore, we report the in vitro antiprotozoal effects of three
compounds, which will contribute to a better understanding of
sesquiterpene lactones antiprotozoal structure-activity relation-
ships.Materials and Methods
!
Plant collection and identification
Sixty plant species were collected between 1996 and 2002 at a
variety of locations in South Africa. The selected plant species
were based on their traditional uses against parasitic diseases
(unpublished work). The species were identified by personnel of
the South African National Biodiversity Institute (SANBI) where
the voucher specimens were deposited (Table S1 in the Support-
ing Information).
Plant extract preparations
The plant parts (roots, leaves, twigs, fruit, and stem bark) were
dried in an oven at 30–60°C, and extracts from finely ground
plant parts were prepared as previously described [5]. Stock solu-
tions were prepared at 10mg/mL in DMSO and stored at − 80°C
until use. Dilutions for biological testing were freshly prepared
in culture medium on the day of testing (< 1% DMSO).
Isolation and purification of active
compounds 1, 2, and 3
For compounds 1, 2, and 3, semipreparative HPLC purification
was performed using an Agilent HPLC 1200 series consisting of a
low-pressure mixing pump with a degasser module, column
oven, and PDA detector (Agilent). The extracts of the whole plant
of Schkuhria pinnata (Lam.) Cabrera and Vernonia mespilifolia
Less. (100mg/mL in DMSO, respectively) were prepared by dis-
solving 1.0 g of DCM/MeOH (1:1) extract, filtered through
0.45 µm Millipore membrane filters. Several repetitions of
200 µL injections were made. The separation was performed on
aWaters Sunfire RP-18 column (10 × 150mm i.d.; 10 µm;Waters
GmbH). The mobile system used was made up of water (A) and
acetonitrile (B). The elution gradient was linear from A:B
(90:10) to (0 :100) in 30min at a flow rate of 6.0mL/min, fol-
lowed by 5min of acetonitrile washing, and returned to the ini-
tial elution conditions (90:10) over 5min. The separation of all
components was detected at a wavelength of 254 nm.okoka TA et al. Antiprotozoal Screening of… Planta Med 2013; 79: 1380–1384
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Fig. 1 HPLC-based activity profiling of Schkuhria
pinnata organic extract against T.b. rhodesiense. The
bar graphs show the inhibitory activity of individual
HPLC fractions collected from a single separation of
the crude extract. The HPLC chromatogram was
measured at 254 nm.
Table 2 Antiprotozoal activity (IC50 values in µM) of schkuhrin I (1), schkuhrin II (2), and cynaropicrin (3) against T.b. rhodesiense, T. cruzi, L. donovani, and P.
falciparum.
T.b. rhodesiense T. cruzi L. donovani P. falciparum Cytotox. L6
IC50 SI IC50 SI IC50 SI IC50 SI IC50
Schkuhrin I (1) 0.86 6.12 16.40 0.32 39.00 0.13 2.05 2.57 5.26
Schkuhrin II (2) 1.50 6.02 26.96 0.33 65.00 0.14 1.67 5.41 9.03
Cynaropicrin (3) 0.23 5.61 5.14 0.25 1.56 0.83 1.56 0.83 1.29
Melarsoprol 0.01
Benznidazole 2.25
Miltefosine 0.47
Chloroquine 0.015
Podophyllotoxin 0.02
Fig. 2 HPLC-based activity profiling of Vernonia
mespilifolia organic extract against T.b. rhodesiense.
The bar graphs show the inhibitory activity of indi-
vidual HPLC fractions collected from a single sepa-
ration of the crude extract. The HPLC chromato-
gram was measured at 254 nm.
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All extracts were screened as previously described [5] against P.
falciparum (NF-54 strain), T.b. rhodesiense (STIB 900 strain), T.
cruzi trypomastigote forms (Tulahuen strain), and L. donovani
(strain MHOM/ET/67/L82) at 10 (high concentration) and 2 µg/
mL (low concentration). Half maximal inhibition concentrations
(IC50s) were determined by serial dilution, and represent theM
84mean of at least two independent experiments. HPLC-based ac-
tivity profiling was done as previously described [7]. Positive
controls, melarsoprol (Sanofi-Aventis) (T.b. rhodesiense), benzni-
dazole (Sigma) (T. cruzi), miltefosine (VWR) (L. donovani), chloro-
quine (Sigma) (P. falciparum), and podophyllotoxin (Sigma) (L6
cells) were used. The purity of all controls was > 95% according
to the suppliers.okoka TA et al. Antiprotozoal Screening of… Planta Med 2013; 79: 1380–1384
Fig. 3 Structures of
the isolated com-
pounds from Schkuhria
pinnata and Vernonia
mespilifolia crude ex-
tracts.
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Data on the antiprotozoal activity of 60 South African medicinal
plants, protocols for the purification and isolation of schkuhrin I,
schkuhrin II, and cynaropicrin, as well as detailed protocols for
the bioassays are available as Supporting Information.D
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Table 1S. Antiprotozoal activity of 60 South African medicinal plants species against Trypanosoma brucei rhodesiense, 
Trypanosoma cruzi, Leishmania donovani, and P. falciparum. The activity is expressed as percentage (%) growth 
inhibition. Plants extracts showing more than 95% growth inhibition at 10 µg/mL were considered potential “hits”. The tests 
were done twice and in duplicate. 
          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Fabaceae 
Abrus precatorius L. 
subsp. africanus 
Verdc. 
Whole plant 
DCM/MeOH 
(1:1) 
P06218B 100.0 100.0 44.0 16.7 75.5 16.1 97.8 37.0 
Fabaceae 
Acacia caffra 
(Thunb.) Willd. 
Leaves 
DCM/MeOH 
(1:1) 
P00855B 3.0 0.0 42.3 17.6 33.5 8.3 19.9 0.3 
Fabaceae 
Acacia caffra 
(Thunb.) Willd. 
Roots 
DCM/MeOH 
(1:1) 
P00866B 93.9 0.0 46.1 25.7 34.7 8.9 55.0 7.0 
Fabaceae 
Acacia erioloba 
E.Mey. 
Roots 
DCM/MeOH 
(1:1) 
P08470B 18.6 6.4 48.9 18.8 50.2 26.3 61.4 72.6 
Euphorbiaceae 
Acalypha 
peduncularis E.Mey. 
ex Meisn. 
Leaves 
DCM/MeOH 
(1:1) 
P02855B 98.8 0.0 37.2 8.5 60.2 0.0 77.7 19.2 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Asparagaceae 
Asparagus virgatus 
Baker 
Leaves 
DCM/MeOH 
(1:1) 
P00558B 10.3 0.0 47.6 15.7 0.0 0.0 36.5 0.0 
Lamiaceae 
Becium obovatum 
(E.Mey. ex Benth.) 
N.E.Br. subsp. 
obovatum  var. 
obovatum  
Roots 
DCM/MeOH 
(1:1) 
P04123B 49.4 11.9 37.5 3.9 97.5 5.7 99.3 38.2 
Scrophulariaceae 
Bowkeria cymosa 
MacOwan 
Leaves 
DCM/MeOH 
(1:1) 
P11785B 46.1 17.6 59.8 26.2 94.1 31.2 87.0 27.8 
Scrophulariaceae 
Bowkeria cymosa 
MacOwan 
Twigs 
DCM/MeOH 
(1:1) 
P11786B 14.0 4.6 36.9 8.4 47.5 24.3 60.1 7.6 
Scrophulariaceae 
Bowkeria cymosa 
MacOwan 
Roots 
DCM/MeOH 
(1:1) 
P11787B 17.1 0.0 53.0 15.2 39.9 17.0 80.7 14.6 
Scrophulariaceae 
Bowkeria cymosa 
MacOwan 
Stems 
DCM/MeOH 
(1:1) 
P11788B 5.6 0.0 54.0 22.3 31.7 17.1 45.2 3.5 
88
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Asteraceae 
Brachylaena 
discolor DC. 
Roots 
DCM/MeOH 
(1:1) 
P04199B 20.9 10.3 35.0 7.4 28.9 14.5 38.2 4.8 
Asteraceae 
Brachylaena 
discolor DC. 
Lleaves 
DCM/MeOH 
(1:1) 
P04321B 50.0 12.6 34.2 15.3 30.4 19.0 71.5 10.3 
Asteraceae 
Brachylaena 
discolor DC. 
Roots 
DCM/MeOH 
(1:1) 
P04459B 37.0 16.0 37.4 15.4 36.4 18.8 60.2 15.9 
Euphorbiaceae 
Bridelia micrantha 
(Hochst.) Baill. 
Leaves 
DCM/MeOH 
(1:1) 
P04722B 98.0 0.0 38.2 11.6 30.7 0.0 84.3 12.8 
Euphorbiaceae 
Bridelia micrantha 
(Hochst.) Baill. 
Stems 
DCM/MeOH 
(1:1) 
P04806B 58.4 24.3 37.5 13.7 54.0 20.0 92.5 23.3 
Euphorbiaceae 
Bridelia micrantha 
(Hochst.) Baill. 
Roots 
DCM/MeOH 
(1:1) 
P04815B 42.0 0.0 30.6 14.3 15.8 0.0 80.7 34.6 
Rubiaceae 
Canthium 
mundianum (Cham. 
Leaves 
DCM/MeOH 
(1:1) 
P00413B 12.8 0.0 48.9 20.2 30.7 23.0 24.1 0.0 
89
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
& Schltdl.) Lantz 
Rubiaceae 
Canthium 
mundianum (Cham. 
& Schltdl.) Lantz 
Leaves MeOH P00413C 10.1 0.0 45.0 16.3 30.8 28.3 22.6 0.0 
Rubiaceae 
Canthium 
mundianum (Cham. 
& Schltdl.) Lantz 
Roots DCM P00414A 23.1 0.0 49.9 22.3 65.7 22.4 87.1 15.5 
Rubiaceae 
Canthium 
mundianum (Cham. 
& Schltdl.) Lantz 
Roots 
DCM/MeOH 
(1:1) 
P00414B 14.5 0.0 49.9 18.5 31.8 21.4 29.6 0.0 
Rubiaceae 
Canthium 
mundianum (Cham. 
& Schltdl.) Lantz 
Roots MeOH P00414C 12.8 0.0 43.0 24.7 29.4 19.8 30.1 0.0 
Rubiaceae 
Canthium 
mundianum (Cham. 
& Schltdl.) Lantz 
Fruits 
DCM/MeOH 
(1:1) 
P00415B 10.6 0.0 46.7 20.3 20.5 19.0 26.3 0.0 
Rubiaceae Canthium 
mundianum (Cham.) 
Fruits MeOH P00415C 0.7 0.0 38.1 9.7 0.0 0.0 25.2 0.1 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
& Schltdl.) Lantz 
Capparaceae 
 
Capparis tomentosa 
Lam. 
Capparis tomentosa 
Lam. 
Capparis tomentosa 
Lam. 
Roots 
DCM/MeOH 
(1:1) 
P06167B 31.2 30.2 30.5 13.1 35.1 23.8 76.3 26.4 
Fruits 
DCM/MeOH 
(1:1) 
P06168B 17.7 0.0 24.8 15.7 17.6 19.6 37.8 3.7 
Stems 
DCM/MeOH 
(1:1) 
P06169B 34.0 3.4 67.1 17.2 86.5 32.7 93.5 30.9 
Asteraceae 
 
Cirsium vulgare 
(Savi) Ten. 
Cirsium vulgare 
(Savi) Ten. 
Cirsium vulgare 
(Savi) Ten. 
Whole plant DCM P02112A 10.2 0.0 49.1 30.2 33.1 24.9 46.3 0.0 
Whole plant 
DCM/MeOH 
(1:1) 
P02112B 23.2 5.3 42.9 29.3 30.7 27.6 49.1 0.0 
Leaves 
DCM/MeOH 
(1:1) 
P06377B 11.3 1.4 42.2 10.2 39.7 18.4 81.0 20.6 
Roots 
DCM/MeOH 
(1:1) 
P06381B 28.7 1.8 8.3 5.3 38.2 16.7 51.9 11.8 
Asteraceae 
Cirsium vulgare 
(Savi) Ten. 
Stems 
DCM/MeOH 
(1:1) 
P06384B 5.9 0.0 46.8 20.6 35.3 15.2 70.6 16.5 
Rutaceae 
Clausena anisata 
(Willd.) Hook.f. ex 
Benth. var. anisata  
Leaves 
DCM/MeOH 
(1:1) 
P04413B 98.8 13.6 28.8 8.7 53.3 4.5 77.8 15.4 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Rutaceae 
Clausena anisata 
(Willd.) Hook.f. ex 
Benth. var. anisata  
Roots 
DCM/MeOH 
(1:1) 
P04411B 82.5 6.3 25.0 7.1 71.4 1.4 100.0 51.5 
Lamiaceae  
Clerodendrum 
glabrum E.Mey. 
Stems 
DCM/MeOH 
(1:1) 
P09466B 5.5 0.0 42.3 15.3 42.8 18.7 82.5 19.1 
Lamiaceae  
Clerodendrum 
glabrum E.Mey. 
Roots 
DCM/MeOH 
(1:1) 
P09467B 19.7 0.0 50.0 17.7 69.8 31.5 58.6 4.5 
Euphorbiaceae 
Clutia pulchella L. 
var. pulchella 
Twigs DCM P00020A 18.2 6.8 28.8 16.7 38.2 21.3 69.4 2.4 
Euphorbiaceae 
Clutia pulchella L. 
var. pulchella 
Twigs 
DCM/MeOH 
(1:1) 
P00020B 20.0 10.8 37.6 23.1 33.3 20.9 38.0 2.7 
Euphorbiaceae 
Clutia pulchella L. 
var.  pulchella 
Twigs MeOH P00020C 18.3 9.9 38.1 16.5 31.9 19.3 36.0 0.0 
Euphorbiaceae 
Clutia pulchella L. 
var.  pulchella 
Leaves 
DCM/MeOH 
(1:1) 
P00476B 11.8 4.7 48.2 24.6 34.3 24.9 59.9 1.1 
Euphorbiaceae 
Clutia pulchella L. 
var. pulchella 
Leaves MeOH P00476C 3.8 0.0 48.5 22.6 31.2 20.6 53.1 8.3 
Euphorbiaceae 
Clutia pulchella L. 
var. pulchella 
Roots 
DCM/MeOH 
(1:1) 
P10738B 12.5 1.9 47.6 16.6 14.2 0.0 97.7 75.0 
Euphorbiaceae 
Clutia pulchella L. Leaves & DCM/MeOH 
P10739B 42.3 8.3 34.7 19.9 40.1 14.1 74.0 12.5 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
var. pulchella stems (1:1) 
Euphorbiaceae 
Clutia pulchella L. 
var. pulchella 
Stems 
DCM/MeOH 
(1:1) 
P10740B 19.2 5.0 40.2 24.3 48.3 17.1 76.8 19.1 
Euphorbiaceae 
Croton gratissimus 
Burch. var. 
gratissimus 
Leaves 
DCM/MeOH 
(1:1) 
P07086B 40.1 3.2 38.0 15.6 96.4 26.1 71.8 27.1 
Euphorbiaceae 
Croton gratissimus 
Burch. var. 
gratissimus  
Stems 
DCM/MeOH 
(1:1) 
P07087B 38.9 6.4 25.3 12.7 60.6 0.0 83.2 42.9 
Euphorbiaceae 
Croton gratissimus 
Burch. var. 
gratissimus  
Bark 
DCM/MeOH 
(1:1) 
P07089B 100.0 1.9 13.3 16.0 67.2 29.6 79.6 31.0 
Iridaceae 
Dietes iridioides (L.) 
Sweet ex Klatt 
Leaves 
DCM/MeOH 
(1:1) 
P08597B 98.8 0.0 43.5 22.9 30.4 18.1 69.4 8.4 
Iridaceae 
Dietes iridioides (L.) 
Sweet ex Klatt 
Roots 
DCM/MeOH 
(1:1) 
P08598B 97.9 0.0 35.0 0.0 0.0 0.0 77.7 24.0 
Iridaceae 
Dietes iridioides (L.) 
Sweet ex Klatt 
Flowers 
DCM/MeOH 
(1:1) 
P08599B 99.9 0.0 41.8 13.1 55.8 17.1 69.9 24.8 
Iridaceae 
Dietes iridioides (L.) 
Sweet ex Klatt 
Fruits 
DCM/MeOH 
(1:1) 
P08600B 100.0 4.7 31.3 12.2 42.8 19.3 76.9 12.1 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Leaves DCM P00933A 20.6 0.0 49.0 26.5 80.4 28.2 78.2 9.9 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Leaves 
DCM/MeOH 
(1:1) 
P00933B 6.0 0.0 46.0 16.1 35.5 25.2 37.9 0.0 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Roots DCM P00940A 12.7 0.0 38.9 18.2 57.3 27.2 43.8 0.0 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Roots 
DCM/MeOH 
(1:1) 
P00940B 18.6 0.0 58.7 13.9 35.3 26.5 61.7 0.0 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Twigs 
DCM/MeOH 
(1:1) 
P03406B 14.7 0.0 50.0 17.8 54.6 15.7 73.0 10.0 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Leaves & 
Twigs 
DCM/MeOH 
(1:1) 
P03407B 40.0 3.0 34.5 5.3 86.2 18.9 97.4 19.5 
Apocynaceae 
Diplorhynchus 
condylocarpon 
(Müll.Arg.) Pichon 
Stems 
DCM/MeOH 
(1:1) 
P07108B 21.1 1.9 40.2 10.3 47.1 24.9 93.3 28.2 
Euphorbiaceae 
Drypetes gerrardii 
Stems 
DCM/MeOH 
P05778B 60.7 28.5 30.9 0.0 80.5 24.9 100.0 99.5 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Hutch. var. gerrardii (1:1) 
Euphorbiaceae 
Drypetes gerrardii 
Hutch. var. gerrardii  
Leaves 
DCM/MeOH 
(1:1) 
P05800B 96.5 37.3 32.0 6.9 28.1 23.6 69.9 21.6 
Meliaceae 
Ekebergia capensis 
Sparrm. 
Leaves 
DCM/MeOH 
(1:1) 
P04616B 98.8 0.9 39.3 13.3 50.6 0.0 71.9 13.8 
Meliaceae 
Ekebergia capensis 
Sparrm. 
Roots 
DCM/MeOH 
(1:1) 
P04929B 100.0 100.0 102.4 95.3 100.0 56.9 98.6 57.0 
Euphorbiaceae 
Euphorbia 
clavarioides Boiss. 
var. truncata 
(N.E.Br.) A.C.White, 
R.A.Dyer & B.Sloane 
Leaves 
DCM/MeOH 
(1:1) 
P01559B 7.6 0.0 37.8 32.4 42.5 12.5 59.9 12.7 
Euphorbiaceae 
Euphorbia 
clavarioides Boiss. 
var. truncata 
(N.E.Br.) A.C.White, 
R.A.Dyer & B.Sloane 
Roots 
DCM/MeOH 
(1:1) 
P01568B 17.2 0.0 46.8 25.5 45.9 17.4 63.9 5.4 
Euphorbiaceae 
Euphorbia 
pulcherrima Willd. 
ex Klotzsch 
Leaves 
DCM/MeOH 
(1:1) 
P10453B 11.8 0.0 30.7 21.1 42.8 20.4 63.4 6.3 
Euphorbiaceae Euphorbia 
pulcherrima Willd. 
Stems 
DCM/MeOH 
(1:1) 
P10454B 17.8 0.0 45.6 15.4 55.2 22.9 86.5 16.4 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
ex Klotzsch 
Euphorbiaceae 
Euphorbia 
pulcherrima Willd. 
ex Klotzsch 
Roots 
DCM/MeOH 
(1:1) 
P10455B 13.5 0.0 45.4 17.4 42.7 18.5 81.7 23.2 
Asteraceae 
Felicia filifolia 
(Vent.) Burtt Davy 
subsp. filifolia 
Leaves 
DCM/MeOH 
(1:1) 
P10676B 7.3 1.1 45.2 11.5 0.0 14.9 88.2 19.3 
Asteraceae 
Helichrysum 
mundtii Harv. 
Stems DCM P00464A 19.3 0.0 79.0 34.9 64.7 31.0 84.3 20.7 
Asteraceae 
Helichrysum 
mundtii Harv. 
Stems 
DCM/MeOH 
(1:1) 
P00464B 9.9 4.4 75.4 33.2 61.5 28.0 81.1 14.2 
Asteraceae 
Helichrysum 
mundtii Harv. 
Stems MeOH P00464C 2.0 0.0 59.2 26.7 38.4 29.5 34.9 0.0 
Asteraceae 
Helichrysum 
mundtii Harv. 
Roots DCM P00466A 38.8 0.0 89.9 44.2 80.7 35.1 89.7 19.9 
Asteraceae 
Helichrysum 
mundtii Harv. 
Roots 
DCM/MeOH 
(1:1) 
P00466B 15.2 0.7 73.7 32.8 47.8 27.4 71.5 3.2 
Asteraceae 
Helichrysum 
mundtii Harv. 
Roots MeOH P00466C 17.3 0.0 58.9 28.0 36.9 23.9 55.2 0.0 
Asteraceae 
Helichrysum 
Leaves 
DCM/MeOH 
P00467B 7.7 0.0 52.2 19.0 32.3 21.2 46.5 0.3 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
mundtii Harv. (1:1) 
Asteraceae 
Helichrysum 
mundtii Harv. 
Leaves MeOH P00467C 5.5 0.0 46.1 15.2 0.0 0.0 37.1 3.5 
Asteraceae 
Helichrysum 
pedunculatum 
Hilliard & B.L.Burtt 
Whole plants 
DCM/MeOH 
(1:1) 
P08309B 9.2 0.0 40.0 8.1 36.3 31.8 61.9 24.0 
Apiaceae 
Heteromorpha 
arborescens 
(Spreng.) Cham. & 
Schltdl. var. 
abyssinica (A.Rich.) 
H.Wolff 
Roots 
DCM/MeOH 
(1:1) 
P12488B 17.3 0.0 40.2 26.8 38.0 32.0 66.2 27.7 
Apiaceae 
Heteromorpha 
arborescens 
(Spreng.) Cham. & 
Schltdl. var. 
abyssinica (A.Rich.) 
H.Wolff 
Bark 
DCM/MeOH 
(1:1) 
P12489B 19.0 0.0 33.4 14.9 44.8 28.2 84.0 26.5 
Lamiaceae 
Hyptis pectinata (L.) 
Poit. 
Leaves, 
stems, fruits 
DCM/MeOH 
(1:1) 
P02459B 32.2 0.0 53.4 17.4 53.5 18.2 85.0 19.9 
Proteaceae 
Leucospermum 
cuneiforme 
(Burm.f.) Rourke 
Leaves 
DCM/MeOH 
(1:1) 
P02599B 21.8 6.4 44.0 23.1 50.6 10.5 99.4 21.3 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Proteaceae 
Leucospermum 
cuneiforme 
(Burm.f.) Rourke 
Roots 
DCM/MeOH 
(1:1) 
P02606B 18.5 3.3 49.0 19.7 11.1 3.5 41.2 9.9 
Euphorbiaceae 
Macaranga capensis 
(Baill.) Benth. ex 
Sim 
Leaves 
DCM/MeOH 
(1:1) 
P04676B 83.4 7.9 55.0 17.2 49.6 0.0 91.7 22.0 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Leaves DCM P00488A 18.1 0.0 49.2 25.9 42.5 22.9 71.1 3.4 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Leaves MeOH P00488C 99.3 0.0 50.8 24.2 28.5 23.3 30.1 0.0 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Fruits DCM P00489A 18.6 0.0 48.0 27.0 40.6 26.8 53.2 0.0 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Fruits MeOH P00489C 6.7 0.0 45.2 27.9 48.5 26.2 26.2 0.0 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Roots DCM P00490A 10.3 0.0 46.7 22.1 45.9 27.9 83.4 9.3 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Roots MeOH P00490C 9.4 0.0 41.6 23.3 35.0 22.9 27.3 0.0 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Stems DCM P00491A 12.8 0.0 40.9 29.0 56.0 27.2 88.7 14.8 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Stems MeOH P00491C 17.6 0.0 48.1 27.8 27.7 21.9 23.8 0.0 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Leaves & 
twigs 
DCM P02237A 34.0 0.0 48.0 25.3 61.6 27.9 98.5 16.6 
Sapotaceae 
Mimusops zeyheri 
Sond. 
Leaves & 
twigs 
DCM/MeOH 
(1:1) 
P02237B 99.5 0.0 42.5 24.9 27.4 23.0 26.4 0.0 
Euphorbiaceae 
Monadenium 
lugardiae N.E.Br. 
Whole plants 
DCM/MeOH 
(1:1) 
P02587B 97.8 2.3 40.6 15.8 69.5 16.1 97.7 27.7 
Lamiaceae 
Ocimum 
gratissimum L. 
subsp. gratissimum  
var. gratissimum  
Leaves DCM P00766A 12.3 0.0 47.9 29.2 55.5 14.6 88.7 25.7 
Lamiaceae 
Ocimum 
gratissimum L. 
subsp. gratissimum  
var. gratissimum  
Leaves 
DCM/MeOH 
(1:1) 
P00766B 0.3 0.0 43.2 21.3 0.0 0.0 51.9 21.0 
Lamiaceae 
Ocimum 
gratissimum L. 
subsp. gratissimum  
var. gratissimum  
Roots 
DCM/MeOH 
(1:1) 
P00775B 6.7 4.8 45.6 11.8 30.5 11.6 22.0 10.8 
Lamiaceae 
Ocimum 
gratissimum L. 
subsp. gratissimum  
Stems DCM P00777A 26.5 3.7 39.0 22.9 52.9 17.9 90.5 29.2 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
var. gratissimum  
Lamiaceae 
Ocimum 
gratissimum L. 
subsp. gratissimum  
var. gratissimum  
Stems 
DCM/MeOH 
(1:1) 
P00777B 0.5 0.0 44.3 22.0 33.6 11.5 28.4 0.0 
Asteraceae 
Oedera genistifolia 
(L.) Anderb. & 
K.Bremer 
Whole plant 
DCM/MeOH 
(1:1) 
P03206B 100.0 100.0 50.8 18.6 100.0 69.8 100.0 99.3 
Asteraceae 
Othonna carnosa 
Less. var. carnosa 
Stems 
DCM/MeOH 
(1:1) 
P02700B 100.0 2.3 43.9 17.1 29.0 3.8 98.5 37.8 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Whole plant DCM P00437A 100.0 67.1 41.9 23.2 87.1 22.8 74.7 15.7 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Whole plant 
DCM/MeOH 
(1:1) 
P00437B 100.0 0.0 51.1 24.0 82.7 26.1 81.5 18.1 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Whole plant MeOH P00437C 99.6 0.0 40.2 10.9 33.3 24.1 39.1 0.0 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Stems DCM P00439A 3.6 0.0 42.7 15.8 97.4 23.7 85.9 25.1 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Stems 
DCM/MeOH 
(1:1) 
P00439B 99.1 0.0 40.3 29.5 39.9 23.3 54.9 0.0 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Stems MeOH P00439C 99.6 0.0 35.1 21.9 30.1 25.3 31.2 1.4 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Leaves 
DCM/MeOH 
(1:1) 
P00440B 100.0 0.0 34.2 24.3 43.7 22.6 47.7 0.0 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Leaves DCM P00440A 98.3 0.0 42.2 20.4 80.2 25.2 82.0 13.4 
Anacardiaceae 
Ozoroa 
sphaerocarpa 
R.Fern. & A.Fern. 
Leaves MeOH P00440C 100.0 0.0 42.3 26.7 32.0 20.8 22.8 0.0 
Sapindaceae 
Pappea capensis 
Eckl. & Zeyh. 
Roots DCM P00397A 100.0 9.7 34.0 17.6 40.5 14.8 76.0 100.0 
Sapindaceae 
Pappea capensis 
Eckl. & Zeyh. 
Roots 
DCM/MeOH 
(1:1) 
P00397B 0.1 0.0 40.0 14.7 0.0 0.0 37.4 4.5 
Sapindaceae 
Pappea capensis 
Eckl. & Zeyh. 
Roots MeOH P00397C 19.5 0.0 46.0 26.6 30.7 25.3 36.7 1.1 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Sapindaceae 
Pappea capensis 
Eckl. & Zeyh. 
Leaves 
DCM/MeOH 
(1:1) 
P10670B 99.7 0.0 17.6 15.5 15.5 0.0 79.2 35.9 
Sapindaceae 
Pappea capensis 
Eckl. & Zeyh. 
Bark 
DCM/MeOH 
(1:1) 
P10671B 14.5 0.0 29.7 22.4 30.6 22.2 78.3 25.8 
Sapindaceae 
Pappea capensis 
Eckl. & Zeyh. 
Roots 
DCM/MeOH 
(1:1) 
P10673B 15.2 0.0 29.5 25.7 44.5 25.4 95.9 54.1 
Geraniaceae 
Pelargonium zonale 
(L.) L'Hér. 
Stems DCM P01688A 1.7 0.0 43.4 5.1 26.0 23.6 30.9 0.0 
Geraniaceae 
Pelargonium zonale 
(L.) L'Hér. 
Stems 
DCM/MeOH 
(1:1) 
P01688B 99.4 0.0 40.0 21.8 28.7 24.1 33.5 0.0 
Geraniaceae 
Pelargonium zonale 
(L.) L'Hér. 
Twigs 
DCM/MeOH 
(1:1) 
P03391B 15.7 4.1 44.4 19.9 26.9 17.2 52.1 5.1 
Geraniaceae 
Pelargonium zonale 
(L.) L'Hér. 
Leaves 
DCM/MeOH 
(1:1) 
P03392B 16.4 2.8 43.4 11.2 24.0 10.1 88.2 3.9 
Fabaceae 
Peltophorum 
africanum Sond. 
Roots DCM P00394A 99.9 26.0 34.2 18.6 44.9 21.0 84.3 17.4 
Fabaceae 
Peltophorum 
africanum Sond. 
Roots 
DCM/MeOH 
(1:1) 
P00394B 100.0 8.2 34.9 18.0 26.2 20.6 54.0 2.0 
Fabaceae 
Peltophorum 
africanum Sond. 
Roots MeOH P00394C 100.0 6.1 32.1 12.2 23.9 21.7 34.8 0.0 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Fabaceae 
Peltophorum 
africanum Sond. 
Stems DCM P00401A 99.6 49.3 60.7 29.0 31.5 22.4 90.2 31.6 
Fabaceae 
Peltophorum 
africanum Sond. 
Stems 
DCM/MeOH 
(1:1) 
P00401B 100.0 10.6 52.4 25.2 28.8 21.6 63.8 11.4 
Fabaceae 
Peltophorum 
africanum Sond. 
Stems MeOH P00401C 100.0 11.6 51.6 15.2 29.8 22.0 66.5 9.2 
Fabaceae 
Peltophorum 
africanum Sond. 
Leaves & 
twigs 
DCM P02244A 100.0 0.0 56.5 23.9 78.3 28.5 98.8 29.6 
Fabaceae 
Peltophorum 
africanum Sond. 
Leaves & 
twigs 
DCM/MeOH 
(1:1) 
P02244B 57.6 0.0 40.6 22.1 28.2 22.8 49.7 3.7 
Fabaceae 
Peltophorum 
africanum Sond. 
leaves & 
twigs 
MeOH P02244C 95.4 0.0 40.5 6.7 0.0 0.0 30.3 0.0 
Asteraceae 
Phymaspermum 
acerosum (DC.) 
Källersjö 
Whole plant 
DCM/MeOH 
(1:1) 
P03661B 100.0 13.1 44.5 13.1 67.7 17.8 98.6 37.8 
Lamiaceae 
Plectranthus 
laxiflorus Benth. 
Whole plants 
DCM/MeOH 
(1:1) 
P12870B 92.1 9.9 40.0 14.4 51.5 29.0 59.9 14.6 
Polygalaceae 
Polygala fruticosa 
P.J. Bergius 
Leaves 
DCM/MeOH 
(1:1) 
P03756B 37.3 14.4 68.9 34.7 65.6 0.0 98.6 35.6 
Polygalaceae 
Polygala fruticosa 
Twigs 
DCM/MeOH 
P03757B 24.7 11.7 46.8 17.8 35.3 0.0 82.5 23.2 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
P.J. Bergius (1:1) 
Fabaceae 
Psoralea pinnata L. 
var. pinnata  
Leaves DCM P01617A 98.7 100.0 36.6 30.0 91.9 26.9 98.8 19.0 
Fabaceae 
Psoralea pinnata L. 
var. pinnata  
Leaves 
DCM/MeOH 
(1:1) 
P01617B 99.7 99.2 32.1 19.8 73.3 22.7 83.9 0.6 
Fabaceae 
Psoralea pinnata L. 
var. pinnata  
Stems DCM P01676A 7.5 0.0 52.8 20.5 32.4 15.9 52.4 1.9 
Fabaceae 
Psoralea pinnata L. 
var. pinnata  
Stems 
DCM/MeOH 
(1:1) 
P01676B 4.3 0.0 47.3 16.4 0.0 0.0 38.5 7.1 
Fabaceae 
Psoralea pinnata L. 
var. pinnata  
Roots DCM P01679A 8.6 0.0 44.7 24.1 35.5 23.2 41.0 0.0 
Fabaceae 
Psoralea pinnata L. 
var. pinnata  
Roots MeOH 
P01679C
/B 
8.2 0.0 44.9 12.4 24.5 21.2 39.3 0.0 
Rubiaceae 
Psychotria capensis 
(Eckl.) Vatke subsp. 
capensis var. 
capensis  
Roots 
DCM/MeOH 
(1:1) 
P09181B 17.4 0.0 31.1 13.0 39.0 21.4 28.9 5.5 
Rubiaceae 
Psychotria capensis 
(Eckl.) Vatke subsp. 
capensis var. 
capensis  
Leaves 
DCM/MeOH 
(1:1) 
P09182B 18.4 0.0 30.6 14.8 37.4 20.4 36.7 10.3 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Rubiaceae 
Psychotria capensis 
(Eckl.) Vatke subsp. 
capensis var. 
capensis  
Stems 
DCM/MeOH 
(1:1) 
P09183B 99.9 0.0 36.7 3.1 39.4 19.1 30.1 0.0 
Lamiaceae 
Rabdosiella 
calycina (Benth.) 
Codd 
Stems DCM P00451A 98.4 0.0 45.3 8.6 103.4 40.6 77.5 11.3 
Lamiaceae 
Rabdosiella 
calycina (Benth.) 
Codd 
Stems 
DCM/MeOH 
(1:1) 
P00451B 38.1 0.0 48.8 23.2 14.1 0.0 49.2 2.8 
Lamiaceae 
Rabdosiella 
calycina (Benth.) 
Codd 
Stems MeOH P00451C 99.9 0.0 44.4 18.3 59.7 24.6 51.2 9.6 
Lamiaceae 
Rabdosiella 
calycina (Benth.) 
Codd 
Leaves 
DCM/MeOH 
(1:1) 
P00453B 5.4 0.0 52.0 16.0 33.3 21.1 33.0 0.0 
Lamiaceae 
Rabdosiella 
calycina (Benth.) 
Codd 
Leaves MeOH P00453C 0.0 0.0 44.4 26.5 32.5 21.9 27.9 0.0 
Lamiaceae 
Rabdosiella 
calycina (Benth.) 
Codd 
Whole plant 
DCM/MeOH 
(1:1) 
P08318B 99.6 0.0 44.1 12.1 80.4 22.6 76.9 20.6 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Myrsinaceae 
Rapanea 
melanophloeos (L.) 
Mez 
Leaves 
DCM/MeOH 
(1:1) 
P08222B 19.9 34.7 37.3 14.8 60.6 30.8 44.7 5.1 
Myrsinaceae 
Rapanea 
melanophloeos (L.) 
Mez 
Twigs 
DCM/MeOH 
(1:1) 
P08223B 95.8 0.0 41.3 15.5 100.0 28.5 43.1 10.8 
Myrsinaceae 
Rapanea 
melanophloeos (L.) 
Mez 
Stems 
DCM/MeOH 
(1:1) 
P09405B 33.3 0.0 32.1 8.7 38.7 17.8 16.6 0.6 
Myrsinaceae 
Rapanea 
melanophloeos (L.) 
Mez 
Roots 
DCM/MeOH 
(1:1) 
P09406B 99.0 0.0 38.3 18.6 67.0 20.6 17.8 13.0 
Vitaceae 
Rhoicissus 
tridentata (L.f.) Wild 
& R.B.Drumm. 
subsp. cuneifolia 
(Eckl. & Zeyh.) 
Urton 
Leaves 
DCM/MeOH 
(1:1) 
P09322B 82.2 0.0 46.0 16.8 39.5 18.5 37.0 4.1 
Vitaceae 
Rhoicissus 
tridentata (L.f.) Wild 
& R.B.Drumm. 
subsp. cuneifolia 
(Eckl. & Zeyh.) 
Fruits 
DCM/MeOH 
(1:1) 
P09323B 99.7 0.0 41.1 17.6 47.0 25.7 54.3 11.7 
106
22 
 
          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Urton 
Vitaceae 
Rhoicissus 
tridentata (L.f.) Wild 
& R.B.Drumm. 
subsp. cuneifolia 
(Eckl. & Zeyh.) 
Urton 
Roots 
DCM/MeOH 
(1:1) 
P09324B 0.0 0.0 46.7 24.6 38.5 20.8 30.4 9.9 
Vitaceae 
Rhoicissus 
tridentata (L.f.) Wild 
& R.B.Drumm. 
subsp. cuneifolia 
(Eckl. & Zeyh.) 
Urton 
Bark 
DCM/MeOH 
(1:1) 
P09325B 97.9 0.0 44.4 19.8 29.9 17.7 32.1 1.0 
Vitaceae 
Rhoicissus 
tridentata (L.f.) Wild 
& R.B.Drumm. 
subsp. cuneifolia 
(Eckl. & Zeyh.) 
Urton 
Stems 
DCM/MeOH 
(1:1) 
P09326B 13.5 0.0 45.2 22.1 26.5 14.8 50.9 2.3 
Apocynaceae 
Sarcostemma 
viminale (L.) R.Br. 
Leaves MeOH P00363C 18.1 2.2 33.4 15.3 36.4 20.4 49.6 7.4 
Apocynaceae 
Sarcostemma 
viminale (L.) R.Br. 
Stems DCM P01381A 12.1 0.0 40.1 27.4 38.4 23.8 70.0 2.7 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Apocynaceae 
Sarcostemma 
viminale (L.) R.Br. 
Whole plant 
DCM/MeOH 
(1:1) 
P02503B 33.8 7.1 46.4 21.7 18.3 4.3 74.9 12.9 
Apocynaceae 
Sarcostemma 
viminale (L.) R.Br. 
Roots 
DCM/MeOH 
(1:1) 
P06980B 99.5 7.0 46.3 20.0 57.6 24.3 99.3 31.8 
Asclepiadaceae 
Sarcostemma 
viminale (L.) R.Br. 
Stems 
DCM/MeOH 
(1:1) 
P01381B 6.5 0.0 46.0 17.3 29.7 22.2 35.5 0.0 
Asteraceae 
Schkuhria pinnata 
(Lam.) Kuntze ex 
Thell. 
Whole plants 
DCM/MeOH 
(1:1) 
P03491B 99.4 97.1 67.4 16.9 69.7 0.0 100.0 73.8 
Fabaceae 
Senna 
septemtrionalis 
(Viv.) H.S.Irwin & 
Barneby 
Roots 
DCM/MeOH 
(1:1) 
P06145B 43.0 5.9 33.8 17.2 24.9 22.0 45.6 14.4 
Fabaceae 
Senna 
septemtrionalis 
(Viv.) H.S.Irwin & 
Barneby 
Stems 
DCM/MeOH 
(1:1) 
P06146B 98.5 11.4 37.5 10.7 23.8 15.0 45.4 15.3 
Fabaceae 
Senna 
septemtrionalis 
(Viv.) H.S.Irwin & 
Barneby 
Leaves 
DCM/MeOH 
(1:1) 
P06147B 39.7 9.7 40.2 18.7 33.9 13.4 83.7 18.5 
Fabaceae Senna 
septemtrionalis 
Seeds 
DCM/MeOH 
P06148B 0.0 0.0 34.7 12.7 0.5 0.0 33.6 11.4 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
(Viv.) H.S.Irwin & 
Barneby 
(1:1) 
Apiaceae 
Steganotaenia 
araliacea Hochst. 
var. araliacea  
Roots DCM P00758A 20.6 0.0 52.5 44.4 35.1 24.3 64.9 11.0 
Malvaceae 
Sterculia rogersii 
N.E.Br. 
Leaves 
DCM/MeOH 
(1:1) 
P03870B 100.0 13.0 32.8 8.6 44.7 18.4 61.6 18.6 
Malvaceae 
Sterculia rogersii 
N.E.Br. 
Roots 
DCM/MeOH 
(1:1) 
P03872B 14.1 5.9 35.8 13.8 39.9 14.7 42.4 15.6 
Malvaceae 
Sterculia rogersii 
N.E.Br. 
Bark 
DCM/MeOH 
(1:1) 
P03873B 32.9 33.7 25.1 12.5 62.0 18.4 91.9 30.2 
Rutaceae 
Toddalia asiatica 
(L.) Lam. 
Roots 
DCM/MeOH 
(1:1) 
P00599B 98.1 0.0 45.4 17.4 36.0 20.8 94.2 25.6 
Rutaceae 
Toddalia asiatica 
(L.) Lam 
Leaves & 
twigs 
DCM/MeOH 
(1:1) 
P02460B 16.7 0.0 40.3 14.2 53.5 20.2 68.5 14.3 
Ulmaceae 
Trema orientalis (L.) 
Blume 
Leaves 
DCM/MeOH 
(1:1) 
P11527B 98.3 0.0 82.3 10.9 100.0 27.6 94.5 24.3 
Ulmaceae 
Trema orientalis (L.) 
Blume 
Flowers 
DCM/MeOH 
(1:1) 
P11528B 3.6 0.0 36.2 14.3 41.7 23.0 85.0 21.2 
Ulmaceae 
Trema orientalis (L.) 
Roots 
DCM/MeOH 
P11529B 14.4 2.2 49.7 27.3 34.0 17.1 74.5 13.2 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Blume (1:1) 
Ulmaceae 
Trema orientalis (L.) 
Blume 
Stems 
DCM/MeOH 
(1:1) 
P11530B 11.7 3.1 46.9 18.3 0.0 19.2 88.8 27.1 
Meliaceae 
Turraea floribunda 
Hochst. 
Bark 
DCM/MeOH 
(1:1) 
P05214B 93.5 12.8 28.3 15.6 28.4 20.4 89.9 39.9 
Meliaceae 
Turraea floribunda 
Hochst. 
Leaves 
DCM/MeOH 
(1:1) 
P05294B 100.0 14.2 38.1 22.3 39.7 22.2 78.3 27.4 
Meliaceae 
Turraea floribunda 
Hochst. 
Roots 
DCM/MeOH 
(1:1) 
P05329B 64.4 10.0 18.3 18.8 53.6 21.3 98.9 58.6 
Rubiaceae 
Vangueria infausta 
Burch. subsp. 
infausta  
Fruits DCM P00008A 29.5 18.9 31.2 7.4 0.0 0.0 35.7 3.1 
Rubiaceae 
Vangueria infausta 
Burch. subsp. 
infausta  
Fruits 
DCM/MeOH 
(1:1) 
P00008B 21.6 13.3 43.1 14.1 23.1 20.0 33.6 2.6 
Rubiaceae 
Vangueria infausta 
Burch. subsp. 
infausta  
Fruits MeOH P00008C 17.3 7.6 45.0 16.0 31.5 21.4 30.4 0.0 
Rubiaceae 
Vangueria infausta 
Burch. subsp. 
infausta  
Roots 
DCM/MeOH 
(1:1) 
P09344B 17.4 5.2 37.4 14.6 16.8 0.0 44.6 14.1 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Rubiaceae 
Vangueria infausta 
Burch. subsp. 
infausta  
Stems 
DCM/MeOH 
(1:1) 
P09345B 22.2 10.2 38.1 14.9 38.1 17.3 43.9 11.6 
Rubiaceae 
Vangueria infausta 
Burch. subsp. 
infausta  
Leaves 
DCM/MeOH 
(1:1) 
P09346B 99.2 0.0 36.9 10.5 45.5 19.8 52.9 15.2 
Asteraceae 
Vernonia 
mespilifolia Less 
Leaves 
DCM/MeOH 
(1:1) 
P11137B 100.0 100.0 90.1 34.5 100.0 29.5 96.6 32.5 
Asteraceae 
Vernonia 
mespilifolia Less 
Stems 
DCM/MeOH 
(1:1) 
P11138B 95.1 0.0 35.1 25.9 84.5 29.8 55.8 8.4 
Asteraceae 
Vernonia 
mespilifolia Less 
Roots 
DCM/MeOH 
(1:1) 
P11139B 16.8 0.0 38.9 21.5 36.4 26.1 48.4 9.6 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Roots DCM P00170A 7.7 0.0 37.4 14.5 0.0 0.0 36.9 15.8 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Roots 
DCM/MeOH 
(1:1) 
P00170B 13.6 4.3 46.0 24.6 32.5 17.0 37.0 12.2 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Leaves DCM P00171A 8.6 0.0 36.5 19.3 39.0 16.6 59.5 7.5 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Leaves 
DCM/MeOH 
(1:1) 
P00171B 1.5 0.0 30.5 22.1 36.0 21.5 29.2 1.9 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Leaves MeOH P00171C 0.2 0.0 39.1 23.5 36.4 26.5 26.3 6.2 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Stems DCM P00172A 5.3 0.0 40.0 17.0 37.4 25.6 32.6 14.9 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Stems MeOH P00172C 0.0 0.0 43.2 14.8 32.6 21.1 17.0 0.0 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Seeds DCM P00173A 0.0 0.0 39.6 20.0 35.7 19.0 32.9 0.4 
Asteraceae 
Vernonia myriantha 
Hook.f. 
Seeds 
DCM/MeOH 
(1:1) 
P00173B 0.0 0.0 35.8 18.1 38.0 22.1 36.9 0.1 
Olacaceae 
Ximenia caffra 
Sond. var. caffra  
Leaves 
DCM/MeOH 
(1:1) 
P03508B 25.3 15.2 42.7 17.3 33.9 26.7 51.9 0.0 
Olacaceae 
Ximenia caffra 
Sond. var. caffra  
Twigs  
DCM/MeOH 
(1:1) 
P03509B 40.7 0.0 32.7 10.8 0.0 0.0 50.1 9.2 
Rutaceae 
Zanthoxylum 
capense (Thunb.) 
Harv. 
Leaves 
DCM/MeOH 
(1:1) 
P07947B 34.0 0.0 39.5 16.6 46.1 30.1 99.7 38.8 
Rutaceae 
Zanthoxylum 
capense (Thunb.) 
Harv. 
Stems 
DCM/MeOH 
(1:1) 
P07948B 27.5 5.7 39.0 18.8 51.7 27.0 95.4 40.0 
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          Percentage (%) growth inhibition 
  T. b. rhodesiense T. cruzi L. donovani P. falciparum 
Family Species Plant part Extract type 
Extract 
no. 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
10 
µg/mL 
2 
µg/mL 
Rutaceae 
Zanthoxylum 
capense (Thunb.) 
Harv. 
Roots 
DCM/MeOH 
(1:1) 
P07949B 11.6 34.3 44.2 7.2 47.5 29.3 86.1 32.5 
Rutaceae 
Zanthoxylum 
capense (Thunb.) 
Harv. 
Fruits 
DCM/MeOH 
(1:1) 
P07950B 7.2 0.0 37.1 19.8 36.2 27.9 70.0 14.3 
Rutaceae 
Zanthoxylum davyi 
(I.Verd.) 
P.G.Waterman 
Leaves 
DCM/MeOH 
(1:1) 
P10430B 49.3 2.2 35.7 12.7 88.9 30.3 82.2 25.4 
Rutaceae 
Zanthoxylum davyi 
(I.Verd.) 
P.G.Waterman 
Fruits 
DCM/MeOH 
(1:1) 
P10431B 5.2 0.0 32.0 7.9 30.4 26.1 44.3 8.5 
Rutaceae 
Zanthoxylum davyi 
(I.Verd.) 
P.G.Waterman 
Stems 
DCM/MeOH 
(1:1) 
P10432B 23.7 14.8 39.0 18.4 34.3 16.9 84.0 30.1 
 
Purification and isolation of schkuhrin I and schkuhrin II 
The (DCM/MeOH; 1:1) extract of Schkuhria pinnata (8.0 g) was suspended in a mixture of methanol and dichloromethane 
and chromatographed on silica gel 60 (80 g). The column was initially eluted with a mixture of hexane (Hex) and ethyl 
acetate (EtOAc) (1:1). Twenty fractions of 50 mL each were collected and thereafter the polarity was increased to Hex: 
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EtOAc (4:6) and a further twenty-six fractions collected. Finally, the polarity was increased to 100% EtOAc and 30% 
methanol (MeOH), respectively. The collected fractions were analysed using thin-layer chromatography (TLC) plates and 
similar fractions were combined resulting in twelve (A-L) fractions. Semipreparative RP-HPLC purification was employed 
using a SunFire™ C18 column (3.5 μm, 10 × 150 mm; Waters) with H2O (solvent A) and MeCN (solvent B) to give fraction 
I (950 mg) and fraction J (300 mg) which were further purified to yield schkuhrin I (1) (250 mg) and schkuhrin II (2) (120 
mg), respectively. The structures and stereochemistry of 1 [6] and 2 [6] were compared to that of published data and the 
purity of the compounds was > 95% as determined by the NMR data. 
Purification and isolation of cynaropicrin (3) 
The (DCM/MeOH; 1:1) extract of Vernonia mespilifolia (1.0 g) was suspended in chloroform and chromatographed on 
silica gel 60 (10 g). The column was eluted with a mixture of hexane (Hex) and ethylacetate (EtOAc) (6:4). Finally, the 
polarity was increased to 30% methanol (MeOH). The collected fractions (50 mL) were monitored by TLC and similar 
fractions were combined. Fraction J (30 mg) was further purified by semipreparative RP-HPLC using a SunFire™ C18 
column (3.5 μm, 10 × 150 mm; Waters) with H2O (solvent A) and MeCN (solvent B), resulting in the isolation of 
cynaropicrin (3) (11.0 mg). The structure of 3 [7] was compared to that of published data and the purity of cynaropicrin (3) 
was > 95% as determined by NMR.  
Bioassays 
a. In vitro test against Trypanosoma brucei rhodesiense 
Trypanosoma brucei rhodesiense (STIB 900) were grown in axenic medium as previously described [3].The compounds 
were tested using a modified Alamar Blue assay protocol [4] to determine the 50% inhibitory concentration (IC50). Serial 
threefold drug dilutions were prepared in 96-well microtitre plates and 50 μL of T. b. rhodesiense STIB 900 bloodstream 
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forms were added to each well except for the negative controls. Melarsoprol (Arsobal®; Sanofi-Aventis) was used as a 
reference drug. After 70 h of incubation, the Alamar Blue marker (12.5 mg resazurin dissolved in 100 mL distilled water) 
was added. The plates were then incubated for an additional 2 to 5 h. A Spectramax Gemini XS microplate fluorescence 
reader (Molecular Devices Cooperation) with an excitation wavelength of 536 nm and an emission wavelength of 588 nm 
was used to read the plates. The IC50 values were calculated from the sigmoidal growth inhibition curves using Softmax 
Pro software (Molecular Devices). 
 
b. In vitro testing against Plasmodium falciparum 
A modification of the [3H]-hypoxanthine incorporation assay was used to determine the intra-erythrocyticantiplasmodial 
activity (Desjardins 1979) of the extract library and purified compounds in 96-well plates. Chloroquine (Sigma-Aldrich) and 
artesunate (Mepha) were used as standard drugs. Briefly, infected human red blood cells in RPMI 1640 medium (100 µL 
per well with 2.5% haematocrit and 0.3% parasitaemia) were exposed to twofold serial drug dilutions in 96-well microtitre 
plates. After 48 h incubation, 0.5 μCi [3H]-hypoxanthine was added to each well. The plates were incubated for a further 
24 h before being harvested using a Betaplate cell harvester (Wallac) The radioactivity was counted with a Betaplate 
liquid scintillation counter (Wallac) as counts per minute per well at each drug concentration and compared to the 
untreated controls. IC50 values were calculated from sigmoidal inhibition curves using Microsoft Excel.  All assays were 
run in duplicate and repeated three times [5].  
 
c. In vitro cytotoxicity testing 
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Cytotoxicity was assessed using a similar Alamar Blue assay protocol [3] whereby 4000 rat myoblast cells/well were 
seeded in RPMI 1640 medium. All following steps were according to the T.b. rhodesiense protocol. Podophyllotoxin 
(Sigma-Aldrich) was used as the reference drug. 
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Dashnie Naidoo, Gerda Fouche, Vinesh Maharaj, Marcel Kaiser, Reto Brun, Matthias Hamburger 
Planta Med., 2013, 79: 492–498.  DOI: 10.1055/s-0032-1328298 
 
 
 
HPLC-based activity profiling allowed the identification of 5 isoflavanquinones from Abrus precatorius. 
Two of them were new compounds and one was a new natural product. Abruquinones I and B showed 
strong in vitro activity against Trypanosoma brucei rhodesiense and remarkable selectivity. These results 
classified abruquinones I and B for in vivo evaluation of their trypanocidal activity.          
 
 
 
 
My contributions to this work were: (1) HPLC microfractionation; (2) isolation of isoflavanquinones; (3) 
recording and interpretation of analytical data for structure elucidation (HPLC-PDA-ESI-MS, TOF-MS, 
1D and 2D NMR, CD measurements) and other measurements such as optical rotation; (4) writing of the 
first draft of the manuscript, preparation of figures, tables, and supporting information.  
Samad Ebrahimi did the quantum-chemical calculation of ECD spectra, and under his supervision I 
participated in the respective data analysis. Melanie Raith supervised structure elucidation. In vitro tests 
were performed by Stefanie Zimmermann and the team of the Swiss TPH. The crude extract was provided 
by the CSIR team. 
Yoshie Hata-Uribe 
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Abstract
!
A library of 206 extracts from selected South Afri-
can plants was screened in vitro against a panel of
protozoan parasites, Plasmodium falciparum, Try-
panosoma brucei rhodesiense, and Leishmania do-
novani. A CH2Cl2/MeOH (1:1) extract of Abrus
precatorius L. ssp. africanus strongly inhibited P.
falciparum (98%), T.b. rhodesiense (100%), and
L. donovani (76%) when tested at a concentration
of 10.0 µg/mL. The active constituents were
tracked by HPLC-based activity profiling and iso-
lated by preparative and semipreparative RP-
HPLC chromatography. Structures were estab-
lished by HR-ESIMS, and 1D and 2DNMR (1H, 13C,
COSY, HMBC, HSQC, and NOE difference spectros-
copy). Five compounds were obtained and identi-
fied as two isoflavan hydroquinones, abruqui-
none H (1) and abruquinone G (2), and three iso-
flavan quinones, abruquinone I (3), abruquinone
B (4), and 7,8,3′‚5′-tetramethoxyisoflavan-1′,4′-
quinone (5). Compounds 1 and 3 were new natu-
ral products. The absolute configuration of com-
pounds was determined by comparison of elec-
tronic circular dichroism spectra with calculated
ECD data. Compounds 3 and 4 showed strong ac-
tivity against T.b. rhodesiense (IC50 values of 0.30
and 0.16 µM, respectively) and good selectivity
(selectivity indices of 73.7 and 50.5, respectively).
Abbreviations
!
NTDs: neglected tropical diseases
HAT: human African trypanosomiasis
DALYS: disability-adjusted life years
ELSD: evaporative light scattering detector
HR-ESIMS: high-resolution electrospray
ionization mass spectrometry
AC: absolute configuration
ECD: electronic circular dichroism
CE: Cotton effect
DTF: density functional theory
TD‑DFT: time-dependent density functional
theory
CPCM: conductor polarized continuum
model
SCRF: self-consistent reaction field
OPLS: optimized potential for liquid
simulations
B3LYP: Becke, 3-parameter, Lee-Yang-Parr
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l.Introduction
!
NTDs affect the lives of a billion people world-
wide, in particular in developing countries. Some
of these are caused by protozoan parasites, such
as HAT, leishmaniasis, malaria, and Chagas dis-
ease. The responsible parasites are Trypanosoma
brucei rhodesiense and T.b. gambiense (HAT),
Leishmania sp., Plasmodium spp. (P. falciparum, P.
vivax, P. ovale, P. malariae, and P. knowlesi), and
Trypanosoma cruzi, respectively [1,2]. These dis-
eases cause an enormous burden, and accordinguinones… Planta Med 2013; 79: 492–498
118to the WHO, HAT is accountable for 1673000,
leishmaniasis for 1974000, malaria for
33976000 and Chagas for 430000 DALYs [1,3].
Drugs currently available to treat these illnesses
are old, limited in efficacy, and cause severe side
effects [4,5]. Hence, new drugs with better thera-
peutic profiles are urgently needed.
Natural products such as quinine and artemisinin
have significantly contributed to the development
of modern antiprotozoal drugs. We have recently
embarked on a library-based discovery of natural
product leads with antiprotozoal activity [6–9]. In
493Original Papersa library of 206 extracts prepared from ethnobotanically prese-
lected medicinal plants from South Africa, a CH2Cl2/MeOH (1:1)
extract from aerial parts of Abrus precatorius L. ssp. africanus
Verdc. (Fabaceae) strongly inhibited P. falciparum (98%), T.b. rho-
desiense (100%), and L. donovani (76%) when tested at a concen-
tration of 10.0 µg/mL. In contrast, it did not show inhibition
against T. cruzi.
A. precatorius is a climber shrub native from India but now also
grows in other regions of the world [10–12]. The seeds are highly
toxic due to abrin, a ribosome-inactivating lectin [10]. However,
leaves and roots are used in folk medicine to treat different con-
ditions like skin diseases, hepatitis, bronchitis, laryngitis, and
malaria [13–15]. Antiplatelet, anti-inflammatory, antiallergic
[13], antimalarial [14,15], and antitubercular activities [16] have
been reported. A spectrum of secondary metabolites have been
identified from A. precatorius, including triterpenoids [12,17,
18], alkaloids [19], flavonoids [12,20], and isoflavanquinones
[11,13,16,21]. We report here on the localization and identifica-
tion of active isoflavan quinones from the extract with the aid of
HPLC-based activity profiling [6,22], determination of absolute
configuration by ECD, and in vitro testing of pure compounds.D
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l.Materials and Methods
!
General experimental procedures
HPLC-grade methanol (MeOH), acetonitrile (MeCN) (Scharlau
Chemie S.A.), and water (obtained by an EASY-pure II from Barn-
stead water purification system) were used for HPLC separations.
HPLC solvents contained 0.1% HCOOH (Sigma) for analytical sep-
arations. Chloroform-d (100 atom% D) and methanol-d4 (100
atom% D) for NMR were purchased from Armar Chemicals. Sol-
vents used for extraction were of analytical grade (Romil Pure
Chemistry). Reference drugs for bioassays were artesunate (pu-
rity > 95%; Mepha), melarsoprol (purity > 95%; Sanofi-Aventis),
benznidazole (purity > 95%; Sigma-Aldrich), miltefosine (purity
> 95%; VWR), and podophyllotoxin (purity > 95%; Sigma-Al-
drich). HPLC‑PDA‑MS analyses were performed with an Agilent
1100 system consisting of a degasser, a quaternary pump, a col-
umn oven, a PDA detector connected to a Gilson 215 injector
and to an Esquire 3000 plus ion trap mass spectrometer (Bruker
Daltonics). Data acquisition and processing were performed us-
ing HyStar 3.0 software (Bruker Daltonics). Preparative HPLC
was carried out on a Shimadzu LC-8A instrument equipped with
a SCL-10AVP system controller, an LC-8A pump, an SPD-M10AVP
PDA detector, and VP 6.14 SP2A control software. Semiprepara-
tive HPLC was performed with an Agilent 1100 series instrument
equipped with a PDA detector. Data acquisition and processing
were performed using HyStar 3.2 software (Bruker Daltonics).
Chromatographic purity of the isolated compounds was assessed
on an Alliance 2695 HPLC system (Waters) equipped with 996
PDA (Waters) and Alltech 2000ES ELSD detectors. For HR-ESIMS,
a micrOTOF ESI‑MS system (Bruker Daltonics) was used. Mass
calibration was performed with a solution of formic acid 0.1% in
2-propanol/water (1 :1) containing 5mM NaOH. Mass spectra
were recorded in the range of m/z 150–1500 in the positive ion
mode with the aid of micrOTOF control software 1.1 (Bruker Dal-
tonics). NMR spectra were recorded on a Bruker AVANCE III™
500MHz spectrometer equipped with a 1-mm TXI microprobe
(1H and 2DNMR) or a 5-mm BBO probe (13C NMR) (Bruker Bio-
Spin) operating at 500 (1H) and 125MHz (13C). Chemical shifts
are reported as δ values (ppm) with the residual solvent signal119as the internal reference, J in Hz. Standard pulse sequences from
Topspin 2.1 software package were used. Further spectroscopic
data were acquired on a Hewlett Packard 8453 photometer
(UV), an AVIV CD spectrometer Model 62ADS (CD), and a Perkin
Elmer polarimeter (model 341) equipped with a 1-dm microcell
(OR).
Plant material
Samples of the whole plant of A. precatoriuswere collected at Jo-
zini, KwaZulu Natal Province in South Africa during November
2001 by a botanist, Mr. Hans Vahrmeijer. A plant specimen was
deposited at the South African National Biodiversity Institute
(SANBI), and the plant was identified as Abrus precatorius L. ssp.
africanus Verdc. (Fabaceae) (voucher specimen number PRE
442421).
Extraction
The whole plant was dried in an oven at 30–60°C. Dried plant
material was ground to a coarse powder using a hammer mill
and stored at ambient temperature prior to extraction. 200 g of
dried, ground material was extracted with 1 L of a mixture of
CH2Cl2 and MeOH (1:1) at room temperature for 1 h with occa-
sional stirring. The solvent was filtered, and the residual plant
material was further extracted overnight with 500mL CH2Cl2/
MeOH (1:1) followed by filtration. Finally, a third extraction of
the pulp was done with 500mL solvent for 1 h with filtration.
The pulp was discarded, and the filtrates combined and concen-
trated using a rotary vacuum evaporator at a temperature below
45°C and then further dried in vacuo at room temperature for
24 h. The dried extract of 15.4 g (7.7%, w/w) was stored at − 20°C.
Microfractionation and activity profiling
Microfractionation for HPLC-activity profiling was performed as
previously described [6], on a SunFire™ C18 column (3.5 µm,
3.0 × 150mm; Waters) with H2O (solvent A) and MeCN (solvent
B) using the following gradient profile: 10% → 100% B (0–
30min), 100% B (31–32min). The flow rate was 0.5mL/min.
35 µL of a solution of the extract (10mg/mL in DMSO) was in-
jected. 32 one-minute fractions were collected by the aid of a
F204 fraction collector (Gilson) into a 96-deep-well plate (Eppen-
dorf). After solvent removal in an Evaporex 96 channel N2-evap-
orator (Apricot Designs), the dried fractions were redissolved in
methanol (100 µL) and transferred to 96-v-well plates (Thermo
Scientific), dried again, and stored in a refrigerator (2–8°C) until
assayed.
Preparative isolation of abruquinones
For isolation of compounds, 850mg of a CH2Cl2/MeOH (1:1) ex-
tract of the whole plant was separated in a SunFire™ RP‑C18 col-
umn (5 µm, 30mm × 150mm;Waters) with a gradient consisting
of H2O (solvent A) and MeOH (solvent B) as follows: 10%→ 100%
B (0–30min), 100% B (31–35min). The flow rate was 20mL/min.
The extract was dissolved in DMSO at a concentration of 100mg/
mL, and aliquots of 380 µL were injected. Fraction 1 (28.1mg, tR
21.0min), fraction 2 (33.2mg, tR 22.8min), fraction 3 (29.8mg,
tR 23.8min), and fraction 4 (47.6mg, tR 25.3min) were collected
and purified by semipreparative RP-HPLC using a SunFire™ C18
column (3.5 µm, 10 × 150mm; Waters) with H2O (solvent A) and
MeCN (solvent B) and the following gradient: 10% → 100% B (0–
30min), 100% B (31–35min). The flow rate was 5mL/min. The
fractions were dissolved in DMSO (10 and 20mg/mL, depending
on their solubility) and injected in aliquots of 250 µL. CompoundHata Y et al. Antiprotozoal Isoflavan Quinones… Planta Med 2013; 79: 492–498
Table 1 1H and 13C NMR spectroscopic data for compounds 1 and 3 (500MHz for δH, 125MHz for δC).
Position 1a 1b 3a
δH δCc δH δC δH δC
2α 4.30 (dd, 10.7, 5.1) 66.6 4.50 (dd, 10.7, 4.7) 67.7 4.21 (ddd, 10.7, 3.4, 2.1) 68.2
2β 3.66 (dd, 10.7, 11.1) 3.86 (dd, 10.7,10.7) 4.43 (dd, 10.7,10.4)
3 3.51 (1H, m) 40.9 3.77 (1H, m) 42.4 3.60 (1H, m) 31.3
4 5.43 (d, 7.0) 78.1 5.68 (d, 7.0) 80.8 Hα 3.12 (dd, 15.5, 12.3)
Hβ 2.65 (ddd, 15.5, 4.7, 1.8)
29.3
5 6.62 (1H, s) 103.9 6.85 (1H, s) 104.8 6.49 (d, 8.9) 119.2
6 – 147.7 – 149.4 6.44 (d, 8.5) 104.5
7 – 137.5 – 139.0 – 134.2
8 – ndd – 140.6 – 145.7
9 – 138.3 – 140.7 – 142.3
10 – 114.8 – 116.8 – 115.8
1′ – 143.6 – 145.0 – 186.8
2′ – 136.9 – 141.4 5.82 (1H, s) 107.6
3′ – 139.0 – 139.6 – 157.4
4′ – ndd – 146.1 – 178.3
5′ 6.58 (1H, s) 105.0 6.79 (1H, s) 107.4 – 155.9
6′ – 122.4 – 124.6 – 131.3
2′- OCH3 3.89 (3H, s) 60.9 4.04 (3H, s) 61.7 – –
3′- OCH3 3.96 (3H, s) 60.9 4.13 (3H, s) 61.0 3.77 (3H, s) 56.6
5′- OCH3 – – – – 3.93 (3H, s) 61.7
6- OCH3 3.85 (3H, s) 56.3 4.02 (3H, s) 56.8 – –
7- OCH3 3.90 (3H, s) 60.3 4.05 (3H, s) 61.3 3.83 (3H, s) 56.7
8-OH – – – – 5.43 (br s)
a In CDCl3; b in CD3OD; c 13C NMR signals reported here were obtained indirectly from HSQC and HMBC spectra; d not detected
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l.1 (1.7mg, tR 12.0min) was obtained from fraction 1. Compounds
2 (3.9mg, tR 14.6min) and 3 (5.8mg, tR 14.3min) were isolated
from fraction 2. Compounds 4 (14.7mg, tR 16.2min) and 5
(2.4mg, tR 16.8min) were purified from fractions 3 and 4, respec-
tively. Purity of compounds 1 and 3-5 was > 95% as determined
by 1H‑NMR and HPLC-ELSD analyses. Compound 2 showed a sin-
gle peak in HPLC analysis, but the 1H NMR spectrum revealed the
presence of about 15% of an unidentified related metabolite
(Fig. 5S, Supporting Information).
(3S‑4R)-4,8,1′‚4′-tetrahydroxy-6,7,2′,3′-tetramethoxyisoflavan
(abruquinone H, 1): Colorless amorphous substance; UV (MeOH):
λmax (log ε) = 206 (4.59), 295 (3.67) nm; [α]D18: − 192 (c = 0.1,
MeOH); CD (MeOH): Δε212 nm = − 31.5, Δε238 nm = − 6.89 (sh),
Δε285 nm = − 1.02, Δε302 nm = + 1.43; 1H and 13C NMR data in CDCl3
and CD3OD, see l" Table 1; HR-ESIMS:m/z = 399.1023 [M – H2O +
Na]+ (calcd. for C19H22NaO9: 399.1050).
(3S‑4R)-4,1′‚4′-trihydroxy-6,7,8,2′,3′-pentamethoxyisoflavan
(abruquinone G, 2) [16]: For physicochemical characterization,
see Supporting Information. [α]D18: − 59.9 (c = 0.1, MeOH); CD
(MeOH): Δε215 nm = − 49.0; Δε232 nm = − 12.2; Δε285 nm = − 2.24;
Δε304 nm = + 4.35.
(3R)-8-hydroxy-7,3′‚5′-trimethoxyisoflavan-1′,4′-quinone (abru-
quinone I, 3): Yellow amorphous substance; UV (MeOH): λmax
(log ε) = 205 (4.58), 286 (4.07) nm; [α]D19: + 21.0 (c = 0.1, MeOH);
CD (MeOH): Δε212 nm = + 8.40, Δε215 nm = + 4.84, Δε233 nm = − 0.62,
Δε256 nm = + 0.20, Δε283 = − 0.20, Δε305 nm = + 0.06; 1H and 13C NMR
data in CDCl3, see l" Table 1; HR-ESIMS:m/z = 369.0908 [M + Na]+
(calcd. for C18H18NaO7: 369.0945).
(3R)-6,7,8,2′,3′-pentamethoxyisoflavan-1′,4′-quinone (abruqui-
none B, 4) [11,13,16,21]: For physicochemical characterization,
see Supporting Information. [α]D20: − 9.0 (c = 0.1, CHCl3); [α]D19:
− 65.0 (c = 0.1, MeOH); CD (MeOH): Δε212 nm = − 7.46; Δε258 nm =
− 4.45; Δε293 nm = + 1.92; Δε312 nm = − 0.22; Δε393 nm = + 0.55.Hata Y et al. Antiprotozoal Isoflavan Quinones… Planta Med 2013; 79: 492–498
1(3S)-7,8,3′‚5′-tetramethoxyisoflavan-1′,4′-quinone (5) [23]: For
physicochemical characterization, see Supporting Information.
[α]D20: − 1.3 (c = 0.1, CHCl3); [α]D19: − 19 (c = 0.1, MeOH); CD
(MeOH): Δε216 nm = − 6.74; Δε238 nm = − 3.62; Δε274 nm = − 0.37;
Δε294 nm = + 0.39.
Conformational analysis, geometrical optimization,
and ECD calculation
Conformational analysis of 2, 3, 4, and 5 was accomplished with
Schrödinger MacroModel 9.1 software employing the OPLS 2005
(optimized potential for liquid simulations) force field in H2O.
Conformers within a 1 Kcal/mol energy window from the global
minimum were picked for geometrical optimization and energy
calculation applying DFTwith the Beckeʼs nonlocal three param-
eter exchange and correlation functional, and the Lee-Yang-Parr
correlation functional level (B3LYP) using the 6–31G** basis set
in the gas phase with the Gaussian 09 program package [24]. Vi-
brational evaluation was done at the same level to confirm mini-
ma. Excitation energy (denoted by wavelength in nm), rotator
strength dipole velocity (Rvel), and dipole length (Rlen) were cal-
culated in MeOH by TD‑DFT/B3LYP/6–31G**, using the SCRF
method, with the CPCM model. ECD curves were obtained on
the basis of rotator strengths with a half-band of 0.2 eV using
SpecDis v1.51 [25]. The spectra were combined after Boltzmann
weighting according to their population contribution.
Bioassays
The antiprotozoal activity of the CH2Cl2/MeOH (1:1) extract of
A. precatorius was tested in vitro against Plasmodium falciparum
(K1 strain), Trypanosoma brucei rhodesiense (STIB 900 strain),
Trypanosoma cruzi (Tulahuen strain C2C4w/LacZ), and Leishman-
ia donovani (strain MHOM/ET/67/L82), in 96-well microtiter
plates at concentrations of 10.0 µg/mL and 2.0 µg/mL. HPLC mi-20
Fig. 1 HPLC-based ac-
tivity profiling of
A. precatorius extract for
antiprotozoal proper-
ties. HPLC chromato-
gram (190–700 nm) for
32 one-minute frac-
tions from 350 µg of
extract (A) and inhibi-
tion (in %) of three dif-
ferent parasites P. falci-
parum (B), T.b. rhode-
siense (C), and
L. donovani (D) by the
time-based collected
fractions.
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l.crofractionations were assayed against P. falciparum, T.b. rhode-
siense, and L. donovani. Isolated compounds were evaluated for
their antiprotozoal activity using the parasites as described
above. Additionally, cytotoxicity was determined using the rat
skeletal myoblast cell line (L-6 cells). For the assays, DMSO stock
solutions (10mg/mL) of extracts and purified compounds were
each time freshly diluted in medium (final DMSO concentration
in assay < 1%). Assays were performed with three independent
repetitions, except for L. donovani. Details on culturing of para-
sites and assay protocols are provided as Supporting Information.
Supporting information
Detailed protocols of biological activity, NMR spectra (1D and 2D)
of compounds 1 and 3, 1H NMR spectra of all compounds, physi-
cochemical and spectroscopic data of compounds 2, 4, and 5, as
well as experimental and calculated ECD spectra of all com-
pounds are provided.Results and Discussion
!
The CH2Cl2/MeOH (1:1) extract of A. precatorius inhibited P. fal-
ciparum (98%) and L. donovani (76%) at a concentration of
10.0 µg/mL. Additionally, it completely inhibited T.b. rhodesiense
(100%) at 2.0 µg/mL. In contrast, the extract did not show any ac-
tivity against T. cruzi at these concentrations. The extract was
submitted to HPLC-based activity profiling using a previously
validated protocol [6]. An aliquot (350 µg) of the extract was sep-
arated by analytical HPLC, and 32 one-minute microfractions
were collected into a 96-deep-well plate. After drying, they were
tested against P. falciparum, L. donovani, and T.b. rhodesiense. The
HPLC chromatogram and the corresponding activity profiles are
shown inl" Fig. 1. The chromatogram showed strong UV-absorb-
ing peaks at trs = 12.9, 14.8, 15.3, 15.8, 17.3, and 18.0min. In this
time window (minutes 13–18), inhibition of P. falciparum,
L. donovani, and T.b. rhodesiensewas observed, corresponding to
fractions 15 and 17 (P. falciparum by 54% and 99%, respectively),121fractions 14 to 16 (L. donovani by 62% and 64%, respectively), and
fractions 13 and 14 to 18 (T.b. rhodesiense by 99% to 100%).
Isolation of compounds 1–5 (l" Fig. 2) in the active time window
was achieved by preparative RP-HPLC followed by final purifica-
tion on semipreparative RP-HPLC. Structures were established by
NMR spectroscopy (1H, 13C, COSY, HSQC, and HMBC), HR-ESIMS,
and ECD. Compounds 2 [(3S-4R)-4,1′‚4′-trihydroxy-6,7,8,2′,3′-
pentamethoxyisoflavan] and 4 [(3R)-6,7,8,2′,3′-pentamethoxyi-
soflavan-1′,4′-quinone] have been reported as abruquinones G
and B, respectively [11,13,16,21]. Compound 5 [(3S)-7,8,3′‚5′-
tetramethoxyisoflavan-1′,4′-quinone] has been previously de-
scribed as a synthetic derivative but not as a natural product
[23]. Compounds 1 [(3S-4R)-4,8,1′‚4′-tetrahydroxy-6,7,2′,3′-tet-
ramethoxyisoflavan] and 3 [(3R)-8-hydroxy-7,3′‚5′-trimethoxyi-
soflavan-1′,4′-quinone] are new and have been designated as
abruquinone H and abruquinone I, respectively.
A molecular formula of C19H22O9 for compound 1 was deduced
from HR-ESIMS (m/z 399.1023 [M – H2O + Na]+; calcd.:
399.1050). The formula accounted for 9 degrees of unsaturation.
The 1H and 13C NMR spectra (l" Table 1) showed 18 proton and 19
carbon signals, respectively. Twelve of the carbon signals were in
the region between δC 103.9 and 147.7, and were indicative of a
highly substituted aromatic ring system. The 1H NMR spectrum
in CDCl3 (l" Table 1) displayed four singlets of aromatic methoxy
groups (δH 3.96, 3.90, 3.89, and 3.85), in accordancewith four car-
bon signals at δC 60.9, 60.9, 60.3, and 56.3. Additionally, the 1H
NMR spectrum showed four aliphatic signals at δH 5.43 (d,
J = 7.0 Hz), 4.30 (dd, J = 10.7, 5.1 Hz), 3.66 (dd, J = 10.7, 11.1 Hz),
and 3.51 (m), suggesting an isoflavan scaffold with a hydroxyl
group at C-4. Unambiguous assignment of 1H and 13C NMR data
was achieved by a combination of COSY, HMBC, HSQC, and NOE
difference experiments, together with the comparison with re-
ported data of abruquinones and ‑hydroquinones [11,13,16,21].
The connectivity of the rings as well as the positions of the
methoxy groups were determined with the aid of HMBC correla-
tions (l" Fig. 3). The connectivity of rings A and C was confirmed
by 3JC–H coupling between C-9 (δc 138.3) and H-5 (δH 6.62, ring A)
and H-4 (δH 5.43, ring C). An HMBC correlation between H-3 (δH
3.51, ring C) and C-6′ (δc 122.4, ring B) corroborated the connec-
tivity between rings B and C and the presence of an isoflavan
scaffold. The vicinal coupling constants H-2α/H-3 (J = 5.1 Hz) and
H-2β/H-3 (J = 11.1 Hz) corresponded to dihedral angles of 60° and
180°, respectively, indicating an axial orientation of H-3. The cou-
pling constant H-4/H-3 (J = 7.0 Hz) agreed with a dihedral angle
of 30 to 50° or 130 to 150°, indicating two possible orientations
for H-4 in a half-chair. Both possible orientations – pseudo-axial
or pseudo-equatorial – of H-4 are in accordance with the NOE ef-
fect observed between H-4 (δH 5.43) and H-3 (δH 3.51). The pseu-
do-axial orientation of H-4 was finally derived from the ECD
spectrum in comparison with the calculated spectrum of com-
pound 2 (see below).
The NMR spectra of compounds 1 and 2 were similar (l" Table 1;
Table 1S, Supporting Information), the only major difference
being in the substituent at C-8 (hydroxyl in 1 and methoxyl in 2)
[16].
The absolute configuration of 2was established by comparing its
experimental ECD spectrum with calculated data of the (3S,4R)-
and (3S,4S)-diastereomers (l" Fig. 4A). Conformational analysis
revealed 68 and 51 conformers, respectively, within a 1 Kcal/mol
energy window from the particular global minimum. The con-
formers were subjected to geometrical optimization DTF and
B3LYP level using the 6–31 G** basis set in the gas phase. Vibra-Hata Y et al. Antiprotozoal Isoflavan Quinones… Planta Med 2013; 79: 492–498
Fig. 2 Structures of compounds 1–5.
Fig. 3 Key HMBC and COSY correlations for compounds 1 and 3.
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l.tional analysis was performed to confirm minima. No imaginary
frequencies were found. In total, 49 and 30 stable conformers, re-
spectively, were obtained (l" Fig. 4B; Fig. 14S A, Supporting Infor-
mation). ECD spectra of the conformers were calculated by
TDDFT‑B3LYP using 6–31 G** as basis set in MeOH as the solvent
and the SCRF method with the CPCM model. For the (3S,4R)-ste-
reoisomer, the calculated ECD spectrum showed one positive CE
around 290 nm along with three negative CEs around 220, 250,
and 285 nm (l" Fig. 4A). For the (3S,4S)-stereoisomer, the aver-
aged ECD spectrum showed two positive CEs at 290 and 250 nm,
and two negative CEs around 220 and 240 nm (l" Fig. 4A). Even
though both spectra were relatively similar, the pattern for the
(3S,4R)-stereoisomer matched well with the experimental ECD
spectrum. In particular, the negative CEs at 220, 250, and
285 nm were in very good agreement with the experimental da-
ta. We thus concluded that 2was (3S,4R)-abruquinone G. The ex-
perimental ECD spectrum of 1 was comparable to that of 2, and
we therefore conclude that abruquinone H also has the (3S,4R)-
configuration.
Compound 3 had a molecular formula of C18H18O7, as derived
from HR‑ESI‑MS (m/z 369.0908 [M + Na]+; calcd.: 369.0945). The
1H and 13C NMR spectra (l" Table 1) showed the presence of 18
proton and 18 carbon signals, respectively. Ten carbon signals in
the region between δC 104.5 and 155.9 were indicative of a highly
substituted aromatic ring system. Two resonances at δC 178.3 and
186.8 were indicative of conjugated carbonyl groups. The 1H NMR
spectrum (l" Table 1) showed three singlets for three methoxy
groups (δH 3.93, 3.83, and 3.77), in agreement with the respective
carbon signals at δC 61.7, 56.7, and 56.6. Five signals at δH 4.43
(dd, J = 10.7 and 10.4 Hz), 4.21 (ddd, J = 10.7, 3.4, 2.1 Hz), 3.60
(m), 3.12 (dd, J = 15.5, 12.3 Hz), and 2.65 (ddd, J = 15.5, 4.7,
1.8 Hz) were indicative of an isoflavan scaffold. A comparison of
the 13C NMR data of ring A with those of laurentiquinone [26]
suggested a methoxy group at C-7 and a hydroxy residue at C-8.
13C NMR data of ring C were comparable to those of compound 5
(l" Table 1 and Table 1S). Connectivity of the rings and positions
of the methoxy groups were corroborated by HMBC correlations
(l" Fig. 3). 3JC–H correlation between C-9 (δc 142.3) and H-5 (δH
6.49, ring A) and H-4α and H-4β (δH 3.12 and 2.65, ring C) con-
firmed the connectivity of rings A and C. A correlation between
H-3 (δH 3.60, ring C) and C-6′ (δc 131.3, ring B) confirmed the
presence of an isoflavan scaffold. Vicinal coupling constants in
ring C and NOE difference measurements were used to establish
the relative configuration. The vicinal coupling constants H-2α/
H-3 (J = 3.4 Hz) and H-2β/H-3 (J = 10.4 Hz) corresponded to dihe-
dral angles of 60° and 180°, respectively, indicating an axial ori-Hata Y et al. Antiprotozoal Isoflavan Quinones… Planta Med 2013; 79: 492–498
1entation of H-3. The coupling constants H-4α/H-3 (J = 12.3 Hz)
and H-4β/H-3 (J = 4.7 Hz) were in accordance with dihedral an-
gles of 140 to 160° and 40 to 60°, respectively, indicating that H-
4αwas in a pseudo-axial orientation, and H-4β in a pseudo-equa-
torial position, respectively [27].
Conformational analysis of 3 displayed 10 conformers within a 1
Kcal/mol energy window from the particular global minimum.
Geometrical optimization and energy calculation followed by cal-
culation of ECD spectra were performed as described above. We
obtained 9 stable conformers (l" Fig. 5B; Fig. 14S B, Supporting
Information). The calculated ECD spectrum of the (3R)-enantio-
mer showed one positive CE at 206 nm along with two negative
CEs around 260 and 320 nm (l" Fig. 5A). The experimental ECD
spectrum showed a positive CE at 212 and a negative CE at 233.
The pattern of the calculated ECD spectrum for the (3R)-configu-
ration was in good agreement with the experimental ECD spec-
trum, while the calculated ECD spectra of the (3S)-enantiomer
(l" Fig. 5A) showed CEs with opposite signs around 206 and
260 nm. As a result, we concluded that abruquinone I (3) had
the (3R)-configuration.
The absolute configuration of compounds 4 (Figs. 13S A and 14S
C, Supporting Information) and 5 (see Figs. 13S B and 14S D, Sup-
porting Information) has been established by comparison of the
experimental and calculated ECD spectra as 3R and 3S, respec-
tively. The absolute configuration of abruquinone B (4) had been
previously determined by different methods, but reports were
contradictory and suggest that both enantiomers may have been
isolated from this plant. On the basis of ORD data, a compound
was described as (3S)-abruquinone [11], and a positive optical
rotation was reported [16]. On the other hand, an ECD study as-
signed the (3R)-configuration to the enantiomer exhibiting nega-
tive optical rotation [21]. Our ECD data and the sign of optical ro-
tation were in good agreement with [21], which corroborates the22
Fig. 4 Comparison of the experimental ECD of 1
and 2 with calculated spectra for the (3S,4R)- and
(3S,4S)-diastereomers of 2 (A). DFT optimized con-
formers at the B3LYP/6–31 G** level in the gas
phase (within 1 kcal/moL range from the global
minimum) of the (3S,4R)-stereoisomer. Fifty-two
conformers grouped in three different core con-
formers which differed in the alignment of the B
ring (B). (Color figure available online only.)
Fig. 5 Comparison of the experimental ECD of 3,
with calculated spectra for the (3S)- and (3R)-enan-
tiomers (A). DFT optimized conformers at the
B3LYP/6–31G** level in the gas phase (within
1 kcal/moL range from the global minimum) of the
(3R)-enantiomer. Nine conformers were grouped in
three core conformers differing in the alignment of
the B ring (B). (Color figure available online only.)
Table 2 In vitro antiprotozoal activities of 1–5 against P. falciparum, T.b. rhodesiense, and L. donovani, as well as cytotoxic activity against L-6 cells.
Compound P. falciparum T.b. rhodesiense L. donovani Cytotoxicity
IC50 (µM)a SI IC50 (µM)a SI IC50 (µM) SI IC50 (µM)a
1 8.0 ± 1.1 15.4 12.0 ± 3.8 0.2 inactiveb – 122.8 ± 21.3
2d inactivec – 17.0 ± 4.2 3.0 35.3 1.5 51.8 ± 11.1
3 20.4 ± 1.3 1.1 0.3 ± 0.1 73.7 3.4 6.5 22.1 ± 3.5
4 4.1 ± 0.4 2.5 0.2 ± 0.1 50.5 2.9 3.5 10.1 ± 1.3
5 8.9 ± 4.2 0.4 0.9 ± 0.1 4.3 5.0 0.9 3.9 ± 0.4
Artesunatee 0.002 ± 0.001 – – – – – –
Melarsoprole – – 0.007 ± 0.002 – – – –
Miltefosinee – – – – 0.285 ± 0.059 – –
Podophyllotoxine – – – – – – 0.014 ± 0.006
a Values are expressed asmean ± standard error of themean; b No activity observed at the highest test concentration of 10 µg/mL, which corresponds tomolar test concentrations
of 24.5 to 28.9 µM; c No activity observed at the highest test concentration of 90 µg/mL, which corresponds to molar test concentrations of 260.0 to 220.5 µM; d Compound 2
contains about 15% of an unidentified related metabolite; e Reference drugs. SI (Selectivity index): Quotient of IC50 in L-6 cells and IC50 against parasite
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l.(3R)-configuration of 4. As to compound 5 the negative sign of
optical rotation agrees with the data reported before for the
(3S)-enantiomer prepared by semisynthesis starting from (3S)-
duartin [23].123Isoflavonoid hydroquinones 1 and 2 exhibited low activity in
both antiprotozoal and cytotoxicity tests (l" Table 2). In contrast,
quinone-type isoflavonoids 3, 4, and 5 showed strong activity
against T.b. rhodesiense (IC50s of 0.3, 0.2, and 0.9 µM, respective-
ly). Compounds 3 and 4 showed low cytotoxicity in the L-6 cellHata Y et al. Antiprotozoal Isoflavan Quinones… Planta Med 2013; 79: 492–498
498 Original Papersline (IC50 values of 22.1 and 10.1 µM, respectively). A selectivity
index (SI) of 73.7 and 50.5 qualifies the compounds as good can-
didates for assessment of in vivo activity in a murine model [28].
Cytotoxicity of compound 5, in contrast, was considerably higher
(IC50 of 3.9 µM) and resulted in a low SI. We are currently isolat-
ing compounds 3 and 4 at a larger scale for an in vivo study. There
has been so far only one plant-derived natural product, cynaropi-
crin [8], for which in vivo activity against T. brucei has been dem-
onstrated. Given that abruquinones 3 and 4 possess a tenfold
higher SI than cynaropicrin, these compounds are of considerable
interest.at
er
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Assays for in vitro antiprotozoal activity  
Antiplasmodial activity was determined by a modification of the 
3
[H]-hypoxanthine 
incorporation assay [1] with the P. falciparum K1 strain (resistant to chloroquine and 
pyrimethamine), growth according to the method described by Trager and Jensen [2]. 
Artesunate (purity 95%, Sigma-Aldrich) was used as positive control. 
Briefly, a suspension of infected red blood cells (final parasitemia 0.3% and hematocrit 1.25%) 
in RPMI 1640 medium supplemented with 2 M L-glutamine, 5.95 g/L Hepes, 2 g/L NaHCO3, 
and 5% of Albumax II was exposed to serial drug dilutions covering a range from 10 g/mL 
to 0.156 μg/mL.in 96-well microtiter plates.  After 48 h of incubation (4% CO2, 3% O2, and 
93% N2 at 37°C), 50 L of 
3
[H]-hypoxanthine (0.25 M) were added to each well (Costar). 
The plates were incubated for further 24 h before being harvested by using a Betaplate cell 
harvester (Wallac) onto glass-fiber filters and then washed with distilled water. The dried 
filters were inserted into plastic foils with 10 mL scintillation fluid. The radioactivity was 
counted with a Betaplate liquid scintillation counter (Wallac) as counts per minute per well at 
each drug concentration and compared to the untreated controls. Counts were expressed as 
percentages of the control and presented as sigmoidal inhibition curves. IC50 values were 
calculated by linear interpolation.  
 
Antitrypanosomal activity against T. brucei rhodesiense STIB 900 was determined according 
to [3]. Melarsoprol (Arsorbal, purity 95%, Sanofi-Aventis) was used as positive control. 
Minimum essential medium (MEM) with Earle’s salts supplemented with 2-mercaptoethanol, 
as described by Baltz et al. [4], 1 mM sodium pyruvate, 0.5 mM hypoxanthine, and 15% heat-
inactivated horse serum was added (50 L) to each well of a 96-well microtiter plate (Costar) 
except of the negative control. Serial drugs dilutions were prepared covering range from 90 to 
0.123 g/mL followed by the parasite suspension of 2000 T. brucei rhodesiense STIB 900 
bloodstream forms/well. After 70 hours of incubation (humidified 5% CO2 atmosphere at 
37°C), 10 L resazurin solution (12.5 mg resazurin (Sigma-Aldrich) dissolved in 100 mL of 
distilled water) were added and incubation was continued for further 2 to 6 h. The plate was 
read with a Spectramax Gemini XS microplate fluorescence reader (Molecular Devices) with 
an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Fluorescence 
development was expressed as percentage of the control and the IC50 values were determined 
from the sigmoid curves using Softmax Pro Software (Molecular Devices). 
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The assay with T. cruzi was performed according to [5], with some modifications. Rat skeletal 
myoblast cells (L6-cells) were seeded in 96-well microtiter plates (Costar) at 2000 
cell/well/100 L in RPMI 1640 medium supplemented with10% fetal bovine serum (FBS) 
and 2 mM L-glutamine). After 24 h of incubation (humidified 5% CO2 atmosphere at 37°C, 
the medium was replaced by 100 L of  fresh medium containing 5000 trypomastigote forms 
of T. cruzi/well (Tulahuen strain C2C4 containing the -galactosidase (Lac Z) gene). After 48 
h, the medium was removed from the wells and replaced by 100 L of fresh medium with the 
serial drug dilution, covering a range from 90 g/mL to 0.123 g/mL. After 96 h ofincubation 
50 L chlorophenyl red -D-galactopyranoside agent (CPRG)/Nonident (Sigma - Aldrich) 
was added to all wells. The plates were read photometrically at 540 nm [5]. Optical density 
values were expressed as percentages of control, and IC50 values were calculated from the 
sigmoid inhibition curve. Benzinidazole (purity 95%, Sigma-Aldrich) was used as positive 
control.  
  
Leishmanicidal activity was determined with L. donovani (axenic amastigotes) MHOM-
ET/67/L82 strain according to [6], with some modifications. Fifty microlitres of SM medium 
at pH 5.4 supplemented with 10% heat-inactivated FBS was added to each well of 96-well 
microtiter plate (Costar). Serial drug dilutions were prepared covering a range from 90 to 
0.123 g/mL. Then, 105 axenically growth L. donovani amastigotes in 50 L medium, were 
added to each well and the plate was incubated for 72 h (humidified 5% CO2 atmosphere at 
37°C). Ten microlitres resazurin solution (12.5 mg resazurin (Sigma-Aldrich) dissolved in 
100 mL of distilled water) were added to each well and incubated for further 2 to 4 h. The 
plate was read with a Spectramax Gemini XS microplate fluorescence reader (Molecular 
Devices) with an excitation wavelength of 536 nm and an emission wavelength of 588 nm. 
Fluorescence development was expressed as percentage of the control and the IC50 values 
were determined from the sigmoid curves using Softmax Pro Software (Molecular Devices). 
Miltefosine (purity 95%, VWR) was used as positive control.  
 
In vitro cytotoxicity assay 
The cytotoxicity assay was performed using a protocol based on the Alamar Blue assay [7], 
whereby rat skeletal myoblast cells (L-6 cells) were seeded in 96-well microtiter plates using 
MEM supplemented with 10% heat inactivated FBS (4000 cells/well). Serial threefold drug 
dilutions ranging from 90 to 0.123 mg/mL were prepared. After 72 h, 10 L resazurin 
127
4 
 
solution was added (12.5 mg resazurin (Sigma-Aldrich) dissolved in 100 mL of distilled water) 
and the plates were incubated for further 2 to 4 h. A Spectramax Gemini XS micro plate 
fluorescence reader (Molecular Devices) was used to measure the plates at an excitation 
wavelength of 536 nm and an emission wavelength of 588 nm. Fluorescence development 
was expressed as percentage of the control and the IC50 values were determined from the 
sigmoid curves using Softmax Pro Software (Molecular Devices). Podophyllotoxin (purity 
˃95%, Sigma-Aldrich) was used as a reference drug. 
 
Physicochemical data of 2, 4 and 5 
 
(3S-4R)-4,1'‚4'-trihydroxy-6,7,8,2',3'-pentamethoxyisoflavan (Abruquinone G, 2) [8]: White 
amorphous substance; UV (MeOH): max (log ) = 205 (4.66), 296 (3.88) nm; 
1
H and 
13
C 
NMR data, see Table 1S; HRESI-MS: m/z = 413.1178 [M-H2O+Na]
+
 (calcd. for C20H24NaO9: 
413.1027). 
 
(3R)-6,7,8,2',3'-pentamethoxyisoflavan-1',4'-quinone (Abruquinone B, 4) [8, 9, 10, 11]: Red-
brown amorphous substance; UV (MeOH): max nm (log ) = 203 (4.61), 268 (4.06) nm; 
1
H 
NMR data, see Table 1; 
13
C NMR data, see Table 1; HRESI-MS: m/z = 413.1182 [M+Na]
+
 
(calcd. for C20H22NaO8: 413.1207). 
 
(3S)-7,8,3'‚5'-tetramethoxyisoflavan-1',4'-quinone (5) [12]: Orange amorphous substance; UV 
(MeOH): max (log ) = 205 (4.59) nm, 286 (3.91) nm; 
1
H NMR data, see Table 1; 
13
C NMR 
data, see Table 1; HRESI-MS: m/z = 383.1143 [M+Na]
+
 (calcd. for C19H20NaO7: 383.1101). 
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Table 1S. 
1
H and 
13
C NMR data (CD3OD, 500 MHz for 
1
H, 125 MHz for 
13
C) for compounds 2, 4, and 5. 
 2
 
  4
 
  5
 
  
position H C
a
 H C
 
 H C
a
 
2a 3.60 (dd, 11.1, 4.8) 
66.3 
4.23 (dd, 10.7, 3.2) 68.2 4.43 (dd,10.7, 10.4) 67.8 
2b 2.91 (dd, 11.1, 10.7) 4.21 (dd, 10.7, 6.3)  4.23 (ddd,10.7, 3.8, 1.6)  
3 2.79 (1H, m) 40.7 3.42 (1H, m) 31.0 3.60 (1H, m) 31.0 
4a 
4b 
4.71 (1H, d, 6.9) 78.1 
Ha 3.02 (dd, 16.3, 6.3) 
Hb 2.69 (dd, 16.3, 6.4) 
29.5 
Ha 3.15 (dd, 15.5, 12.4) 
Hb 2.66 (ddd, 15.5, 5.1, 1.6) 
29.3 
5 6.81 (1H, s) 108.1 6.31 (1H, s) 107.1 6.69 (1H, d, 8.5) 123.3 
6 - 148.1 - 147.7 6.47 (1H, d, 8.5) 105.0 
7 - 143.7 - 141.9* - 151.2 
8 - 142.5 - 142.5 - 137.6 
9 - 143.7 - 146.5 - 148.3 
10 - 114.9 - 115.1 - 115.9 
1' - 143.6 - 183.7 - 186.7 
2' - 137.7 - 145.3* 5.84 (1H, s) 107.3 
3' - 139.2 - 144.9 - 156.9 
4' - ndb - 184.2 - 178.7 
5' 5.87 (1H, s) 104.6 6.32 (1H, br d, 1.1) 131.2 - 155.4 
6' - 122.9 - 141.9 - 131.0 
2'- OCH3 3.98 (3H, s) 60.1 3.99 (3H, s) 61.5 - - 
3'- OCH3 3.99 (3H, s) 61.1 3.98 (3H, s) 61.5 3.79 (3H, s) 56.2 
5'- OCH3 - - - - 3.95 (3H, s) 61.2 
6- OCH3 3.77 (3H, s) 56.4 3.77 (3H, s) 56.5 - - 
7- OCH3 3.85 (3H, s) 61.1 3.85 (3H, s) 61.5 3.83 (3H, s) 56.2 
8- OCH3 3.85 (3H, s) 61.0 3.85 (3H, s) 61.5 3.85 (3H, s) 60.7 
a
 
13
C NMR signals were extracted from HSQC and HMBC spectra, 
b
 not detected. *interchangable 
 
 
 
 
 
 
129
6 
 
 
Fig. 1S. 
1
H NMR spectrum of Abruquinone H (1) in CD3OD. 
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Fig. 2S. 
1
H 
1
H COSY spectrum of Abruquinone H (1) in CD3OD.  
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Fig. 3S. HSQC and HMBC overlaid spectra of Abruquinone H (1) in CD3OD. 
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Fig. 4S. DEPTQ spectrum of Abruquinone H (1) in CD3OD.  
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Fig. 5S. 
1
H NMR spectrum of Abruquinone G (2) in CDCl3.  
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Fig. 6S. 
1
H NMR spectrum of Abruquinone I (3) in CDCl3. 
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Fig. 7S. 
1
H 
1
H COSY spectrum of Abruquinone I (3) in CDCl3. 
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Fig. 8S. HMQC and HMBC overlaid spectra of Abruquinone I (3) in CDCl3. 
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Fig. 9S. DEPTQ spectrum of Abruquinone I (3) in CDCl3. 
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Fig. 10S. 
1
H NMR spectrum of Abruquinone B (4) in CDCl3.  
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Fig. 11S. 
1
H NMR spectrum of compound 5 in CDCl3. 
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Fig. 12S Key HMBC and COSY correlations for 2, 4 and 5. 
 
 
 
Table 2S. Conformers resulting of the conformational analysis for compounds 2, 3, 4, and 5 
 
Compound Isomer 
Conformation 
analysis  
Optimized conformers 
2 
3S,4R 68 49 
3S,4S 51 30 
3 
3R 10 9 
3S 17 9 
4 3R 96 72 
5 3R 29 11 
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 Fig. 13S Comparison of the experimental ECD of 4 and calculated spectra for the (3R)-
enantiomer (A). Comparison of the experimental ECD of 5 and calculated spectra for (3S)-
enantiomer (B). 
142
19 
 
 
 
 
Fig. 14S. Superimposed lowest energy conformers (within 1 kcal/moL range from the global minimum) obtained from the conformational search 
were re-calculated using DFT at the B3LYP/6-31G** level in the gas phase. Thirty conformers obtained for the (3S,4S)-stereoisomer of 2 were 
grouped in three distinct core conformers (A). Fourteen conformers of (3S)-3 corresponded to four different core conformers (B). 
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Fig. 14S Seventy two conformers of (3R)-4 were grouped in four distinct core conformers (C). Eleven conformers of (3S)-5 were grouped in three 
different core conformers (D). 
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A           B       
 
Fig. 15S Calculated ECD spectra in MeOH (CPCM) for the minimized conformers (DTF/B3LYP/6-31G**) of compound 2.  Spectra of individual 
conformers (within an energy range of 1 Kcal/mol) for the (3S,4R)-stereoisomer (A); for individual conformers (within an energy range of 1 
Kcal/mol) for the (3S,4S)-stereoisomer (B). 
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A           B 
 
Fig. 16S Calculated ECD spectra in MeOH (CPCM) for the minimized conformers (DTF/B3LYP/6-31G**) of compound 3. Spectra of individual 
conformers (within an energy range of 1 Kcal/mol) for the (3S)-enantiomer (A); spectra of individual conformers (within an energy range of 1 
Kcal/mol) for the (3R)-enantiomer(B). 
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Fig. 17S Calculated ECD spectra in MeOH (CPCM) for the minimized conformers (DTF/B3LYP/6-31G**) of compound 4. Spectra of individual 
conformers (within an energy range of 1 Kcal/mol) for the (3R)-enantiomer are shown.  
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Fig. 18S Calculated ECD spectra in MeOH (CPCM) of the minimized conformers (DTF/B3LYP/6-31G**) of compound 5. Spectra of individual 
conformers (within an energy range of 1 Kcal/mol) for the (3R)-enantiomer are shown.  
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3.4 Antitrypanosomal Activity of  Isoflavan Quinones from Abrus precatorius  
Yoshie Hata, Samad Nejad Ebrahimi, Maria de Mieri, Stefanie Zimmermann, Tsholofelo Mokoka, 
Dashnie Naidoo, Gerda Fouche, Vinesh Maharaj, Marcel Kaiser, Reto Brun, Olivier Potterat, Matthias 
Hamburger 
Fitoterapia 93 (2014) 91-87. DOI: 10.1016/j.fitote.2013.12.015 
 
 
In an attempt to isolate sufficient amounts of abruquinone B and I (at least 30 mg of each one) to perform 
in vivo trypanocidal assays in mice, a second batch of Abrus precatorius was recollected. The chemical 
profiles of batch I and II were compared, and major differences were found. Five abruquinones were 
isolated as minor compounds, 3 of them resulted to be new compounds. Four of the substances showed 
high in vitro activity against Trypanosoma brucei rhodesiense and remarkable selectivity. Even though 
the initial goal of isolating abruquinones B and I in large amounds could not be accomplished, we isolated 
new antiprotozoal abruquinones, confirming our findings that these compounds are promising for further 
in vivo evaluation. 
 
 
My contributions to this work were: (1) large scale separation of the CH2Cl2/MeOH (1:1) extract of A. 
precatorius; (2) isolation of abruquinones; (3) recording and interpretation of analytical data for 
structure elucidation (HPLC-PDA-ESI-MS, TOF-MS, 1D and 2D NMR, CD measurements) and other 
measurements such us optical rotation; (4) writing of the draft manuscript, preparation of figures, tables, 
and supporting information.  
Samad Ebrahimi did the quantum-chemical calculation of ECD spectra and, under his supervision I 
participated in the respective analysis. Maria De Mieri supervised structure elucidation. In vitro 
antiprotozoal and cytotoxicity tests were performed in the Swiss TPH. The crude extract was provided by 
the CSIR team. 
Yoshie Hata-Uribe 
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ECD1. Introduction
Human African trypanosomiasis (HAT) is a neglected
tropical disease caused by two subspecies of Trypanosoma
brucei. T. b. gambiense is endemic in 24 countries of western
and central Africa and causes more than 95% of the reported
cases of HAT, while T. b. rhodesiense is endemic in 13
countries of eastern and southern Africa. Trypanosomiasis
mainly affects population located in poor and remote rural
regions. The number of infected individuals reported annu-
ally is decreasing since the turn of the millennium reaching
7200 reported cases in 2012 while the estimated number of
cases is 20,000 to 30,000 [1,2].cal Biology, University
erland. Tel.: +41 61
. Hamburger).
ll rights reserved.
151Four drugs are currently used for the treatment of HAT,
namely pentamidine, suramin, melarsoprol, and eflornithine.
However, these drugs suffer from severe limitations, such as
(i) lack of oral bioavailability (all of themmust be administered
parenterally) and chemical stability (suramin rapidly decom-
poses in air), (ii) complicated and long dose regimens (suramin
administration can last up to 30 days) and short half-life (four
infusions of eflornithine per day are necessary), and (iii) severe
adverse drug reactions (pentamidine is nephrotoxic, and
melarsoprol causes a fatal encephalopathy in up to 10% of the
treated patients) [2–4]. The need for better drugs is urgent
[3,5,6].
Natural products have been a promising source for drugs,
especially for treatment of infectious and neglected diseases
[4,7,8]. In a medium throughput screening of an extract library
of South African medicinal plants with traditional use in
protozoan diseases [8–12] the CH2Cl2/MeOH (1:1) extract of
Abrus precatorius L. ssp. africanus Verdc had shown in vitro
82 Y. Hata et al. / Fitoterapia 93 (2014) 81–87activity against T. b. rhodesiense. With the aid of HPLC-based
activity profiling we then identified two isoflavan quinones
with potent in vitro activity and promising selectivity [11]. The
two compounds, abruquinones B and I, fulfilled the criteria for
progressing to an in vivo assessment of their trypanocidal
activity. However, the amounts of pure compound available at
that time were not sufficient for a preliminary study in mice.
Therefore, a second batch of plant material was collected for
the purpose of a large scale isolation of abruquinones B and I.
This second collection was carried out at the same location as
the first one, albeit at a different time of the year (November for
the first, and April for the second collection). When comparing
the phytochemical profiles of extracts from the first and second
collection of A. precatorius (batch I and II, respectively) by TLC
and HPLC-PDA-MS, we found substantial differences in their
chemical composition. Most important, no peaks correspond-
ing to abruquinones B and I were detected in batch II (Fig. 1).
Isoflavonoids were found only after enrichment by flash
chromatography. Given that the HPLC-PDA-MS data suggested
the presence of new isoflavan quinones in these fractions, we
proceeded to a targeted isolation of these compounds.
2. Materials and methods
2.1. General experimental procedures
HPLC-grade acetonitrile (MeCN) (Scharlau Chemie S.A.), and
water (obtained by an EASY-pure II from Barnstead waterFig. 1. HPLC-PDA analysis of batch I and II of A. precatorius. For separation con
18, refer to the abruquinones isolated from batch I [11]. Abruquinone H (A), a
tetramethoxyisoflavan-1′,4′-quinone (E). No peaks are present, in the same tim
152purification system, Dubuque) were used for HPLC separations.
HPLC solvents contained 0.1% HCOOH (Sigma) for analytical
separations. Chloroform-d (100 atom% D) and benzene-d6
(100 atom% D) for NMR were purchased from Armar
Chemicals. Solvents used for extraction were of analytical
grade (Romil Pure Chemistry). Reference drugs for bioassays
were chloroquine (N98%, Sigma-Aldrich), melarsoprol (N95%,
Sanofi-Aventis), miltefosine (N95%, VWR), and podophyllotoxin
(N95%, Sigma-Aldrich). HPLC-PDA-MS analyses were per-
formedwith an Agilent 1100 system consisting of a degasser,
a quaternary pump, a column oven, and a PDA detector con-
nected to a Gilson 215 injector and to an Esquire 3000 plus ion
trapmass spectrometer (Bruker Daltonics). Data acquisition and
processing were done by using HyStar 3.0 software (Bruker
Daltonics).
Flash chromatography was carried out with a PuriFlash®
4100 chromatography system (Interchim) controlled by
InterSoft V5.0 software. Semi-preparative HPLC was per-
formed with an Agilent 1100 series instrument equipped
with a PDA detector. Data acquisition and processing were
performed using HyStar 3.2 software (Bruker Daltonics). For
HR-ESI-MS a micrOTOF ESI-MS system (Bruker Daltonics)
was used. Mass calibration was performed with a solution of
formic acid 0.1% in 2-propanol/water (1:1) containing 5 mM
NaOH. Mass spectra were recorded in the range of m/z 150–
1500 in positive ion mode with the aid of micrOTOF control
software 1.1 (Bruker Daltonics). NMR spectra were recorded
on a Bruker AVANCE III™ 500 MHz spectrometer equippedditions, see Section 2.3. Peak letters, in batch I between minutes 13 and
bruquinone G (B), abruquinone I (C), abruquinone B (D), and 7,8,3′‚5′-
e window, in batch II.
83Y. Hata et al. / Fitoterapia 93 (2014) 81–87with a 1 mm TXI microprobe (1H and 2D NMR) or a 5 mm BBO
probe (13C NMR) (Bruker BioSpin) operating at 500 (1H) and
125 MHz (13C). Chemical shifts are reported as δ values (ppm)
with the residual solvent signal as internal reference, J in Hz.
Standard pulse sequences from Topspin 3.0 software package
were used. CD spectra were recorded with a Chirascan™ CD
Spectrometer, Pro-Data Software V2.4.2 and optical rota-
tion with a Jasco P-2000 polarimeter, equipped with a 1 dm
microcell and software Spectra Manager version 2.
2.2. Plant material
Samples of the whole plant of A. precatorius (batch II)
were collected at Jozini, KwaZulu Natal Province in South
Africa during April 2012 by a botanist, Mr. Hans Vahrmeijer.
The plant was identified as Abrus precatorius L. ssp. africanus
Verdc, and a herbarium specimen was deposited at the South
African National Biodiversity Institute (SANBI) (voucher
specimen number PRE 782945).
The whole plant was dried in an oven at 30–60 °C. Dried
plant material was ground to a coarse powder using a hammer
mill and stored at ambient temperature prior to extraction. One
kilogram of dried, ground material was extracted with 5 L of a
mixture of CH2Cl2 andMeOH(1:1) at room temperature for 1 h
with occasional stirring. The solvent was filtered and the
residual plant material further extracted overnight with 2.5 L
CH2Cl2/MeOH (1:1) followed by filtration. Finally, a third
extraction of the pulp was done with 2.5 L solvent for 1 h
with filtration. The pulp was discarded and the filtrates
combined and concentrated using a rotary vacuum evaporator
at a temperature below 45 °C and then further dried in vacuo at
room temperature for 24 h. The dried extract of 55.0 g (5.5%,
w/w) was stored at−20 °C.Table 1
1H and 13C NMR spectroscopic data for compounds 1, 2, and 3 (CDCl3, 500 MHz for
Position 1 2
δH δC δH
2α 4.19 (dd, 10.8, 5.0) 66.9 4.19 (dd, 10.9, 5
2β 3.62 (dd, 10.8, 10.8) 3.61 (dd, 10.9, 1
3 3.52 (ddd, 10.8, 6.9, 5.0) 40.6 3.45 (ddd, 10.8,
4 5.49 (d, 6.9) 79.6 5.42 (d, 6.9)
5 7.09 (s) 115.7 6.96 (s)
6 – 140.8 –
7 – 148.2 –
8 6.43 (s)a 100.2 6.51 (s)
9 – 149.4 –
10 – 112.0 –
1′ – 146.4 –
2′ – 130.98 –
3′ – 148.3 –
4′ 6.42 (d, 8.0)a 104.0 –
5′ 6.70 (dd, 8.0, 1.0) 114.9 6.57 (s)
6′ – 121.8 –
2′-OCH3 – – 3.89 (s)
3′-OCH3 3.84 (s) 56.7 3.96 (s)
6-OCH3 – – 3.87 (s)
7-OCH3 3.82 (s) 56.2 –
–OH – – –
–OH – – –
a Overlapping signals within the same column.
1532.3. Fractionation and isolation
The CH2Cl2/MeOH (1:1) extract of the whole plant (15 g)
was separated by flash chromatography on a silica gel (15–
40 μm) column (50 × 3500 mm, 300 g) by a gradient elution
with ethyl acetate (B) in n-hexane (A) as follows 0%→ 40% B
(0–3 h), 40% B (1 h), and 40%→ 100% B (1 h) at a flow rate of
22 mL/min. Fractions (22 mL each) were combined based on
TLC analysis. Twenty two fractions were obtained and
analyzed by HPLC-PDA-MS on a SunFire™ C18 column
(3.5 μm, 3.0 × 150 mm; Waters) with H2O (solvent A) and
MeCN (solvent B) using the flowing gradient profile: 10%→
100% B (0–30 min) and 100% B (31–32 min). The flow rate
was 0.5 mL/min. Fractions F12 (19.1 mg), F13 (36.0 mg), F16
(23.4 mg), and F17 (31.1 mg) were found to contain
abruquinones (Fig. A1 of Appendix A). These fractions were
purified by semi-preparative RP-HPLC using a SunFire™ C18
column (3.5 μm, 10 × 150 mm, Waters) with H2O (solvent
A) and MeCN (solvent B) and the following gradient 25%→
42% B (0–11.1 min), 42% → 48% B (11.1–20.9 min), 48% →
100% B (20.9–27.2 min), and 100% B (27.2–34.8 min). The
flow rate was 4 mL/min. Fractions were dissolved in DMSO
(10 or 20 mg/mL, depending on their solubility) and injected
in aliquots of 300 μL. Eight compounds were obtained.
Compounds 1 to 5 were obtained only from batch II.
Compound 1 (5.1 mg, tR 13.7 min) was isolated from F16
and F17, compound 2 (6.1 mg, tR 15.2 min) from F17,
compound 3 (1.3 mg, tR 12.6 min) from F13, compound 4
(3.4 mg, tR 17.9 min) from F13 and compound 5 (3.2 mg, tR
12.4 min) from F16 and F17. In addition, previously reported
[11] abruquinone H (A) (2.3 mg, tR 12.9 min) was obtained
from F16 and F17, abruquinone I (C) (3.1 mg, tR 14.9 min)
from F13, and 7,8,3′‚5′-tetramethoxyisoflavan-1′,4′-quinoneδH, 125 MHz for δC).
3
δC δH δC
.0) 66.5 4.25 (ddd, 10.5, 3.1, 1.6) 69.6
0.8) 3.97 (dd, 10.0, 9.8)
6.9, 5.0) 40.8 3.52 (dddd, 11.0, 9.0, 5.5, 3.5) 32.3
78.9 Hα 2.87a 30.5
Hβ 2.87a
112.2 6.52 (s) 112.0
142.3 – 141.3
147.5 – 145.1
103.7 6.45 (s) 103.5
150.5 – 148.8
110.9 – 112.7
143.8 – 140.7
139.2 5.82 (s) 138.6
137.9 – 139.7
144.2 – 142.5
104.7 6.46 (s) 108.6
123.4 – 122.9
61.6 3.87 (s) 61.0
60.8 3.90 (s) 61.1
56.5 3.79 (s) 56.8
– – –
5.44 (br s) –
5.66 (br s) –
84 Y. Hata et al. / Fitoterapia 93 (2014) 81–87(E) (3.7 mg, tR 17.0 min) from F12 and F13 (Fig. 1). Purity of
compounds 1–5 was N95% as determined by 1H-NMR
(Fig. A2, A11, A16, A20, and A21 of Appendix A).
(3S,4S)-4,6,1′‚2′-tetrahydroxy-7,3′-dimethoxyisoflavan
(abruquinone J, 1): colorless amorphous compound;
[α]D20-173 (c 0.1, CHCl3); UV (MeOH) λmax (log ε) 208
(4.92), 295 (3.88) nm; CD (MeOH): Δε201 nm = +48.8,
Δε213 nm = −71.4, Δε236 nm = −10.1 (sh), Δε293 nm =
+3.55; 1H and 13C NMR data in CDCl3 and C6D6, see
Table 1 and Table A1 of Appendix A; HR-ESI-MS: m/z =
339.0848 [M-H2O + Na]+ (calculated for C17H18O7:
334.1053).
(3S,4R)-4,7,1′‚4′-tetrahydroxy-6,2′,3′-trimethoxyisoflavan
(abruquinone K, 2): colorless amorphous substance; [α]D20-153
(c 0.1, CHCl3); UV (MeOH) λmax (log ε) 205 (4.69), 295
(3.81) nm; CD (MeOH): Δε200 nm = +25.9, Δε210 nm = −45.1,
Δε235 nm = −7.82 (sh), Δε284 nm = −1.28, Δε304 nm =+2.97;
1H and 13C NMR data in CDCl3, see Table 1; HR-ESI-MS: m/z =
369.1000 [M-H2O + Na]+ (calculated for C18H20O8: 364.1158).
(3R)-7,1′‚4′-trihydroxy-6,2′‚3′-trimethoxyisoflavan
(abruquinone L, 3): orange amorphous substance; [α]D20-45.5
(c 0.1, CHCl3); UV (MeOH) λmax (log ε) 201 (4.77), 293 (3.90)
nm; CD (MeOH): Δε202 nm = +10.5, Δε212 nm = −7.26,
Δε228 nm = -3.29 (sh), Δε272 nm = −0.33, Δε301 = +0.60;
1H and 13C NMR data in CDCl3 see Table 1; HR-ESI-MS:
m/z = 371.1155 [M + Na]+ (calculated for C18H20O7:
348.1209).
(3R)-6,7,2′,3′-tetramethoxyisoflavan-1′,4′-quinone
(abruquinone A, 4) [13]: For physico-chemical characteriza-
tion, see Appendix A. CD (MeOH) Δε199 nm = +4.19;
Δε210 nm = -3.28; Δε236 nm = +0.99; Δε254 nm = −2.71;
Δε293 nm = +1.45; 1H and 13C NMR data in CDCl3; see
Table A1.
(3R)-7-hydroxy-6,2′,3′-trimethoxyisoflavan-1′,4′-quinone
(abruquinoneD,5) [14]: for physico-chemical characterization,
see Appendix A. CD (MeOH) Δε198 nm = +0.77;
Δε209 nm = −2.85; Δε236 nm = +0.18; Δε258 nm = −1.46,
Δε291 nm = +0.60; 1H and 13C NMR data in CDCl3; see
Table A1.2.4. Electronic circular dichroism
The absolute configuration (AC) of compounds 1 and 3
was established by electronic circular dichroism (ECD).
Experimental ECD spectra were compared with calculatedFig. 2. Structure of co
154data, as previously described [11,15,16]. A detailed procedure
is given in Appendix A.
2.5. Antiprotozoal and cytotoxicity tests
The in vitro antiprotozoal activity of compounds was tested
against Plasmodium falciparum (K1 strain), Trypanosoma brucei
rhodesiense (STIB 900 strain), Trypanosoma cruzi (Tulahuen
strain C2C4 w/LacZ), and Leishmania donovani (strain MHOM/
ET/67/L82). Cytotoxicity was determined with the rat skeletal
myoblast cell line (L-6 cells). For the assays DMSO stock
solutions (10 mg/mL) of extracts and purified compounds
were freshly diluted in medium prior to testing (final DMSO
concentration in assay b1%). Assays were performed in three
independent repetitions. Details on culturing of parasites and
assay protocols are provided as Appendix A.
3. Results and discussion
The phytochemical profiles of batches I and II were
compared by HPLC-PDA-MS (Fig. 1). In the CH2Cl2/MeOH
(1:1) extract of batch II no abruquinones were detected. After
an enrichment by silica gel flash chromatography, isoflavan
quinones could be detected, albeit in much lower concentra-
tions than in batch I. Purification of isoflavonoids was achieved
by semi-preparative RP-HPLC of selected fractions, and a total
of eight compounds were obtained in milligram amounts.
Structures were established by NMR spectroscopy (1H, 13C,
COSY, HSQC, and HMBC), HR-ESI-MS and ECD. Compounds 1
[(3S,4S)-4,6,1′‚2′-tetrahydroxy-7,3′-dimethoxyisoflavan], 2
[(3S,4R)-4,7,1′‚4′-tetrahydroxy-6,2′,3′-trimethoxyisoflavan],
and 3 [(3R)-7,1′‚4′-trihydroxy-6,2′‚3′-trimethoxyisoflavan] are
newnatural products andhave beendesignated as abruquinones
J, K, and L, respectively (Fig. 2).
For compound 1, a molecular formula of C17H18O7 was
deduced from HR-ESI-MS (m/z 339.0848 [M-H2O + Na]+;
calculated: 334.1053). The 13C NMR spectrum (Table 1)
showed 17 signals, twelve of which were found in the region
between δC 100.2 and 149.4. This was indicative of a highly
substituted aromatic ring system. The remaining carbon
resonances were attributed to an oxygenated methine (δC
79.6), an oxygenated methylene (δC 66.9), two methoxy (δC
56.7 and 56.2), and one methine group (δC 40.6). The 1H NMR
spectrum (Table 1) displayed signals indicative of four
aromatic protons (δH 7.09 (s), 6.70 (dd, J = 8.0, 1.0 Hz),
6.43 (s) and 6.42 (d, J = 8.0 Hz)), and two aromatic methoxympounds 1–5.
Fig. 3. Key HMBC and COSY correlations for compounds 1 and 3.
85Y. Hata et al. / Fitoterapia 93 (2014) 81–87groups (δH 3.84 and 3.82). Four aliphatic protons were
observed at δH 5.49 (d, J = 6.9 Hz), 3.52 (ddd, J = 10.8, 6.8,
5.0 Hz), 3.62 (t, J = 10.7 Hz), and 4.19 (dd, J = 10.8, 4.9 Hz),
suggesting an isoflavan scaffold with a hydroxy group at C-4.
Unambiguous assignment of 1H and 13C NMR data was
achieved by a combination of COSY, HMBC, HSQC, and NOESY
experiments, and by comparison with reported data of
isoflavan quinones and -hydroquinones [11,13,14,17,18].
The connectivity of rings A and C was confirmed by 3JC-H
coupling between H-5 (δH 7.09, ring A) and C-4 (δc 79.6, ring
C), and HMBC correlations between H-3 (δH 3.52, ring C) and
C-6′ (δc 121.8, ring B), and H-5′ (δH 6.70, ring B) and C-3 (δC
40.6, ring C) corroborated the connectivity between rings B
and C (Fig. 3). The vicinal coupling constants H-2α/H-3 (J =
5.0 Hz) and H-2β/H-3 (J = 10.8 Hz) corresponded to
dihedral angles of 60° and 180°, respectively, and indicated
an axial orientation of H-3. The coupling constant H-4/H-3
(J = 6.9 Hz) agreed with a dihedral angle of 30° to 50°, or
130° to 150°, indicating two possible orientations for H-4 in a
half-chair [19]. The NOESY contact observed between H-4 (δH
5.49) and H-3 (δH 3.52) did not allow for the unambiguous
differentiation between a pseudo-axial or pseudo-equatorial
orientation of H-4. The pseudo-equatorial orientation of H-4
was finally deduced from a conformational analysis per-
formed for the calculation of the ECD spectrum of compound
1. The absolute configuration was established by comparing
the experimental ECD spectrum with data calculated for the
(3S,4R) and (3S,4S) diastereomers (Fig. 4). A total of 8 and 6
conformers, respectively, were found within a 1 Kcal/mol
energy window from the particular global minimum (Fig. A24
of Appendix A). The conformers were subjected to geometricalFig. 4. Comparison of the experimental ECD of 1 with calcula
155optimization in the gas phase [20,21], ECD spectra were
calculated for each one of them (Fig. A26 of Appendix A), and
a final ECD spectrum was obtained after combination of the
individuals spectra, according to their population contribution.
The calculated ECD spectrum for the (3S,4R)-stereoisomer
showed three negative CEs around 200, 213, and 280 nm, and
two positive CEs at 230 and 263 nm (Fig. 4), while the ECD
spectrum for the (3S,4S)-stereoisomer showed a positive CE
around 200 nm. Hence, the strong positive CE around 200 nm
and the general appearance of the experimental ECD spectrum
matched well with the calculated spectrum of the (3S,4S)-
stereoisomer, and compound 1was thus established as (3S,4S)-
4,6,1′‚2′-tetrahydroxy-7,3′-dimethoxyisoflavan.
Compound 2 had a molecular formula of C18H20O8, as
derived from HR-ESI-MS (m/z 369.1000 [M-H2O + Na]+;
calculated: 364.1158). The 13C NMR and 1H NMR spectra
(Table 1) showed an additional methoxy group when
compared to 1. Like compound 1, the 1H NMR spectrum of
2 showed four aliphatic protons. The COSY and HMBC
correlations (Fig. 3) confirmed the presence of an isoflavan
scaffold with a hydroxyl group at C-4. A pseudo-axial
orientation of H-4 was finally derived from a conformational
analysis performed for calculation of the ECD spectrum [11].
Compound 2 showed a strong negative CE around 210 nm,
and a weak negative CE at 290 nm (Fig. A23A of Appendix A),
similar to (3S,4R)-abruquinone G [11]. Therefore, the abso-
lute configuration was established as (3S,4R). Compound 3
had a molecular formula of C18H20O7, as indicated by its
HR-ESI-MS (m/z 371.1155 [M-H2O + Na]+; calculated:
348.1209). Analysis of the 13C NMR and 1H NMR spectra
(Table 1) showed that 3was closely related to isoflavonoid 2,ted spectra for the (3S,4R) and (3S,4S)-diastereomers.
Fig. 5. Comparison of the experimental ECD of 3, with calculated spectra for the (3R)-enantiomer.
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group (m, δH 2.87, δC 30.5) instead of an oxygenated methine.
The COSY and HMBC correlations (Fig. 3) were in agreement
with those observed for 2 and confirmed the presence of an
isoflavan scaffold. The equatorial orientation of the B-ring
was deduced from the vicinal coupling pattern of 3-H
(δH 3.52, dddd J = 11.0, 9.0, 5.5, 3.5) that indicated a
trans-diaxial orientation of H-2axial/H-3 (J = 11.0 Hz), and
H-3/H-4pseudoaxial (J = 9.0 Hz). A conformational analysis of
3 revealed 11 conformers within a 1 Kcal/mol energy
window from the particular global minimum (Fig. A25 of
Appendix A). The calculated ECD spectrum of the (3R)-
enantiomer showed a positive CE around 204 nm, and two
negative CEs at 212 and 235 nm. This pattern fitted well with
the experimental spectrum of 3 (Fig. 5) which showed a strong
positive CE at 202 nm and two negative CEs at 212 and
233 nm. Compound 3 was thus (3R)-7,1′‚4′-trihydroxy-6,
2′‚3′-trimethoxyisoflavan.
Isoflavonoids 4 and 5were identified from their HR-ESI-MS,
1D and 2D NMR data, as abruquinones A [13,14] and D [14],
respectively. The AC of both compounds was assessed by ECD
(Fig. A23B and A23C of Appendix A). Their experimental
spectra were very similar and fitted well with the spectrum
of (3R)-abruquinone B [11]. Accordingly, 4 and 5 were
thus [(3R)-6,7,2′,3′-tetramethoxyisoflavan-1′,4′-quinone] andTable 2
In vitro antiprotozoal activities of 1–5 against P. falciparum, T. b. rhodesiense, and cy
Compound P. falciparum T. b. rhodesiense
IC50 (μM)a SI IC50 (μM)a
1 83.7 ± 4.0 1.8 11.2 ± 3.337
2 14.1 ± 0.4 4.1 0.11 ± 0.053
3 13.4 ± 0.6 0.6 0.02 ± 0.003
4 9.2 ± 1.5 3.7 0.02 ± 0.003
5 3.5 ± 0.16 1.4 0.01 ± 0.001
Chloroquinec 0.004 ± 0.001 – –
Melarsoprolc – – 0.003 ± 0.002
Miltefosinec – – –
Podophyllotoxinc – – –
a Values are expressed as mean ± standard error of the mean.
b No activity observed at the highest test concentration of 90 μg/mL (247.2 to 26
c Reference drugs. SI (selectivity index): quotient of IC50 value for L-6 cells and I
156[(3R)-7-hydroxy-6,2′,3′-trimethoxyisoflavan-1′,4′-quinone], re-
spectively. The AC of 4 had been reported earlier, but reports
were contradictory and suggested that both enantiomers had
been found in A. precatorius [11,13,14]. In contrast, our findings
for 5were in agreementwith the literature [14]. Abruquinone H,
I and 7,8,3′‚5′-tetramethoxyisoflavan-1′,4′-quinone had been
previously isolated from batch I of A. precatorius [11].
Compounds 2 to 5 showed strong in vitro activity against
T. b. rhodesiense (IC50 values of 0.11, 0.02, 0.02, and 0.01 μM,
respectively) and low cytotoxicity in L-6 cells (IC50 values of
57.3, 7.5, 34.5, and 4.8 μM, respectively). The selectivity
indices (SIs of 508, 374, 1379, and 668) are high enough to
warrant in vivo tests in mice. In addition, in vitro activity
against P. falciparum and L. donovani was assessed (Table 2).
However, all compounds showed low or no inhibitory effect
at the concentrations tested.
Even though the initial goal of isolating abruquinones B
and I for in vivo testing was not achieved, we were able to
identify a series of new isoflavan quinones with promising in
vitro activity. This corroborates our earlier findings that these
compounds warrant an in vivo evaluation in the acute rodent
model of T. b. rhodesiense [22]. The qualitative and quantita-
tive differences in isoflavonoids between the two batches
appear to be a seasonal effect given that the material was
collected in the same location, but at different times of thetotoxic activity in L-6 cells.
L. donovani Cytotoxicity
SI IC50 (μM) SI IC50 (μM)a
13.6 Inactiveb – 152.1 ± 7.8
508.5 Inactiveb – 57.3 ± 4.3
374.3 Inactiveb – 7.5 ± 1.2
1379.4 Inactiveb – 34.5 ± 16.3
668.0 Inactiveb – 4.8 ± 1.6
– – – –
– – – –
– 1.536 ± 0.051 – –
– – – 0.019 ± 0.006
9.4 μM).
C50 for parasite.
87Y. Hata et al. / Fitoterapia 93 (2014) 81–87year (November (summer) for batch I, April (autumn) for
batch II). From soybeans it is known that isoflavonoid
accumulation is affected by environmental factors such as
temperature and water regimen [23].
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Appendix A. Supplementary data
Detailed protocols of biological activity, NMR spectra (1D
and 2D) of compounds 1 to 5, physicochemical, spectroscopic
data of compounds 4 and 5, and additional ECD data are
provided as Supplementary data. Supplementary data asso-
ciated with this article can be found, in the online version, at
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Assays for in vitro antiprotozoal activity  
Antiplasmodial activity was determined by a modification of the 3[H]-hypoxanthine 
incorporation assay [1] with the P. falciparum K1 strain (resistant to chloroquine and 
pyrimethamine), growth according to the method described by Trager and Jensen [2]. 
Artesunate (purity >95%, Sigma-Aldrich) was used as positive control. 
Briefly, a suspension of infected red blood cells (final parasitemia 0.3% and hematocrit 1.25%) 
in RPMI 1640 medium supplemented with 2 µM L-glutamine, 5.95 g/L Hepes, 2 g/L 
NaHCO3, and 5% of Albumax II was exposed to serial drug dilutions covering a range from 
10 µg/mL to 0.156 μg/mL in 96-well microtiter plates.  After 48 h of incubation (4% CO2, 3% 
O2, and 93% N2 at 37°C), 50 µL of 3[H]-hypoxanthine (0.25 µM) were added to each well 
(Costar). The plates were incubated for further 24 h before being harvested by using a 
Betaplate cell harvester (Wallac) onto glass-fiber filters and then washed with distilled water. 
The dried filters were inserted into plastic foils with 10 mL scintillation fluid. The 
radioactivity was counted with a Betaplate liquid scintillation counter (Wallac) as counts per 
minute per well at each drug concentration and compared to the untreated controls. Counts 
were expressed as percentages of the control and presented as sigmoidal inhibition curves. 
IC50 values were calculated by linear interpolation.  
 
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 was 
determined according to [3]. Melarsoprol (Arsorbal, purity >95%, Sanofi-Aventis) was used 
as positive control. Minimum essential medium (MEM) with Earle’s salts supplemented with 
2-mercaptoethanol, as described by Baltz et al. [4], 1 mM sodium pyruvate, 0.5 mM 
hypoxanthine, and 15% heat-inactivated horse serum was added (50 µL) to each well of a 96-
well microtiter plate (Costar) except of the negative control. Serial drugs dilutions were 
prepared covering a range from 90 to 0.123 µg/mL followed by the addition of 2000 T. brucei 
rhodesiense STIB 900 bloodstream forms/well. After 70 hours of incubation (humidified 5% 
CO2 atmosphere at 37°C), 10 µL resazurin solution (12.5 mg resazurin (Sigma-Aldrich) 
dissolved in 100 mL of distilled water) were added and incubation was continued for further 2 
to 6 h. The plate was read with a Spectramax Gemini XS microplate fluorescence reader 
(Molecular Devices) with an excitation wavelength of 536 nm and an emission wavelength of 
588 nm. Fluorescence development was expressed as percentage of the control and the IC50 
values were determined from the sigmoid curves using Softmax Pro Software (Molecular 
Devices). 
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 Leishmanicidal activity was determined with L. donovani (axenic amastigotes) MHOM-
ET/67/L82 strain according to [6], with some modifications. Fifty microlitres of SM medium 
at pH 5.4 supplemented with 10% heat-inactivated FBS was added to each well of 96-well 
microtiter plate (Costar). Serial drug dilutions were prepared covering a range from 90 to 
0.123 µg/mL. Then, 105 axenically grown L. donovani amastigotes in 50 µL medium were 
added to each well and the plate was incubated for 72 h (humidified 5% CO2 atmosphere at 
37°C). Ten microlitres resazurin solution (12.5 mg resazurin (Sigma-Aldrich) dissolved in 
100 mL of distilled water) were added to each well and incubated for further 2 to 4 h. The 
plate was read with a Spectramax Gemini XS microplate fluorescence reader (Molecular 
Devices) with an excitation wavelength of 536 nm and an emission wavelength of 588 nm. 
Fluorescence development was expressed as percentage of the control and the IC50 values 
were determined from the sigmoid curves using Softmax Pro Software (Molecular Devices). 
Miltefosine (purity >95%, VWR) was used as positive control.  
 
In vitro cytotoxicity assay 
The cytotoxicity assay was performed using a protocol based on the Alamar Blue assay [7], 
whereby rat skeletal myoblast cells (L-6 cells) were seeded in 96-well microtiter plates using 
MEM supplemented with 10% heat inactivated FBS (4000 cells/well). Serial threefold drug 
dilutions ranging from 90 to 0.123 mg/mL were prepared. After 72 h, 10 µL resazurin 
solution was added (12.5 mg resazurin (Sigma-Aldrich) dissolved in 100 mL of distilled water) 
and the plates were incubated for further 2 to 4 h. A Spectramax Gemini XS micro plate 
fluorescence reader (Molecular Devices) was used to measure the plates at an excitation 
wavelength of 536 nm and an emission wavelength of 588 nm. Fluorescence development 
was expressed as percentage of the control and the IC50 values were determined from the 
sigmoid inhibition curves using Softmax Pro Software (Molecular Devices). Podophyllotoxin 
(purity ˃95%, Sigma-Aldrich) was used as a reference drug. 
Calculation of electronic circular dichroism (ECD) spectra  
Conformational analysis of 1, 2, and 3 was accomplished with Schrödinger MacroModel 9.1 
software employing the OPLS 2005 (optimized potential for liquid simulations) force field in 
H2O. Conformers within a 1 Kcal/mol energy window from the global minimum were picked 
for geometrical optimization and energy calculation applying density functional theory (DFT) 
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with the Becke's nonlocal three parameter exchange and correlation functional, and the Lee-
Yang-Parr correlation functional level (B3LYP, Becke, 3-paramiter, Lee-Yang-Parr) using the 
6-31G** basis set in the gas phase with the Gaussian 09 program package [8]. Vibrational 
evaluation was done at the same level to confirm minima. Excitation energy (denoted by 
wavelength in nm), rotator strength dipole velocity (Rvel), and dipole length (Rlen) were 
calculated in MeOH by TD-DFT/B3LYP/6-31G**, using self-consistent reaction field (SCRF) 
method, with the conductor polarized continuum model (CPCM) model. ECD curves were 
obtained on the basis of rotator strengths using a half-band of 0.2 eV using SpecDis v1.51 [9]. 
The spectra were combined after Boltzmann weighting according to their population 
contribution. 
 
Physicochemical data of 4 and 5 
 
(3R)-6,7,2',3'-Tetramethoxyisoflavan-1',4'-quinone (Abruquinone A, 4) [10]: Orange 
amorphous substance; UV (MeOH): λmax (log ε) = 200 (4.57), 268 (3.91) nm; 1H and 13C 
NMR data, see Table 1S; HRESI-MS: m/z = 383.1135 [M+Na]+ (calcd. for C19H20O7: 
360.1209). 
 
(3R)-7-Hydroxy-6,2',3'-trimethoxyisoflavan-1',4'-quinone (Abruquinone D', 5) [11]: Orange 
amorphous substance; UV (MeOH): λmax nm (log ε) = 198 (4.33), 268 (3.68) nm; 1H NMR 
data, see Table 1; 13C NMR data, see Table 1; HRESI-MS: m/z = 369.0963 [M+Na]+ (calcd. 
for C18H18O7: 346.1053). 
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 Table A.1. 1H and 13C NMR data (500 MHz for 1H, 125 MHz for 13C) for compounds 1, 4, 
and 5.  
 1a  4 b   5 b  
position δH δCc δH δCc   δH δCc 
2a 3.97 (dd, 10.8, 5.1) 66.5 4.17 68.0  4.16 (dd,10.7, 2.5) 67.9 
2b 3.54 (dd, 10.8, 10.7)   3.97 (dd, 10.9, 2.9)d   3.98d  
3 3.09 (m)d 40.6 3.39 (m) 30.8  3.39 (m) 30.8 
4a 
4b 5.18 (d, 7.1) 79.0 
Ha 3.39 (dd, 15.9, 6.3) 
Hb 2.99 (dd, 15.9, 6.3) 29.1 
 Ha 3.00 (dd, 16.0, 6.1) 
Hb 2.65 (dd, 16.0, 6.1) 29.3 
5 7.26 (s) 115.8 6.49 (s) 112.5  6.48 (s) 111.3 
6 - 140.8 - 143.8  - 141.4 
7 - 147.9 - 148.3  - 145.0 
8 6.33 (s) 100.0 - 147.7  6.40 (s) 103.2 
9 - 149.0 - 146.5  - 148.2 
10 - 112.5 - 110.4  - 110.4 
1' - 147.5 - 183.2  - 183.4 
2' - 131.5 - 144.8  5.84 (s) 149.4 
3' - 148.4 - 144.8  - 144.9 
4' 6.15 (d, 8.2) 104.0 - 174.6  - ndf 
5' 6.42 (dd, 8.2, 0.6) 114.1 6.33 (s) 130.8  6.33 (d 1.1) 130.8 
6' - 121.9 - 146.7  - 146.3 
2'- OCH3 - - 3.97 (s)d,e 61.1  3.98 (s) d 61.1 
3'- OCH3 3.26  55.9 3.97 (s)d,e 61.1  3.98 (s) d 61.1 
5'- OCH3 - - - -  6.33 (s) 130.8 
6- OCH3 - - 3.77 (s) 56.0  3.80 (s) 56.4 
7- OCH3 3.08 (s)d 55.0 3.78 (s) 55.9  3.83 (s) 56.2 
8- OCH3 - - 3.85 (s) 61.5  3.85 (s) 60.7 
 
 ameasured in C6D6, bmeasured in CDCl3, c13C NMR signals were extracted from HSQC and 
HMBC spectra, doverlapping signals within the same column, einterchangeable data, fnot 
detected 
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Fig. A.1. HPLC-PDA analysis of whole extract of A. precatorius batch II (top) and selected 
fractions after flash chromatography. Peak numbering refers to compounds 1-5 isolated from 
batch II, and peaks labelled with A, C, and E refer to compounds previously found in batch I. 
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Fig. A.2. 1H NMR spectrum of abruquinone J (1) in CDCl3 
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Fig. A.3. 1H 1H COSY spectrum of abruquinone J (1) in CDCl3. 
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Fig. A.4. HSQC and HMBC overlaid spectra of abruquinone J (1) in CDCl3. 
167
 
 
Fig. A.5. 1H 1H NOESY spectrum of abruquinone J (1) in CDCl3. 
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Fig. A.6. DEPTQ spectrum of abruquinone J (1) in CDCl3. 
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Fig. A.7. 1H NMR spectrum of abruquinone J (1) in C6D6. 
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Fig. A.8. 1H 1H COSY spectrum of abruquinone J (1) in C6D6. 
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Fig. A.9. HSQC and HMBC overlaid spectra of abruquinone J (1) in C6D6. 
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Fig. A.10. 1H 1H NOESY spectrum of abruquinone J (1) in C6D6. 
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Fig. A.11. 1H NMR spectrum of abruquinone K (2) in CDCl3. 
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Fig. A.12. 1H 1H COSY spectrum of abruquinone K (2) in CDCl3. 
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Fig. A.13. HMQC and HMBC overlaid spectra of abruquinone K (2) in CDCl3. 
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Fig. A.14. 1H 1H NOESY NMR spectrum of abruquinone K (2) in CDCl3. 
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Fig. A.15. DEPTQ spectrum of abruquinone K (2) in CDCl3. 
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Fig. A.16. 1H NMR spectrum of abruquinone L (3) in CDCl3. 
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Fig. A.17. 1H 1H COSY spectrum of abruquinone L (3) in CDCl3. 
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Fig. A.18. HMQC and HMBC overlaid spectra of abruquinone L (3) in CDCl3. 
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Fig. A.19. DEPTQ spectrum of abruquinone L (3) in CDCl3. 
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Fig. A.20. 1H NMR spectrum of abruquinone A (4) in CDCl3. 
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Fig. A.21. 1H NMR spectrum of abruquinone D (5) in CDCl3
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Fig. A.22 Key HMBC and COSY correlations for 4 and 5. 
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Fig. A.23 Experimental ECD spectra of compounds 2 (A), 4 (B), and 5 (C). 
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Fig. A.24. Lowest energy conformers (within 1 kcal/moL range from the global 
minimum) for (3S,4S)-1 (A) and (3S,4R)-1 (B). They were calculated using DFT at the 
B3LYP/6-31G** level in the gas phase. Eight conformers were obtained for the (3S,4S)-1 
(A), and six for (3S,4R)-1 stereoisomer (B). 
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Fig. A.25. Lowest energy conformers (within 1 kcal/moL range from the global 
minimum) for (3R)-3. Data obtained from the conformational search were re-calculated 
using DFT at the B3LYP/6-31G** level in the gas phase. Eleven conformers were 
obtained for the (3R)-3 enantiomer. 
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Fig. A.26. Calculated ECD spectra in MeOH (CPCM) of the minimized conformers 
DTF/B3LYP/6-31G**) of compound 1. Spectra of individual conformers (within an 
energy range of 1 Kcal/mol) for the (3S,4S)-(A) and (3S,4R)-stereoisomers (B) are shown. 
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Fig. A.27. Calculated ECD spectra in MeOH (CPCM) of the minimized conformers 
DTF/B3LYP/6-31G**) of compound 3. Spectra of individual conformers (within an 
energy range of 1 Kcal/mol) for the (3R)-enantiomer are shown. 
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3.5 Identification of two new phenathrenones and a saponin as antiprotozoal constituents of 
Drypetes gerrardii 
 
Yoshie Hata1,4*, Maria De Mieri1*, Samad Nejad Ebrahimi1,5, Tsholofelo Mokoka3, .Gerda Fouche3,  
Marcel Kaiser2, Reto Brun2, Olivier Potterat1, and Matthias Hamburger1 
 
Phytochemistry letters. Accepted.  
 
HPLC-based activity profiling allowed the identification of a new phenanthrenone from the stems extract 
of Drypetes gerrardii. Alongside, its dimer could be isolated. Both compounds showed activity against 
Plasmodium falciparum. However, the phenanthrenone exhibited more potency and selectivity than the 
dimer. As a result, the phenanthrenone was isolation in large scale for in vivo assessment. Interestingly, 
the compound turned out to be inactive. Furthermore, a saponin with weak trypanocidal activity, 
putranoside A, could be isolated from the leaves extract after being localized by the aid of a HPLC-based 
activity profiling.  
 
My contributions to this work were: (1) HPLC microfractionation of the CH2Cl2/MeOH (1:1) extract of 
Drypetes gerrardii (stems); (2) isolation of a phenanthrenone and its dimer, (3) recording and 
interpretation of analytical data for structure elucidation (HPLC-PDA-ESI-MS, TOF-MS, 1D and 2D 
NMR); (4) large scale isolation of the phenanthrenone for in vivo antimalarial test; (5) HPLC 
microfractionation of the CH2Cl2/MeOH (1:1) extract of D. gerrardii (leaves); (6) isolation of a saponin, 
hydrolysis, recording and interpretation of analytical data for structure elucidation (HPLC-PDA-ESI-
MS, TOF-MS, 1D and 2D NMR), data analysis, (7) writing of the manuscript draft, preparation of 
figures, tables, and supporting information.  
Maria de Mieri supported the structure elucidation of the phenanthrenones and wrote the corresponding 
results section in the paper. Melanie Raith supervised the saponin structure elucidation. In vitro 
antiprotozoal and cytotoxicity tests were performed at the Swiss TPH. The crude extracts were provided 
by the CSIR team. 
Yoshie Hata-Uribe 
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Abstract 
In an in vitro screen of 206 extracts from South African plants, the CH2Cl2/MeOH (1:1) stem 
extract of Drypetes gerrardii Hutch. var gerrardii (Putranjivaceae) inhibited Plasmodium 
falciparum and Leishmania donovani (IC50s of 0.50 and 7.31 µg/ml, respectively). In 
addition, the CH2Cl2/MeOH (1:1) extract of the leaves showed activity against Trypanosoma 
brucei rhodesiense (IC50 of 12.1 µg/ml). The active constituents were tracked by HPLC-based 
activity profiling, and isolated by preparative and semi-preparative RP-HPLC 
chromatography. Their structures were established by HRESIMS, and 1D and 2D NMR (1H, 
13C, COSY, HMBC, HSQC, and NOESY). From the stem extract, a new phenanthrenone 
derivative, drypetenone D (1), and a phenanthrenone heterodimer, drypetenone E (2), were 
isolated. Compound 1 showed potent in vitro activity against P. falciparum (IC50 of 0.9 µM) 
with a selectivity index (SI) of 71, as calculated from cytotoxicity data for L-6 cells. These 
data qualified 1 for in vivo assessment in the Plasmodium berghei mouse model, but the 
compound turned out to be inactive. Compound 2 also exhibited good in vitro antiplasmodial 
activity (IC50 of 2.0 µM) and selectivity (SI 31). From the leaf extract, the saponin 
putranoside A (3) was isolated and identified. Compound 3 showed weak in vitro trypanocidal 
activity, with an IC50 of 18.0 µM, and a SI of 4.  
  
Keywords: Antiprotozoal, Drypetes gerrardii, Putranjivaceae, phenanthrenones, HPLC-
based activity profiling.   
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1. Introduction 
Tropical parasitic diseases have devastating social and economic effects for Third World 
countries (Renslo and McKerrow, 2006). According to WHO estimations, 207 million cases 
of malaria infections and 627000 malaria deaths occurred worldwide in 2012. Malaria is 
transmitted by mosquitoes of the genus Anopheles and caused by five Plasmodium species. 
Artemisinin derivatives are the most recent drugs, but artemisinin-resistant P. falciparum 
strains have already emerged in Asia (Miller et al., 2013; WHO, 2013). Human African 
trypanosomiasis (HAT) is confined to sub-Saharan African countries where tsetse flies (genus 
Glossina) transmit the disease. The number of reported cases was 7197 in 2012. Trypanosoma 
brucei gambiense accounts for more than 98% of the reported cases of HAT and T. b. 
rhodesiense for the rest. Drugs in current use show varying degrees of toxicity and efficacy, 
and all require parenteral administration (WHO, June, 2013; Brun et al., 2011). There are 
more than 21 species of Leishmania sp. that cause various forms of leishmaniasis ranging 
from the cutaneous form to the lethal, if untreated, visceral form (VL). VL has an estimated 
global incidence of 200000 – 500000 cases and a prevalence of 5 million cases worldwide. 
Antileishmanial drugs are available, but suffer from limited efficacy, long treatments, or high 
costs (Stuart et al., 2008; WHO, 2010). In view of the unsatisfactory therapeutic options 
currently available, there is an urgent need for new drugs to treat these diseases (Renslo and 
McKerrow, 2006; Stuart et al., 2008). 
Natural products constitute an invaluable source of new drug scaffolds, particularly in the area 
of infectious diseases (Hannaert, 2011; Renslo, 2013). In the search for new antiprotozoal 
compounds, we screened a library of South African medicinal plants for antiprotozoal activity 
(Hata et al., 2013; Hata et al., 2011; Mokoka et al., 2011; Mokoka et al., 2013). A stem extract 
from Drypetes gerrardii Hutch. var. gerrardii (Putranjivaceae) showed pronounced 
antiplasmodial and antileishmanial activities. In addition, a leaf extract of the same plant 
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exhibited trypanocidal properties (Mokoka et al., 2013). There are few reports about the 
phytochemistry of D. gerrardii. So far, triterpenes belonging to the friedelane, hopane and 
lupane series, and flavone dimers, amentoflavone and drypetdimer A, have been isolated 
(Ng'ang'a et al., 2008; Ng'ang'a et al., 2011). The antiplasmodial activity of the dimeric 
flavonoids was evaluated against the K1 strain of P. falciparum (Ng'ang'a et al., 2012). We 
report here on the identification of the antiprotozoal constituents from stem and leaf extracts, 
and on the biological assessment of the isolated compounds.  
2. Results and discussion  
The CH2Cl2/MeOH 1:1 extract of the stems of D. gerrardii inhibited P. falciparum and L. 
donovani with IC50 values of 0.50 µg/ml and 7.31 µg/ml, respectively. Activity in the extract 
was tracked by HPLC-based activity profiling (Fig. 1). The chromatogram exhibited a strong 
UV-absorbing peak at tr = 19.0 min which correlated with 71% inhibition of L. donovani, and 
95% inhibition of P. falciparum. The compound was isolated by flash chromatography of the 
CH2Cl2/MeOH (1:1) extract, followed by semi-preparative RP-HPLC. In addition, a 
structurally related compound 2 was obtained. The structures of 1 and 2 were determined by 
HRESIMS and NMR analyses (1H NMR, 13C NMR, HMBC, HSQC, and NOESY).  
Compound 1 had a molecular formula of C17H16O2 (HRESIMS m/z = 275.1067 [M+Na]+ 
(calcd. for C17H16NaO2, 275.1043), thus requiring 10 degrees of indices of hydrogen 
deficiency. The 1H and 13C NMR spectra displayed resonances in the low field region of the 
spectrum and were indicative of a highly substituted aromatic ring system. The 1H NMR 
spectrum in CDCl3 displayed an AX olefinic spin system at δH 8.20 (d, J = 10.1 Hz) and 6.29 
(d, J = 10.1 Hz), two ortho coupled aromatic protons at δH 7.75 (d, J = 8.5 Hz) and 7.39 (d, J 
= 8.5 Hz), two aromatic protons as singlets at δH 7.59 and 7.53, an aliphatic geminal dimethyl 
group δH 1.51 (6H, s), and an aromatic methyl group at δH 2.42. The 13C NMR spectrum 
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displayed seventeen signals consistent with three methyls, six methines, eight quaternary 
carbons including a carbonyl (δC 205.5), one oxygenated aromatic carbon (δC 154.7) and a 
quaternary carbon bearing the gem-dimethyl group (δC 48.1). A careful analysis of HMBC 
and NOESY correlations (Fig. 4) suggested that 1 possessed a phenanthrenone skeleton 
similar to trigohowilol A (4) (Tang et al., 2012) except for the absence of the hydroxyl group 
at C-9 and of the O-methyl substituent at C-6 in 1. The location of the scalar coupled doublets 
(δH 7.75 and 7.39, J = 8.5 Hz) at positions C-9 and C-10, respectively, was inferred from 
HMBC correlations from H-9 to C-8, C-4b and C-10a, and from H-10 to C-4a and C-8a. This 
structural assignment was corroborated by a NOESY correlation between H-9 and H-8, and 
between H-10 and the gem-dimethyl group at C-1. Thus, the structure of 1 was established as 
shown in Fig. 3 and the compound was named drypetenone D. 
The molecular formula of compound 2 was determined as C34H30O4 (HRESIMS m/z = 
525.2063 [M+Na]+ (calcd. for C34H30NaO4, 525.2036), with 20 indices of hydrogen 
deficiency. The 1H and 13C spectra showed the presence of two sets of signals resembling 
those found for compound 1, thus suggesting a heterodimeric structure for 2. The 1H NMR 
spectrum displayed the resonances of: (1) two gem-dimethyl groups, Me-1 (δH 1.43, s) and 
Me-1' (δH 1.45, s); (2) two aromatic methyl groups CH3-7 (δH 2.76, s), CH3-7' (δH 2.51, s); (3) 
two sets of AX olefinic doublets H-3 (δH 6.03) and H-3' (δH 5.96), H-4 (δH 7.40) and H-4' (δH 
8.70); (4) two sets of ortho coupled aromatic protons H-9 (δH 7.78) and H-9' (δH 7.88), H-10 
(δH 7.43) and H-10' (δH 7.49); (5) three uncoupled aromatic protons H-5 (δH 6.93), H-8 (δH 
7.77) and H-8' (δH 7.66). 
The 13C NMR spectrum showed the signals for the aforementioned protonated carbons (see 
Table 1) and additionally: (1) two carbonyl C-atoms resonating at δC 204.5 (C-2) and δC 
203.9 (C-2'); (2) three oxygen bearing aromatic carbons δC 154.6 (C-6), δC 147.7 (C-6') and 
δC 134.2 (C-5'); (3) two aliphatic quaternary carbons δC 48.0 (C-1), δC 48.6 (C-1'); (4) ten 
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aromatic quaternary carbons δC 122.2 (C-4a) and δC 121.7 (C-4a'), 130.3 (C-4b) and δC 123.5 
(C-4b'), 127.0 (C-7) and δC 127.6 (C-7'), 129.0 (C-8a) and δC 128.7 (C-8a'), 147.5 (C-10a) 
and δC 149.2 (C-10a'). Based on HMBC and NOESY correlations the two substructures A and 
B (Fig. 5) were identified. Substructure A corresponded to compound 1, while in substructure 
B position C-5' was hydroxylated. In substructure B, the substitution of the aromatic C ring 
unit was established on the basis of the NOESY correlations between H-8' and H-9' and 
between H-8' and CH3-7'. The positions C-6' (δC 147.7) and C-5' (134.2) of ring C were 
oxygenated; C-6' chemical shift was assigned to be δC 147.7 by the 3JH-C HMBC correlation 
from 7'-CH3 while the remaining upfield shifted 13C resonance was assigned to position C-5'. 
Considering the substituents of the substructures A and B it became obvious that they were 
connected through an ether linkage between position C-6 of substructure A and positions C-5' 
or C-6' of substructure B. Unfortunately, no cross peaks were detected in the HMBC spectrum 
from H-5 to substructure B. In a further effort to discriminate between the two possible 
regioisomers, a long-range optimized (4 Hz) HMBC spectrum was measured. No correlations 
between the C rings of the two substructures were detected. However, position C-5’ could be 
unequivocally assigned by the 4JH-C HMBC observed with H-9' and H-8'. It was identified as 
the point of attachment of the ether linkage on substructure B considering the diagnostic 
upfield shift of δC C-5' (δC 134.2), with respect to C-6' (δC 147.7). A further support to this 
structure assignment came from the NOESY spectrum that showed a strong dipolar coupling 
between CH3-7 (δH 2.76) and H-4' (δH 8.70). On the basis of these data the structure of 2 was 
assigned as reported in Fig. 3 and the new compound named drypetenone E.  
A conformational analysis of 2 was performed, followed by geometrical optimization for the 
conformers found within 1 Kcal/mol from the corresponding global minimum energy. Two 
iso-energetic conformers were found (Fig. 6). DFT-optimized structures showed that the two 
substructures A and B were almost perpendicular and the distance between CH3-7 and H-4' 
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was 3.45 Å for both conformers, thus matching the observed dipolar coupling. The 
tridimensional rearrangement of drypetenone E (2) could also provide an explanation of the 
significant differences in the 1H chemical shift between drypetenone D (1) and substructure A 
of 2.  
There are few reports of naturally occurring phenanthrenones. Such compounds have been 
isolated from a marine bacterium, Pseudomonas stutzeri (Uzair et al., 2008), and from 
terrestrial plants of the genera Strophioblachia (Seephonkai et al., 2013a, b; Seephonkai et al., 
2009) and Trigonostemon (Hu et al., 2009; Kokpol et al., 1990; Tang et al., 2012; Zhu et al., 
2010), which belong to the Euphorbiaceae family. Interestingly, the genus Drypetes was 
formerly included in this family. 
Compound 1 showed low in vitro activity against L. donovani (Table 2). In contrast, 1 
remarkably inhibited P. falciparum (IC50 of 0.96 µM) and displayed low cytotoxicity for the 
L-6 cell line (IC50 of 68 µM). The selectivity index (SI) calculated as the quotient of IC50 for 
L-6 cells and IC50 against parasites gave a value of 71. Compound 2 displayed good in vitro 
activity against P. falciparum (IC50 of 2.0 µM), even though the selectivity (SI = 31) was not 
as high as the one of 1. The low yield of the compound probably explains that its activity was 
not detected in the HPLC-based activity profiling. These results granted in vivo assessment of 
the antimalarial efficacy of 1 in a mouse model. The full suppressive four-day test was 
performed on female NMRI mice infected with a GFP-transfected P. berghei strain ANKA. 
Animals treated with compound 1 showed no parasitemia reduction on day 4 compared to 
untreated control mice. The absence of activity in this model can be due either to absorption 
problems or unfavourable PK.  
                            
Molecular properties associated with drug-likeness and toxicity are essential in early 
compound selection. Descriptors, such us Lipinski’s “rule of 5” (molecular weight, log P, sum 
of H-donors/acceptors), rotatable bonds, and polar surface area (PSA) can predict drug-
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likeness. Compound 1 had a molecular weight of 252 Da, log P of 3.96, sum of H-
donors/acceptors of 2, 0 rotatable bonds and a PSA of 37.3 Å2, as calculated by 
Molinspiration Cheminformatics software (Cheminformatics, 2014). All these values fulfil 
established drug-likeness criteria (Lipinski and Hopkins, 2004; Pajouhesh and Lenz, 2005). 
Accordingly, oral absorption and blood-brain barrier permeability can be expected for 
compound 1. Oral availability is a desired characteristic for an ideal antimalarial drug (Fidock 
et al., 2004) while blood-brain barrier permeability is prerequisite for an advanced HAT 
infection (Brun et al., 2011). 
An early in silico toxicity prediction can help to anticipate potential “off-target” activity.  
There are a series of proteins involved in development of adverse effects. When the ability of 
a compound to bind to these proteins is simulated and quantified in silico, it is possible to 
obtain an estimated toxic potential (TP). By using the virtual technology “Virtual ToxLab” we 
estimated a TP of endocrine and/or metabolic disruption, carcinogenicity, and cardiotoxicity 
(Vedani et al., 2012). Binding affinities of 1 toward 16 target proteins, were calculated to 
obtain a TP of 0.52. This TP value categorizes 1 as a class I compound (in a scale of 0 to IV, 
being IV the most toxic). The binding affinity to critical proteins such as hERG, a potassium 
ion channel related with cardiotoxicity (IC50 of 40.2 µM), was low. Nevertheless, 1 bound the 
progesterone receptor with high affinity (IC50 of 46.8 nM). In case the compound progresses 
through the drug discovery pipeline, this aspect would require further attention since this 
receptor has a fundamental role during pregnancy and antimalarial drugs are expected to be 
administered also to pregnant women (Fidock et al., 2004). 
The second active extract, the CH2Cl2/MeOH 1:1 leaf extract, showed inhibition against T. b. 
rhodesiense with an IC50 of 12.1 µg/ml. HPLC-based activity profiling revealed strong 
inhibition in the time window of 19 – 20 min which matched with an intense peak in the 
HPLC-ELSD chromatogram (Fig. 2). Targeted isolation of this compound by a combination 
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of flash chromatography and open column chromatography afforded 3. Acid hydrolysis 
afforded two sugar moieties which were identified by GC-MS analysis after derivatization 
with cysteine methyl ester and silylation (Severi et al., 2010) as L-rhamnose and D-glucuronic 
acid. The compound was identified by means of HRESIMS, extensive NMR analyses (1H 
NMR, 13C NMR, HMBC, HSQC, and NOESY) and comparison with literature data as 3-O-
[α-L-rhamnopyranosyl-(1→3)-β-D-glucuropyranosyl] oleanolic acid, known as putranoside A 
(Fig. 3)  (Borel and Hostettmann, 1987; Hariharan, 1973, 1974; Melek et al., 2003). 
Compound 3 showed weak in vitro trypanocidal (IC50 of 18.0 µM) and antileishmanial 
activities (IC50 of 7.8 µM). 
It is noteworthy that the antiplasmodial triterpenoids which were previously reported from the 
leaves and stems of D. gerradii, including the most active lupane-type derivative resinone 
(IC50 of 0.09 mg/ml, SI 942) (Ng'ang'a et al., 2012; Ng'ang'a et al., 2011), were not detected 
by HPLC-MS analysis in the course of our study.  
 
 
 
3. Materials and Methods 
3.1 General experimental procedures 
HPLC-grade methanol (MeOH), acetonitrile (MeCN) (Scharlau Chemie S.A.), and water 
(obtained by an EASY-pure II from Barnstead water purification system, Dubuque) were used 
for HPLC separations. HPLC solvents contained 0.1% HCO2H (Sigma) for analytical 
separations. CDCl3 (100 atom% D), DMSO-d6 (100 atom% D), and pyridine-d5 (100 atom% 
D) for NMR were purchased from Armar Chemicals (Switzerland). Solvents used for 
extraction were of analytical grade (Romil Pure Chemistry). Reference drugs for bioassays 
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were chloroquine (>98%, Sigma-Aldrich), melarsoprol (purity >95%, Sanofi-Aventis), 
miltefosine (purity >95%, VWR), and podophyllotoxin (purity >95%, Sigma-Aldrich). 
HPLC-PDA-MS analyses were performed on an Agilent 1100 system consisting of a 
degasser, a quaternary pump, a column oven, a PDA detector and to an Esquire 3000 plus ion 
trap mass spectrometer (Bruker Daltonics). Data acquisition and processing were performed 
using HyStar 3.0 software (Bruker Daltonics). HPLC-PDA-ELSD analyses were carried out 
on an Alliance 2695 HPLC system (Waters) equipped with a 996 PDA (Waters) and an 
Alltech 2000ES ELSD. ELSD parameters were set as follows: N2 flow = 3.2 l/min, temp. = 
115ºC, gain = 8, impactor = off. Empower Pro software (Waters) was used to acquire and 
process data. Sugar analysis of compound 3 was performed with a HP 5890 Series II gas 
chromatograph equipped with a HP 5971 mass detector. He was used as a carrier gas. Flash 
chromatography was carried out on a chromatography system PuriFlash® 4100 (Interchim), 
controlled with InterSoft V5.0 software. Semi-preparative HPLC was performed on an 
Agilent 1100 series instrument equipped with a PDA detector. Data acquisition and 
processing were carried out using HyStar 3.2 software (Bruker Daltonics). For HRESIMS a 
micrOTOF ESI-MS system (Bruker Daltonics) was used. Mass calibration was performed 
with a solution of formic acid 0.1% in 2-PrOH/H2O (1:1) containing 5mM NaOH. Mass 
spectra were recorded in the range of m/z 150 – 1500 in positive ion mode with the aid of 
micrOTOF control software 1.1 (Bruker Daltonics). NMR spectra were recorded at 18 °C on a 
Bruker AVANCE IIITM 500 MHz spectrometer operating at 500.13 (1H) and 125.77 MHz 
equipped with a 1 mm TXI microprobe (1H and 2D NMR) or a 5 mm BBO probe (13C NMR) 
(Bruker BioSpin). The 13C spectrum of 2 was recorded on a Bruker AscendTM III 600 MHz 
spectrometer equipped with a QCI cryoprobe. Chemical shifts are reported as δ values (ppm) 
with the residual solvent signal as internal reference, J in Hz. Standard pulse sequences from 
Topspin 3.0 software package were used.  
202
11 
 
3.2 Plant material 
Samples of the stems of D. gerrardii were collected at Hlatikulu Forest on top of the 
Lebombo mountains in Gwalewemi, KwaZulu Natal Province in South Africa in April 2012 
by a botanist, Mr. Hans Vahrmeijer. A plant specimen was deposited at the South African 
National Biodiversity Institute (SANBI), and the plant identified as Drypetes gerrardii Hutch. 
var. gerrardii (Putranjivaceae) (voucher specimen number PRE 45954). 
 
3.3 Extraction 
Stems and leaves were collected, separated and dried separately in an oven at 30-60°C. Dried 
plant material was ground to a coarse powder using a hammer mill, and stored at ambient 
temp. prior to extraction. 800 g of dried, ground stems were extracted with 4 l of a mixture of 
CH2Cl2 and MeOH (1:1) at room temp. for 1h with occasional stirring. The extract was 
filtered, and the residual plant material further extracted overnight with 2 l CH2Cl2/MeOH 
(1:1), followed by filtration. Finally, a third extraction of the pulp was carried out with 2 l 
solvent for 1h with filtration. The filtrates were combined and concentrated using a rotary 
vacuum evaporator at a temp. below 45°C, and the residue dried in vacuo at room temp. for 
24 h. The dried extract of 35.0 g (4.4%, w/w) was stored at –20°C. 
The dried, ground leaves (115 g) of the plant were extracted in a similar way as described 
above to yield 6.31 g (5.5%, w/w) of extract. 
 
3.4 Microfractionation and activity profiling 
HPLC-based activity profiling was performed on a SunFire™ C18 column (3.5 µm, 
3.0 × 150 mm, Waters) equipped with a precolumn (3 x 10 mm) as previously described 
(Adams et al., 2009). H2O (solvent A) and MeCN (solvent B) were used as solvents, and the 
following gradient was applied: 10% → 100% B in 30 min, then 100% B for 1 min. The flow 
rate was 0.5 ml/min. Aliquots (35 µl) of extracts (10 mg/ml in DMSO) were injected, and 32 
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one-minute fractions collected into a 96 deep well plate (Eppendorf) with the aid of a F204 
fraction collector (Gilson). After solvent removal in an Evaporex 96 channel N2-evaporator 
(Apricot Designs), the dried fractions were re-dissolved in methanol (100 µl) and transferred 
to 96 v-well plates (Thermo Scientific), dried again, and stored in a refrigerator (2 – 8ºC) until 
use for bioassay.  
 
3.5 Preparative isolation  
The CH2Cl2/MeOH (1:1) stem extract of D. gerrardii (3.4 g) was fractionated by flash 
chromatography on a silica gel 60 column (15 – 40 µM, 35 x 430 mm, 180 g) with a gradient 
of 100-0% hexane in EtOAc in 3 h, using a flow rate of 40 ml/min. Fractions (22 ml each) 
were collected and compared by TLC analysis [silica gel; hexane/EtOAc (9:1 and 7:3); 
anisaldehyde/sulphuric acid spraying reagent, heated  at 110ºC]. Fractions 10 (121.4 mg) and 
11 (34.8 mg) were found to contain phenanthrenones. They were purified by semi-preparative 
RP-HPLC using a SunFireTM C18 column (3.5 µM, 10 x 150 mm; Waters) equipped with a 
precolumn (10 x 10 mm).  H2O (Solvent A) and MeCN (Solvent B) were used as solvents and 
the following gradient was applied: 40% → 60% B in 5 min, then 60% → 70% B in 25 min. 
The flow rate was 4 ml/min. The fractions were dissolved in DMSO (Fr.10: 10 mg/ml; Fr. 11: 
20 mg/ml) and injected in aliquots of 300 µl. Compound 1 (24.8 mg, tR 7.7 min) was isolated 
from Fr. 10 and Fr. 11. Compound 2 (1.4 mg, tR 24.0 min) was obtained from Fr. 10.  
The CH2Cl2/MeOH (1:1) leaf extract (355 mg) was separated by flash chromatography on a 
Sepacore® system system (Büchi) by using a pre-packed silica gel 60 cartridge (40 - 63 µm, 
40 x 150 mm) with a gradient of 0 - 60% EtOAc in MeOH, over 2 h. The flow rate was 15 
ml/min. Fractions (20 ml; each) were combined based on TLC analysis [silica gel; 
CHCl3/MeOH/H2O (65:30:5); vanillin/sulphuric acid reagent, heated at 110ºC]. Similar 
fractions were pooled into four fractions (Fr. A - D). Fr. B (148.7 mg) was further purified by 
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CC on silica gel (40 - 63 µm, 8 x 160 mm, 12.1 g) using a step gradient of CHCl3 and MeOH 
(100:0, 95:5, 92.5:7.5, 90:10 87.5:12.5, 85:15, 80:20, 70:30, 60:40, 50:50; 50 ml each) to 
yield 9 sub-fractions (Fr. B1 - B9). Subfraction Fr. B4 eluted with CHCl3/MeOH (80:20) 
afforded pure compound 3 (31.3 mg).  
Purity of compounds 1 and 3 was > 95%, and that of 2 > 90%, as determined by 1H NMR 
(Figs. 1S, 5S, 9S, and 15S of Supplementary content).   
6-Hydroxy-1,1,7-trimethylphenanthren-2(1H)-one (drypetenone D, 1): Yellow amorphous 
substance; 1H and 13C NMR data in CDCl3 and DMSO-d6, see Table 1; HRESIMS: m/z = 
275.1067 [M+Na]+ (calcd. for C17H16Na O2, 275.1043). 
6-Hydroxy-1,1,7-trimethyl-5-((2,8,8-trimethyl-7-oxo-7,8-dihydrophenanthren-3-
yl)oxy)phenanthren-2(1H)-one (drypetenone E, 2): Yellow amorphous substance; 1H and 13C 
NMR data in CDCl3, see Table 1; HRESIMS: m/z = 525.2063 [M+Na]+ (calcd. for 
C34H30NaO4, 525.2036). 
3-O-[α-L-rhamnopyranosyl-(1→3)-β-D-glucuropyranosyl] oleanolic acid (putranoside A, 3) 
[37-40]: White amorphous substance; 1H and 13C NMR data see Table 1S Supplementary 
content; HRESIMS: m/z = 801.4396 [M+Na]+ (calcd. for C42H66NaO13, 801.4396).  
 
3.6 Conformational analysis and geometrical optimization  
Conformational analysis of compound 2 was accomplished with Schrödinger MacroModel 9.1 
software employing the OPLS 2005 (optimized potential for liquid simulations) force field in 
H2O. Conformers within a 1 Kcal/mol energy window from the global minimum were picked 
for geometrical optimization and energy calculation applying DFT with the B3LYP functional 
using the 6-31G (d,p) basis set in the gas phase with the Gaussian 09 program package 
(Frisch, 2009). Vibrational evaluation was done at the same level to confirm minima.  
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3.7 Bioassays 
Extracts were tested in vitro against Plasmodium falciparum (NF54 strain), Trypanosoma 
brucei rhodesiense (STIB 900 strain), and Leishmania donovani (strain MHOM/ET/67/L82), 
in 96-well microtiter plates at concentrations of 10.0 µg/ml and 2.0 µg/ml. IC50s were 
subsequently determined for active extracts. HPLC microfractions from the CH2Cl2/MeOH 
(1:1) stem extract of D. gerrardii were assayed against P. falciparum and L. donovani. Those 
from the CH2Cl2/MeOH (1:1) leaf extract were tested on T. b. rhodesiense. Compounds 1and 
3 were evaluated for their antiprotozoal activity against the three parasites. Due to the scarcity 
of isolated material, compound 2 was tested only against P. falciparum. Additionally, for pure 
compounds, cytotoxicity was determined by using a rat skeletal myoblast cell line (L-6 cells). 
For the assays DMSO stock solutions (10 mg/ml) of extracts and purified compounds were 
freshly diluted in medium (final DMSO concentration in assay <1%). Assays were performed 
in two independent replicates. In vivo antimalarial activity was assessed as previously 
described (Peters, 1987) and conducted according to the rules and regulations for the 
protection of animal rights (‘Tierschutzverordnung’) of the Swiss ‘Bundesamt für 
Veterinärwesen’. They were approved by the veterinary office of the Canton Basel-Stadt, 
Switzerland. The animal experiment approval number for in vivo testing against P. berghei is 
1731. Details on assay protocols are provided as Supplementary content. 
 
Appendix A. Supplementary data 
Supplementary data associated with this article can be found, in the online version, at  
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Table 1. 1H and 13C NMR spectroscopic data of compounds 1 and 2 in CDCl3  
position 1 2a   
δH (J in Hz) δCb δH (J in Hz) δCc HMBC (H → C) 
      
1 - 48.1 - 48.0  
2 - 205.5 -   204.5                                                          
3 6.29 (d, 10.1) 123.6 6.03 (d, 10.4 Hz) 124.0 C-1,C-4a, 
4 8.20 (d, 10.1) 139.9 7.40 (d, 10.4 Hz) 138.8 C-2,C-4b,C-10a 
5 7.53 (s) 104.2 6.93 (s) 103.0 C-6,C-7,C-4a,C-8a 
6 - 154.7 -  154.6  
7 - 126.8 -  127.0  
8 7.59 (s) 130.2 7.77 (s)  131.3 C-6 
9 7.75 (d, 8.5) 130.2 7.78 (d, 8.7 Hz)  130.0 C-4b,C-10a 
10 7.39 (d, 8.5) 121.8 7.43 (d, 8.7 Hz)       123.0 C-1,C-4a,C-8a 
4a - 121.6 - 122.2  
4b - 131.0 - 130.3  
8a - 127.9 - 129.0  
10a - 147.1 - 147.5  
1-Me x 2 1.51 (s) 28.0 1.43 27.8 C-1,C-2,C-10a 
7-Me 2.42 (s) 16.4 2.76 17.2 C-6,C-7,C-8 
1'   - 48.6  
2'   - 203.9 
3'   5.96 (d, 10.6 Hz) 123.0 C-1',C-4a' 
4'   8.70 (d, 10.6 Hz) 141.8 C-2',C-4b',C-10a' 
5'   - 134.2  
6'   - 147.7  
7'   - 127.6  
8'   7.66 (s) 128.0 C-6',C-9',C-4b' 
9'   7.88 (d, 8.6 Hz)     131.0 C-4b',C-10a' 
10'   7.49 (d, 8.6 Hz) 122.9 C-1,C4a',C-8a' 
4a'   - 121.7  
4b'    - 123.5  
8a'    -                                 128.7  
10a'    - 149.2  
1'-Me x 2   1.45 27.8 C-1', C-2', C-10a' 
7'-Me   2.51 16.5 C-6', C-7', C-8' 
aThe numbering does not follow the IUPAC nomenclature b125.77 MHz,
 
c150.95 MHz 
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Table 2 In vitro antiprotozoal activities of 1 – 3 against P. falciparum, T. b. rhodesiense, L. 
donovani, and cytotoxic activity against L-6 cells 
 
 Compound P. falciparum T. b. rhodesiense L. donovani Cytotoxicity 
IC50 (µM)a  SI IC50 (µM)a  SI IC50 (µM)a  SI IC50 (µM)a  
1 0.96 ± 0.25 71.4 6.0 ± 2.7 11.5 14.0  4.9 68.4 ± 4.6 
2 2.04 ± 0.15 31.4 - - - - 64.0 ± 22.4 
3 inactive b  18.0 ± 2.6 3.8 7.8 8.8 68.2 ± 3.9 
Chloroquinec 0.004 ± 0.001 - - - - - - 
Melarsoprolc - - 0.003 ± 0.001  - - - - 
Miltefosinec - - - - 0.552 ± 0.051 - - 
Podophyllotoxinc - - - - - - 0.019 ± 0.006  
a
 Values are expressed as mean ± standard error of the mean. 
b
 No activity observed at the highest test concentration of 90 µg/ml, which corresponds to a 
molar test concentration of 115.7 µM.  
c Reference drugs.  
SI (Selectivity index): Quotient of IC50 for L-6 cells and IC50 against parasite.  
  
214
23 
 
 
 
 
Fig. 1 HPLC-based activity profiling of the CH2Cl2/MeOH (1:1) stem extract of D. gerrardii 
for antiprotozoal activity. HPLC-UV chromatogram (210-700 nm) (A), and inhibition (in %) 
of L. donovani (B) and P. falciparum (C) by microfractions.  
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Fig. 2 HPLC-based activity profiling of the CH2Cl2/MeOH (1:1) leaf extract of D. gerrardii 
for antitrypanosomal activity. HPLC-ELSD chromatogram (A) and inhibition (in %) of T. b. 
rhodesiense (B) by microfractions.  
 
 
Fig. 3 Structures of compounds 1 - 4. 
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Fig. 4 Key HMBC and NOESY correlations of compound 1. 
 
Fig. 5 Key HMBC and NOESY correlations for substructures A and B of compound 2. 
 
Fig. 6 DFT optimized conformers of compound 2. Atoms CH3-7 and H-4' showing a key 
NOESY correlation between the 2 substructures. Intramolecular distance between CH3-7 and 
H-4' was 3.45 Å in both conformers. 
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Highlights  
• HPLC-based activity profiling led us to identify the antiprotozoal compounds.   
• A new phenanthrenone (1) with high antiplasmodial in vitro activity was discovered.  
• A new heterodimer (2) with antiplasmodial in vitro activity was isolated.  
• A saponin (3) was isolated and showed weak trypanocidal activity.    
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Assays for in vitro Antiprotozoal Activity  
Antiplasmodial activity was determined by a modification of the 3[H]-hypoxanthine 
incorporation assay [1] with the P. falciparum NF54 strain, growth according to the method 
described by Trager and Jensen [2]. Chloroquine (purity >95%, Sigma-Aldrich) was used as 
positive control. 
Briefly, a suspension of infected red blood cells (final parasitemia 0.3% and hematocrit 
1.25%) in RPMI 1640 medium supplemented with 2 µM L-glutamine, 5.95 g/l Hepes, 2 g/l 
NaHCO3, and 5% of Albumax II was exposed to serial drug dilutions covering a range from 
10 µg/mL to 0.156 µg/ml in 96-well microtiter plates.  After 48 h of incubation (4% CO2, 3% 
O2, and 93% N2 at 37°C), 50 µl of 3[H]-hypoxanthine (0.25 µM) were added to each well 
(Costar). The plates were incubated for further 24 h before being harvested by using a 
Betaplate cell harvester (Wallac) onto glass-fiber filters and then washed with distilled water. 
The dried filters were inserted into plastic foils with 10 ml scintillation fluid. The radioactivity 
was counted with a Betaplate liquid scintillation counter (Wallac) as counts per minute per 
well at each drug concentration and compared to the untreated controls. Counts were 
expressed as percentages of the control and presented as sigmoidal inhibition curves. IC50 
values were calculated by linear interpolation.  
 
Antitrypanosomal activity against T. brucei rhodesiense STIB 900 was determined according 
to [3]. Melarsoprol (Arsorbal, purity >95%, Sanofi-Aventis) was used as positive control. 
Minimum essential medium (MEM) with Earle’s salts supplemented with 2-mercaptoethanol, 
as described by Baltz et al. [4], 1 mM sodium pyruvate, 0.5 mM hypoxanthine, and 15% heat-
inactivated horse serum was added (50 µl) to each well of a 96-well microtiter plate (Costar) 
except of the negative control. Serial drugs dilutions were prepared covering range from 90 to 
0.123 µg/ml followed by the parasite suspension of 2000 T. brucei rhodesiense STIB 900 
bloodstream forms/well. After 70 hours of incubation (humidified 5% CO2 atmosphere at 
37°C), 10 µl resazurin solution (12.5 mg resazurin (Sigma-Aldrich) dissolved in 100 ml of 
distilled water) were added and incubation was continued for further 2 to 6 h. The plate was 
read with a Spectramax Gemini XS microplate fluorescence reader (Molecular Devices) with 
an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Fluorescence 
development was expressed as percentage of the control and the IC50 values were determined 
from the sigmoid curves using Softmax Pro Software (Molecular Devices). 
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Leishmanicidal activity was determined with L. donovani (axenic amastigotes) MHOM-
ET/67/L82 strain according to [5], with some modifications. Fifty microlitres of SM medium 
at pH 5.4 supplemented with 10% heat-inactivated FBS was added to each well of 96-well 
microtiter plate (Costar). Serial drug dilutions were prepared covering a range from 90 to 
0.123 µg/ml. Then, 105 axenically growth L. donovani amastigotes in 50 µl medium, were 
added to each well and the plate was incubated for 72 h (humidified 5% CO2 atmosphere at 
37°C). Ten microlitres resazurin solution (12.5 mg resazurin (Sigma-Aldrich) dissolved in 
100 ml of distilled water) were added to each well and incubated for further 2 to 4 h. The 
plate was read with a Spectramax Gemini XS microplate fluorescence reader (Molecular 
Devices) with an excitation wavelength of 536 nm and an emission wavelength of 588 nm. 
Fluorescence development was expressed as percentage of the control and the IC50 values 
were determined from the sigmoid curves using Softmax Pro Software (Molecular Devices). 
Miltefosine (purity >95%, VWR) was used as positive control.  
 
In vitro Cytotoxicity Assay 
The cytotoxicity assay was performed using a protocol based on the Alamar Blue assay [6], 
whereby rat skeletal myoblast cells (L-6 cells) were seeded in 96-well microtiter plates using 
MEM supplemented with 10% heat inactivated FBS (4000 cells/well). Serial threefold drug 
dilutions ranging from 90 to 0.123 mg/ml were prepared. After 72 h, 10 µl resazurin solution 
was added (12.5 mg resazurin (Sigma-Aldrich) dissolved in 100 ml of distilled water) and the 
plates were incubated for further 2 to 4 h. A Spectramax Gemini XS micro plate fluorescence 
reader (Molecular Devices) was used to measure the plates at an excitation wavelength of 536 
nm and an emission wavelength of 588 nm. Fluorescence development was expressed as 
percentage of the control and the IC50 values were determined from the sigmoid curves using 
Softmax Pro Software (Molecular Devices). Podophyllotoxin (purity ˃95%, Sigma-Aldrich) 
was used as a reference drug. 
Assays for in vivo Antimalarial Activity  
In vivo antimalarial activity was assessed basically as previously described [7]. Groups of 
three female NMRI mice (20–22 g) were intravenously infected with 2 x107 with GFP-
transfected P. berghei strain ANKA [8] parasitized erythrocytes on day 0. Compounds were 
dissolved in 100% DMSO, diluted 10-fold in distilled water and administered 
intraperitoneally in a volume of 10 ml/kg (dose of 50 mg/Kg) on four consecutive days (4, 24, 
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48 and 72 h post infection). Parasitemia was determined on day 4 post infection (24 h after 
last treatment) by FACS analysis. Activity was calculated as the difference between the mean 
per cent parasitemia for the control (n=5 mice) and treated groups expressed as a per cent 
relative to the control group. The survival time in days was also recorded up to 30 days after 
infection. A compound was considered curative if the animal survived to day 30 after 
infection with no detectable parasites. Mice were euthanized by carbon dioxide inhalation. 
Protocol for Acid Hydrolysis of Compound 3 
 
Compound 3 (2.0 mg) was dissolved in 4 ml of a mixture 1:1 of dioxane/TFA 2N and heated 
at 105°C for 2 h. The solvent was evaporated and the remaining solution was extracted three 
times with 1 ml of CHCl3. TLC analysis of the organic phase revealed decomposition of the 
aglycone. The aqueous phase was dried and the residue re-dissolved in anhydrous pyridine. 
The sugars were derivatized with L-cysteine methyl ester hydrochloride (200 µl, 60°C, 1 h) 
and subsequently silylated with hexamethyldisilzane and chlorotrimethylsilane (Fluka) in 
pyridine (2:1:10, 300 µl; 60°C, 30 min). GC analysis on a capillary DB-225MS column (30 m 
x 0,25 mm i.d., 0,25 m; Agilent; column temp. 150°C for 2 min, then 5°C/min. to 210°C, then 
10°C/min to 240°C).  
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Table 1S. 1H and 13C NMR spectroscopic data for compound 1 (DMSO-d6, 500 MHz) 
position 1 
δ H (J in Hz) δCa 
   
1 - 47.2 
2 - 203.1 
3 6.25 (d, 10.2) 122.8 
4 8.27 (d, 10.2) 139.2 
5 7.62 (s) 103.1 
6 - 156.1 
7 - 126.9 
8 7.64 (s) 129.0 
9 7.80 (d, 8.6) 129.4 
10 7.45 (d, 8.6) 120.6 
4a - 120.3
4b - 130.3
8a - 126.4 
10a - 145.9 
1-Me x 2 1.41 (s) 27.0 
7-Me 2.31 (s) 15.9 
 
a 13C NMR signals reported here were obtained indirectly from HSQC and HMBC spectra  
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Table 2S. 1H and 13C NMR data (pyridine-d5, 500 MHz for 1H, 125 MHz for 13C) for 
compound 3. 
   
 
Position 
 
 
δH (J in Hz) 
 
 
δC 
 
Triterpene moiety 
 
1 1.38
a 
0.84a 
38.8 
2 2.16(m)
a
 
1.77 (m)a 
26.8 
3 3.27 (m) 89.4 
4 - 39.7 
5 0.77 a 55.9 
6 1.30
a 
1.50(m)a 
18.7 
7 1.20 (m)
a 
1.46a 
33.5 
8 n.d. 40.0 
9 1.64 (dd, 8.9, 8.7) 48.2 
10 - 37.2 
11 1.87 (m)
a 
2.13 
24.0 
12 5.44 (br m) 122.8 
13 - 145.1 
14 - 42.4 
15 1.18 (m)
a 
2.13a 
28.6 
16 1.93 (m)
a
 
1.93 (m)a 
23.9 
17 - 46.9 
18 3.27 (m) 42.2 
19 1.27 (m)
a 
1.80a 
46.7 
20 - 31.2 
21 1.20 (m)
a
 
1.44a 
34.5 
22 1.78 (m) 2.00 (dt, 13.7, 4.0) 
33.4 
23 1.23 (s) 28.4 
24 0.93 (s) 17.2 
25 0.80 (s) 15.7 
26 0.95 (s) 17.6 
27 1.31 (s) 26.5 
28 - 180.4 
29 0.96 (s) 33.5 
30 1.00 (s) 24.0 
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 position δH (J in Hz) δC 
3-O-Sugar Glc A 
1 4.81 (d, 6.5) 107.2 
2 3.98 (dd, 7.6, 7.4 ) 76.0 
3 4.34 (m) a 82.0 
4 4.34 (m) a 72.0 
5 4.45 (m) a 77.9 
6 - n.d. 
Rham  
1 6.19 (br s) 103.1 
2 4.67 (br s) 72.7 
3 4.50 (dd, 9.0, 3.0) 72.9 
4 4.23 (dd, 9.5, 9.4) 74.3 
5 4.95 (m) 70.0 
6 1.64 (d, 5.9) 18.9 
 
aOverlapping signals. n.d. not detected.  
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Fig. 1S. 1H NMR spectrum of 1 in CDCl3. 
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Fig. 2S. DEPTQ spectrum of 1 in CDCl3. 
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Fig. 3S. 1H 1H COSY spectrum of 1 in CDCl3 
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Fig. 4S. HSQC and HMBC overlaid spectra of 1 in CDCl3. 
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Fig. 5S. 1H NMR spectrum of 1 in DMSO-d6. 
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Fig. 6S. 1H 1H COSY spectrum of 1 in DMSO-d6 
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Fig. 7S. HSQC and HMBC overlaid spectra of 1 in DMSO-d6. 
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Fig. 8S. 1H 1H NOESY spectrum of 1 in DMSO-d6. 
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Fig. 9S. 1H NMR spectrum of 2 in CDCl3. 
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Fig. 10S. 13C spectrum of 2 in CDCl3. 
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Fig. 11S. 1H 1H COSY spectrum of 2 in CDCl3   
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Fig. 12S. HSQC and HMBC overlaid spectra of 2 in CDCl3. 
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Fig. 13S. HSQC and long range HMBC overlaid spectra of 2 in CDCl3. 
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Fig. 14S. 1H 1H NOESY spectrum of 2 in CDCl3. 
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Fig. 15S.1H NMR spectrum of 3 in pyridine-d5. 
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Fig. 16S. DEPTQ spectrum of 3 in pyridine-d5.
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Five pyrethrins were isolated from Chrysantemum cinerariifolium. Their antiprotozoal activity was 
evaluated against Plasmodium falciparum and Trypanosoma brucei rhodesiense and compared with 
synthetic pyrethroids. Pyrethrin II and Jasmolin II inhibited P. falciparum. Natural pyrethrins were more 
active than pyrethroids.  
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ABSTRACT: In a screen of 1800 plant and fungal extracts for antiplasmodial, antitrypanosomal, and leishmanicidal activity, the
n-hexane extract of Chrysanthemum cinerariifolium (Trevir.) Vis. flowers showed strong activity against Plasmodium falciparum. We
isolated the five pyrethrins [i.e., pyrethrin II (1), jasmolin II (2), cinerin II (3), pyrethrin I (4), and jasmolin I (5)] from this extract.
These were tested together with 15 synthetic pyrethroids for their activity against P. falciparum and Trypanosoma brucei rhodesiense
and for cytotoxicity in rat myoblast L6 cells. The natural pyrethrins showed antiplasmodial activity with IC50s between 4 and 12 μM,
and antitrypanosomal activity with IC50s from 7 to 31 μM. The pyrethroids exhibited weaker antiplasmodial and antitrypanosomal
activity than the pyrethrins. Both pyrethrins and pyrethroids showed moderate cytotoxicity against L6 cells. Pyrethrin II (1) was the
most selective antiplasmodial compound, with a selectivity index of 24.
KEYWORDS: Chrysanthemum cinerariifolium, Asteraceae, pyrethrins, pyrethroids, antiplasmodial, antitrypanosomal, malaria,
trypanosomiasis
’ INTRODUCTION
Pyrethrum (Chrysanthemum cinerariifolium (Trevir.) Vis.
(synonyms Tanacetum cinerariifolium (Trevir.) Schultz Bip. and
Pyrethrum cinerariifolium (Trevir.)), a herbaceous perennial of
the Asteraceae family, is the most widely used botanical insecti-
cide. Currently, it is cultivated in Kenya, Australia, and United
States of America, among other countries.13 The secondary
metabolites responsible for the insecticidal activity of pyrethrum
are six closely related esters of the pyrethric and chrysanthemic
acids and the pyrethrolone, cinerolone, or jasomolone alcohols.1,3,4
Pyrethrins are very potent and selective natural insecticides.
However, these compounds are quickly degraded when they
are exposed to air and sunlight, which limits their efficacy.1,5
To overcome instability issues, pyrethrin-inspired synthetic
insecticides, the pyrethroids, were developed. They have
increased photostability while maintaining the potent, rapid
insecticidal activity, and relatively low acute mammalian toxicity
of the pyrethrins.1,5 Currently, pyrethroids are used in agriculture
and as active ingredients of household insecticidal products. They
have been applied to control vectors of human diseases such as
Anopheles gambiae, an important carrier for malaria transmission. As
a result, pyrethrins occupy an important place in the world’s
insecticide market, representing 18% of the U.S. dollar value.5,6
Pyrethroids can be classified into the classes type I and type II,
the main structural difference being the presence of an R-cyano-
3-phenoxybenzylalcohol moiety in type II pyrethroids.79 Pyr-
ethrins and pyrethroids exert their insecticidal activity by mod-
ification of the insect’s voltage-gated sodium channels by slowing
the kinetics of channel gate activation and inactivation. This results
in increased anion permeability leading to membrane depolar-
ization and a subsequent rise of neuronal action potential.5,10,11
Besides sodium channels, pyrethrins and pyrethroids can interact
with voltage-gated calcium, potassium, and chloride channels, as
well as GABA, glutamate, and acetylcholine receptors.5,8,10
Pyrethrins and type I pyrethroids have quantitatively and
qualitatively different effects than the type II pyrethroids on ion
channels and different visible effects on insects.711
The biological activity of pyrethrins beyond their insecticidal pro-
perties has not been extensively investigated. However, some data
on antimycobacterial (M. avium and M. tuberculosis H37Rv) and
antiviral properties (Herpes Simplex Virus, HSV-1,Maclntyre strain
ATCCNo. VR-539 and HSV-2, MS strain)4,12 have been reported.
Our interest in pyrethrum was raised when, in a project for
natural product based lead discovery, we performed an antipro-
tozoal screen of 1800 plant and fungal extracts for effects against
the parasites Trypanosoma brucei rhodesiense, Trypanosoma cruzi,
Plasmodium falciparum, and Leishmania donovani. These proto-
zoal parasites are the causal agents of human African trypanoso-
miasis, Chagas disease, malaria, and leishmaniasis, respectively.
The extract library included an n-hexane extract of pyrethrum
flowers that exhibited potent activity against P. falciparum and T.
brucei rhodesiense at a test concentration of 4.8 μg/mL; the
inhibition was 87% and 99%, respectively. To identify the
compounds responsible for the activity, a series of pyrethrins
Received: May 12, 2011
Accepted: July 25, 2011
Revised: July 19, 2011
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(Figure 1) were isolated from the n-hexane extract and evaluated
for their in vitro antiprotozoal activity. Since the natural products
showed activity against the two protozoan parasites, we included
six type I pyrethroids and nine type II pyrethroids (Figure 1) to
evaluate their effects on the parasites too. The idea was that these
commercial compounds, if exerting their antiprotozoal activity
possibly on the same targets as the active natural products, might
be good leads due to their favorable physicochemical properties,
potency, and stability. Besides the antiprotozoal activity, cyto-
toxicity in rat L6-cells was determined to assess the selectivity of
an inhibitory effect on the parasites rather than mammalian cells.
’MATERIALS AND METHODS
General Experimental Procedures. Analytical grade solvents
for extraction and HPLC grade solvents for chromatography were
purchased from Scharlau (Barcelona, Spain). HPLC grade water was
obtained by an EASY-pure II from a Barnstead water purification system
(Dubuque, Iowa). Formic acid (98.0100.0%) was from Sigma-Aldrich
(Buchs, Switzerland). Artemisinin was obtained from Sigma Aldrich
(Buchs, Switzerland) and melarsoprol (Arsobal) from Sanofi-Aventis,
(Geneva, Switzerland). The pyrethroids tetramethrin (10), bifenthrin
(11), τ-fluvalinat (19), and flucythrinate (20) were purchased from
Sigma-Aldrich (Buchs, Switzerland). Dr. Ehrenstorfer GmbH (Augsburg,
Germany) provided phenothrin (6), allethrin (7), resmethrin (8),
permethrin (9), deltamethrin (12), cyphenothrin (13), λ-cyhalothrin
(14), cypermethrin (15), cyfluthrin (16), fenpropathrin (17), and
fenvalerate (18).
Preparative HPLC was done on a LC-8A preparative system con-
sisting of two Model LC-8A pumps, a Model SPD-M10A VP PDA
detector, and VP2 software (all from Shimadzu, Tokyo, Japan). Medium
pressure liquid chromatography (MPLC) was performed using a B€uchi
Figure 1. Structures of the pyrethrins 15, type I pyrethroids 611, and type II pyrethroids 1220. The comercial pyrethroids (620) are
diasteromeric mixtures, with the exception of 11 (Z)-(1S,3S) and 12 (S)-(1R,3R).
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Sepacore system (B€uchi, Flawil, Switzerland), consisting of a control
unit C-620, a fraction collector C-660, a UV photometer C-635, and two
pump modules C-605, on a prepacked silica gel (4063 μm) poly-
propylene cartridge (40  150 mm, B€uchi). TLC was conducted on
precoated Kieselgel 60 F254, 0.25 mm plates (Merck, Darmstadt,
Germany). NMR data were acquired at a target temperature of 18 C
on an Avance III 500 MHz spectrometer (Bruker, F€allanden, Switzerland)
operating at 500.13 MHz for 1H and 125.77 MHz for 13C. A 1 mmTXI-
microprobe with a z-gradient was used for 1H-detected experiments. For
processing and evaluation Topspin 2.1 (Bruker) software was used.
NMR experiments were done as previously described.13
Plant Material. Dried flowers of Chrysanthemum cinerariifolium
(Trevir.) Vis. (Asteraceae) were purchased from Dixa AG (St. Gallen,
Switzerland). A voucher specimen (NL 769) is deposited at Herbarium
of the Division of Pharmaceutical Biology, University of Basel, Switzerland.
Extraction and Isolation. One kilogram of finely ground plant
material was extracted three times with three liters of n-hexane for two
hours each, at room temperature. Extracts were combined, and the
solvent was evaporated at reduced pressure to yield 16.2 g of crude
extract. The pyrethrins were isolated from this extract by preparative
chromatography in two steps. The first isolation step consisted of
MPLC. A portion (10.9 g) of extract was separated on a silica gel
prepacked cartridge (40  150 mm) by gradient elution with 025%
ethyl acetate in n-hexane over 4 h. The flow rate was 20 mL/min.
Fractions were collected every 60 s and compared by TLC [mobile
phase: ethyl acetate/n-hexane (25:75 v/v)]. Pyrethrins were detected as
dark blue spots after spraying with vanillin sulfuric acid reagent (solvent A,
vanillin 1% in ethanol; and solvent B, ethanolic solution of sulfuric
acid 10%) and heating at 110 C.14 Similar fractions were pooled to give
two pyrethrin-enriched fractions 3 (570 mg) and 6 (118 mg). Preparative
HPLC was used for the isolation of pyrethrins from these fractions. The
column employed was a SunFire RP-18 column (5 μm, 30 mm150 mm;
Waters, Wexford, Ireland). The mobile system was water (solvent A)
andmethanol (solvent B) using the following gradient: 50%B to 100%B
in 30 min, then 100% B for 5 min. The flow rate was 20 mL/min. Sixty
milligrams of the fraction in 300 μL of tetrahydrofuran was injected in
each run. The UV absorption was monitored at 230 nm.
From fraction number 3, we isolated pyrethrin I (4) (10.4 mg),
jasmolin I (5) (0.8mg), and jasmolin II (2) (0.7mg). Fraction 6 afforded
pyrethrin II (1) (9.4 mg) and cinerin II (3) (0.6 mg). Extract, fractions,
isolated pyrethrins, as well all the commercial pyrethroids were stored
protected from light and oxygen, at 28 C under an argon atmosphere.
The structures of pyrethrins were established by 1D and 2D NMR
(COSY, HMBC, HSQC, and NOESY). The data are provided as Sup-
porting Information and are in good accordance with the literature.3,4,15
Purity of pyrethrins was >95% as determined by the integration of
1H NMR spectra.
Biological Tests. The n-hexane extract, pyrethrins, and the syn-
thetic pyrethroids were dissolved in DMSO to obtain a final stock
solution concentration of 10 mg/mL. The samples were stored at
20 C until they were used. Further dilutions were done in media so
that the DMSO concentration in the highest test concentration before
serial dilution was <1%. The screening of the extract library against P.
falciparum and T. brucei rhodesiense was performed in 96 well plates
(Costar, Kennebunk, ME), at concentrations of 4.81 and 0.81 μg/mL.16
Tests were done in triplicate and repeated twice. IC50 values against both
parasites as well as rat myoblasts (L6-cells) were determined by serial
dilution in duplicate and repeated three times.
Testing against P. falciparum K1 Strain. A modification of the [3H]-
hypoxanthine incorporation assay was used to determine intraerythro-
cytic inhibition of parasite growth. Infected erythrocytes (final para-
sitemia and hematocrit were 0.3% and 1.25%, respectively) in RPMI
1640 medium were exposed to 2-fold serial drug dilution in 96 well
plates (Costar, Kennebunk,ME), which covered a range from 10 μg/mL
(19.8 to 33.1 μM) to 0.156 μg/mL (0.31 to 0.52 μM). After 48 h of
incubation, 50 μL of [3H]-hypoxanthine (0.5 μCi) in the medium was
added, and plates were incubated for an additional 24 h. Parasites were
harvested onto glass-fiber filters, and radioactivity was counted using a
Betaplate liquid scintillation counter (Wallac, Z€urich, Switzerland). The
results were recorded as counts per minute (cpm) per well at each drug
concentration and expressed as a percentage of untreated controls.13,16
Testing against T. brucei rhodesiense STIB 900. Minimum essential
medium (MEM) supplemented with 2-mercaptoethanol and 15% heat-
inactivated horse serum was used for determining the inhibition of
parasite growth. Serial 3-fold drug dilution, which covered a range of
90 μg/mL (178 to 298 μM) to 0.123 μg/mL (0.24 to 0.41 μM), was
prepared in 96 well plates. Bloodstream forms of T. brucei rhodesiense in
50 μL of medium were added to each well except of the background.
The plate was incubated under humidified 5% CO2 atmosphere at
37 C for 68 h. Resazurin (Sigma-Aldrich, Z€urich, Switzerland) solution
(12.5 mg of resazurin dissolved in 100 mL of distilled water; 10 μL) was
then added to all wells and the incubation continued for a further
2 to 4 h. The plate was read in a Spectramax Gemini XS micro plate
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA) using an
excitation wavelength of 536 nm and an emission wavelength of 588 nm.
Fluorescence development was measured and expressed as a percentage
of the control.16,17
Cytotoxicity Test Using L6 Cells. The rat skeletal myoblast cell line
(L-6 cells) was used to assess cytotoxicity. The cells were seeded in
RPMI 1640 medium supplemented with 1% L-glutamine (200 nM) and
10% fetal bovine serum under humidified 5% CO2 at 37 C. Assays were
performed in 96 well microtiter plates, with each well receiving 100 mL
of culture medium with 4  104 cells. After 24 h, the medium was
removed from all wells, and serial 3-fold drug dilutions were prepared
covering a range from 90 (178.1 to 297.9 μM) to 0.123 μg/mL (0.24 to
0.41 μM). After 68 h of incubation, the plates were inspected under an
inverted microscope to ensure the growth of the controls and sterile
conditions. Then, 10 μL of resazurin solution (12.5 mg of resazurin
dissolved in 100 mL of distilled water) was added to each well, and the
plates were incubated for another 2 h. Then, the plates were read with a
Spectramax Gemini XS Microplate fluorometer (Molecular Devices
Cooperation, Sunnyvale, CA) using an excitation wavelength of 536 nm
and an emission wavelength of 588 nm. IC50 values were determined
using the microplate reader software Softmax Pro (Molecular Devices
Cooperation, Sunnyvale, CA).18
’RESULTS AND DISCUSSION
A medium throughput screen showed that the n-hexane
extract of C. cinerariifolium flowers had significant activity against
P. falciparum (86% inhibition at a test concentration of 4.8 μg/mL)
and against T. brucei rhodesiense (99% inhibition at the same
concentration). Since highly lipophilic pyrethrins are the char-
acteristic secondary metabolites in an n-hexane extract of pyre-
thrum flowers, we carried out a targeted isolation of pyrethrins.
Among the compounds extracted were three esters of pyrethric
acid, [pyrethrin II (1), jasmolin II (2), and cinerin II (3)], and
two esters of chrysantemic acid, [pyrethrin I (4) and jasmolin I
(5)] (Figure 1). When tested against P. falciparum, T. brucei
rhodesiense, and L-6 cells, most of these exhibited antiprotozoal
activity and low cytotoxicity (Table 1). The most active com-
pound in the antiplasmodial assay was 1with an IC50 of 4.0( 1.1
μM, followed by 2 and 3 with IC50 values of 5.0( 0.4 and 5.8(
0.4 μM, respectively. Compounds 4 and 5 were somewhat less
active (IC50 values of 11.7( 1.5 and 9.3( 1.2 μM, respectively).
Accordingly, the three derivatives of pyrethric acid showed the
most potent antiplasmodial effect.
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The antitrypanosomal activity of the isolated compounds was
less pronounced (Table 1). Pyrethrin I (4) showed an IC50 of
6.9( 1.1 μM. The IC50 values of compounds 1, 2, 3, and 5 were
above 10 μM (10.6 ( 0.4, 12.1 ( 0.2, 12.2 ( 0.02, and 30.9 (
1.4 μM, respectively).
The compound with the lowest cytotoxicity against L6 cells
was 4 followed by 1 (Table 1). With a SI of 23.6, pyrethrin II (1)
was the most selective compound against P. falciparum. The
other four pyrethrins showed selectivity indices (SI) between 4.9
and 12.6 (Table 1). Pyrethrin I (4) showed the highest SI (21.2)
against T. brucei rhodesiense, while the other four pyrethrins
exhibited SI between 2.3 and 9.0.
We then tested a series of 6 type I (611) and 9 type II
pyrethroids (1220). Type I pyrethroids were more active
against P. falciparum than type II compounds but less active than
the pyrethrins (1  5), with the exception of 11, which showed
an IC50 of 8.9( 2.0 μM. Six (1216 and 19) of the nine type II
pyrethroids did not show antiplasmodial activity at the highest
tested concentration of 10 μg/mL. This corresponds to the
molar test concentrations ranging from 19.8 to 33.1 μM for the
various substances (Table 1).
Both, type I and type II pyrethroids displayed low activity
against T. brucei rhodesiense (Table 1). Their IC50 values were
in the range of 12.9 ( 2.2 μM for 10 (a type I pyrethroid) and
57.8 ( 6.2 μM for 18 (a type II pyrethroid). Selectivity toward
the protozoa was low.
In conclusion, pyrethrins were the compounds responsible for
the antiplasmodial activity of the lipophilic pyrethrum extract.
These compounds had reasonably selective antiplasmodial prop-
erties and weaker trypanocidal activity. Among them, pyrethrin II
(1) was the most active and selective compound. In contrast, all
15 pyrethroids showed a weaker and less selective inhibition on
P. falciparum and T. brucei rhodesiense.
As mentioned above, the main target for pyrethrins and pyre-
throids in insects are voltage-gated sodium channels. Neither in P.
falciparum nor in T. brucei rhodesiense has the presence of such
channels been reported.1921 The antiprotozoal effects reported
here may involve some of the other channels or structurally related
ones with which pyrethrins and pyrethroids can interact. For
instance T. brucei rhodesiense has potassium channels,19 and P.
falciparum has channels such as aquaporin PfAQP, which could
possibly be targets for these compounds.20,21
’ASSOCIATED CONTENT
bS Supporting Information. 1H NMR spectroscopic data
(500 MHz, CDCl3) for compounds (15). This material is
available free of charge via the Internet at http://pubs.acs.org.
Table 1. In Vitro Antiprotozoal Activities of Isolated Natural Pyrethrins 15 and Synthetic Pyrethroids 620 against Plasmodium
falciparum and Trypanosoma brucei rhodesiense, Cytotoxic Activity in L-6 Cells, and Selectivity Indices (IC50 L-6 cells/IC50
parasite)a
IC50 (μM) ( SEM selectivity index
compound P. falciparum T.b. rhodesiense L-6 cells P. falciparum T.b. rhodesiense
pyrethrin II (1) 4.0 ( 1.1 10.6 ( 0.4 95.1 ( 2.5 23.6 9.0
jasmolin II (2) 5.0 ( 0.4 12.0 ( 0.2 31.5 ( 2.3 6.3 2.6
cinerin II (3) 5.8 ( 0.4 12.2 ( 0.0 28.0 ( 7.8 4.9 2.3
pyrethrin I (4) 11.7 ( 1.5 6.9 ( 1.1 146.6 ( 34.5 12.6 21.2
jasmolin I (5) 9.3 ( 1.2 30.9 ( 1.4 86.6 ( 12.9 9.3 2.8
phenothrin (6) inactiveb 36.4 ( 2.4 57.4 ( 3.1 1.6
allethrin (7) 18.0 ( 1.5 26.4 ( 3.4 21.2 ( 1.7 1.2 0.8
resmethrin (8) 26.1 ( 2.1 25.5 ( 1.1 51.6 ( 1.4 2.0 2.0
permethrin (9) 22.4 ( 0.7 24.5 ( 2.3 66.7 ( 2.2 3.0 2.7
tetramethrin (10) inactiveb 12.9 ( 2.2 15.5 ( 1.32 1.2
bifenthrin (11) 8.9 ( 2.0 24.1 ( 2.0 61.1 ( 6.3 6.9 2.5
deltamethrin (12) inactiveb 51.4 ( 2.1 142.0 ( 10.5 2.8
cyphenothrin (13) inactiveb 29.8 ( 0.1 93.1 ( 2.8 3.1
λ-cyhalothrin (14) inactiveb inactivec 181.2 ( 15.9
cypermethrin (15) inactiveb 49.9 ( 0.5 150.7 ( 6.7 3.0
cyfluthrin (16) inactiveb 27.4 ( 2.6 119.1 ( 14.6 4.4
fenpropathrin (17) inactive 26.2 ( 4.4 21.1 ( 1.9 0.8
fenvalerate (18) 14.8 ( 0.9 57.8 ( 6.2 111.0 ( 6.4 7.5 1.9
τ-fluvalinate (19) inactiveb 26.2 ( 2.6 47.7 ( 2.3 1.8
flucythrinate (20) 17.6 ( 0.8 33.4 ( 1.9 111.1 ( 5.5 6.3 3.3
artesunated 0.01 ( 0.006 n.d. n.d.
chloroquined 0.40 ( 0.252 n.d. n.d.
melarsoprole n.d. 0.01 ( 0.001 n.d.
podophyllotoxinf n.d. n.d. 0.02 ( 0.004
a n.d. not determined. SEM: standard error of the mean. Selectivity index: quotient of the activity of the compounds on the parasites and the
mammalian cells. bNo activity observed at the highest test concentration of 10 μg/mL, which corresponds to molar test concentrations of 19.8 to 33.1 μM.
cNo activity observed at the highest test concentration of 90 μg/mL, which corresponds tomolar test concentrations of 178 to 298 μM. dReference drug
P. falciparum assay. eReference drug T. b. rhodesiense assay. fReference drug cytotoxicity assay.
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Table S1. 1H NMR spectroscopic data (500 MHz, CDCl3) for compounds (1-5)  
                                                                  1
δH (J in Hz) 
2 
δH (J in Hz) 
3 
δH (J in Hz) 
4 
δH (J in Hz) 
5 
δH (J in Hz) 
1 1.75, dd (5.3) 1.68, d (5.2) 1.67, d (6.3) 1.37,  d (5.4) 1.32, d (5.4) 
3 2.20, m* 2.16, m* 2.19, m*  2.04, m* 2.00, dd (6.1,  6.7) 
5 1.20, s 1.26, s 1.20, s 1.10, s 1.05, s 
6 1.28, s 1.18, s 1.28, s 1.23, s 1.18, s 
7 6.43, dd (9.5, 1.2) 6.41, dd (9.4, 1.2) 6.44, dd (9.5, 1.3) 4.88, dd (7.4, 1.2) 4.84, d (7.4) 
9 1.92, br  s  1.89, s 1.92, d (1.3) 1.67, s 1.63, s  
10 - - 1.70, d (5.2) 1.69, s 1.62, s 
11 3.70, s 3.68, s 3.70, s - - 
1´ 5.64, br d (6.2) 5.61, br d (6.5) 5.64, br dd (6.0, 0.6) 5.63, br d (6.2) 5.58, br d (6.0) 
5a´  2.20, m*  2.16, m* 2.19, m* 2.19, dd (18.5, 1.9) 2.13, dd (18.7, 1.8) 
5b´ 2.84, dd (18.6, 6.2)  2.80, dd (18.7 ,6.4)  2.83 dd (18.5, 6.2)  2.62 dd (18.5, 6.3) 2.75, dd (18.7, 6.3) 
6´ 2.00, s 1.98, s 2.00, s 2.00,  s 1.95, s 
7´ 3.10, d (7.7) 2.93, d (7.2) 2.96, d (7.1) 3.09,  d (7.6) 2.89, d (7.2) 
8´ 5.32, ddd (10.2, 7.3, 7.3) 5.37, m  5.48, m  5.32,  ddd (10.4, 7.6, 7.6) 5.33, m  
9´ 6.01, dd (10.6, 10.6) 5.19, m  5.27, m  6.00, dd (10.8, 10.8)  5.16, m 
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10´ 6.73, ddd (16.5, 10.4, 10.4) 2.10, m  1.70, d (5.07) 6.72, ddd (16.9, 10.4, 10.4) 2.03, m  
11 Ha  5.15 d br (10.3);  0.94, t (7.5) -  5.13, d br (10.7); 0.90, t (7.6) 
 
Hb 5.21 d br (16.5)   5.19, d br (17.6)  
 
* Overlapping signals.
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Figure S1 1H-NMR spectrum in CDCl3 and chemical structure of 1. 
 
 
 
254
7 
 
 
 
 
 
 
Figure S2 1H-NMR spectrum in CDCl3 and chemical structure of 2. 
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Figure S3 1H-NMR spectrum in CDCl3 and chemical structure of 3. 
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Figure S4 1H-NMR spectrum in CDCl3 and chemical structure of 4. 
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Figure S5 1H-NMR spectrum in CDCl3 and chemical structure of 5. 
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Adams 
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As a contribution to the structure activity relationship (SAR) of trypanocidal sesquiterpene lactones from 
different botanical sources, the activity of the germacrolides costunolide, eupatoriopicrin, and partenolide 
was compared with the activity of guaianolides dehydrocostuslacone and zaluzanin D, and the 
eudesmanolides arbusculin B and α-cyclocostunolide. The germacrolides were the most active class of 
sesquiterpene lactones. 
 
 
 
My contributions to this work were: (1) recollection of Eupatorium cannabium; (2) extraction of plant 
material; (3) isolation of the sesquiterpene lactone eupatoriopicrin; (4) recording and interpretation of 
analytical data for structure elucidation (HPLC-PDA-ESI, TOF-MS, 1D and 2D NMR); (5) extraction of 
plant material of Laurus nobilis; (6) isolation of the sesquiterpene lactones costunolide and zaluzanin D; 
(7) recording and interpretation of analytical data for structure elucidation (HPLC-PDA-ESI, TOF-MS, 
1D NMR and 2D NMR; (8) providing the corresponding data for manuscript, figure, table, and 
supporting information preparation.   
Inken Plitzko and Melanie Quitschau supervised structure elucidation. In vitro trypanocidal and 
cytotoxicity tests were performed by Stefanie Zimmermann in the Swiss TPH. Tasqiah Julianti isolated 
costunolide, dehydrocostuslacone, and other sesquiterpenlactones from S. costus and wrote the 
manuscript draft.  
Yoshie Hata-Uribe 
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Saussurea costus roots potently inhibited the growth of Trypanosoma brucei rhodesiense.
Subsequent HPLC based activity profiling led to the identification of the sesquiterpene lactones
arbusculin B (1), α-cyclocostunolide (2), costunolide (3), and dehydrocostuslactone (4). They
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HPLC-based activity profiling1. Introduction
The fragrant roots of Saussurea costus (Falc.) Lipschitz
(Asteraceae), synonym: Saussurea lappa C.B. Clarke, have
been used for thousands of years as medicines, incenses and
ointments by many cultures. In India they are called Kur or
Kushtha, and in China Yúnmù xiāng (云木香). In the Ayurveda,
Siddha, and Unani medicinal systems S. costus roots are used
alone or in combination with other drugs to treat asthma,
cholera, chronic skin diseases, rheumatism, cough and cold,
quartan malaria, leprosy, persistent hiccups, rheumatism,
stomach-ache, toothache, and typhoid fever [1,2].
A broad spectrum of biological activities such as anti-
inflammatory, anticancer, immunomodulatory, CNS depres-
sant, and antimicrobial properties have been reported for
S. costus extracts [3–5]. Activities have commonly been relatedical Sciences, Division
56 Basel, Switzerland.
ms).
All rights reserved.
260to the presence of sesquiterpene lactones. Furthermore,
tannins, steroids, alkaloids, glycosides, terpenoids, flavonoids,
peptides, and organic acids have been reported from this plant
[3,4].
Our interest in this plant was raised when we performed
an antiprotozoal screen of 1800 plant and fungal extracts for
effects against the parasites Trypanosoma brucei rhodesiense,
Trypanosoma cruzi, Plasmodium falciparum and Leishmania
donovani, the causal agents of human African trypanosomi-
asis, Chagas disease, malaria, and leishmaniasis, respectively
[6–8]. Amongst the most potent extracts in this screen was
an ethyl acetate extract of S. costus roots which inhibited
T. b. rhodesiense by 96% at a test concentration of 4.8 μg/ml.
HPLC based activity profiling was used to identify the
active constituents in the extract. In this approach sub-
milligramme amounts of extract are separated by analytical
scale HPLC and automatically fractionated into 96 well plates.
The microfractions obtained are submitted to the bioassay,
and the resulting activity profile can be overlaid with the
HPLC trace to correlate peaks of activity with peaks in the
HPLC chromatogram. On-line spectroscopic data (UV–Vis and
MS) collected during separation, combined with database
956 T. Julianti et al. / Fitoterapia 82 (2011) 955–959searches provide structural information on the active princi-
ples [6–8].
We here report on the identification and isolation of
antitrypanosomal compounds from S. costus, and also on the
comparative testing of some related sesquiterpene lactones
for antiprotozoal and cytotoxic activities. This study was part
of a larger screen for new antiprotozoal leads using HPLC
based activity profiling which has led to the identification of
numerous active compounds [8–11].2. Materials and methods
2.1. General experimental procedures
Analytical grade solvents for extraction and HPLC-grade
eluents for chromatography were purchased from Scharlau
(Barcelona, Spain), if not stated otherwise. HPLC-grade water
was obtained with an EASY-pure II water purification system
(Barnstead; Dubuque, IA, USA). Formic acid was from Sigma-
Aldrich (Buchs, Switzerland).
Initial screening of the extract library was done as
previously described [6]. HPLC based activity profiling:
Separations for microfractionation and for on line data
collection were carried out on an Agilent series 1100 system
equipped with degasser, binary high pressure mixing pump,
column oven and PDA detector (all from Agilent; Waldbronn,
Germany). MS spectra were recorded in the range ofm/z 200–
1500 positive and negative mode on an Esquire 3000 Plus ion
trap mass spectrometer equipped with an electrospray
interface (Bruker Daltonics; Bremen, Germany). Microfrac-
tionation was performed with 350 μg of extract in DMSO
(10 mg/ml) which were separated on a RP-HPLC SunFire C18
column (3.5 μm, 3×150 mm) (Waters; Wexford, Ireland)
with gradient A (water+0.1% formic acid) and B (acetoni-
trile+0.1% formic acid), 10–100% B in 30 min and hold at
100% B for 2 min, at a flow rate of 0.5 ml/min. Hystar 3.2
software (Bruker Daltonics; Bremen, Germany) was used to
monitor the HPLC system. An FC 204 fraction collector
(Gilson; Middleton, WI, USA) was attached to the HPLC to
collect a total of 32 microfractions of 60 s each into 96-deep
well plates (Whatman; Florham Park, NJ, USA). The plates
were dried in a Genevac EZ-2 Plus™ vacuum centrifuge
(Avantec; Ipswich, UK), andmicrofractions redissolved in 5 μl
of DMSO prior to testing for antitrypanosomal activity as
described [6].
Semipreparative HPLC for compound isolation was done
on an Agilent 1100 series HPLC system consisting of a 1100
series quaternary low-pressure mixing pump with degasser
module, column oven, and a 1100 series PDA detector with a
1000 μl loop. A SunFire C18 column (5 μm, 10×150 mm)
(Waters) was used. The mobile phase was: A (water) and B
(MeOH) with a gradient of 60–100% B in 20 min, followed by
flushing 5 min with 100% B, the flow rate was 5 ml/min, and
monitored at 220 nm. In each run 15 mg of fraction in 50 μl
DMSO was injected.
High resolution HPLC–MS was recorded with an Agilent
1100 series HPLC linked to a micrOTOF-ESI-MS system
(Bruker). MS calibration was performed using a reference
solution of sodium formate 0.1% in isopropanol–water (1:1)
containing 5 mM sodium hydroxide. The typical mass261accuracy was ±3 ppm. HyStar 3.0 software (Bruker Dal-
tonics) was used for data acquisition and processing.
NMR experiments were recorded in d6-DMSO and CDCl3
on a Bruker Avance III spectrometer (Bruker; Fallanden,
Switzerland) operating at 500.13 MHz at a target tempera-
ture of 18 °C. 1H NMR, COSY, HSQC, and HMBC spectra were
measured with a 1 mm TXI probe. The 2D pulse programs
were hsqcedetpg, hmbcgplpndqf, and cosygpqf. Spectra
processing and analysing was done with Bruker TopSpin 2.1
software.2.2. Plant material
The dried roots of S. costus (MTS 577) were purchased
from Peter Weinfurth in 2008 (Bochum, Germany). The
leaves of Laurus nobilis L. (MTS 693) were purchased from
Dixa AG (St. Gallen, Switzerland). The aerial parts of
Eupatorium cannabinum L. (MTS 771) were harvested near
Liestal, Canton Basel Land, Switzerland. The authentication of
collected E. cannabinum was carried out by Dr. M. Adams.
Voucher specimens of all samples are deposited at the
Institute of Pharmaceutical Biology, University of Basel,
organised under the MTS numbers shown above.2.3. Extraction and preparative isolation
Dried roots of S. costus were finely ground using a ZM1
ultra centrifugal mill (Retsch; Haan, Germany). Maceration of
900 g of the powdered material four times with 4 l of ethyl
acetate overnight at room temperature in a glass column
15×26 cm (Pyrex, Ostermundigen, Switzerland) yielded 40 g
of a thick brown extract. An aliquot of 30 g of extract was
fractionated by open column chromatography (9×59 cm)
filled with silica gel (Kieselgel 60™, particle size 40–63 μm)
(Merck; Darmstadt, Germany) and isocratic elution with n-
hexane-ethyl acetate (9:1) at a flow rate of 20 ml/min.
Fractions of 500 ml each were collected and monitored with
TLC on pre-coated Kieselgel 60 F254, 0.25 mm plates from
Merck with a mobile phase of: toluene:ethyl acetate (9:1);
detection with vaniline-H2SO4. Similar fractions were pooled
resulting in 7 fractions. Fraction 5 was obtained as a brown
oil (160 mg) and was separated by semi-preparative HPLC
as described above to obtain compounds arbusculin B (1)
(2.5 mg) and α-cyclocostunolide (2) (26 mg). Fraction 6
totalling 2.2 g afforded pure costunolide (3) (670 mg) and
fraction 7 (9.7 g) gave dehydrocostuslactone (4) (6.5 g).
Zaluzanin D (6) from the ethyl acetate extract of the dried
leaves of Laurus nobilis L. (Myrtaceae) and eupatoriopicrin (7)
from the aerial parts of Eupatorium cannabinum L. (Aster-
aceae) were isolated by semipreparative HPLC as described
above. Isolated substances 1–4, 6, and 7 were more than 95%
pure according to their 1H NMR spectra. Parthenolide (5) was
purchased from Alexis Biochemicals (Lausen, Switzerland)
with more than 95% pure as stated by the supplier. The
compounds 7were identified by comparison of 1D and 2D 1H
NMR, HPLC-HRTOF–MS data with published studies: 1 [12], 2
[13], 3 and 4 [14,15], 6 [16], and 7 [17]. Proton and carbon
NMR data of all the isolated compounds are given in the
supporting information (Table S1).
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Preparation of T. b. rhodesiense STIB 900 stocks and culture
media for the bloodstream forms was done according to Baltz
et al. [18] with the following modifications: 2-mercaptoetha-
nol 0.2 mM, sodium pyruvate 1 mM, hypoxanthine 0.5 mM,
and 15% heat-inactivated horse serum. In vitro screening for
antitrypanosomal activity was done with of Alamar Blue®
assay [19]. Stock solutions of test compounds and their serial
dilutions (5 μl) were transferred into 96 well plates (Costar;
Corning Inc., Lowell, MA, USA) containing 50 μl of culture
medium per well. Bloodstream forms of STIB 900 in 45 μl of
mediumwere added to eachwell and the plate was incubated
at 37 °C under 5% CO2 atmosphere for 72 h. Ten microliters of
resazurin solution (12.5 mg dissolved in 100 ml distilled
water) (Sigma-Aldrich; Zürich, Switzerland) was then added
and incubated for further 2–4 h. The fluorescence develop-
ment was measured in a Spectramax Gemini XS microplate
fluorometer (Molecular Devices Corp.; Sunnyvale, CA, USA),
operating with an excitation wavelength of 536 nm and an
emission wavelength of 588 nm and expressed as percentage
of the control. The IC50 values were calculated in the graphic
programme Softmax Pro (Molecular Devices Corp.). Tests
were done at least in three independent experiments in
duplicate.2.5. Cytotoxicity assay
Cytotoxicity was determined using rat skeletal myoblast
(L6 cells). The culture medium was RPMI 1640 medium
supplemented with L-glutamine 2 mM, HEPES 5.95 g/l,
NaHCO3 2 g/l and 10% foetal bovine serum. Podophyllotoxin
(Sigma-Aldrich) was used as the reference drug. The assay
was performed following the antitrypanosomal assay proto-
col [19]. The IC50s were calculated from the sigmoidal growth
inhibition curves using Softmax Pro software (Molecular
Devices Corp.). Tests were done in three independent ex-
periments in duplicate.Fig. 1. The antitrypanosomal activity of the 32 one-minute microfractions plotted a
positive scan m/z 200–1500).
2623. Results and discussion
The preliminary screen of our in house extract library
showed the ethyl acetate extract of S. costus to be highly
active against T. b. rhodesiense with 96% inhibition at
4.8 μg/ml. This extract was subjected to HPLC based acti-
vity profiling to track the activity and identify the active
principles. The activity was almost entirely focused in
minutes 22 and 23 with 99% to 100% of inhibition. Fig. 1
shows the overlay of the chromatogram (ESI positive MS
trace at scan m/z 200–1500) with the percent inhibition of
these microfractions. Subsequently, compounds 3 and 4
from these two active windows were isolated.
The major compound 3 (tR 22.4 min) had a molecular
formula of C15H20O2 withm/z 465.3182 [2M+H]+ (calcd. for
C30H41O4 465.3006) and was identified as costunolide.
Compound 4 (tR 23.0 min) with a molecular formula of
C15H18O2 derived from m/z 461.2869 [2M+H]+ (calcd. for
C30H37O4 461.2693) was dehydrocostuslactone. In addition,
compounds 1 (tR 24.2 min) and 2 (tR 25.3 min) were isolated
and both had the sum formula C15H20O2 as suggested by the
m/z 465.3185 [2M+H]+ (calcd. for C30H41O4 465.3006) and
m/z 465.3190 [2M+H]+ (calcd. for C30H41O4 465.3006). They
were identified as the known compounds arbusculin B (1)
and α-cyclocostunolide (2) (Fig. 2).
Compounds 2, 3, and 4 have been isolated from S. costus
previously [20]. Whilst compound 1 is reported here for the
first time from this plant.
Further possibly active compounds present in the extract
in minor concentrations, like the peaks seen in minute 11 and
20, were not isolated. This may be done in further studies.
From L. nobilis we isolated the sesquiterpene lactone 6
and from Eupatorium cannabium substance 7. Compound 6
with sum formula of C17H20O4, m/z 311.1289 [M+Na]+
(calcd. for C17H20O4Na 311.1254) was determined as
zaluzanin D and compound 7 with molecular formula of
C20H26O6, m/z 385.1614 [M+Na]+ (calcd. for C20H26O6Na
385.1622) was characterised as eupatoriopicrin. Substance
5 was from a commercial source. The 1H and 13C NMR datagainst the mass trace of the ethyl acetate extract of Saussurea costus (ESI-MS
Fig. 2. Chemical structures of seven sesquiterpene lactones isolated from Saussurea costus(1–4), Laurus nobilis (6) and Eupatorium cannabinum (7). Compound 5
was from a commercial source.
958 T. Julianti et al. / Fitoterapia 82 (2011) 955–959for compounds 1–4, 6, and 7 are attached as supporting
information (Table S1).
Sesquiterpene lactones are classified into several classes
based on their carbocyclic skeleton [21]. The compounds in
this study are eudesmanolides (6/6 bicyclic), germacrano-
lides (10 member-ring monocyclic), and guaianolides (5/7
bicyclic).
The antitrypanosomal and cytotoxic IC50 of the 7 com-
pounds were established (Table 1). The three germacrano-
lides parthenolide (5), eupatoriopicrin (7), and costunolide
(3) were the most antitrypanosomally active compounds in
this study, followed by the guaianolides dehydrocostuslac-
tone (4) and zaluzanin D (6), and the eudesmanolides
arbusculin B (1), andα-cyclocostunolide (2). The cytotoxicityTable 1
In vitro antitrypanosomal activity and cytotoxicity of sesquiterpene lactones
against T. b. rhodesiense and cytotoxic effects against L6 cells. Results are
expressed as IC50 values with the standard deviation (SD) and shown
alongside the positive controls.
Compound T. b. rhodesiense L6 cells SI
IC50 (μM±SD) IC50 (μM±SD)
1 Arbusculin B 12.0±3.3 6.2±2.3 0.5
2 α-Cyclocostunolide 21.9±1.1 19.4±7.9 0.9
3 Costunolide 1.3±0.4 7.7±1.3 5.9
4 Dehydrocostuslactone 4.4±1.4 8.3±1.9 1.9
5 Parthenolide 0.8±0.5 5.2±0.9 6.5
6 Zaluzanin D 10.8 a 15.6 a 1.4
7 Eupatoriopicrin 1.2±0.2 1.6±0.08 1.3
Melarsoprol 0.006±0.003
Podophyllotoxin 0.01±0.002
a IC50 value is obtained from a single experiment done in duplicate.
263of all compounds was within range of IC50s from 1.6 to
19.4 μM and selectivity indices between 0.5 and 6.5.
The three active germacranolides 3, 5, and 7 had similar
IC50 values, suggesting that the presence of the epoxide in 3 or
the esterified hydroxyl side chain in 7 did not greatly affect
the antitrypanosomal activity. Compounds 3 and 5weremore
selective towards T. b. rhodesiense than towards mammalian
cells (SI: 5.9 and 6.5) whereas 7 was more toxic (SI: 1.3).
Amongst the guaianolides, dehydrocostuslactone (4) had the
threefold activity and twofold toxicity of zaluzanin D (6).
They both had similar selectivity indices (1.9 and 1.4). The
lowest antitrypanosomal activities and selectivitieswere seen
for the two eudesmanolides arbusculin B (1) and α-
cyclocostunolide (2) which were both more active against
mammalian cells than against the parasites with selectivity
indices of 0.5 and 0.9.
Lirussi et al. [22] report the potent inhibition (IC50=
2.4 μg/ml) of T. cruzi epimastigotes by a methanol extract of
S. costus roots. Schmidt et al. [23] report parthenolide (5) to
be highly active against T. b. rhodesiense and T. cruzi. The
study also shows that the tested eudesmanolides tended to
have lower antitrypanosomal activities and selectivities
than some other types of sesquiterpene lactones. Izumi et
al. [24] also previously publish the potent effect of partheno-
lide (5) against T. cruzi. The other compounds in this study
have so far not been tested for antitrypanosomal effects.
We recently reported the potent in vitro and in vivo activity
of cynaropicrin, a guaianolide sesquiterpene lactone with a
2-hydroxymethyl-2-propenoyl moiety at C-8, against T. b.
rhodesiense [9].
Sesquiterpene lactones may exert their various biologi-
cal activities by the interaction of their α-methylene-γ-
butyrolactone moiety with the thiol groups of biomacromo-
lecules through Michael-addition [25].
959T. Julianti et al. / Fitoterapia 82 (2011) 955–959A comprehensive study on 40 sesquiterpene lactones from
five sesquiterpene lactone classes confirms the influence of this
α-methylene-γ-butyrolactone moiety to their antitrypanoso-
mal and cytotoxic activity. The most potent and selective
sesquiterpene lactones reported so far were the pseudoguaia-
nolide helenalin and the xanthanolide 8-epixanthatin-1,5-
epoxide. However, a high degree of correlation is also found
between such compounds' antiprotozoal activity and mamma-
lian cytotoxicity so that it may be difficult to find a structural
explanation for the selectivity observedwith some compounds
[23]. Cytotoxicity studies of sesquiterpene lactones related to
the lactone moiety were shown by Kupchan et al. [26,27].
This study suggests that sesquiterpene lactones may have
potential for the development of new leads to treat infection
caused by trypanosomes. Further comprehensive structure
activity studies to clarify the contribution of sesquiterpene ring
systemsand/or substitutionpatternsof sesquiterpene lactones to
the overall activity against both T. b. rhodesiense andmammalian
cell like those reported by Schmidt et al. [23] and especially
further in vivo data like Zimmermann et al. [9] are needed.
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S Table 1. 13C (125 Mhz) and 1H (500 MHz) data for compounds 1-4 in DMSO-d6 and compounds 6 and 7 in CDCl3 (δ in ppm and J in 
Hz). Assignment of 13C shifts was done via HSQC and HMBC correlations. 
Position 
1 2 3 4 6 7 
δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) 
1 
41.3, CH2* 1.58, m; 
1.41, m 
21.5, CH2 1.62, m; 
1.99, m 
126.7, CH 4.82, dd 
(11.3, 4.3) 
47.0, CH 2.95, m 50.3, CH 2.93, m 130.7, CH 4.87, dd  
(2.8, 11.0) 
2 
18.8, CH2* 1.57, m 23.0, CH2 2.04, m 26.1, CH2 2.27, m; 
2.10, m 
30.2, CH2 1.89, m; 
1.82, m 
36.0, CH2 2.43, m; 
1.82, m 
26.1, CH 2.31, m; 
2.20, m 
3 
31.0, CH2* 2.00, m; 
1.89, m 
122.5, CH 5.37, brs 39.3, CH2 2.25, m; 
1.98, m 
32.6, CH2 2.48, m 74.9, CH 5.57, m 39.4, CH2 2.35, m; 
2.07, m 
4 139.7, qC   133.2, qC  141.0, qC  152.3, qC  148.9, qC  142.5, qC  
5 
130.0, qC  50.7, CH 2.35, brd 127.8, CH 4.77, t (9.7) 52.0, CH 2.86, dd 
(10.0, 8.8) 
44.2, CH 3.01, m 127.2, CH 4.76, d (10.1) 
6 
83.2, CH 4.61, brd 
(11.5) 
82.0, CH 3.94, t (11.2) 81.7, CH 4.71, t (9.8) 85.0, CH 3.98 t (9.2) 84.5, CH 4.10, dd 
(9.4, 9.4) 
75.4, CH 5.16, dd  
(9.0, 9.7) 
7 50.0, CH 2.55, m 51.0, CH 2.59, m 50.0, CH 2.63, m 44.6, CH 2.97, m 45.1, CH 2.97, m 52.9, CH 2.93, m 
8 
23.0, CH2 2.06, m; 
1.63, m 
39.0, CH2 1.52, m; 
1.39, m 
27.7, CH2 2.12, m; 
1.69, m 
30.8, CH2 2.25, m; 
1.33, m 
30.4, CH2 2.01, m; 
1.44 m 
72.3, CH 5.80, d (3.2) 
9 
40.6, CH2* 1.50, m; 
1.36, m 
37.5, CH2 1.45, m; 
1.36, m 
40.9, CH2 2.33, m; 
2.08, m 
36.2, CH2 2.43, m; 
2.14, m 
34.4, CH2 2.51, m; 
2.21, m 
44.2, CH2 2.84, m; 
2.32, m 
10 37.7, qC  23.3, qC  137.3, qC  150.2, qC  149.0, qC  134.0, qC  
11 127.0, qC  139.8, qC  141.2, qC  140.2, qC  139.8, qC  136.8, qC  
12 170.3, qC  170.7, qC  170.4, qC  169.8, qC  171.0, qC  170.6, qC  
13 
118.4, CH2 6.00, d (3.1); 
5.56, d (3.0) 
116.5, CH 5.91, d (3.1); 
5.48, d (3.1) 
119.6, CH2 6.07, d (3.6) 
5.67, d (3.3) 
120.1, CH2 6.09, d (3.6); 
5.66, d (3.2) 
119.0, CH2 6.13, d (3.5); 
5.59, d (3.2) 
120.9, CH2 6.29, d (3.5); 
5.57, d (3.0) 
14 
27.2, CH3 1.09, s 17.5, CH3 0.86, s 16.1, CH3 1.39, s 112.3, CH2 4.89, brs; 
4.79, brs 
112.8, CH2 4.96, s 17.5, CH3 1.46, s 
15 
20.6, CH3 1.80, s 23.8, CH3 1.76, s 17.3, CH3 1.66 s 108.6, CH2 5.13, brs; 
5.03, brs 
111.5, CH2 5.38, m; 
5.23,m 
19.0, CH3 1.75, s 
1’         170.5, qC  165.9, qC  
2’         19.6, CH3 2.10, s 131.8, qC  
3’ 
          144.7, CH 6.84, dd  
(5.7, 5.7) 
4’           58.9, CH2 4.40, d (5.9) 
5’           57.3, CH2 4.33, s 
* These signals may be interchangeable.  
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As a result of a first screening campaign, 10 extracts, which belong to 10 different species and 7 families 
were chosen based on the following criteria: i) antiprotozoal activity; ii) selectivity; and iii) different 
genus [1]. Seventeen HPLC-based activity profiles were obtained. However, in most of the cases no 
activity was observed after micro-fractionation. Only the DCM extract of Eucomis autumnalis 
(flowers/buds) showed activity (90%) against L. donovani, but the dereplication of 4'-O-methyl-punctatin 
(homoflavonoid), as a major active compound was performed. Due to these poor results, a second 
screening was carried out [2]. The extracts of Abrus precatorius, Clutea pulchella, Drypetes gerrardii, 
and Turraea floribunda fulfilled the requirements for a follow up by HPLC-based activity profiling. 
Eighteen HPLC-based activity profiles were obtained by analytical separation of sub-milligram amounts 
of the extracts. Activity profiles of A. precatorius, C. pulchella, and D. gerrardii exhibited antiprotozoal 
inhibition of greater than 50%. 
Abruquinone B was dereplicated from the A. precatorius HPLC-activity profile. Nevertheless, the 
chromatogram showed additionally active peaks. Consequently, this extract was prioritized. No records 
were found for peaks present in the active windows of the HPLC-activity profiles of D. gerrardii and C. 
pulchella. Hence, the extracts were also prioritized in the mentioned order. 
Preparative isolation of active compounds to perform structure elucidation and in vitro test was achieved. 
Thanks to the combination of chromatographic techniques such as flash chromatography and semi-
preparative HPLC chromatography, only a small amount of crude extracts (1.0 g) from A. precatorius 
(Batch I) and D. gerrardii was needed to obtain compounds in multi-milligram amounts. Structures were 
elucidated by HR-ESIMS, and 1D and 2D NMR (1H, 13C, COSY, HMBC, HSQC, and NOESY) 
spectroscopy by using a 500 MHz spectrometer equipped with 1mm microprobe. When new chiral 
compounds were found, their absolute configuration was determined by comparison of the electronic 
circular dichroism (ECD) spectra with calculated ECD.  
In addition to South African plants, some European plants such as, Chrysanthemum cinerariifolium, 
Laurus nobilis, and Eupatorium cannabium were investigated. Nine compounds were isolated from these 
plants.  
In total, 22 secondary metabolites were isolated. Their in vitro antiprotozoal activity and selectivity are 
listed in Table 6. Following the criteria of activity and selectivity of the Swiss TPH (see Table 5), 15 
compounds showed parasite inhibition to some extent, ranging from active to moderately active. The 
remaining 7 compounds exhibited no activity against the mentioned parasites. The selectivity was 
calculated by dividing the IC50 value for L6 cells by the IC50 value in the parasite assay. Both, activity and 
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selectivity of pure substances, in addition to their structure novelty were criteria to prioritize compounds 
for large scale isolation to perform primary in vivo assays.  
Pyrethrin II and Jasmolin II, isolated from C. cinerariifolium, showed moderate activity against P. 
falciparum, and low selectivity (IC50 4.0 ± 1.1 µM and 5.0 ± 0.4 µM, SIs of 24 and 6, respectively). 
Pyrethrins were inactive against T. b. rhodesiense. Antiprotozoal properties of pyrethrins were compared 
with those of pyrethroids. Albeit pyrethrins were more active than pyrethroids (IC50 from 8.9 ± 2.0 µM to 
inactive), neither activity, nor selectivity were sufficient to warrant in vivo studies [3]. 
Sesquiterpene lactones were isolated from L. nobilis and E. cannabinum to investigate their antiprotozoal 
properties, and to start a structure-activity relationship study. Two germacrolides, costunolide and 
eupatoriopicrin, showed higher trypanocidal activity (IC50 of 1.3 ± 0.4 µM and 1.2 ± 0.2 µM, 
respectively) than the guaianolide zaluzanin D (IC50 of 10.8 µM) [4]. Other guaianolides, such as 
cynaropicrin, had shown high trypanocidal activity (IC50 of 0.28 ± 0.001 µM) [5]. As a result of  further 
studies performed by our research group, it is now known that an acyl side chain at OH-8, lacking in 
zaluzanin D and present in cynaropicrin, is essential for such activity [6]. None of the isolated 
sesquiterpene lactones in this work showed sufficient activity and selectivity to pursue in vivo tests.  
Abruquinones B and I from A. precatorius [7] and the phenanthrenone drypenenone D from D. gerrardii 
[8] fulfilled activity and selectivity requirements to conduct primary in vivo tests. Hence, a second batch 
of each plant was collected to perform large scale isolation since a minimum amount of 25 mg for each 
pure compound is needed for primary in vivo assays. 
Phytochemical profiles of batch I and II (second recollection) from A. precatorius were compared. Major 
differences were found in their composition. Abruquinones in batch II were only detected after 
enrichment by flash chromatography. The isolation of five additional abruquinones was achieved, 
although in low quantities only. Their trypanocidal activity was assessed in vitro (Table 6). All five 
abruquinones showed remarkable and selective inhibition of T. b. rhodesiense. Even though the goal of a 
large scale isolation of abruquinones from batch II was not achieved, we were able to isolate additional 
active abruquinones, confirming that this class of compounds shows interesting trypanocidal activity [9]. 
The inhibition (ranging from 0.28 to 0.007 µM) and selectivity (ranging from 51 to 1379) of active 
abruquinones were better than inhibition and selectivity of some lead compounds currently under clinical 
trials for HAT, namely fexinidazole (IC50 0.7 - 3.3 µM, SI >100, Phase II/III) and oxaborole SCYX-7158 
(IC50 0.2 – 1.0 µM, SI >100, Phase I) [10, 11]. Thus the in vivo assessment of abruquinones is highly 
recommended. 
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 Table 6. Isolated Compounds, Antiprotozoal Activity and Cytotoxicity in L6-cells 
 
 
Plant Compound 
P. falciparum T. b. rhodesiense L. donovani Cytotoxicity  
IC50 (µM)a SI IC50 (µM) SI IC50 (µM) SI (IC50) (µM) 
 Isoflavan quinones        
A. precatorius 
Batch I 
 
 
Abruquinone Bd 4.1 ± 0.4 2.5 0.16 ± 0.06 51  2.9 b 3.5 10.0 ± 1.3 
Abruquinone Id 20.4 ± 1.3 1.1 0.28 ± 0.05 78 3.4 6.5 22.1 ± 3.5 
Abruquinone G Inactive c - 17.0 ± 4.17 3.0 35 1.5 51.7 ± 11 
Abruquinone H 8.0 ± 1.1 15 12.0 ± 3.83 10 Inactive b - 122 ± 21 
(3S)-7,8,3'‚5'-tetramethoxyisoflavan-
1',4'-quinoned 
8.9 ± 4.2 0.4 0.88 ± 0.14 4.5 5.0 0.8 3.9 ± 0.44 
A. precatorius 
Batch II 
 
Abruquinone Kd 14.1 ± 0.4 4.1 0.113 ± 0.053 508 Inactive b - 57 ± 4.3 
Abruquinone Ld 13.4 ± 0.6 0.6 0.020 ± 0.003 374 Inactive b - 7.5 ± 1.2 
Abruquinone Ad 9.2 ± 1.5 3.7 0.025 ± 0.003 1379 Inactive b - 34.5 ± 16 
Abruquinone Dd 3.5 ± 0.2 1.4 0.007 ± 0.002 668 Inactive b - 4.8 ± 1.6 
Abruquinone J 84 ± 4.0 1.8 11.2 ± 13.6 13.6 Inactive b - 152 ± 7.8 
 Phenanthrenones        
D. gerrardii 
Phenanthrenoned 0.96 ± 0.25  71 6.0 ± 2.7 11 14.0 4.9 68 ± 4.6 
Phenanthrenone Dimerd 2.03 ± 0.15 31 - - - - 64 ± 22 
 Terpenes        
D. gerrardii Putranoside Ad Inactive c - 18.0 ± 2.6 3.8 7.8 8.8 68 ± 4.0 
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Plant Compound 
P. falciparum T. b. rhodesiense L. donovani Cytotoxicity  
IC50 (µM)a SI IC50 (µM) SI IC50 (µM) SI (IC50) (µM) 
C. 
cinerariifolium 
Pyrethrin IId 4.0 ± 1.1 24 10.6 ± 0.4 9.0 - - 95 ± 2.5 
Jasmolin IId 5.0 ± 0.4 6.3 12.1 ± 0.2 2.6 - - 32 ± 2.3 
Cinerin II 5.8 ± 0.4 4.8 12.2 ± 0.02 2.3 - - 28 ± 7.8 
Pyrethrin I 11.9 ± 1.5 12.6 6.9 ± 1.1 21 - - 146 ± 34 
Jasmolin I 9.3 ± 1.2 9.2 30.9 ± 1.4 2.8 - - 86 ± 12 
L. nobilis 
Costunolided -  1.3 ± 0.4 5.9 -  7.7 ± 1.3 
Zaluzanin D -  10.8* 6.5 -  15.6*  
Spirofolided -  0.3* 4.3 -  1.3* 
E.cannabium Eupatoriopicrind -  1.2 ± 0.2 1.3 -  1.6 ± 0.1 
 
a
 Values are expressed as mean ± standard error of the mean. b No activity observed at the highest test concentration of 90 µg/mL, which 
corresponds to molar test concentrations of 269.4 to 220.5 µM. c No activity observed at the highest test concentration of 10 µg/mL, which 
corresponds to molar test concentrations of 24.5 to 1.29 µM. d Active compounds against at least one parasite. 
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No obvious structure activity relationship (SAR) was observed among the ten abruquinones. 
Qualitative and quantitative differences in abruquinones content between batch I and II could be due to 
seasonal effects. Batch I was collected in summer, whereas batch II was collected in autumn. The 
variation in the content of abruquinone should be taken into account for further material recollection. 
Additionally, to assure a botanical source of abruquinones, for further phases of discovery, it is necessary 
to perform studies on the influence of different factors such as, environment and genetics, on the 
production of abruquinones [12]. Optimization of the extraction method could also be considered. 
Recently, a method for obtaining abruquinone A from the roots of A. precatorius has been patented [13].  
Late approaches that endeavour to re-establish natural products in the modern, HTS-based lead discovery 
paradigm have focused on early compound selection driven by molecular properties associated with lead- 
and drug likeness [14, 15]. Some descriptors, namely Lipinski’s parameters [molecular weight ≤ 500, log 
P ≤ 5, sum of H-donors/acceptors ≤ 10], rotatable bonds (≤ 10), and polar surface area (PSA) (≤ 60-70 
Å2) can predict permeability across biological barriers [16, 17]. In general, abruquinones complied with 
Lipinski’s “rule of 5” requirements, except for abruquinone K, for which the sum of H-donors/acceptors 
is 12 (Table 7). Accordingly, oral bioavailability of abruquinones can be expected, which is one of the 
main requirements for an antiprotozoal drug. Abruquinones also fulfil the flexibility criterion (measured 
as rotatable bonds), but not the PSA requirements. With a PSA higher than 60-70 Å, blood-brain barrier 
(BBB) permeability might be limited [30]. In drug discovery for HAT, there is a need to find drugs acting 
against the second stage of the disease, when parasites have already crossed the BBB. Regardless of the 
high PSA of abruquinones, it is known that some flavonoids are able to reach the brain. One example is 
kaempferol, a flavonoid which is able to cross the BBB, despite of its high PSA (111.1 Å) [14, 18]. 
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Table 7. Physico-chemical Properties of Most Active and Selective Compounds  
 
Plant Compounds H-acceptors H-donors MW CLogPa 
Rotatable  
bonds 
PSA 
(Å2) 
 Isoflavan quinones       
A. precatorius  
Batch I 
Abruquinone Bb 8 0 390.4 -0.67 6 89.5 
Abruquinone Ib 7 1 346.3 -0.81 5 91.3 
 Abruquinone Ab 7 0 360.4 -0.55 5 80.3 
A. precatorius  
Batch II 
Abruquinone Dc 7 1 346.3 -0.81 4 91.3 
Abruquinone Kc 8 4 364.4 1.30 4 117.8 
 Abruquinone Lc 7 3 348.4 2.34 4 97.6 
 Phenanthrenones       
D. gerarrdii Phenanthrenonec 2 0 252.3 3.96 0 37.3 
MW: molecular weight PSA: polar surface area; aValues calculated with ChemBioDrawUltra, bValues 
obtained from SciFinder (calculated with ACD/Labs), cCalculated with software Molinspiration 
Cheminformatics [19]. 
In addition to molecular parameters, generation of early safety data is crucial to avoid failure in further 
steps of development [20]. There are a series of proteins involved in development of adverse effects. 
When the ability of a compound to bind to these proteins is simulated and quantified in silico, it is 
possible to obtain an estimated toxic potential. By using “Virtual ToxLab” technology, binding affinities 
of the abruquinones toward 16 target proteins were calculated and, hence, an estimated potential of 
endocrine and/or metabolic disruption, carcinogenicity and cardiotoxicity was obtained. The toxic 
potential generated must be interpreted as “toxic alerts”, i.e. compounds featuring a low toxic potential 
should not be interpreted as benign, as adverse effects may be mediated through other targets or might 
trigger undesirable effects under different conditions [21]. Results for abruquinones are shown in Table 8. 
According to their toxic potential, abruquinones were categorized from low to class II (TP from 0 to IV). 
Abruquinones which are in class 0, such as abruquinones B, A, and L are unlikely to show adverse 
effects, triggered by the 16 target proteins tested. Abruquinone I, and D were ranked in class II because 
both of them showed a high in silico binding to glucocorticoid receptor. This might be a potential “off-
target” activity of these compounds, which should be further studied, in case the compounds show in vivo 
trypanocidal activity. Importantly, their interactions with the hERG receptor, a potassium ion channel 
related to cardiotoxicity, were low (ranging from no binding to an affinity of 5.40 µM). 
In vitro trypanocidal activity results, together with encouraging drug-like properties, and low to moderate 
in silico predicted toxicity render abruquinones interesting hits to be pursued by medicinal chemists.   
273
 In the case of D. gerrardii, there were no major differences between the phytochemical profiles of the 
first and second batch. Thus, obtaining of sufficient amounts of drypetenone D (25 mg) for in vivo 
antimalarial tests was possible. However the compound was inactive when tested in the four-day 
suppressive test in mice against P. berghei (ANKA strain).  
The failure in this animal model might be due to either low systemic exposure or/and low specific activity 
against the parasite. Even though P. berghei is the species of choice for in vivo screening, some specific 
genes of this rodent Plasmodium may have significantly diverged from the human pathogen. Thus, there 
is a risk of not identifying compounds selectively inhibiting P. falciparum. This is the case of diamidine 
derivatives, which are known to be efficacious against P. falciparum in humans but not against P. 
berghei. To overcome this drawback some authors propose to test failed compounds against P. berghei in 
the Pf-huMouse [22]. Nevertheless, ethical and economical considerations must be taken into account.  
Drypenenone D fulfils the established drug-likeness criteria (Table 7) and, therefore, oral bioavailability 
and BBB permeability can be expected. This makes feasible an oral administration, one of the desired 
characteristics for an ideal antimalarial drug and a potential applicability for the treatment of cerebral 
malaria [23].  
The estimated toxic potential calculated by the “Virtual ToxLab” for drypenenone D was 0.52 (Table 8). 
This toxic potential value categorized it as a class I compound. Drypenenone D bound to the progesterone 
receptor with high affinity (IC50 of 46.8 nM). This receptor has a fundamental roll during pregnancy. 
Since antimalarial drugs are expected to be administered in pregnant women, this aspect requires 
particular attention [23]. However, it is important to note that in silico binding affinity to hERG was low 
(IC50 of 40.2 µM).  
When applying the Medicines for Malaria Venture (MVV) compound progression criteria for drug 
discovery pipeline of compounds against malaria [24], drypenenone D fulfills some of the requirements to 
become a validated hit, such as i) sufficient activity against P. falciparum (in vitro cell-based assay ˂ 1 
µM); ii) sufficient selectivity (SI > 10); iii) drug-like properties; iv) clear identification of the botanical 
species which contain the active compound. However, it is still necessary to i) establish a possible SAR; 
ii) predict ADME properties by applying computational models and iii) guarantee a source of plant 
material to obtain sufficient compound for further steps. D. gerrardii is distributed in South Africa, 
Namibia, Botswana, Lesotho, Swaziland, and Zimbabwe, and occurs also in the tropical region along the 
eastern African coastline. Abundance of the species must be carefully evaluated, taking into  
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Table 8. Binding Affinity to the 16 Chosen Targets and Resulting Predicted Toxicity Potential (TP) 
of the Most Active and Selective Compounds  
 
Plant Compounds 
Binding affinity 
TP  
TP 
Class N VL L M H VH 
 Isoflavan quinones    
A. precatorius  
Batch I 
Abruquinone Bb 9 0 3 3 1 0 ≤ 5 Low 
Abruquinone Ib 6 0 5 4 1 0 0.63 Class II 
Abruquinone Gb 13 0 0 1 1 0 0.54 Class I 
A. precatorius  
Batch II 
Abruquinone Ab 9 0 3 4 0 0 0.48 Low 
Abruquinone Dc 3 0 2 10 1 0 0.59 Class II 
Abruquinone Lc 10 0 4 2 0 0 ≤ 5 Low 
 Phenanthrenones    
D. gerarrdii Phenanthrenonec 6 0 3 6 1  0.52 Class I 
N: none (IC50 > 100 mM), VL: very low (IC50 > 1 mM), L: low (IC50 > 10 µM), M: medium (IC50 > 100 
nM), H: high (IC50 > 1n M), VH: very high (IC50 ˂ 1n M).  
TP > 0.8 (extreme, class IV), 0.7 ˂ TP ≤ 0.8 (high, class III), 0.6 ˂ TP ≤ 0.7 (elevated, class II), 0.5 ˂ TP 
≤ 0.6 (moderated, class I), TP ≤ 0.5 (low, Class 0). 
 
account that it is necessary to use stems for drypenenone D extraction, as well as the ecological impact of 
future recollections [25].  So far, there are no reports of any straightforward method of synthesis that 
allow us to use this alternative.  
According to the MMV progression criteria (Table 4) [24], drypenenone D should meet the following 
criteria to become an early lead compound i) depress parasitemia in a mouse model. So far, this is the 
main drawback of drypenenone D; ii) not be toxic in mice. Drypenenone D did not show signs of toxicity 
when tested at 50 mg/Kg in mice; even so, an in vivo toxicity test should be conducted; iii) have no 
known toxicophores/reactive groups. So far, according to the results of the predicted in silico toxicity, the 
toxic potential of the compound is low; iv) have a known mode of action or plans in place to address this; 
v) be stable in mouse and human plasma; vi) offer initial SAR opportunities for chemical targets with 
straightforward synthesis. 
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